INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51001, 17825, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51002, 18099, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51003, 18890, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51004, 18892, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51005, 19827, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51006, 20026, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51007, 20027, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51008, 27484, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51009, 27485, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51010, 27486, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51011, 28793, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51012, 28794, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51013, 28843, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51014, 28844, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51015, 29713, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51016, 29714, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51017, 29715, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51018, 30137, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51019, 30613, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51020, 30614, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51021, 31533, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51022, 32311, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51023, 727, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51024, 4751, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51025, 4752, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51026, 7996, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51027, 11962, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51028, 12664, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51029, 12665, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51030, 17824, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51031, 17825, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51032, 18099, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51033, 18890, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51034, 18892, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51035, 19827, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51036, 20026, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51037, 20027, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51038, 27484, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51039, 27485, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51040, 27486, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51041, 28793, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51042, 28794, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51043, 28843, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51044, 28844, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51045, 29713, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51046, 29714, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51047, 29715, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51048, 30137, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51049, 30613, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51050, 30614, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51051, 31533, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51052, 32311, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51053, 810, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|"Product Information. Axid (nizatidine)." Lilly, Eli and Company  (2002):|"Product Information. Tagamet (cimetidine)." SmithKline Beecham  (2001):|"Product Information. Tritec (ranitidine bismuth citrate)." Glaxo Wellcome  (2001):|"Product Information. Zantac 75 (ranitidine)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51054, 812, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|"Product Information. Axid (nizatidine)." Lilly, Eli and Company  (2002):|"Product Information. Tagamet (cimetidine)." SmithKline Beecham  (2001):|"Product Information. Tritec (ranitidine bismuth citrate)." Glaxo Wellcome  (2001):|"Product Information. Zantac 75 (ranitidine)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51055, 814, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|"Product Information. Axid (nizatidine)." Lilly, Eli and Company  (2002):|"Product Information. Tagamet (cimetidine)." SmithKline Beecham  (2001):|"Product Information. Tritec (ranitidine bismuth citrate)." Glaxo Wellcome  (2001):|"Product Information. Zantac 75 (ranitidine)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51056, 817, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|"Product Information. Axid (nizatidine)." Lilly, Eli and Company  (2002):|"Product Information. Tagamet (cimetidine)." SmithKline Beecham  (2001):|"Product Information. Tritec (ranitidine bismuth citrate)." Glaxo Wellcome  (2001):|"Product Information. Zantac 75 (ranitidine)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51057, 2432, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|"Product Information. Axid (nizatidine)." Lilly, Eli and Company  (2002):|"Product Information. Tagamet (cimetidine)." SmithKline Beecham  (2001):|"Product Information. Tritec (ranitidine bismuth citrate)." Glaxo Wellcome  (2001):|"Product Information. Zantac 75 (ranitidine)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51058, 2932, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|"Product Information. Axid (nizatidine)." Lilly, Eli and Company  (2002):|"Product Information. Tagamet (cimetidine)." SmithKline Beecham  (2001):|"Product Information. Tritec (ranitidine bismuth citrate)." Glaxo Wellcome  (2001):|"Product Information. Zantac 75 (ranitidine)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51059, 4632, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|"Product Information. Axid (nizatidine)." Lilly, Eli and Company  (2002):|"Product Information. Tagamet (cimetidine)." SmithKline Beecham  (2001):|"Product Information. Tritec (ranitidine bismuth citrate)." Glaxo Wellcome  (2001):|"Product Information. Zantac 75 (ranitidine)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51060, 4633, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|"Product Information. Axid (nizatidine)." Lilly, Eli and Company  (2002):|"Product Information. Tagamet (cimetidine)." SmithKline Beecham  (2001):|"Product Information. Tritec (ranitidine bismuth citrate)." Glaxo Wellcome  (2001):|"Product Information. Zantac 75 (ranitidine)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51061, 4635, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|"Product Information. Axid (nizatidine)." Lilly, Eli and Company  (2002):|"Product Information. Tagamet (cimetidine)." SmithKline Beecham  (2001):|"Product Information. Tritec (ranitidine bismuth citrate)." Glaxo Wellcome  (2001):|"Product Information. Zantac 75 (ranitidine)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51062, 4636, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|"Product Information. Axid (nizatidine)." Lilly, Eli and Company  (2002):|"Product Information. Tagamet (cimetidine)." SmithKline Beecham  (2001):|"Product Information. Tritec (ranitidine bismuth citrate)." Glaxo Wellcome  (2001):|"Product Information. Zantac 75 (ranitidine)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51063, 5362, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|"Product Information. Axid (nizatidine)." Lilly, Eli and Company  (2002):|"Product Information. Tagamet (cimetidine)." SmithKline Beecham  (2001):|"Product Information. Tritec (ranitidine bismuth citrate)." Glaxo Wellcome  (2001):|"Product Information. Zantac 75 (ranitidine)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51064, 5363, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|"Product Information. Axid (nizatidine)." Lilly, Eli and Company  (2002):|"Product Information. Tagamet (cimetidine)." SmithKline Beecham  (2001):|"Product Information. Tritec (ranitidine bismuth citrate)." Glaxo Wellcome  (2001):|"Product Information. Zantac 75 (ranitidine)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51065, 6823, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|"Product Information. Axid (nizatidine)." Lilly, Eli and Company  (2002):|"Product Information. Tagamet (cimetidine)." SmithKline Beecham  (2001):|"Product Information. Tritec (ranitidine bismuth citrate)." Glaxo Wellcome  (2001):|"Product Information. Zantac 75 (ranitidine)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51066, 6825, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|"Product Information. Axid (nizatidine)." Lilly, Eli and Company  (2002):|"Product Information. Tagamet (cimetidine)." SmithKline Beecham  (2001):|"Product Information. Tritec (ranitidine bismuth citrate)." Glaxo Wellcome  (2001):|"Product Information. Zantac 75 (ranitidine)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51067, 10381, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|"Product Information. Axid (nizatidine)." Lilly, Eli and Company  (2002):|"Product Information. Tagamet (cimetidine)." SmithKline Beecham  (2001):|"Product Information. Tritec (ranitidine bismuth citrate)." Glaxo Wellcome  (2001):|"Product Information. Zantac 75 (ranitidine)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51068, 11825, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|"Product Information. Axid (nizatidine)." Lilly, Eli and Company  (2002):|"Product Information. Tagamet (cimetidine)." SmithKline Beecham  (2001):|"Product Information. Tritec (ranitidine bismuth citrate)." Glaxo Wellcome  (2001):|"Product Information. Zantac 75 (ranitidine)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51069, 14254, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|"Product Information. Axid (nizatidine)." Lilly, Eli and Company  (2002):|"Product Information. Tagamet (cimetidine)." SmithKline Beecham  (2001):|"Product Information. Tritec (ranitidine bismuth citrate)." Glaxo Wellcome  (2001):|"Product Information. Zantac 75 (ranitidine)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51070, 14256, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|"Product Information. Axid (nizatidine)." Lilly, Eli and Company  (2002):|"Product Information. Tagamet (cimetidine)." SmithKline Beecham  (2001):|"Product Information. Tritec (ranitidine bismuth citrate)." Glaxo Wellcome  (2001):|"Product Information. Zantac 75 (ranitidine)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51071, 14259, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|"Product Information. Axid (nizatidine)." Lilly, Eli and Company  (2002):|"Product Information. Tagamet (cimetidine)." SmithKline Beecham  (2001):|"Product Information. Tritec (ranitidine bismuth citrate)." Glaxo Wellcome  (2001):|"Product Information. Zantac 75 (ranitidine)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51072, 18355, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|"Product Information. Axid (nizatidine)." Lilly, Eli and Company  (2002):|"Product Information. Tagamet (cimetidine)." SmithKline Beecham  (2001):|"Product Information. Tritec (ranitidine bismuth citrate)." Glaxo Wellcome  (2001):|"Product Information. Zantac 75 (ranitidine)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51073, 19600, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|"Product Information. Axid (nizatidine)." Lilly, Eli and Company  (2002):|"Product Information. Tagamet (cimetidine)." SmithKline Beecham  (2001):|"Product Information. Tritec (ranitidine bismuth citrate)." Glaxo Wellcome  (2001):|"Product Information. Zantac 75 (ranitidine)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51074, 19605, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|"Product Information. Axid (nizatidine)." Lilly, Eli and Company  (2002):|"Product Information. Tagamet (cimetidine)." SmithKline Beecham  (2001):|"Product Information. Tritec (ranitidine bismuth citrate)." Glaxo Wellcome  (2001):|"Product Information. Zantac 75 (ranitidine)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51075, 24714, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|"Product Information. Axid (nizatidine)." Lilly, Eli and Company  (2002):|"Product Information. Tagamet (cimetidine)." SmithKline Beecham  (2001):|"Product Information. Tritec (ranitidine bismuth citrate)." Glaxo Wellcome  (2001):|"Product Information. Zantac 75 (ranitidine)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51076, 24715, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|"Product Information. Axid (nizatidine)." Lilly, Eli and Company  (2002):|"Product Information. Tagamet (cimetidine)." SmithKline Beecham  (2001):|"Product Information. Tritec (ranitidine bismuth citrate)." Glaxo Wellcome  (2001):|"Product Information. Zantac 75 (ranitidine)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51077, 24718, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|"Product Information. Axid (nizatidine)." Lilly, Eli and Company  (2002):|"Product Information. Tagamet (cimetidine)." SmithKline Beecham  (2001):|"Product Information. Tritec (ranitidine bismuth citrate)." Glaxo Wellcome  (2001):|"Product Information. Zantac 75 (ranitidine)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51078, 26877, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|"Product Information. Axid (nizatidine)." Lilly, Eli and Company  (2002):|"Product Information. Tagamet (cimetidine)." SmithKline Beecham  (2001):|"Product Information. Tritec (ranitidine bismuth citrate)." Glaxo Wellcome  (2001):|"Product Information. Zantac 75 (ranitidine)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51079, 810, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', 'Halstenson CE, Abraham PA, Opsahl JA, Chremos AN, Keane WF, Matzke GR "Disposition of famotidine in renal insufficiency." J Clin Pharmacol 27 (1987):  782-7|Gladziwa U, Klotz U, Krishna DR, Schmitt H, Glockner WM, Mann H "Pharmacokinetics and dynamics of famotidine in patients with renal failure." Br J Clin Pharmacol 26 (1988):  315-21|Hachisu T, Yokoyama T, Oda Y, Ando K, Hattori Y, Yoshida T "Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure." Clin Ther 10 (1988):  656-63|Takabatake T, Ohta H, Maekawa M, Yamamoto Y, Ishida Y, Hara H, Nakamura S, Ushiogi Y, Kawabata M, Hashimoto N, et al. "Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function." Eur J Clin Pharmacol 28 (1985):  327-31|Kroemer H, Klotz U "Pharmacokinetics of famotidine in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  458-63|"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|Gladziwa U, Klotz U "Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure." Clin Pharmacokinet 27 (1994):  393-408', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51080, 812, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', 'Halstenson CE, Abraham PA, Opsahl JA, Chremos AN, Keane WF, Matzke GR "Disposition of famotidine in renal insufficiency." J Clin Pharmacol 27 (1987):  782-7|Gladziwa U, Klotz U, Krishna DR, Schmitt H, Glockner WM, Mann H "Pharmacokinetics and dynamics of famotidine in patients with renal failure." Br J Clin Pharmacol 26 (1988):  315-21|Hachisu T, Yokoyama T, Oda Y, Ando K, Hattori Y, Yoshida T "Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure." Clin Ther 10 (1988):  656-63|Takabatake T, Ohta H, Maekawa M, Yamamoto Y, Ishida Y, Hara H, Nakamura S, Ushiogi Y, Kawabata M, Hashimoto N, et al. "Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function." Eur J Clin Pharmacol 28 (1985):  327-31|Kroemer H, Klotz U "Pharmacokinetics of famotidine in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  458-63|"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|Gladziwa U, Klotz U "Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure." Clin Pharmacokinet 27 (1994):  393-408', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51081, 814, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', 'Halstenson CE, Abraham PA, Opsahl JA, Chremos AN, Keane WF, Matzke GR "Disposition of famotidine in renal insufficiency." J Clin Pharmacol 27 (1987):  782-7|Gladziwa U, Klotz U, Krishna DR, Schmitt H, Glockner WM, Mann H "Pharmacokinetics and dynamics of famotidine in patients with renal failure." Br J Clin Pharmacol 26 (1988):  315-21|Hachisu T, Yokoyama T, Oda Y, Ando K, Hattori Y, Yoshida T "Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure." Clin Ther 10 (1988):  656-63|Takabatake T, Ohta H, Maekawa M, Yamamoto Y, Ishida Y, Hara H, Nakamura S, Ushiogi Y, Kawabata M, Hashimoto N, et al. "Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function." Eur J Clin Pharmacol 28 (1985):  327-31|Kroemer H, Klotz U "Pharmacokinetics of famotidine in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  458-63|"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|Gladziwa U, Klotz U "Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure." Clin Pharmacokinet 27 (1994):  393-408', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51082, 817, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', 'Halstenson CE, Abraham PA, Opsahl JA, Chremos AN, Keane WF, Matzke GR "Disposition of famotidine in renal insufficiency." J Clin Pharmacol 27 (1987):  782-7|Gladziwa U, Klotz U, Krishna DR, Schmitt H, Glockner WM, Mann H "Pharmacokinetics and dynamics of famotidine in patients with renal failure." Br J Clin Pharmacol 26 (1988):  315-21|Hachisu T, Yokoyama T, Oda Y, Ando K, Hattori Y, Yoshida T "Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure." Clin Ther 10 (1988):  656-63|Takabatake T, Ohta H, Maekawa M, Yamamoto Y, Ishida Y, Hara H, Nakamura S, Ushiogi Y, Kawabata M, Hashimoto N, et al. "Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function." Eur J Clin Pharmacol 28 (1985):  327-31|Kroemer H, Klotz U "Pharmacokinetics of famotidine in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  458-63|"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|Gladziwa U, Klotz U "Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure." Clin Pharmacokinet 27 (1994):  393-408', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51083, 2432, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', 'Halstenson CE, Abraham PA, Opsahl JA, Chremos AN, Keane WF, Matzke GR "Disposition of famotidine in renal insufficiency." J Clin Pharmacol 27 (1987):  782-7|Gladziwa U, Klotz U, Krishna DR, Schmitt H, Glockner WM, Mann H "Pharmacokinetics and dynamics of famotidine in patients with renal failure." Br J Clin Pharmacol 26 (1988):  315-21|Hachisu T, Yokoyama T, Oda Y, Ando K, Hattori Y, Yoshida T "Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure." Clin Ther 10 (1988):  656-63|Takabatake T, Ohta H, Maekawa M, Yamamoto Y, Ishida Y, Hara H, Nakamura S, Ushiogi Y, Kawabata M, Hashimoto N, et al. "Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function." Eur J Clin Pharmacol 28 (1985):  327-31|Kroemer H, Klotz U "Pharmacokinetics of famotidine in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  458-63|"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|Gladziwa U, Klotz U "Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure." Clin Pharmacokinet 27 (1994):  393-408', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51084, 2932, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', 'Halstenson CE, Abraham PA, Opsahl JA, Chremos AN, Keane WF, Matzke GR "Disposition of famotidine in renal insufficiency." J Clin Pharmacol 27 (1987):  782-7|Gladziwa U, Klotz U, Krishna DR, Schmitt H, Glockner WM, Mann H "Pharmacokinetics and dynamics of famotidine in patients with renal failure." Br J Clin Pharmacol 26 (1988):  315-21|Hachisu T, Yokoyama T, Oda Y, Ando K, Hattori Y, Yoshida T "Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure." Clin Ther 10 (1988):  656-63|Takabatake T, Ohta H, Maekawa M, Yamamoto Y, Ishida Y, Hara H, Nakamura S, Ushiogi Y, Kawabata M, Hashimoto N, et al. "Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function." Eur J Clin Pharmacol 28 (1985):  327-31|Kroemer H, Klotz U "Pharmacokinetics of famotidine in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  458-63|"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|Gladziwa U, Klotz U "Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure." Clin Pharmacokinet 27 (1994):  393-408', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51085, 4632, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', 'Halstenson CE, Abraham PA, Opsahl JA, Chremos AN, Keane WF, Matzke GR "Disposition of famotidine in renal insufficiency." J Clin Pharmacol 27 (1987):  782-7|Gladziwa U, Klotz U, Krishna DR, Schmitt H, Glockner WM, Mann H "Pharmacokinetics and dynamics of famotidine in patients with renal failure." Br J Clin Pharmacol 26 (1988):  315-21|Hachisu T, Yokoyama T, Oda Y, Ando K, Hattori Y, Yoshida T "Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure." Clin Ther 10 (1988):  656-63|Takabatake T, Ohta H, Maekawa M, Yamamoto Y, Ishida Y, Hara H, Nakamura S, Ushiogi Y, Kawabata M, Hashimoto N, et al. "Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function." Eur J Clin Pharmacol 28 (1985):  327-31|Kroemer H, Klotz U "Pharmacokinetics of famotidine in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  458-63|"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|Gladziwa U, Klotz U "Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure." Clin Pharmacokinet 27 (1994):  393-408', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51086, 4633, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', 'Halstenson CE, Abraham PA, Opsahl JA, Chremos AN, Keane WF, Matzke GR "Disposition of famotidine in renal insufficiency." J Clin Pharmacol 27 (1987):  782-7|Gladziwa U, Klotz U, Krishna DR, Schmitt H, Glockner WM, Mann H "Pharmacokinetics and dynamics of famotidine in patients with renal failure." Br J Clin Pharmacol 26 (1988):  315-21|Hachisu T, Yokoyama T, Oda Y, Ando K, Hattori Y, Yoshida T "Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure." Clin Ther 10 (1988):  656-63|Takabatake T, Ohta H, Maekawa M, Yamamoto Y, Ishida Y, Hara H, Nakamura S, Ushiogi Y, Kawabata M, Hashimoto N, et al. "Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function." Eur J Clin Pharmacol 28 (1985):  327-31|Kroemer H, Klotz U "Pharmacokinetics of famotidine in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  458-63|"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|Gladziwa U, Klotz U "Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure." Clin Pharmacokinet 27 (1994):  393-408', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51087, 4635, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', 'Halstenson CE, Abraham PA, Opsahl JA, Chremos AN, Keane WF, Matzke GR "Disposition of famotidine in renal insufficiency." J Clin Pharmacol 27 (1987):  782-7|Gladziwa U, Klotz U, Krishna DR, Schmitt H, Glockner WM, Mann H "Pharmacokinetics and dynamics of famotidine in patients with renal failure." Br J Clin Pharmacol 26 (1988):  315-21|Hachisu T, Yokoyama T, Oda Y, Ando K, Hattori Y, Yoshida T "Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure." Clin Ther 10 (1988):  656-63|Takabatake T, Ohta H, Maekawa M, Yamamoto Y, Ishida Y, Hara H, Nakamura S, Ushiogi Y, Kawabata M, Hashimoto N, et al. "Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function." Eur J Clin Pharmacol 28 (1985):  327-31|Kroemer H, Klotz U "Pharmacokinetics of famotidine in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  458-63|"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|Gladziwa U, Klotz U "Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure." Clin Pharmacokinet 27 (1994):  393-408', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51088, 4636, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', 'Halstenson CE, Abraham PA, Opsahl JA, Chremos AN, Keane WF, Matzke GR "Disposition of famotidine in renal insufficiency." J Clin Pharmacol 27 (1987):  782-7|Gladziwa U, Klotz U, Krishna DR, Schmitt H, Glockner WM, Mann H "Pharmacokinetics and dynamics of famotidine in patients with renal failure." Br J Clin Pharmacol 26 (1988):  315-21|Hachisu T, Yokoyama T, Oda Y, Ando K, Hattori Y, Yoshida T "Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure." Clin Ther 10 (1988):  656-63|Takabatake T, Ohta H, Maekawa M, Yamamoto Y, Ishida Y, Hara H, Nakamura S, Ushiogi Y, Kawabata M, Hashimoto N, et al. "Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function." Eur J Clin Pharmacol 28 (1985):  327-31|Kroemer H, Klotz U "Pharmacokinetics of famotidine in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  458-63|"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|Gladziwa U, Klotz U "Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure." Clin Pharmacokinet 27 (1994):  393-408', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51089, 5362, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', 'Halstenson CE, Abraham PA, Opsahl JA, Chremos AN, Keane WF, Matzke GR "Disposition of famotidine in renal insufficiency." J Clin Pharmacol 27 (1987):  782-7|Gladziwa U, Klotz U, Krishna DR, Schmitt H, Glockner WM, Mann H "Pharmacokinetics and dynamics of famotidine in patients with renal failure." Br J Clin Pharmacol 26 (1988):  315-21|Hachisu T, Yokoyama T, Oda Y, Ando K, Hattori Y, Yoshida T "Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure." Clin Ther 10 (1988):  656-63|Takabatake T, Ohta H, Maekawa M, Yamamoto Y, Ishida Y, Hara H, Nakamura S, Ushiogi Y, Kawabata M, Hashimoto N, et al. "Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function." Eur J Clin Pharmacol 28 (1985):  327-31|Kroemer H, Klotz U "Pharmacokinetics of famotidine in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  458-63|"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|Gladziwa U, Klotz U "Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure." Clin Pharmacokinet 27 (1994):  393-408', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51090, 5363, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', 'Halstenson CE, Abraham PA, Opsahl JA, Chremos AN, Keane WF, Matzke GR "Disposition of famotidine in renal insufficiency." J Clin Pharmacol 27 (1987):  782-7|Gladziwa U, Klotz U, Krishna DR, Schmitt H, Glockner WM, Mann H "Pharmacokinetics and dynamics of famotidine in patients with renal failure." Br J Clin Pharmacol 26 (1988):  315-21|Hachisu T, Yokoyama T, Oda Y, Ando K, Hattori Y, Yoshida T "Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure." Clin Ther 10 (1988):  656-63|Takabatake T, Ohta H, Maekawa M, Yamamoto Y, Ishida Y, Hara H, Nakamura S, Ushiogi Y, Kawabata M, Hashimoto N, et al. "Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function." Eur J Clin Pharmacol 28 (1985):  327-31|Kroemer H, Klotz U "Pharmacokinetics of famotidine in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  458-63|"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|Gladziwa U, Klotz U "Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure." Clin Pharmacokinet 27 (1994):  393-408', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51091, 6823, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', 'Halstenson CE, Abraham PA, Opsahl JA, Chremos AN, Keane WF, Matzke GR "Disposition of famotidine in renal insufficiency." J Clin Pharmacol 27 (1987):  782-7|Gladziwa U, Klotz U, Krishna DR, Schmitt H, Glockner WM, Mann H "Pharmacokinetics and dynamics of famotidine in patients with renal failure." Br J Clin Pharmacol 26 (1988):  315-21|Hachisu T, Yokoyama T, Oda Y, Ando K, Hattori Y, Yoshida T "Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure." Clin Ther 10 (1988):  656-63|Takabatake T, Ohta H, Maekawa M, Yamamoto Y, Ishida Y, Hara H, Nakamura S, Ushiogi Y, Kawabata M, Hashimoto N, et al. "Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function." Eur J Clin Pharmacol 28 (1985):  327-31|Kroemer H, Klotz U "Pharmacokinetics of famotidine in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  458-63|"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|Gladziwa U, Klotz U "Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure." Clin Pharmacokinet 27 (1994):  393-408', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51092, 6825, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', 'Halstenson CE, Abraham PA, Opsahl JA, Chremos AN, Keane WF, Matzke GR "Disposition of famotidine in renal insufficiency." J Clin Pharmacol 27 (1987):  782-7|Gladziwa U, Klotz U, Krishna DR, Schmitt H, Glockner WM, Mann H "Pharmacokinetics and dynamics of famotidine in patients with renal failure." Br J Clin Pharmacol 26 (1988):  315-21|Hachisu T, Yokoyama T, Oda Y, Ando K, Hattori Y, Yoshida T "Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure." Clin Ther 10 (1988):  656-63|Takabatake T, Ohta H, Maekawa M, Yamamoto Y, Ishida Y, Hara H, Nakamura S, Ushiogi Y, Kawabata M, Hashimoto N, et al. "Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function." Eur J Clin Pharmacol 28 (1985):  327-31|Kroemer H, Klotz U "Pharmacokinetics of famotidine in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  458-63|"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|Gladziwa U, Klotz U "Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure." Clin Pharmacokinet 27 (1994):  393-408', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51093, 10381, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', 'Halstenson CE, Abraham PA, Opsahl JA, Chremos AN, Keane WF, Matzke GR "Disposition of famotidine in renal insufficiency." J Clin Pharmacol 27 (1987):  782-7|Gladziwa U, Klotz U, Krishna DR, Schmitt H, Glockner WM, Mann H "Pharmacokinetics and dynamics of famotidine in patients with renal failure." Br J Clin Pharmacol 26 (1988):  315-21|Hachisu T, Yokoyama T, Oda Y, Ando K, Hattori Y, Yoshida T "Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure." Clin Ther 10 (1988):  656-63|Takabatake T, Ohta H, Maekawa M, Yamamoto Y, Ishida Y, Hara H, Nakamura S, Ushiogi Y, Kawabata M, Hashimoto N, et al. "Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function." Eur J Clin Pharmacol 28 (1985):  327-31|Kroemer H, Klotz U "Pharmacokinetics of famotidine in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  458-63|"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|Gladziwa U, Klotz U "Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure." Clin Pharmacokinet 27 (1994):  393-408', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51094, 11825, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', 'Halstenson CE, Abraham PA, Opsahl JA, Chremos AN, Keane WF, Matzke GR "Disposition of famotidine in renal insufficiency." J Clin Pharmacol 27 (1987):  782-7|Gladziwa U, Klotz U, Krishna DR, Schmitt H, Glockner WM, Mann H "Pharmacokinetics and dynamics of famotidine in patients with renal failure." Br J Clin Pharmacol 26 (1988):  315-21|Hachisu T, Yokoyama T, Oda Y, Ando K, Hattori Y, Yoshida T "Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure." Clin Ther 10 (1988):  656-63|Takabatake T, Ohta H, Maekawa M, Yamamoto Y, Ishida Y, Hara H, Nakamura S, Ushiogi Y, Kawabata M, Hashimoto N, et al. "Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function." Eur J Clin Pharmacol 28 (1985):  327-31|Kroemer H, Klotz U "Pharmacokinetics of famotidine in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  458-63|"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|Gladziwa U, Klotz U "Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure." Clin Pharmacokinet 27 (1994):  393-408', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51095, 14254, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', 'Halstenson CE, Abraham PA, Opsahl JA, Chremos AN, Keane WF, Matzke GR "Disposition of famotidine in renal insufficiency." J Clin Pharmacol 27 (1987):  782-7|Gladziwa U, Klotz U, Krishna DR, Schmitt H, Glockner WM, Mann H "Pharmacokinetics and dynamics of famotidine in patients with renal failure." Br J Clin Pharmacol 26 (1988):  315-21|Hachisu T, Yokoyama T, Oda Y, Ando K, Hattori Y, Yoshida T "Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure." Clin Ther 10 (1988):  656-63|Takabatake T, Ohta H, Maekawa M, Yamamoto Y, Ishida Y, Hara H, Nakamura S, Ushiogi Y, Kawabata M, Hashimoto N, et al. "Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function." Eur J Clin Pharmacol 28 (1985):  327-31|Kroemer H, Klotz U "Pharmacokinetics of famotidine in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  458-63|"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|Gladziwa U, Klotz U "Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure." Clin Pharmacokinet 27 (1994):  393-408', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51096, 14256, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', 'Halstenson CE, Abraham PA, Opsahl JA, Chremos AN, Keane WF, Matzke GR "Disposition of famotidine in renal insufficiency." J Clin Pharmacol 27 (1987):  782-7|Gladziwa U, Klotz U, Krishna DR, Schmitt H, Glockner WM, Mann H "Pharmacokinetics and dynamics of famotidine in patients with renal failure." Br J Clin Pharmacol 26 (1988):  315-21|Hachisu T, Yokoyama T, Oda Y, Ando K, Hattori Y, Yoshida T "Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure." Clin Ther 10 (1988):  656-63|Takabatake T, Ohta H, Maekawa M, Yamamoto Y, Ishida Y, Hara H, Nakamura S, Ushiogi Y, Kawabata M, Hashimoto N, et al. "Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function." Eur J Clin Pharmacol 28 (1985):  327-31|Kroemer H, Klotz U "Pharmacokinetics of famotidine in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  458-63|"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|Gladziwa U, Klotz U "Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure." Clin Pharmacokinet 27 (1994):  393-408', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51097, 14259, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', 'Halstenson CE, Abraham PA, Opsahl JA, Chremos AN, Keane WF, Matzke GR "Disposition of famotidine in renal insufficiency." J Clin Pharmacol 27 (1987):  782-7|Gladziwa U, Klotz U, Krishna DR, Schmitt H, Glockner WM, Mann H "Pharmacokinetics and dynamics of famotidine in patients with renal failure." Br J Clin Pharmacol 26 (1988):  315-21|Hachisu T, Yokoyama T, Oda Y, Ando K, Hattori Y, Yoshida T "Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure." Clin Ther 10 (1988):  656-63|Takabatake T, Ohta H, Maekawa M, Yamamoto Y, Ishida Y, Hara H, Nakamura S, Ushiogi Y, Kawabata M, Hashimoto N, et al. "Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function." Eur J Clin Pharmacol 28 (1985):  327-31|Kroemer H, Klotz U "Pharmacokinetics of famotidine in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  458-63|"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|Gladziwa U, Klotz U "Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure." Clin Pharmacokinet 27 (1994):  393-408', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51098, 18355, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', 'Halstenson CE, Abraham PA, Opsahl JA, Chremos AN, Keane WF, Matzke GR "Disposition of famotidine in renal insufficiency." J Clin Pharmacol 27 (1987):  782-7|Gladziwa U, Klotz U, Krishna DR, Schmitt H, Glockner WM, Mann H "Pharmacokinetics and dynamics of famotidine in patients with renal failure." Br J Clin Pharmacol 26 (1988):  315-21|Hachisu T, Yokoyama T, Oda Y, Ando K, Hattori Y, Yoshida T "Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure." Clin Ther 10 (1988):  656-63|Takabatake T, Ohta H, Maekawa M, Yamamoto Y, Ishida Y, Hara H, Nakamura S, Ushiogi Y, Kawabata M, Hashimoto N, et al. "Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function." Eur J Clin Pharmacol 28 (1985):  327-31|Kroemer H, Klotz U "Pharmacokinetics of famotidine in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  458-63|"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|Gladziwa U, Klotz U "Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure." Clin Pharmacokinet 27 (1994):  393-408', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51099, 19600, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', 'Halstenson CE, Abraham PA, Opsahl JA, Chremos AN, Keane WF, Matzke GR "Disposition of famotidine in renal insufficiency." J Clin Pharmacol 27 (1987):  782-7|Gladziwa U, Klotz U, Krishna DR, Schmitt H, Glockner WM, Mann H "Pharmacokinetics and dynamics of famotidine in patients with renal failure." Br J Clin Pharmacol 26 (1988):  315-21|Hachisu T, Yokoyama T, Oda Y, Ando K, Hattori Y, Yoshida T "Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure." Clin Ther 10 (1988):  656-63|Takabatake T, Ohta H, Maekawa M, Yamamoto Y, Ishida Y, Hara H, Nakamura S, Ushiogi Y, Kawabata M, Hashimoto N, et al. "Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function." Eur J Clin Pharmacol 28 (1985):  327-31|Kroemer H, Klotz U "Pharmacokinetics of famotidine in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  458-63|"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|Gladziwa U, Klotz U "Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure." Clin Pharmacokinet 27 (1994):  393-408', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51100, 19605, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', 'Halstenson CE, Abraham PA, Opsahl JA, Chremos AN, Keane WF, Matzke GR "Disposition of famotidine in renal insufficiency." J Clin Pharmacol 27 (1987):  782-7|Gladziwa U, Klotz U, Krishna DR, Schmitt H, Glockner WM, Mann H "Pharmacokinetics and dynamics of famotidine in patients with renal failure." Br J Clin Pharmacol 26 (1988):  315-21|Hachisu T, Yokoyama T, Oda Y, Ando K, Hattori Y, Yoshida T "Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure." Clin Ther 10 (1988):  656-63|Takabatake T, Ohta H, Maekawa M, Yamamoto Y, Ishida Y, Hara H, Nakamura S, Ushiogi Y, Kawabata M, Hashimoto N, et al. "Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function." Eur J Clin Pharmacol 28 (1985):  327-31|Kroemer H, Klotz U "Pharmacokinetics of famotidine in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  458-63|"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|Gladziwa U, Klotz U "Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure." Clin Pharmacokinet 27 (1994):  393-408', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51101, 24714, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', 'Halstenson CE, Abraham PA, Opsahl JA, Chremos AN, Keane WF, Matzke GR "Disposition of famotidine in renal insufficiency." J Clin Pharmacol 27 (1987):  782-7|Gladziwa U, Klotz U, Krishna DR, Schmitt H, Glockner WM, Mann H "Pharmacokinetics and dynamics of famotidine in patients with renal failure." Br J Clin Pharmacol 26 (1988):  315-21|Hachisu T, Yokoyama T, Oda Y, Ando K, Hattori Y, Yoshida T "Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure." Clin Ther 10 (1988):  656-63|Takabatake T, Ohta H, Maekawa M, Yamamoto Y, Ishida Y, Hara H, Nakamura S, Ushiogi Y, Kawabata M, Hashimoto N, et al. "Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function." Eur J Clin Pharmacol 28 (1985):  327-31|Kroemer H, Klotz U "Pharmacokinetics of famotidine in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  458-63|"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|Gladziwa U, Klotz U "Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure." Clin Pharmacokinet 27 (1994):  393-408', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51102, 24715, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', 'Halstenson CE, Abraham PA, Opsahl JA, Chremos AN, Keane WF, Matzke GR "Disposition of famotidine in renal insufficiency." J Clin Pharmacol 27 (1987):  782-7|Gladziwa U, Klotz U, Krishna DR, Schmitt H, Glockner WM, Mann H "Pharmacokinetics and dynamics of famotidine in patients with renal failure." Br J Clin Pharmacol 26 (1988):  315-21|Hachisu T, Yokoyama T, Oda Y, Ando K, Hattori Y, Yoshida T "Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure." Clin Ther 10 (1988):  656-63|Takabatake T, Ohta H, Maekawa M, Yamamoto Y, Ishida Y, Hara H, Nakamura S, Ushiogi Y, Kawabata M, Hashimoto N, et al. "Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function." Eur J Clin Pharmacol 28 (1985):  327-31|Kroemer H, Klotz U "Pharmacokinetics of famotidine in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  458-63|"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|Gladziwa U, Klotz U "Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure." Clin Pharmacokinet 27 (1994):  393-408', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51103, 24718, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', 'Halstenson CE, Abraham PA, Opsahl JA, Chremos AN, Keane WF, Matzke GR "Disposition of famotidine in renal insufficiency." J Clin Pharmacol 27 (1987):  782-7|Gladziwa U, Klotz U, Krishna DR, Schmitt H, Glockner WM, Mann H "Pharmacokinetics and dynamics of famotidine in patients with renal failure." Br J Clin Pharmacol 26 (1988):  315-21|Hachisu T, Yokoyama T, Oda Y, Ando K, Hattori Y, Yoshida T "Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure." Clin Ther 10 (1988):  656-63|Takabatake T, Ohta H, Maekawa M, Yamamoto Y, Ishida Y, Hara H, Nakamura S, Ushiogi Y, Kawabata M, Hashimoto N, et al. "Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function." Eur J Clin Pharmacol 28 (1985):  327-31|Kroemer H, Klotz U "Pharmacokinetics of famotidine in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  458-63|"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|Gladziwa U, Klotz U "Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure." Clin Pharmacokinet 27 (1994):  393-408', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51104, 26877, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', 'Halstenson CE, Abraham PA, Opsahl JA, Chremos AN, Keane WF, Matzke GR "Disposition of famotidine in renal insufficiency." J Clin Pharmacol 27 (1987):  782-7|Gladziwa U, Klotz U, Krishna DR, Schmitt H, Glockner WM, Mann H "Pharmacokinetics and dynamics of famotidine in patients with renal failure." Br J Clin Pharmacol 26 (1988):  315-21|Hachisu T, Yokoyama T, Oda Y, Ando K, Hattori Y, Yoshida T "Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure." Clin Ther 10 (1988):  656-63|Takabatake T, Ohta H, Maekawa M, Yamamoto Y, Ishida Y, Hara H, Nakamura S, Ushiogi Y, Kawabata M, Hashimoto N, et al. "Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function." Eur J Clin Pharmacol 28 (1985):  327-31|Kroemer H, Klotz U "Pharmacokinetics of famotidine in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  458-63|"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|Gladziwa U, Klotz U "Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure." Clin Pharmacokinet 27 (1994):  393-408', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51105, 0, 'Fedratinib', 'Liver Failure', 'The pharmacokinetics of fedratinib have not been evaluated in patients with severe hepatic impairment (total bilirubin > 3 times ULN and any AST), and its use should be avoided on these patients.', '3', '"Product Information. Inrebic (fedratinib)." Celgene Corporation  (2019):|"Product Information. Inrebic (fedratinib)." Bristol-Myers Squibb  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51106, 0, 'Fedratinib', 'Thiamine Deficiency', 'Serious and fatal encephalopathy, including Wernicke''s disease, has occurred in patients treated with fedratinib.  Wernicke''s encephalopathy is a neurologic emergency.  Assess thiamine levels in all patients prior to starting treatment, periodically during treatment, and as clinically indicated.  Do not start fedratinib in patients with thiamine deficiency; replete thiamine prior to treatment initiation.  If encephalopathy is suspected, immediately discontinue fedratinib and initiate parenteral thiamine.  Patients who develop any change in their mental status during treatment, including confusion or memory impairment, should be evaluated for potential encephalopathy (e.g., neurologic examination, thiamine level assessment, imaging).  Monitor until symptoms resolve or improve and thiamine levels normalize.', '3', '"Product Information. Inrebic (fedratinib)." Celgene Corporation  (2019):|"Product Information. Inrebic (fedratinib)." Bristol-Myers Squibb  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51107, 0, 'Fedratinib', 'Gastrointestinal Diseases', 'Gastrointestinal (GI) toxicities are the most frequent adverse reactions reported with fedratinib; diarrhea, nausea, and vomiting occurred in more than half of patients.  The median time to onset was 1 day, with 75% of cases occurring within 2 weeks of initiating therapy.  Consuming a high-fat meal with fedratinib may reduce GI adverse events.  Prophylactic antiemetic therapy (e.g., 5-HT3 receptor antagonists) should be considered.  Treat diarrhea with antidiarrheals at the first onset of symptoms.  For Grade 3 or higher nausea, vomiting, or diarrhea not responsive to supportive measures within 48 hours:  Interrupt this drug until resolved to Grade 1 or less or baseline; restart dose at 100 mg/day below the last given dose.', '3', '"Product Information. Inrebic (fedratinib)." Bristol-Myers Squibb  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51108, 0, 'Fedratinib', 'Cardiovascular Diseases', 'In a major safety study of a Janus kinase (JAK) inhibitor, tofacitinib, in rheumatoid arthritis patients 50 years and older with at least 1 cardiovascular risk factor, higher rates of all-cause mortality (including sudden cardiovascular death) and major adverse cardiovascular events (MACE) (defined as cardiovascular death, myocardial infarction, and stroke) were observed with the JAK inhibitor when compared with tumor necrosis factor (TNF) blockers; patients who are current or past smokers are at additional increased risk.  Based on a shared mechanism of action, this risk should be considered for other JAK inhibitors, including baricitinib, upadacitinib, ruxolitinib, fedratinib, and pacritinib.  Before starting or continuing therapy, the benefits and risks for the individual patient should be considered, especially in patients with other cardiovascular risk factors and patients who are current or past smokers.  Patients should be informed about the symptoms of serious cardiovascular events and what to do if they occur.  Tofacitinib, baricitinib, and upadacitinib are indicated for patients with inadequate response or intolerance to 1 or more TNF blockers, but should be discontinued in patients who have experienced a myocardial infarction or stroke.  The dosage recommended for tofacitinib should not be exceeded; for the treatment of ulcerative colitis, tofacitinib should be used at the lowest effective dose and for the shortest duration needed to achieve and/or maintain therapeutic response.', '3', '"Product Information. Jakafi (ruxolitinib)." Incyte Corporation  (2011):|"Product Information. Olumiant (baricitinib)." Lilly, Eli and Company  (2018):|"Product Information. Rinvoq (upadacitinib)." AbbVie US LLC  (2019):|"Product Information. Inrebic (fedratinib)." Celgene Corporation  (2019):|"Product Information. Vonjo (pacritinib)." CTI BioPharma Corp.  (2022):|"Product Information. Xeljanz (tofacitinib)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. Inrebic (fedratinib)." Bristol-Myers Squibb  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51109, 0, 'Fedratinib', 'Neoplasms', 'Malignancies (including lymphomas and solid tumors) have been reported in patients treated with tofacitinib and other Janus kinase (JAK) inhibitors used to treat inflammatory conditions; lymphomas and other malignancies have been seen in patients treated with baricitinib or upadacitinib.  Patients who are current or past smokers are at additional increased risk of malignancies.  Based on a shared mechanism of action, this risk should be considered for other JAK inhibitors, including ruxolitinib, pacritinib, and fedratinib.  Before starting or continuing therapy, the benefits and risks for the individual patient should be considered, especially in patients with a known malignancy (other than successfully treated nonmelanoma skin cancer), patients who develop a malignancy during therapy, and patients who are current or past smokers.  Periodic skin examination is recommended for patients who are at increased risk for skin cancer.', '3', '"Product Information. Jakafi (ruxolitinib)." Incyte Corporation  (2011):|"Product Information. Olumiant (baricitinib)." Lilly, Eli and Company  (2018):|"Product Information. Rinvoq (upadacitinib)." AbbVie US LLC  (2019):|"Product Information. Inrebic (fedratinib)." Celgene Corporation  (2019):|"Product Information. Vonjo (pacritinib)." CTI BioPharma Corp.  (2022):|"Product Information. Xeljanz (tofacitinib)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. Inrebic (fedratinib)." Bristol-Myers Squibb  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51110, 0, 'Fedratinib', 'Thrombosis', 'Thrombosis (including deep venous thrombosis, pulmonary embolism, and arterial thrombosis) has occurred in patients treated for inflammatory conditions with Janus kinase (JAK) inhibitors, including baricitinib, tofacitinib, and upadacitinib; many of these adverse events were serious and some resulted in death.  Based on a shared mechanism of action, this risk should be considered for other JAK inhibitors, including ruxolitinib, fedratinib, and pacritinib.  Baricitinib, pacritinib, tofacitinib, and upadacitinib should be avoided in patients who may be at increased risk of thrombosis; for the treatment of ulcerative colitis, tofacitinib should be used at the lowest effective dose and for the shortest duration needed to achieve/maintain therapeutic response.  If symptoms of thrombosis occur, baricitinib, pacritinib, tofacitinib, and upadacitinib should be discontinued and patients should be evaluated promptly and treated appropriately.', '3', '"Product Information. Jakafi (ruxolitinib)." Incyte Corporation  (2011):|"Product Information. Olumiant (baricitinib)." Lilly, Eli and Company  (2018):|"Product Information. Rinvoq (upadacitinib)." AbbVie US LLC  (2019):|"Product Information. Inrebic (fedratinib)." Celgene Corporation  (2019):|"Product Information. Vonjo (pacritinib)." CTI BioPharma Corp.  (2022):|"Product Information. Xeljanz (tofacitinib)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. Inrebic (fedratinib)." Bristol-Myers Squibb  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51111, 0, 'Fedratinib', 'Kidney Diseases', 'Due to potential increase of exposure, patients with preexisting-existing moderate renal impairment require more intensive safety monitoring, and if necessary, dose modifications based on adverse reactions when treated with fedratinib.  Reduce fedratinib dose when administered to patients with severe renal impairment (CrCl 15 mL/min to 29 mL/min by Cockcroft-Gault).  No modification of the starting dose is recommended for patients with mild to moderate renal impairment (CrCl 30 mL/min to 89 mL/min by Cockcroft-Gault).', '2', '"Product Information. Inrebic (fedratinib)." Celgene Corporation  (2019):|"Product Information. Inrebic (fedratinib)." Bristol-Myers Squibb  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51112, 0, 'Fedratinib', 'Cytopenias', 'Adverse hematologic effects including neutropenia, thrombocytopenia, and anemia have been associated with the use of fedratinib.  It is recommended to modify the starting dose in patients with a baseline platelet count (PLT) less than 50 x 10(9)/L.  Therapy should be interrupted until grade 4 thrombocytopenia, grade 3 thrombocytopenia with active bleeding, OR grade 4 neutropenia has normalized to grade 2 or lower (or baseline), then restart treatment at 100 mg/day below the last given dose.  Fedratinib dose reductions should be considered in patients who become dependent on red blood cell transfusions.  CBC counts should be monitored at baseline and every 3 months thereafter; treatment should be modified based on PLT levels and active bleeding.  Caution is recommended in patients who may be at increased risk.', '2', '"Product Information. Inrebic (fedratinib)." Bristol-Myers Squibb  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51113, 0, 'Fedratinib', 'Pancreatitis', 'Pancreatitis occurred in patients receiving fedratinib.  It is recommended to monitor lipase and amylase prior to the start of therapy with fedratinib and periodically thereafter as clinically indicated.  Therapy should be interrupted until grade 3 or higher elevations in amylase and/or lipase levels resolve to grade 1 or less (or baseline), then restart treatment at 100 mg/day below the last given dose.  Care is recommended when using this agent in patients at risk.', '2', '"Product Information. Inrebic (fedratinib)." Bristol-Myers Squibb  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51114, 18905, 'Felodipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996):  921-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51115, 18906, 'Felodipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996):  921-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51116, 18907, 'Felodipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996):  921-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51117, 18908, 'Felodipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996):  921-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51118, 18909, 'Felodipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996):  921-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51119, 18910, 'Felodipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996):  921-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51120, 20281, 'Felodipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996):  921-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51121, 25003, 'Felodipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996):  921-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51122, 25004, 'Felodipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996):  921-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51123, 25005, 'Felodipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996):  921-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51124, 25006, 'Felodipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996):  921-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51125, 25007, 'Felodipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996):  921-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51126, 25008, 'Felodipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996):  921-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51127, 18905, 'Felodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'Schanzenbacher P, Deeg P, Liebau G, Kochsiek K "Paradoxical angina after nifedipine: angiographic documentation." Am J Cardiol 53 (1984):  345-6|Manga P, Vythilingum "Unstable angina precipitated by nifedipine." S Afr Med J 66 (1984):  144|Sia STB, MacDonald PS, Triester B, et al. "Aggravation of myocardial ischaemia by nifedipine." Med J Aust 142 (1985):  48-50|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Lambert CR, Hill JA, Feldman RL, Pepine CJ "Myocardial ischemia during intravenous nicardipine administration." Am J Cardiol 55 (1985):  844-5|Thomassen AR, Bagger JP, Nielsen TT "Hemodynamic and cardiac metabolic changes during nicardipine-induced myocardial ischemia." Cathet Cardiovasc Diagn 14 (1988):  41-3|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|Furberg CD, Psaty BM, Meyer JV "Nifedipine: dose-related increase in mortality in patients with coronary heart disease." Circulation 92 (1995):  1326-31|Kloner RA "Nifedipine in ischemic heart disease." Circulation 92 (1995):  1074-8|Yusuf S "Calcium antagonists in coronary artery disease and hypertension: time for reevaluation?" Circulation 92 (1995):  1079-82|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Oei SG, Oei SK, Brolmann HAM "Myocardial infarction during nifedipine therapy for preterm labor." N Engl J Med 340 (1999):  154|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51128, 18906, 'Felodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'Schanzenbacher P, Deeg P, Liebau G, Kochsiek K "Paradoxical angina after nifedipine: angiographic documentation." Am J Cardiol 53 (1984):  345-6|Manga P, Vythilingum "Unstable angina precipitated by nifedipine." S Afr Med J 66 (1984):  144|Sia STB, MacDonald PS, Triester B, et al. "Aggravation of myocardial ischaemia by nifedipine." Med J Aust 142 (1985):  48-50|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Lambert CR, Hill JA, Feldman RL, Pepine CJ "Myocardial ischemia during intravenous nicardipine administration." Am J Cardiol 55 (1985):  844-5|Thomassen AR, Bagger JP, Nielsen TT "Hemodynamic and cardiac metabolic changes during nicardipine-induced myocardial ischemia." Cathet Cardiovasc Diagn 14 (1988):  41-3|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|Furberg CD, Psaty BM, Meyer JV "Nifedipine: dose-related increase in mortality in patients with coronary heart disease." Circulation 92 (1995):  1326-31|Kloner RA "Nifedipine in ischemic heart disease." Circulation 92 (1995):  1074-8|Yusuf S "Calcium antagonists in coronary artery disease and hypertension: time for reevaluation?" Circulation 92 (1995):  1079-82|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Oei SG, Oei SK, Brolmann HAM "Myocardial infarction during nifedipine therapy for preterm labor." N Engl J Med 340 (1999):  154|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51129, 18907, 'Felodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'Schanzenbacher P, Deeg P, Liebau G, Kochsiek K "Paradoxical angina after nifedipine: angiographic documentation." Am J Cardiol 53 (1984):  345-6|Manga P, Vythilingum "Unstable angina precipitated by nifedipine." S Afr Med J 66 (1984):  144|Sia STB, MacDonald PS, Triester B, et al. "Aggravation of myocardial ischaemia by nifedipine." Med J Aust 142 (1985):  48-50|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Lambert CR, Hill JA, Feldman RL, Pepine CJ "Myocardial ischemia during intravenous nicardipine administration." Am J Cardiol 55 (1985):  844-5|Thomassen AR, Bagger JP, Nielsen TT "Hemodynamic and cardiac metabolic changes during nicardipine-induced myocardial ischemia." Cathet Cardiovasc Diagn 14 (1988):  41-3|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|Furberg CD, Psaty BM, Meyer JV "Nifedipine: dose-related increase in mortality in patients with coronary heart disease." Circulation 92 (1995):  1326-31|Kloner RA "Nifedipine in ischemic heart disease." Circulation 92 (1995):  1074-8|Yusuf S "Calcium antagonists in coronary artery disease and hypertension: time for reevaluation?" Circulation 92 (1995):  1079-82|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Oei SG, Oei SK, Brolmann HAM "Myocardial infarction during nifedipine therapy for preterm labor." N Engl J Med 340 (1999):  154|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51130, 18908, 'Felodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'Schanzenbacher P, Deeg P, Liebau G, Kochsiek K "Paradoxical angina after nifedipine: angiographic documentation." Am J Cardiol 53 (1984):  345-6|Manga P, Vythilingum "Unstable angina precipitated by nifedipine." S Afr Med J 66 (1984):  144|Sia STB, MacDonald PS, Triester B, et al. "Aggravation of myocardial ischaemia by nifedipine." Med J Aust 142 (1985):  48-50|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Lambert CR, Hill JA, Feldman RL, Pepine CJ "Myocardial ischemia during intravenous nicardipine administration." Am J Cardiol 55 (1985):  844-5|Thomassen AR, Bagger JP, Nielsen TT "Hemodynamic and cardiac metabolic changes during nicardipine-induced myocardial ischemia." Cathet Cardiovasc Diagn 14 (1988):  41-3|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|Furberg CD, Psaty BM, Meyer JV "Nifedipine: dose-related increase in mortality in patients with coronary heart disease." Circulation 92 (1995):  1326-31|Kloner RA "Nifedipine in ischemic heart disease." Circulation 92 (1995):  1074-8|Yusuf S "Calcium antagonists in coronary artery disease and hypertension: time for reevaluation?" Circulation 92 (1995):  1079-82|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Oei SG, Oei SK, Brolmann HAM "Myocardial infarction during nifedipine therapy for preterm labor." N Engl J Med 340 (1999):  154|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51131, 18909, 'Felodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'Schanzenbacher P, Deeg P, Liebau G, Kochsiek K "Paradoxical angina after nifedipine: angiographic documentation." Am J Cardiol 53 (1984):  345-6|Manga P, Vythilingum "Unstable angina precipitated by nifedipine." S Afr Med J 66 (1984):  144|Sia STB, MacDonald PS, Triester B, et al. "Aggravation of myocardial ischaemia by nifedipine." Med J Aust 142 (1985):  48-50|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Lambert CR, Hill JA, Feldman RL, Pepine CJ "Myocardial ischemia during intravenous nicardipine administration." Am J Cardiol 55 (1985):  844-5|Thomassen AR, Bagger JP, Nielsen TT "Hemodynamic and cardiac metabolic changes during nicardipine-induced myocardial ischemia." Cathet Cardiovasc Diagn 14 (1988):  41-3|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|Furberg CD, Psaty BM, Meyer JV "Nifedipine: dose-related increase in mortality in patients with coronary heart disease." Circulation 92 (1995):  1326-31|Kloner RA "Nifedipine in ischemic heart disease." Circulation 92 (1995):  1074-8|Yusuf S "Calcium antagonists in coronary artery disease and hypertension: time for reevaluation?" Circulation 92 (1995):  1079-82|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Oei SG, Oei SK, Brolmann HAM "Myocardial infarction during nifedipine therapy for preterm labor." N Engl J Med 340 (1999):  154|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51132, 18910, 'Felodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'Schanzenbacher P, Deeg P, Liebau G, Kochsiek K "Paradoxical angina after nifedipine: angiographic documentation." Am J Cardiol 53 (1984):  345-6|Manga P, Vythilingum "Unstable angina precipitated by nifedipine." S Afr Med J 66 (1984):  144|Sia STB, MacDonald PS, Triester B, et al. "Aggravation of myocardial ischaemia by nifedipine." Med J Aust 142 (1985):  48-50|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Lambert CR, Hill JA, Feldman RL, Pepine CJ "Myocardial ischemia during intravenous nicardipine administration." Am J Cardiol 55 (1985):  844-5|Thomassen AR, Bagger JP, Nielsen TT "Hemodynamic and cardiac metabolic changes during nicardipine-induced myocardial ischemia." Cathet Cardiovasc Diagn 14 (1988):  41-3|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|Furberg CD, Psaty BM, Meyer JV "Nifedipine: dose-related increase in mortality in patients with coronary heart disease." Circulation 92 (1995):  1326-31|Kloner RA "Nifedipine in ischemic heart disease." Circulation 92 (1995):  1074-8|Yusuf S "Calcium antagonists in coronary artery disease and hypertension: time for reevaluation?" Circulation 92 (1995):  1079-82|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Oei SG, Oei SK, Brolmann HAM "Myocardial infarction during nifedipine therapy for preterm labor." N Engl J Med 340 (1999):  154|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51133, 20281, 'Felodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'Schanzenbacher P, Deeg P, Liebau G, Kochsiek K "Paradoxical angina after nifedipine: angiographic documentation." Am J Cardiol 53 (1984):  345-6|Manga P, Vythilingum "Unstable angina precipitated by nifedipine." S Afr Med J 66 (1984):  144|Sia STB, MacDonald PS, Triester B, et al. "Aggravation of myocardial ischaemia by nifedipine." Med J Aust 142 (1985):  48-50|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Lambert CR, Hill JA, Feldman RL, Pepine CJ "Myocardial ischemia during intravenous nicardipine administration." Am J Cardiol 55 (1985):  844-5|Thomassen AR, Bagger JP, Nielsen TT "Hemodynamic and cardiac metabolic changes during nicardipine-induced myocardial ischemia." Cathet Cardiovasc Diagn 14 (1988):  41-3|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|Furberg CD, Psaty BM, Meyer JV "Nifedipine: dose-related increase in mortality in patients with coronary heart disease." Circulation 92 (1995):  1326-31|Kloner RA "Nifedipine in ischemic heart disease." Circulation 92 (1995):  1074-8|Yusuf S "Calcium antagonists in coronary artery disease and hypertension: time for reevaluation?" Circulation 92 (1995):  1079-82|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Oei SG, Oei SK, Brolmann HAM "Myocardial infarction during nifedipine therapy for preterm labor." N Engl J Med 340 (1999):  154|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51134, 25003, 'Felodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'Schanzenbacher P, Deeg P, Liebau G, Kochsiek K "Paradoxical angina after nifedipine: angiographic documentation." Am J Cardiol 53 (1984):  345-6|Manga P, Vythilingum "Unstable angina precipitated by nifedipine." S Afr Med J 66 (1984):  144|Sia STB, MacDonald PS, Triester B, et al. "Aggravation of myocardial ischaemia by nifedipine." Med J Aust 142 (1985):  48-50|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Lambert CR, Hill JA, Feldman RL, Pepine CJ "Myocardial ischemia during intravenous nicardipine administration." Am J Cardiol 55 (1985):  844-5|Thomassen AR, Bagger JP, Nielsen TT "Hemodynamic and cardiac metabolic changes during nicardipine-induced myocardial ischemia." Cathet Cardiovasc Diagn 14 (1988):  41-3|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|Furberg CD, Psaty BM, Meyer JV "Nifedipine: dose-related increase in mortality in patients with coronary heart disease." Circulation 92 (1995):  1326-31|Kloner RA "Nifedipine in ischemic heart disease." Circulation 92 (1995):  1074-8|Yusuf S "Calcium antagonists in coronary artery disease and hypertension: time for reevaluation?" Circulation 92 (1995):  1079-82|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Oei SG, Oei SK, Brolmann HAM "Myocardial infarction during nifedipine therapy for preterm labor." N Engl J Med 340 (1999):  154|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51135, 25004, 'Felodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'Schanzenbacher P, Deeg P, Liebau G, Kochsiek K "Paradoxical angina after nifedipine: angiographic documentation." Am J Cardiol 53 (1984):  345-6|Manga P, Vythilingum "Unstable angina precipitated by nifedipine." S Afr Med J 66 (1984):  144|Sia STB, MacDonald PS, Triester B, et al. "Aggravation of myocardial ischaemia by nifedipine." Med J Aust 142 (1985):  48-50|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Lambert CR, Hill JA, Feldman RL, Pepine CJ "Myocardial ischemia during intravenous nicardipine administration." Am J Cardiol 55 (1985):  844-5|Thomassen AR, Bagger JP, Nielsen TT "Hemodynamic and cardiac metabolic changes during nicardipine-induced myocardial ischemia." Cathet Cardiovasc Diagn 14 (1988):  41-3|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|Furberg CD, Psaty BM, Meyer JV "Nifedipine: dose-related increase in mortality in patients with coronary heart disease." Circulation 92 (1995):  1326-31|Kloner RA "Nifedipine in ischemic heart disease." Circulation 92 (1995):  1074-8|Yusuf S "Calcium antagonists in coronary artery disease and hypertension: time for reevaluation?" Circulation 92 (1995):  1079-82|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Oei SG, Oei SK, Brolmann HAM "Myocardial infarction during nifedipine therapy for preterm labor." N Engl J Med 340 (1999):  154|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51136, 25005, 'Felodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'Schanzenbacher P, Deeg P, Liebau G, Kochsiek K "Paradoxical angina after nifedipine: angiographic documentation." Am J Cardiol 53 (1984):  345-6|Manga P, Vythilingum "Unstable angina precipitated by nifedipine." S Afr Med J 66 (1984):  144|Sia STB, MacDonald PS, Triester B, et al. "Aggravation of myocardial ischaemia by nifedipine." Med J Aust 142 (1985):  48-50|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Lambert CR, Hill JA, Feldman RL, Pepine CJ "Myocardial ischemia during intravenous nicardipine administration." Am J Cardiol 55 (1985):  844-5|Thomassen AR, Bagger JP, Nielsen TT "Hemodynamic and cardiac metabolic changes during nicardipine-induced myocardial ischemia." Cathet Cardiovasc Diagn 14 (1988):  41-3|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|Furberg CD, Psaty BM, Meyer JV "Nifedipine: dose-related increase in mortality in patients with coronary heart disease." Circulation 92 (1995):  1326-31|Kloner RA "Nifedipine in ischemic heart disease." Circulation 92 (1995):  1074-8|Yusuf S "Calcium antagonists in coronary artery disease and hypertension: time for reevaluation?" Circulation 92 (1995):  1079-82|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Oei SG, Oei SK, Brolmann HAM "Myocardial infarction during nifedipine therapy for preterm labor." N Engl J Med 340 (1999):  154|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51137, 25006, 'Felodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'Schanzenbacher P, Deeg P, Liebau G, Kochsiek K "Paradoxical angina after nifedipine: angiographic documentation." Am J Cardiol 53 (1984):  345-6|Manga P, Vythilingum "Unstable angina precipitated by nifedipine." S Afr Med J 66 (1984):  144|Sia STB, MacDonald PS, Triester B, et al. "Aggravation of myocardial ischaemia by nifedipine." Med J Aust 142 (1985):  48-50|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Lambert CR, Hill JA, Feldman RL, Pepine CJ "Myocardial ischemia during intravenous nicardipine administration." Am J Cardiol 55 (1985):  844-5|Thomassen AR, Bagger JP, Nielsen TT "Hemodynamic and cardiac metabolic changes during nicardipine-induced myocardial ischemia." Cathet Cardiovasc Diagn 14 (1988):  41-3|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|Furberg CD, Psaty BM, Meyer JV "Nifedipine: dose-related increase in mortality in patients with coronary heart disease." Circulation 92 (1995):  1326-31|Kloner RA "Nifedipine in ischemic heart disease." Circulation 92 (1995):  1074-8|Yusuf S "Calcium antagonists in coronary artery disease and hypertension: time for reevaluation?" Circulation 92 (1995):  1079-82|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Oei SG, Oei SK, Brolmann HAM "Myocardial infarction during nifedipine therapy for preterm labor." N Engl J Med 340 (1999):  154|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51138, 25007, 'Felodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'Schanzenbacher P, Deeg P, Liebau G, Kochsiek K "Paradoxical angina after nifedipine: angiographic documentation." Am J Cardiol 53 (1984):  345-6|Manga P, Vythilingum "Unstable angina precipitated by nifedipine." S Afr Med J 66 (1984):  144|Sia STB, MacDonald PS, Triester B, et al. "Aggravation of myocardial ischaemia by nifedipine." Med J Aust 142 (1985):  48-50|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Lambert CR, Hill JA, Feldman RL, Pepine CJ "Myocardial ischemia during intravenous nicardipine administration." Am J Cardiol 55 (1985):  844-5|Thomassen AR, Bagger JP, Nielsen TT "Hemodynamic and cardiac metabolic changes during nicardipine-induced myocardial ischemia." Cathet Cardiovasc Diagn 14 (1988):  41-3|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|Furberg CD, Psaty BM, Meyer JV "Nifedipine: dose-related increase in mortality in patients with coronary heart disease." Circulation 92 (1995):  1326-31|Kloner RA "Nifedipine in ischemic heart disease." Circulation 92 (1995):  1074-8|Yusuf S "Calcium antagonists in coronary artery disease and hypertension: time for reevaluation?" Circulation 92 (1995):  1079-82|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Oei SG, Oei SK, Brolmann HAM "Myocardial infarction during nifedipine therapy for preterm labor." N Engl J Med 340 (1999):  154|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51139, 25008, 'Felodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'Schanzenbacher P, Deeg P, Liebau G, Kochsiek K "Paradoxical angina after nifedipine: angiographic documentation." Am J Cardiol 53 (1984):  345-6|Manga P, Vythilingum "Unstable angina precipitated by nifedipine." S Afr Med J 66 (1984):  144|Sia STB, MacDonald PS, Triester B, et al. "Aggravation of myocardial ischaemia by nifedipine." Med J Aust 142 (1985):  48-50|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Lambert CR, Hill JA, Feldman RL, Pepine CJ "Myocardial ischemia during intravenous nicardipine administration." Am J Cardiol 55 (1985):  844-5|Thomassen AR, Bagger JP, Nielsen TT "Hemodynamic and cardiac metabolic changes during nicardipine-induced myocardial ischemia." Cathet Cardiovasc Diagn 14 (1988):  41-3|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|Furberg CD, Psaty BM, Meyer JV "Nifedipine: dose-related increase in mortality in patients with coronary heart disease." Circulation 92 (1995):  1326-31|Kloner RA "Nifedipine in ischemic heart disease." Circulation 92 (1995):  1074-8|Yusuf S "Calcium antagonists in coronary artery disease and hypertension: time for reevaluation?" Circulation 92 (1995):  1079-82|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Oei SG, Oei SK, Brolmann HAM "Myocardial infarction during nifedipine therapy for preterm labor." N Engl J Med 340 (1999):  154|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51140, 18905, 'Felodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'Echizen H, Eichelbaum M "Clinical pharmacokinetics of verapamil, nifedipine and diltiazem." Clin Pharmacokinet 11 (1986):  425-49|Saracheck NS, London RL, Matulewicz TJ, et al. "Diltiazem and granulomatous hepatitis." Gastroenterology 88 (1985):  1260-2|Shallcross H, Padley SP, Glynn MJ, Gibbs DD "Fatal renal and hepatic toxicity after treatment with diltiazem." Br Med J 295 (1987):  1256-7|Colombo G, Zucchella G, Planca E, Grieco A "Intravenous diltiazem in the treatment of unstable angina: a study of efficacy and tolerance." Clin Ther 9 (1987):  536-47|Toft E, Vyberg M, Therkelsen K "Diltiazem-induced granulomatous hepatitis." Histopathology 18 (1991):  474-5|Abramson M, Littlejohn GO "Hepatic reactions to nifedipine." Med J Aust 142 (1985):  47-8|Toner M, White A, Moriarty J, Clancy L "Allergic urticarial eruption, leukocytosis and abnormal liver function tests following nifedipine administration." Chest 93 (1988):  1320-1|Babany G, Uzzan F, Larrey D, et al. "Alcoholic-like liver lesions induced by nifedipine." J Hepatol 9 (1989):  252-5|Brodsky SJ, Cutler SS, Weiner DA, Klein MD "Hepatotoxicity due to treatment with verapamil." Ann Intern Med 94 (1981):  490-1|Somogyi A, Albrecht M, Kliems G, et al. "Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis." Br J Clin Pharmacol 12 (1981):  51-60|Woodcock BG, Rietbrock I, Vohringer HF, Rietbrock N "Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships." Clin Pharmacol Ther 29 (1981):  27-34|Woodcock BG, Rietbrock N "Verapamil bioavailability and dosage in liver disease." Br J Clin Pharmacol 13 (1982):  240-1|Stern EH, Pitchon R, King BD, Wiener I "Possible hepatitis from verapamil." N Engl J Med 306 (1982):  612-3|Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|Hare DL, Horowitz JD "Verapamil hepatotoxicity: a hypersensitivity reaction." Am Heart J 111 (1986):  610-11|Guarascio P, D''Amato C, Sette P, et al. "Liver damage from verapamil." Br Med J 288 (1984):  362-3|Dow RJ, Graham DJM "A reveiw of the human metabolism and pharmacokinetics of nicardipine hydrochloride." Br J Clin Pharmacol 22 (1986):  s195-202|McAllister RG Jr, Hamann SR, Blouin RA "Pharmacokinetics of calcium-entry blockers." Am J Cardiol 55 (1985):  b30-40|Kates RE "Calcium antagonists: pharmacokinetic properties." Drugs 25 (1983):  113-24|Finucci GF, Padrini R, Piovan D, et al. "Verapamil pharmacokinetics and liver function in patients with cirrhosis." Int J Clin Pharmacol Res 8 (1988):  123-6|Giacomini KM, Massoud N, Wong FM, Giacomini JC "Decreased binding of verapamil to plasma proteins in patients with liver disease." J Cardiovasc Pharmacol 6 (1984):  924-8|Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Louis WJ "The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine." Clin Pharmacol Ther 47 (1990):  463-9|Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, Graham DJ "The metabolism of nicardipine hydrochloride in healthy male volunteers." Xenobiotica 16 (1986):  341-9|Benet LZ "Pharmacokinetics and metabolism of bepridil." Am J Cardiol 55 (1985):  c8-13|Kurosawa S, Kurosawa N, Owada E, et al. "Pharmacokinetics of diltiazem in patients with liver cirrhosis." Int J Clin Pharmacol Res 10 (1990):  311-8|Elliott HL, Meredith PA "The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine." Postgrad Med J 67 (1991):  s20-3|Stopher DA, Beresford AP, Macrae PV, Humphrey MJ "The metabolism and pharmacokinetics of amlodipine in humans and animals." J Cardiovasc Pharmacol 12 (1988):  s55-9|Kleinbloesem CH, van Harten J, Wilson JP, et al. "Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration." Clin Pharmacol Ther 40 (1986):  21-8|Raemsch KD, Sommer J "Pharmacokinetics and metabolism of nifedipine." Hypertension 5 (1983):  18-24|Ramsch KD, Graefe KH, Scherling D, et al. "Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine." Am J Nephrol 6 (1986):  73-80|Challenor VF, Waller DG, Renwick AG, et al. "The trans-hepatic extraction of nifedipine." Br J Clin Pharmacol 24 (1987):  473-7|Dunselman PH, Edgar B "Felodipine clinical pharmacokinetics." Clin Pharmacokinet 21 (1991):  418-30|Regardh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C "Pharmacokinetics of felodipine in patients with liver disease." Eur J Clin Pharmacol 36 (1989):  473-9|Cotting J, Reichen J, Kutz K, Laplanche R, Nuesch E "Pharmacokinetics of isradipine in patients with chronic liver disease." Eur J Clin Pharmacol 38 (1990):  599-603|Tse FL, Jaffe JM "Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man." Eur J Clin Pharmacol 32 (1987):  361-5|Graham D, Dow R, Hall D, Alexander O, Mroszczak E, Freedman A "The metabolism and pharmacokinetics of nicardipine hydrochloride in man." Br J Clin Pharmacol 20 (1985):  s23-8|Gengo FM, Fagan SC, Krol G, Bernhard H "Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls." Br J Clin Pharmacol 23 (1987):  47-53|Meredith P, Elliott H "Clinical pharmacokinetics of amlodipine." Clin Pharmacokinet 22 (1992):  22-31|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Johnson KE, Balderston SM, Pieper JA, Mann DE, Reiter MJ "Electrophysiologic effects of verapamil metabolites in the isolated heart." J Cardiovasc Pharmacol 17 (1991):  830-7|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Kumar KL, Colley CA "Verapamil-induced hepatotoxicity." West J Med 160 (1994):  485-6|Traverse JH, Swenson LJ, Mcbride JW "Acute hepatic injury after treatment with diltiazem." Am Heart J 127 (1994):  1636-9|Scherling D, Karl W, Ahr G, Ahr HJ, Wehinger E "Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man." Arzneimittelforschung 38 (1988):  1105-10|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57|"Product Information. Conjupri (levamlodipine)." CSPC Ouyi Pharmaceutical Co, Ltd  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51141, 18906, 'Felodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'Echizen H, Eichelbaum M "Clinical pharmacokinetics of verapamil, nifedipine and diltiazem." Clin Pharmacokinet 11 (1986):  425-49|Saracheck NS, London RL, Matulewicz TJ, et al. "Diltiazem and granulomatous hepatitis." Gastroenterology 88 (1985):  1260-2|Shallcross H, Padley SP, Glynn MJ, Gibbs DD "Fatal renal and hepatic toxicity after treatment with diltiazem." Br Med J 295 (1987):  1256-7|Colombo G, Zucchella G, Planca E, Grieco A "Intravenous diltiazem in the treatment of unstable angina: a study of efficacy and tolerance." Clin Ther 9 (1987):  536-47|Toft E, Vyberg M, Therkelsen K "Diltiazem-induced granulomatous hepatitis." Histopathology 18 (1991):  474-5|Abramson M, Littlejohn GO "Hepatic reactions to nifedipine." Med J Aust 142 (1985):  47-8|Toner M, White A, Moriarty J, Clancy L "Allergic urticarial eruption, leukocytosis and abnormal liver function tests following nifedipine administration." Chest 93 (1988):  1320-1|Babany G, Uzzan F, Larrey D, et al. "Alcoholic-like liver lesions induced by nifedipine." J Hepatol 9 (1989):  252-5|Brodsky SJ, Cutler SS, Weiner DA, Klein MD "Hepatotoxicity due to treatment with verapamil." Ann Intern Med 94 (1981):  490-1|Somogyi A, Albrecht M, Kliems G, et al. "Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis." Br J Clin Pharmacol 12 (1981):  51-60|Woodcock BG, Rietbrock I, Vohringer HF, Rietbrock N "Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships." Clin Pharmacol Ther 29 (1981):  27-34|Woodcock BG, Rietbrock N "Verapamil bioavailability and dosage in liver disease." Br J Clin Pharmacol 13 (1982):  240-1|Stern EH, Pitchon R, King BD, Wiener I "Possible hepatitis from verapamil." N Engl J Med 306 (1982):  612-3|Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|Hare DL, Horowitz JD "Verapamil hepatotoxicity: a hypersensitivity reaction." Am Heart J 111 (1986):  610-11|Guarascio P, D''Amato C, Sette P, et al. "Liver damage from verapamil." Br Med J 288 (1984):  362-3|Dow RJ, Graham DJM "A reveiw of the human metabolism and pharmacokinetics of nicardipine hydrochloride." Br J Clin Pharmacol 22 (1986):  s195-202|McAllister RG Jr, Hamann SR, Blouin RA "Pharmacokinetics of calcium-entry blockers." Am J Cardiol 55 (1985):  b30-40|Kates RE "Calcium antagonists: pharmacokinetic properties." Drugs 25 (1983):  113-24|Finucci GF, Padrini R, Piovan D, et al. "Verapamil pharmacokinetics and liver function in patients with cirrhosis." Int J Clin Pharmacol Res 8 (1988):  123-6|Giacomini KM, Massoud N, Wong FM, Giacomini JC "Decreased binding of verapamil to plasma proteins in patients with liver disease." J Cardiovasc Pharmacol 6 (1984):  924-8|Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Louis WJ "The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine." Clin Pharmacol Ther 47 (1990):  463-9|Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, Graham DJ "The metabolism of nicardipine hydrochloride in healthy male volunteers." Xenobiotica 16 (1986):  341-9|Benet LZ "Pharmacokinetics and metabolism of bepridil." Am J Cardiol 55 (1985):  c8-13|Kurosawa S, Kurosawa N, Owada E, et al. "Pharmacokinetics of diltiazem in patients with liver cirrhosis." Int J Clin Pharmacol Res 10 (1990):  311-8|Elliott HL, Meredith PA "The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine." Postgrad Med J 67 (1991):  s20-3|Stopher DA, Beresford AP, Macrae PV, Humphrey MJ "The metabolism and pharmacokinetics of amlodipine in humans and animals." J Cardiovasc Pharmacol 12 (1988):  s55-9|Kleinbloesem CH, van Harten J, Wilson JP, et al. "Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration." Clin Pharmacol Ther 40 (1986):  21-8|Raemsch KD, Sommer J "Pharmacokinetics and metabolism of nifedipine." Hypertension 5 (1983):  18-24|Ramsch KD, Graefe KH, Scherling D, et al. "Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine." Am J Nephrol 6 (1986):  73-80|Challenor VF, Waller DG, Renwick AG, et al. "The trans-hepatic extraction of nifedipine." Br J Clin Pharmacol 24 (1987):  473-7|Dunselman PH, Edgar B "Felodipine clinical pharmacokinetics." Clin Pharmacokinet 21 (1991):  418-30|Regardh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C "Pharmacokinetics of felodipine in patients with liver disease." Eur J Clin Pharmacol 36 (1989):  473-9|Cotting J, Reichen J, Kutz K, Laplanche R, Nuesch E "Pharmacokinetics of isradipine in patients with chronic liver disease." Eur J Clin Pharmacol 38 (1990):  599-603|Tse FL, Jaffe JM "Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man." Eur J Clin Pharmacol 32 (1987):  361-5|Graham D, Dow R, Hall D, Alexander O, Mroszczak E, Freedman A "The metabolism and pharmacokinetics of nicardipine hydrochloride in man." Br J Clin Pharmacol 20 (1985):  s23-8|Gengo FM, Fagan SC, Krol G, Bernhard H "Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls." Br J Clin Pharmacol 23 (1987):  47-53|Meredith P, Elliott H "Clinical pharmacokinetics of amlodipine." Clin Pharmacokinet 22 (1992):  22-31|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Johnson KE, Balderston SM, Pieper JA, Mann DE, Reiter MJ "Electrophysiologic effects of verapamil metabolites in the isolated heart." J Cardiovasc Pharmacol 17 (1991):  830-7|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Kumar KL, Colley CA "Verapamil-induced hepatotoxicity." West J Med 160 (1994):  485-6|Traverse JH, Swenson LJ, Mcbride JW "Acute hepatic injury after treatment with diltiazem." Am Heart J 127 (1994):  1636-9|Scherling D, Karl W, Ahr G, Ahr HJ, Wehinger E "Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man." Arzneimittelforschung 38 (1988):  1105-10|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57|"Product Information. Conjupri (levamlodipine)." CSPC Ouyi Pharmaceutical Co, Ltd  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51142, 18907, 'Felodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'Echizen H, Eichelbaum M "Clinical pharmacokinetics of verapamil, nifedipine and diltiazem." Clin Pharmacokinet 11 (1986):  425-49|Saracheck NS, London RL, Matulewicz TJ, et al. "Diltiazem and granulomatous hepatitis." Gastroenterology 88 (1985):  1260-2|Shallcross H, Padley SP, Glynn MJ, Gibbs DD "Fatal renal and hepatic toxicity after treatment with diltiazem." Br Med J 295 (1987):  1256-7|Colombo G, Zucchella G, Planca E, Grieco A "Intravenous diltiazem in the treatment of unstable angina: a study of efficacy and tolerance." Clin Ther 9 (1987):  536-47|Toft E, Vyberg M, Therkelsen K "Diltiazem-induced granulomatous hepatitis." Histopathology 18 (1991):  474-5|Abramson M, Littlejohn GO "Hepatic reactions to nifedipine." Med J Aust 142 (1985):  47-8|Toner M, White A, Moriarty J, Clancy L "Allergic urticarial eruption, leukocytosis and abnormal liver function tests following nifedipine administration." Chest 93 (1988):  1320-1|Babany G, Uzzan F, Larrey D, et al. "Alcoholic-like liver lesions induced by nifedipine." J Hepatol 9 (1989):  252-5|Brodsky SJ, Cutler SS, Weiner DA, Klein MD "Hepatotoxicity due to treatment with verapamil." Ann Intern Med 94 (1981):  490-1|Somogyi A, Albrecht M, Kliems G, et al. "Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis." Br J Clin Pharmacol 12 (1981):  51-60|Woodcock BG, Rietbrock I, Vohringer HF, Rietbrock N "Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships." Clin Pharmacol Ther 29 (1981):  27-34|Woodcock BG, Rietbrock N "Verapamil bioavailability and dosage in liver disease." Br J Clin Pharmacol 13 (1982):  240-1|Stern EH, Pitchon R, King BD, Wiener I "Possible hepatitis from verapamil." N Engl J Med 306 (1982):  612-3|Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|Hare DL, Horowitz JD "Verapamil hepatotoxicity: a hypersensitivity reaction." Am Heart J 111 (1986):  610-11|Guarascio P, D''Amato C, Sette P, et al. "Liver damage from verapamil." Br Med J 288 (1984):  362-3|Dow RJ, Graham DJM "A reveiw of the human metabolism and pharmacokinetics of nicardipine hydrochloride." Br J Clin Pharmacol 22 (1986):  s195-202|McAllister RG Jr, Hamann SR, Blouin RA "Pharmacokinetics of calcium-entry blockers." Am J Cardiol 55 (1985):  b30-40|Kates RE "Calcium antagonists: pharmacokinetic properties." Drugs 25 (1983):  113-24|Finucci GF, Padrini R, Piovan D, et al. "Verapamil pharmacokinetics and liver function in patients with cirrhosis." Int J Clin Pharmacol Res 8 (1988):  123-6|Giacomini KM, Massoud N, Wong FM, Giacomini JC "Decreased binding of verapamil to plasma proteins in patients with liver disease." J Cardiovasc Pharmacol 6 (1984):  924-8|Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Louis WJ "The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine." Clin Pharmacol Ther 47 (1990):  463-9|Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, Graham DJ "The metabolism of nicardipine hydrochloride in healthy male volunteers." Xenobiotica 16 (1986):  341-9|Benet LZ "Pharmacokinetics and metabolism of bepridil." Am J Cardiol 55 (1985):  c8-13|Kurosawa S, Kurosawa N, Owada E, et al. "Pharmacokinetics of diltiazem in patients with liver cirrhosis." Int J Clin Pharmacol Res 10 (1990):  311-8|Elliott HL, Meredith PA "The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine." Postgrad Med J 67 (1991):  s20-3|Stopher DA, Beresford AP, Macrae PV, Humphrey MJ "The metabolism and pharmacokinetics of amlodipine in humans and animals." J Cardiovasc Pharmacol 12 (1988):  s55-9|Kleinbloesem CH, van Harten J, Wilson JP, et al. "Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration." Clin Pharmacol Ther 40 (1986):  21-8|Raemsch KD, Sommer J "Pharmacokinetics and metabolism of nifedipine." Hypertension 5 (1983):  18-24|Ramsch KD, Graefe KH, Scherling D, et al. "Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine." Am J Nephrol 6 (1986):  73-80|Challenor VF, Waller DG, Renwick AG, et al. "The trans-hepatic extraction of nifedipine." Br J Clin Pharmacol 24 (1987):  473-7|Dunselman PH, Edgar B "Felodipine clinical pharmacokinetics." Clin Pharmacokinet 21 (1991):  418-30|Regardh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C "Pharmacokinetics of felodipine in patients with liver disease." Eur J Clin Pharmacol 36 (1989):  473-9|Cotting J, Reichen J, Kutz K, Laplanche R, Nuesch E "Pharmacokinetics of isradipine in patients with chronic liver disease." Eur J Clin Pharmacol 38 (1990):  599-603|Tse FL, Jaffe JM "Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man." Eur J Clin Pharmacol 32 (1987):  361-5|Graham D, Dow R, Hall D, Alexander O, Mroszczak E, Freedman A "The metabolism and pharmacokinetics of nicardipine hydrochloride in man." Br J Clin Pharmacol 20 (1985):  s23-8|Gengo FM, Fagan SC, Krol G, Bernhard H "Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls." Br J Clin Pharmacol 23 (1987):  47-53|Meredith P, Elliott H "Clinical pharmacokinetics of amlodipine." Clin Pharmacokinet 22 (1992):  22-31|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Johnson KE, Balderston SM, Pieper JA, Mann DE, Reiter MJ "Electrophysiologic effects of verapamil metabolites in the isolated heart." J Cardiovasc Pharmacol 17 (1991):  830-7|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Kumar KL, Colley CA "Verapamil-induced hepatotoxicity." West J Med 160 (1994):  485-6|Traverse JH, Swenson LJ, Mcbride JW "Acute hepatic injury after treatment with diltiazem." Am Heart J 127 (1994):  1636-9|Scherling D, Karl W, Ahr G, Ahr HJ, Wehinger E "Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man." Arzneimittelforschung 38 (1988):  1105-10|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57|"Product Information. Conjupri (levamlodipine)." CSPC Ouyi Pharmaceutical Co, Ltd  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51143, 18908, 'Felodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'Echizen H, Eichelbaum M "Clinical pharmacokinetics of verapamil, nifedipine and diltiazem." Clin Pharmacokinet 11 (1986):  425-49|Saracheck NS, London RL, Matulewicz TJ, et al. "Diltiazem and granulomatous hepatitis." Gastroenterology 88 (1985):  1260-2|Shallcross H, Padley SP, Glynn MJ, Gibbs DD "Fatal renal and hepatic toxicity after treatment with diltiazem." Br Med J 295 (1987):  1256-7|Colombo G, Zucchella G, Planca E, Grieco A "Intravenous diltiazem in the treatment of unstable angina: a study of efficacy and tolerance." Clin Ther 9 (1987):  536-47|Toft E, Vyberg M, Therkelsen K "Diltiazem-induced granulomatous hepatitis." Histopathology 18 (1991):  474-5|Abramson M, Littlejohn GO "Hepatic reactions to nifedipine." Med J Aust 142 (1985):  47-8|Toner M, White A, Moriarty J, Clancy L "Allergic urticarial eruption, leukocytosis and abnormal liver function tests following nifedipine administration." Chest 93 (1988):  1320-1|Babany G, Uzzan F, Larrey D, et al. "Alcoholic-like liver lesions induced by nifedipine." J Hepatol 9 (1989):  252-5|Brodsky SJ, Cutler SS, Weiner DA, Klein MD "Hepatotoxicity due to treatment with verapamil." Ann Intern Med 94 (1981):  490-1|Somogyi A, Albrecht M, Kliems G, et al. "Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis." Br J Clin Pharmacol 12 (1981):  51-60|Woodcock BG, Rietbrock I, Vohringer HF, Rietbrock N "Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships." Clin Pharmacol Ther 29 (1981):  27-34|Woodcock BG, Rietbrock N "Verapamil bioavailability and dosage in liver disease." Br J Clin Pharmacol 13 (1982):  240-1|Stern EH, Pitchon R, King BD, Wiener I "Possible hepatitis from verapamil." N Engl J Med 306 (1982):  612-3|Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|Hare DL, Horowitz JD "Verapamil hepatotoxicity: a hypersensitivity reaction." Am Heart J 111 (1986):  610-11|Guarascio P, D''Amato C, Sette P, et al. "Liver damage from verapamil." Br Med J 288 (1984):  362-3|Dow RJ, Graham DJM "A reveiw of the human metabolism and pharmacokinetics of nicardipine hydrochloride." Br J Clin Pharmacol 22 (1986):  s195-202|McAllister RG Jr, Hamann SR, Blouin RA "Pharmacokinetics of calcium-entry blockers." Am J Cardiol 55 (1985):  b30-40|Kates RE "Calcium antagonists: pharmacokinetic properties." Drugs 25 (1983):  113-24|Finucci GF, Padrini R, Piovan D, et al. "Verapamil pharmacokinetics and liver function in patients with cirrhosis." Int J Clin Pharmacol Res 8 (1988):  123-6|Giacomini KM, Massoud N, Wong FM, Giacomini JC "Decreased binding of verapamil to plasma proteins in patients with liver disease." J Cardiovasc Pharmacol 6 (1984):  924-8|Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Louis WJ "The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine." Clin Pharmacol Ther 47 (1990):  463-9|Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, Graham DJ "The metabolism of nicardipine hydrochloride in healthy male volunteers." Xenobiotica 16 (1986):  341-9|Benet LZ "Pharmacokinetics and metabolism of bepridil." Am J Cardiol 55 (1985):  c8-13|Kurosawa S, Kurosawa N, Owada E, et al. "Pharmacokinetics of diltiazem in patients with liver cirrhosis." Int J Clin Pharmacol Res 10 (1990):  311-8|Elliott HL, Meredith PA "The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine." Postgrad Med J 67 (1991):  s20-3|Stopher DA, Beresford AP, Macrae PV, Humphrey MJ "The metabolism and pharmacokinetics of amlodipine in humans and animals." J Cardiovasc Pharmacol 12 (1988):  s55-9|Kleinbloesem CH, van Harten J, Wilson JP, et al. "Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration." Clin Pharmacol Ther 40 (1986):  21-8|Raemsch KD, Sommer J "Pharmacokinetics and metabolism of nifedipine." Hypertension 5 (1983):  18-24|Ramsch KD, Graefe KH, Scherling D, et al. "Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine." Am J Nephrol 6 (1986):  73-80|Challenor VF, Waller DG, Renwick AG, et al. "The trans-hepatic extraction of nifedipine." Br J Clin Pharmacol 24 (1987):  473-7|Dunselman PH, Edgar B "Felodipine clinical pharmacokinetics." Clin Pharmacokinet 21 (1991):  418-30|Regardh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C "Pharmacokinetics of felodipine in patients with liver disease." Eur J Clin Pharmacol 36 (1989):  473-9|Cotting J, Reichen J, Kutz K, Laplanche R, Nuesch E "Pharmacokinetics of isradipine in patients with chronic liver disease." Eur J Clin Pharmacol 38 (1990):  599-603|Tse FL, Jaffe JM "Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man." Eur J Clin Pharmacol 32 (1987):  361-5|Graham D, Dow R, Hall D, Alexander O, Mroszczak E, Freedman A "The metabolism and pharmacokinetics of nicardipine hydrochloride in man." Br J Clin Pharmacol 20 (1985):  s23-8|Gengo FM, Fagan SC, Krol G, Bernhard H "Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls." Br J Clin Pharmacol 23 (1987):  47-53|Meredith P, Elliott H "Clinical pharmacokinetics of amlodipine." Clin Pharmacokinet 22 (1992):  22-31|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Johnson KE, Balderston SM, Pieper JA, Mann DE, Reiter MJ "Electrophysiologic effects of verapamil metabolites in the isolated heart." J Cardiovasc Pharmacol 17 (1991):  830-7|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Kumar KL, Colley CA "Verapamil-induced hepatotoxicity." West J Med 160 (1994):  485-6|Traverse JH, Swenson LJ, Mcbride JW "Acute hepatic injury after treatment with diltiazem." Am Heart J 127 (1994):  1636-9|Scherling D, Karl W, Ahr G, Ahr HJ, Wehinger E "Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man." Arzneimittelforschung 38 (1988):  1105-10|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57|"Product Information. Conjupri (levamlodipine)." CSPC Ouyi Pharmaceutical Co, Ltd  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51144, 18909, 'Felodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'Echizen H, Eichelbaum M "Clinical pharmacokinetics of verapamil, nifedipine and diltiazem." Clin Pharmacokinet 11 (1986):  425-49|Saracheck NS, London RL, Matulewicz TJ, et al. "Diltiazem and granulomatous hepatitis." Gastroenterology 88 (1985):  1260-2|Shallcross H, Padley SP, Glynn MJ, Gibbs DD "Fatal renal and hepatic toxicity after treatment with diltiazem." Br Med J 295 (1987):  1256-7|Colombo G, Zucchella G, Planca E, Grieco A "Intravenous diltiazem in the treatment of unstable angina: a study of efficacy and tolerance." Clin Ther 9 (1987):  536-47|Toft E, Vyberg M, Therkelsen K "Diltiazem-induced granulomatous hepatitis." Histopathology 18 (1991):  474-5|Abramson M, Littlejohn GO "Hepatic reactions to nifedipine." Med J Aust 142 (1985):  47-8|Toner M, White A, Moriarty J, Clancy L "Allergic urticarial eruption, leukocytosis and abnormal liver function tests following nifedipine administration." Chest 93 (1988):  1320-1|Babany G, Uzzan F, Larrey D, et al. "Alcoholic-like liver lesions induced by nifedipine." J Hepatol 9 (1989):  252-5|Brodsky SJ, Cutler SS, Weiner DA, Klein MD "Hepatotoxicity due to treatment with verapamil." Ann Intern Med 94 (1981):  490-1|Somogyi A, Albrecht M, Kliems G, et al. "Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis." Br J Clin Pharmacol 12 (1981):  51-60|Woodcock BG, Rietbrock I, Vohringer HF, Rietbrock N "Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships." Clin Pharmacol Ther 29 (1981):  27-34|Woodcock BG, Rietbrock N "Verapamil bioavailability and dosage in liver disease." Br J Clin Pharmacol 13 (1982):  240-1|Stern EH, Pitchon R, King BD, Wiener I "Possible hepatitis from verapamil." N Engl J Med 306 (1982):  612-3|Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|Hare DL, Horowitz JD "Verapamil hepatotoxicity: a hypersensitivity reaction." Am Heart J 111 (1986):  610-11|Guarascio P, D''Amato C, Sette P, et al. "Liver damage from verapamil." Br Med J 288 (1984):  362-3|Dow RJ, Graham DJM "A reveiw of the human metabolism and pharmacokinetics of nicardipine hydrochloride." Br J Clin Pharmacol 22 (1986):  s195-202|McAllister RG Jr, Hamann SR, Blouin RA "Pharmacokinetics of calcium-entry blockers." Am J Cardiol 55 (1985):  b30-40|Kates RE "Calcium antagonists: pharmacokinetic properties." Drugs 25 (1983):  113-24|Finucci GF, Padrini R, Piovan D, et al. "Verapamil pharmacokinetics and liver function in patients with cirrhosis." Int J Clin Pharmacol Res 8 (1988):  123-6|Giacomini KM, Massoud N, Wong FM, Giacomini JC "Decreased binding of verapamil to plasma proteins in patients with liver disease." J Cardiovasc Pharmacol 6 (1984):  924-8|Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Louis WJ "The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine." Clin Pharmacol Ther 47 (1990):  463-9|Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, Graham DJ "The metabolism of nicardipine hydrochloride in healthy male volunteers." Xenobiotica 16 (1986):  341-9|Benet LZ "Pharmacokinetics and metabolism of bepridil." Am J Cardiol 55 (1985):  c8-13|Kurosawa S, Kurosawa N, Owada E, et al. "Pharmacokinetics of diltiazem in patients with liver cirrhosis." Int J Clin Pharmacol Res 10 (1990):  311-8|Elliott HL, Meredith PA "The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine." Postgrad Med J 67 (1991):  s20-3|Stopher DA, Beresford AP, Macrae PV, Humphrey MJ "The metabolism and pharmacokinetics of amlodipine in humans and animals." J Cardiovasc Pharmacol 12 (1988):  s55-9|Kleinbloesem CH, van Harten J, Wilson JP, et al. "Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration." Clin Pharmacol Ther 40 (1986):  21-8|Raemsch KD, Sommer J "Pharmacokinetics and metabolism of nifedipine." Hypertension 5 (1983):  18-24|Ramsch KD, Graefe KH, Scherling D, et al. "Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine." Am J Nephrol 6 (1986):  73-80|Challenor VF, Waller DG, Renwick AG, et al. "The trans-hepatic extraction of nifedipine." Br J Clin Pharmacol 24 (1987):  473-7|Dunselman PH, Edgar B "Felodipine clinical pharmacokinetics." Clin Pharmacokinet 21 (1991):  418-30|Regardh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C "Pharmacokinetics of felodipine in patients with liver disease." Eur J Clin Pharmacol 36 (1989):  473-9|Cotting J, Reichen J, Kutz K, Laplanche R, Nuesch E "Pharmacokinetics of isradipine in patients with chronic liver disease." Eur J Clin Pharmacol 38 (1990):  599-603|Tse FL, Jaffe JM "Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man." Eur J Clin Pharmacol 32 (1987):  361-5|Graham D, Dow R, Hall D, Alexander O, Mroszczak E, Freedman A "The metabolism and pharmacokinetics of nicardipine hydrochloride in man." Br J Clin Pharmacol 20 (1985):  s23-8|Gengo FM, Fagan SC, Krol G, Bernhard H "Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls." Br J Clin Pharmacol 23 (1987):  47-53|Meredith P, Elliott H "Clinical pharmacokinetics of amlodipine." Clin Pharmacokinet 22 (1992):  22-31|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Johnson KE, Balderston SM, Pieper JA, Mann DE, Reiter MJ "Electrophysiologic effects of verapamil metabolites in the isolated heart." J Cardiovasc Pharmacol 17 (1991):  830-7|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Kumar KL, Colley CA "Verapamil-induced hepatotoxicity." West J Med 160 (1994):  485-6|Traverse JH, Swenson LJ, Mcbride JW "Acute hepatic injury after treatment with diltiazem." Am Heart J 127 (1994):  1636-9|Scherling D, Karl W, Ahr G, Ahr HJ, Wehinger E "Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man." Arzneimittelforschung 38 (1988):  1105-10|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57|"Product Information. Conjupri (levamlodipine)." CSPC Ouyi Pharmaceutical Co, Ltd  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51145, 18910, 'Felodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'Echizen H, Eichelbaum M "Clinical pharmacokinetics of verapamil, nifedipine and diltiazem." Clin Pharmacokinet 11 (1986):  425-49|Saracheck NS, London RL, Matulewicz TJ, et al. "Diltiazem and granulomatous hepatitis." Gastroenterology 88 (1985):  1260-2|Shallcross H, Padley SP, Glynn MJ, Gibbs DD "Fatal renal and hepatic toxicity after treatment with diltiazem." Br Med J 295 (1987):  1256-7|Colombo G, Zucchella G, Planca E, Grieco A "Intravenous diltiazem in the treatment of unstable angina: a study of efficacy and tolerance." Clin Ther 9 (1987):  536-47|Toft E, Vyberg M, Therkelsen K "Diltiazem-induced granulomatous hepatitis." Histopathology 18 (1991):  474-5|Abramson M, Littlejohn GO "Hepatic reactions to nifedipine." Med J Aust 142 (1985):  47-8|Toner M, White A, Moriarty J, Clancy L "Allergic urticarial eruption, leukocytosis and abnormal liver function tests following nifedipine administration." Chest 93 (1988):  1320-1|Babany G, Uzzan F, Larrey D, et al. "Alcoholic-like liver lesions induced by nifedipine." J Hepatol 9 (1989):  252-5|Brodsky SJ, Cutler SS, Weiner DA, Klein MD "Hepatotoxicity due to treatment with verapamil." Ann Intern Med 94 (1981):  490-1|Somogyi A, Albrecht M, Kliems G, et al. "Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis." Br J Clin Pharmacol 12 (1981):  51-60|Woodcock BG, Rietbrock I, Vohringer HF, Rietbrock N "Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships." Clin Pharmacol Ther 29 (1981):  27-34|Woodcock BG, Rietbrock N "Verapamil bioavailability and dosage in liver disease." Br J Clin Pharmacol 13 (1982):  240-1|Stern EH, Pitchon R, King BD, Wiener I "Possible hepatitis from verapamil." N Engl J Med 306 (1982):  612-3|Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|Hare DL, Horowitz JD "Verapamil hepatotoxicity: a hypersensitivity reaction." Am Heart J 111 (1986):  610-11|Guarascio P, D''Amato C, Sette P, et al. "Liver damage from verapamil." Br Med J 288 (1984):  362-3|Dow RJ, Graham DJM "A reveiw of the human metabolism and pharmacokinetics of nicardipine hydrochloride." Br J Clin Pharmacol 22 (1986):  s195-202|McAllister RG Jr, Hamann SR, Blouin RA "Pharmacokinetics of calcium-entry blockers." Am J Cardiol 55 (1985):  b30-40|Kates RE "Calcium antagonists: pharmacokinetic properties." Drugs 25 (1983):  113-24|Finucci GF, Padrini R, Piovan D, et al. "Verapamil pharmacokinetics and liver function in patients with cirrhosis." Int J Clin Pharmacol Res 8 (1988):  123-6|Giacomini KM, Massoud N, Wong FM, Giacomini JC "Decreased binding of verapamil to plasma proteins in patients with liver disease." J Cardiovasc Pharmacol 6 (1984):  924-8|Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Louis WJ "The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine." Clin Pharmacol Ther 47 (1990):  463-9|Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, Graham DJ "The metabolism of nicardipine hydrochloride in healthy male volunteers." Xenobiotica 16 (1986):  341-9|Benet LZ "Pharmacokinetics and metabolism of bepridil." Am J Cardiol 55 (1985):  c8-13|Kurosawa S, Kurosawa N, Owada E, et al. "Pharmacokinetics of diltiazem in patients with liver cirrhosis." Int J Clin Pharmacol Res 10 (1990):  311-8|Elliott HL, Meredith PA "The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine." Postgrad Med J 67 (1991):  s20-3|Stopher DA, Beresford AP, Macrae PV, Humphrey MJ "The metabolism and pharmacokinetics of amlodipine in humans and animals." J Cardiovasc Pharmacol 12 (1988):  s55-9|Kleinbloesem CH, van Harten J, Wilson JP, et al. "Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration." Clin Pharmacol Ther 40 (1986):  21-8|Raemsch KD, Sommer J "Pharmacokinetics and metabolism of nifedipine." Hypertension 5 (1983):  18-24|Ramsch KD, Graefe KH, Scherling D, et al. "Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine." Am J Nephrol 6 (1986):  73-80|Challenor VF, Waller DG, Renwick AG, et al. "The trans-hepatic extraction of nifedipine." Br J Clin Pharmacol 24 (1987):  473-7|Dunselman PH, Edgar B "Felodipine clinical pharmacokinetics." Clin Pharmacokinet 21 (1991):  418-30|Regardh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C "Pharmacokinetics of felodipine in patients with liver disease." Eur J Clin Pharmacol 36 (1989):  473-9|Cotting J, Reichen J, Kutz K, Laplanche R, Nuesch E "Pharmacokinetics of isradipine in patients with chronic liver disease." Eur J Clin Pharmacol 38 (1990):  599-603|Tse FL, Jaffe JM "Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man." Eur J Clin Pharmacol 32 (1987):  361-5|Graham D, Dow R, Hall D, Alexander O, Mroszczak E, Freedman A "The metabolism and pharmacokinetics of nicardipine hydrochloride in man." Br J Clin Pharmacol 20 (1985):  s23-8|Gengo FM, Fagan SC, Krol G, Bernhard H "Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls." Br J Clin Pharmacol 23 (1987):  47-53|Meredith P, Elliott H "Clinical pharmacokinetics of amlodipine." Clin Pharmacokinet 22 (1992):  22-31|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Johnson KE, Balderston SM, Pieper JA, Mann DE, Reiter MJ "Electrophysiologic effects of verapamil metabolites in the isolated heart." J Cardiovasc Pharmacol 17 (1991):  830-7|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Kumar KL, Colley CA "Verapamil-induced hepatotoxicity." West J Med 160 (1994):  485-6|Traverse JH, Swenson LJ, Mcbride JW "Acute hepatic injury after treatment with diltiazem." Am Heart J 127 (1994):  1636-9|Scherling D, Karl W, Ahr G, Ahr HJ, Wehinger E "Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man." Arzneimittelforschung 38 (1988):  1105-10|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57|"Product Information. Conjupri (levamlodipine)." CSPC Ouyi Pharmaceutical Co, Ltd  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51146, 20281, 'Felodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'Echizen H, Eichelbaum M "Clinical pharmacokinetics of verapamil, nifedipine and diltiazem." Clin Pharmacokinet 11 (1986):  425-49|Saracheck NS, London RL, Matulewicz TJ, et al. "Diltiazem and granulomatous hepatitis." Gastroenterology 88 (1985):  1260-2|Shallcross H, Padley SP, Glynn MJ, Gibbs DD "Fatal renal and hepatic toxicity after treatment with diltiazem." Br Med J 295 (1987):  1256-7|Colombo G, Zucchella G, Planca E, Grieco A "Intravenous diltiazem in the treatment of unstable angina: a study of efficacy and tolerance." Clin Ther 9 (1987):  536-47|Toft E, Vyberg M, Therkelsen K "Diltiazem-induced granulomatous hepatitis." Histopathology 18 (1991):  474-5|Abramson M, Littlejohn GO "Hepatic reactions to nifedipine." Med J Aust 142 (1985):  47-8|Toner M, White A, Moriarty J, Clancy L "Allergic urticarial eruption, leukocytosis and abnormal liver function tests following nifedipine administration." Chest 93 (1988):  1320-1|Babany G, Uzzan F, Larrey D, et al. "Alcoholic-like liver lesions induced by nifedipine." J Hepatol 9 (1989):  252-5|Brodsky SJ, Cutler SS, Weiner DA, Klein MD "Hepatotoxicity due to treatment with verapamil." Ann Intern Med 94 (1981):  490-1|Somogyi A, Albrecht M, Kliems G, et al. "Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis." Br J Clin Pharmacol 12 (1981):  51-60|Woodcock BG, Rietbrock I, Vohringer HF, Rietbrock N "Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships." Clin Pharmacol Ther 29 (1981):  27-34|Woodcock BG, Rietbrock N "Verapamil bioavailability and dosage in liver disease." Br J Clin Pharmacol 13 (1982):  240-1|Stern EH, Pitchon R, King BD, Wiener I "Possible hepatitis from verapamil." N Engl J Med 306 (1982):  612-3|Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|Hare DL, Horowitz JD "Verapamil hepatotoxicity: a hypersensitivity reaction." Am Heart J 111 (1986):  610-11|Guarascio P, D''Amato C, Sette P, et al. "Liver damage from verapamil." Br Med J 288 (1984):  362-3|Dow RJ, Graham DJM "A reveiw of the human metabolism and pharmacokinetics of nicardipine hydrochloride." Br J Clin Pharmacol 22 (1986):  s195-202|McAllister RG Jr, Hamann SR, Blouin RA "Pharmacokinetics of calcium-entry blockers." Am J Cardiol 55 (1985):  b30-40|Kates RE "Calcium antagonists: pharmacokinetic properties." Drugs 25 (1983):  113-24|Finucci GF, Padrini R, Piovan D, et al. "Verapamil pharmacokinetics and liver function in patients with cirrhosis." Int J Clin Pharmacol Res 8 (1988):  123-6|Giacomini KM, Massoud N, Wong FM, Giacomini JC "Decreased binding of verapamil to plasma proteins in patients with liver disease." J Cardiovasc Pharmacol 6 (1984):  924-8|Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Louis WJ "The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine." Clin Pharmacol Ther 47 (1990):  463-9|Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, Graham DJ "The metabolism of nicardipine hydrochloride in healthy male volunteers." Xenobiotica 16 (1986):  341-9|Benet LZ "Pharmacokinetics and metabolism of bepridil." Am J Cardiol 55 (1985):  c8-13|Kurosawa S, Kurosawa N, Owada E, et al. "Pharmacokinetics of diltiazem in patients with liver cirrhosis." Int J Clin Pharmacol Res 10 (1990):  311-8|Elliott HL, Meredith PA "The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine." Postgrad Med J 67 (1991):  s20-3|Stopher DA, Beresford AP, Macrae PV, Humphrey MJ "The metabolism and pharmacokinetics of amlodipine in humans and animals." J Cardiovasc Pharmacol 12 (1988):  s55-9|Kleinbloesem CH, van Harten J, Wilson JP, et al. "Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration." Clin Pharmacol Ther 40 (1986):  21-8|Raemsch KD, Sommer J "Pharmacokinetics and metabolism of nifedipine." Hypertension 5 (1983):  18-24|Ramsch KD, Graefe KH, Scherling D, et al. "Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine." Am J Nephrol 6 (1986):  73-80|Challenor VF, Waller DG, Renwick AG, et al. "The trans-hepatic extraction of nifedipine." Br J Clin Pharmacol 24 (1987):  473-7|Dunselman PH, Edgar B "Felodipine clinical pharmacokinetics." Clin Pharmacokinet 21 (1991):  418-30|Regardh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C "Pharmacokinetics of felodipine in patients with liver disease." Eur J Clin Pharmacol 36 (1989):  473-9|Cotting J, Reichen J, Kutz K, Laplanche R, Nuesch E "Pharmacokinetics of isradipine in patients with chronic liver disease." Eur J Clin Pharmacol 38 (1990):  599-603|Tse FL, Jaffe JM "Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man." Eur J Clin Pharmacol 32 (1987):  361-5|Graham D, Dow R, Hall D, Alexander O, Mroszczak E, Freedman A "The metabolism and pharmacokinetics of nicardipine hydrochloride in man." Br J Clin Pharmacol 20 (1985):  s23-8|Gengo FM, Fagan SC, Krol G, Bernhard H "Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls." Br J Clin Pharmacol 23 (1987):  47-53|Meredith P, Elliott H "Clinical pharmacokinetics of amlodipine." Clin Pharmacokinet 22 (1992):  22-31|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Johnson KE, Balderston SM, Pieper JA, Mann DE, Reiter MJ "Electrophysiologic effects of verapamil metabolites in the isolated heart." J Cardiovasc Pharmacol 17 (1991):  830-7|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Kumar KL, Colley CA "Verapamil-induced hepatotoxicity." West J Med 160 (1994):  485-6|Traverse JH, Swenson LJ, Mcbride JW "Acute hepatic injury after treatment with diltiazem." Am Heart J 127 (1994):  1636-9|Scherling D, Karl W, Ahr G, Ahr HJ, Wehinger E "Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man." Arzneimittelforschung 38 (1988):  1105-10|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57|"Product Information. Conjupri (levamlodipine)." CSPC Ouyi Pharmaceutical Co, Ltd  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51147, 25003, 'Felodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'Echizen H, Eichelbaum M "Clinical pharmacokinetics of verapamil, nifedipine and diltiazem." Clin Pharmacokinet 11 (1986):  425-49|Saracheck NS, London RL, Matulewicz TJ, et al. "Diltiazem and granulomatous hepatitis." Gastroenterology 88 (1985):  1260-2|Shallcross H, Padley SP, Glynn MJ, Gibbs DD "Fatal renal and hepatic toxicity after treatment with diltiazem." Br Med J 295 (1987):  1256-7|Colombo G, Zucchella G, Planca E, Grieco A "Intravenous diltiazem in the treatment of unstable angina: a study of efficacy and tolerance." Clin Ther 9 (1987):  536-47|Toft E, Vyberg M, Therkelsen K "Diltiazem-induced granulomatous hepatitis." Histopathology 18 (1991):  474-5|Abramson M, Littlejohn GO "Hepatic reactions to nifedipine." Med J Aust 142 (1985):  47-8|Toner M, White A, Moriarty J, Clancy L "Allergic urticarial eruption, leukocytosis and abnormal liver function tests following nifedipine administration." Chest 93 (1988):  1320-1|Babany G, Uzzan F, Larrey D, et al. "Alcoholic-like liver lesions induced by nifedipine." J Hepatol 9 (1989):  252-5|Brodsky SJ, Cutler SS, Weiner DA, Klein MD "Hepatotoxicity due to treatment with verapamil." Ann Intern Med 94 (1981):  490-1|Somogyi A, Albrecht M, Kliems G, et al. "Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis." Br J Clin Pharmacol 12 (1981):  51-60|Woodcock BG, Rietbrock I, Vohringer HF, Rietbrock N "Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships." Clin Pharmacol Ther 29 (1981):  27-34|Woodcock BG, Rietbrock N "Verapamil bioavailability and dosage in liver disease." Br J Clin Pharmacol 13 (1982):  240-1|Stern EH, Pitchon R, King BD, Wiener I "Possible hepatitis from verapamil." N Engl J Med 306 (1982):  612-3|Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|Hare DL, Horowitz JD "Verapamil hepatotoxicity: a hypersensitivity reaction." Am Heart J 111 (1986):  610-11|Guarascio P, D''Amato C, Sette P, et al. "Liver damage from verapamil." Br Med J 288 (1984):  362-3|Dow RJ, Graham DJM "A reveiw of the human metabolism and pharmacokinetics of nicardipine hydrochloride." Br J Clin Pharmacol 22 (1986):  s195-202|McAllister RG Jr, Hamann SR, Blouin RA "Pharmacokinetics of calcium-entry blockers." Am J Cardiol 55 (1985):  b30-40|Kates RE "Calcium antagonists: pharmacokinetic properties." Drugs 25 (1983):  113-24|Finucci GF, Padrini R, Piovan D, et al. "Verapamil pharmacokinetics and liver function in patients with cirrhosis." Int J Clin Pharmacol Res 8 (1988):  123-6|Giacomini KM, Massoud N, Wong FM, Giacomini JC "Decreased binding of verapamil to plasma proteins in patients with liver disease." J Cardiovasc Pharmacol 6 (1984):  924-8|Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Louis WJ "The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine." Clin Pharmacol Ther 47 (1990):  463-9|Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, Graham DJ "The metabolism of nicardipine hydrochloride in healthy male volunteers." Xenobiotica 16 (1986):  341-9|Benet LZ "Pharmacokinetics and metabolism of bepridil." Am J Cardiol 55 (1985):  c8-13|Kurosawa S, Kurosawa N, Owada E, et al. "Pharmacokinetics of diltiazem in patients with liver cirrhosis." Int J Clin Pharmacol Res 10 (1990):  311-8|Elliott HL, Meredith PA "The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine." Postgrad Med J 67 (1991):  s20-3|Stopher DA, Beresford AP, Macrae PV, Humphrey MJ "The metabolism and pharmacokinetics of amlodipine in humans and animals." J Cardiovasc Pharmacol 12 (1988):  s55-9|Kleinbloesem CH, van Harten J, Wilson JP, et al. "Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration." Clin Pharmacol Ther 40 (1986):  21-8|Raemsch KD, Sommer J "Pharmacokinetics and metabolism of nifedipine." Hypertension 5 (1983):  18-24|Ramsch KD, Graefe KH, Scherling D, et al. "Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine." Am J Nephrol 6 (1986):  73-80|Challenor VF, Waller DG, Renwick AG, et al. "The trans-hepatic extraction of nifedipine." Br J Clin Pharmacol 24 (1987):  473-7|Dunselman PH, Edgar B "Felodipine clinical pharmacokinetics." Clin Pharmacokinet 21 (1991):  418-30|Regardh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C "Pharmacokinetics of felodipine in patients with liver disease." Eur J Clin Pharmacol 36 (1989):  473-9|Cotting J, Reichen J, Kutz K, Laplanche R, Nuesch E "Pharmacokinetics of isradipine in patients with chronic liver disease." Eur J Clin Pharmacol 38 (1990):  599-603|Tse FL, Jaffe JM "Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man." Eur J Clin Pharmacol 32 (1987):  361-5|Graham D, Dow R, Hall D, Alexander O, Mroszczak E, Freedman A "The metabolism and pharmacokinetics of nicardipine hydrochloride in man." Br J Clin Pharmacol 20 (1985):  s23-8|Gengo FM, Fagan SC, Krol G, Bernhard H "Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls." Br J Clin Pharmacol 23 (1987):  47-53|Meredith P, Elliott H "Clinical pharmacokinetics of amlodipine." Clin Pharmacokinet 22 (1992):  22-31|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Johnson KE, Balderston SM, Pieper JA, Mann DE, Reiter MJ "Electrophysiologic effects of verapamil metabolites in the isolated heart." J Cardiovasc Pharmacol 17 (1991):  830-7|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Kumar KL, Colley CA "Verapamil-induced hepatotoxicity." West J Med 160 (1994):  485-6|Traverse JH, Swenson LJ, Mcbride JW "Acute hepatic injury after treatment with diltiazem." Am Heart J 127 (1994):  1636-9|Scherling D, Karl W, Ahr G, Ahr HJ, Wehinger E "Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man." Arzneimittelforschung 38 (1988):  1105-10|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57|"Product Information. Conjupri (levamlodipine)." CSPC Ouyi Pharmaceutical Co, Ltd  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51148, 25004, 'Felodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'Echizen H, Eichelbaum M "Clinical pharmacokinetics of verapamil, nifedipine and diltiazem." Clin Pharmacokinet 11 (1986):  425-49|Saracheck NS, London RL, Matulewicz TJ, et al. "Diltiazem and granulomatous hepatitis." Gastroenterology 88 (1985):  1260-2|Shallcross H, Padley SP, Glynn MJ, Gibbs DD "Fatal renal and hepatic toxicity after treatment with diltiazem." Br Med J 295 (1987):  1256-7|Colombo G, Zucchella G, Planca E, Grieco A "Intravenous diltiazem in the treatment of unstable angina: a study of efficacy and tolerance." Clin Ther 9 (1987):  536-47|Toft E, Vyberg M, Therkelsen K "Diltiazem-induced granulomatous hepatitis." Histopathology 18 (1991):  474-5|Abramson M, Littlejohn GO "Hepatic reactions to nifedipine." Med J Aust 142 (1985):  47-8|Toner M, White A, Moriarty J, Clancy L "Allergic urticarial eruption, leukocytosis and abnormal liver function tests following nifedipine administration." Chest 93 (1988):  1320-1|Babany G, Uzzan F, Larrey D, et al. "Alcoholic-like liver lesions induced by nifedipine." J Hepatol 9 (1989):  252-5|Brodsky SJ, Cutler SS, Weiner DA, Klein MD "Hepatotoxicity due to treatment with verapamil." Ann Intern Med 94 (1981):  490-1|Somogyi A, Albrecht M, Kliems G, et al. "Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis." Br J Clin Pharmacol 12 (1981):  51-60|Woodcock BG, Rietbrock I, Vohringer HF, Rietbrock N "Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships." Clin Pharmacol Ther 29 (1981):  27-34|Woodcock BG, Rietbrock N "Verapamil bioavailability and dosage in liver disease." Br J Clin Pharmacol 13 (1982):  240-1|Stern EH, Pitchon R, King BD, Wiener I "Possible hepatitis from verapamil." N Engl J Med 306 (1982):  612-3|Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|Hare DL, Horowitz JD "Verapamil hepatotoxicity: a hypersensitivity reaction." Am Heart J 111 (1986):  610-11|Guarascio P, D''Amato C, Sette P, et al. "Liver damage from verapamil." Br Med J 288 (1984):  362-3|Dow RJ, Graham DJM "A reveiw of the human metabolism and pharmacokinetics of nicardipine hydrochloride." Br J Clin Pharmacol 22 (1986):  s195-202|McAllister RG Jr, Hamann SR, Blouin RA "Pharmacokinetics of calcium-entry blockers." Am J Cardiol 55 (1985):  b30-40|Kates RE "Calcium antagonists: pharmacokinetic properties." Drugs 25 (1983):  113-24|Finucci GF, Padrini R, Piovan D, et al. "Verapamil pharmacokinetics and liver function in patients with cirrhosis." Int J Clin Pharmacol Res 8 (1988):  123-6|Giacomini KM, Massoud N, Wong FM, Giacomini JC "Decreased binding of verapamil to plasma proteins in patients with liver disease." J Cardiovasc Pharmacol 6 (1984):  924-8|Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Louis WJ "The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine." Clin Pharmacol Ther 47 (1990):  463-9|Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, Graham DJ "The metabolism of nicardipine hydrochloride in healthy male volunteers." Xenobiotica 16 (1986):  341-9|Benet LZ "Pharmacokinetics and metabolism of bepridil." Am J Cardiol 55 (1985):  c8-13|Kurosawa S, Kurosawa N, Owada E, et al. "Pharmacokinetics of diltiazem in patients with liver cirrhosis." Int J Clin Pharmacol Res 10 (1990):  311-8|Elliott HL, Meredith PA "The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine." Postgrad Med J 67 (1991):  s20-3|Stopher DA, Beresford AP, Macrae PV, Humphrey MJ "The metabolism and pharmacokinetics of amlodipine in humans and animals." J Cardiovasc Pharmacol 12 (1988):  s55-9|Kleinbloesem CH, van Harten J, Wilson JP, et al. "Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration." Clin Pharmacol Ther 40 (1986):  21-8|Raemsch KD, Sommer J "Pharmacokinetics and metabolism of nifedipine." Hypertension 5 (1983):  18-24|Ramsch KD, Graefe KH, Scherling D, et al. "Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine." Am J Nephrol 6 (1986):  73-80|Challenor VF, Waller DG, Renwick AG, et al. "The trans-hepatic extraction of nifedipine." Br J Clin Pharmacol 24 (1987):  473-7|Dunselman PH, Edgar B "Felodipine clinical pharmacokinetics." Clin Pharmacokinet 21 (1991):  418-30|Regardh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C "Pharmacokinetics of felodipine in patients with liver disease." Eur J Clin Pharmacol 36 (1989):  473-9|Cotting J, Reichen J, Kutz K, Laplanche R, Nuesch E "Pharmacokinetics of isradipine in patients with chronic liver disease." Eur J Clin Pharmacol 38 (1990):  599-603|Tse FL, Jaffe JM "Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man." Eur J Clin Pharmacol 32 (1987):  361-5|Graham D, Dow R, Hall D, Alexander O, Mroszczak E, Freedman A "The metabolism and pharmacokinetics of nicardipine hydrochloride in man." Br J Clin Pharmacol 20 (1985):  s23-8|Gengo FM, Fagan SC, Krol G, Bernhard H "Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls." Br J Clin Pharmacol 23 (1987):  47-53|Meredith P, Elliott H "Clinical pharmacokinetics of amlodipine." Clin Pharmacokinet 22 (1992):  22-31|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Johnson KE, Balderston SM, Pieper JA, Mann DE, Reiter MJ "Electrophysiologic effects of verapamil metabolites in the isolated heart." J Cardiovasc Pharmacol 17 (1991):  830-7|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Kumar KL, Colley CA "Verapamil-induced hepatotoxicity." West J Med 160 (1994):  485-6|Traverse JH, Swenson LJ, Mcbride JW "Acute hepatic injury after treatment with diltiazem." Am Heart J 127 (1994):  1636-9|Scherling D, Karl W, Ahr G, Ahr HJ, Wehinger E "Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man." Arzneimittelforschung 38 (1988):  1105-10|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57|"Product Information. Conjupri (levamlodipine)." CSPC Ouyi Pharmaceutical Co, Ltd  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51149, 25005, 'Felodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'Echizen H, Eichelbaum M "Clinical pharmacokinetics of verapamil, nifedipine and diltiazem." Clin Pharmacokinet 11 (1986):  425-49|Saracheck NS, London RL, Matulewicz TJ, et al. "Diltiazem and granulomatous hepatitis." Gastroenterology 88 (1985):  1260-2|Shallcross H, Padley SP, Glynn MJ, Gibbs DD "Fatal renal and hepatic toxicity after treatment with diltiazem." Br Med J 295 (1987):  1256-7|Colombo G, Zucchella G, Planca E, Grieco A "Intravenous diltiazem in the treatment of unstable angina: a study of efficacy and tolerance." Clin Ther 9 (1987):  536-47|Toft E, Vyberg M, Therkelsen K "Diltiazem-induced granulomatous hepatitis." Histopathology 18 (1991):  474-5|Abramson M, Littlejohn GO "Hepatic reactions to nifedipine." Med J Aust 142 (1985):  47-8|Toner M, White A, Moriarty J, Clancy L "Allergic urticarial eruption, leukocytosis and abnormal liver function tests following nifedipine administration." Chest 93 (1988):  1320-1|Babany G, Uzzan F, Larrey D, et al. "Alcoholic-like liver lesions induced by nifedipine." J Hepatol 9 (1989):  252-5|Brodsky SJ, Cutler SS, Weiner DA, Klein MD "Hepatotoxicity due to treatment with verapamil." Ann Intern Med 94 (1981):  490-1|Somogyi A, Albrecht M, Kliems G, et al. "Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis." Br J Clin Pharmacol 12 (1981):  51-60|Woodcock BG, Rietbrock I, Vohringer HF, Rietbrock N "Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships." Clin Pharmacol Ther 29 (1981):  27-34|Woodcock BG, Rietbrock N "Verapamil bioavailability and dosage in liver disease." Br J Clin Pharmacol 13 (1982):  240-1|Stern EH, Pitchon R, King BD, Wiener I "Possible hepatitis from verapamil." N Engl J Med 306 (1982):  612-3|Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|Hare DL, Horowitz JD "Verapamil hepatotoxicity: a hypersensitivity reaction." Am Heart J 111 (1986):  610-11|Guarascio P, D''Amato C, Sette P, et al. "Liver damage from verapamil." Br Med J 288 (1984):  362-3|Dow RJ, Graham DJM "A reveiw of the human metabolism and pharmacokinetics of nicardipine hydrochloride." Br J Clin Pharmacol 22 (1986):  s195-202|McAllister RG Jr, Hamann SR, Blouin RA "Pharmacokinetics of calcium-entry blockers." Am J Cardiol 55 (1985):  b30-40|Kates RE "Calcium antagonists: pharmacokinetic properties." Drugs 25 (1983):  113-24|Finucci GF, Padrini R, Piovan D, et al. "Verapamil pharmacokinetics and liver function in patients with cirrhosis." Int J Clin Pharmacol Res 8 (1988):  123-6|Giacomini KM, Massoud N, Wong FM, Giacomini JC "Decreased binding of verapamil to plasma proteins in patients with liver disease." J Cardiovasc Pharmacol 6 (1984):  924-8|Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Louis WJ "The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine." Clin Pharmacol Ther 47 (1990):  463-9|Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, Graham DJ "The metabolism of nicardipine hydrochloride in healthy male volunteers." Xenobiotica 16 (1986):  341-9|Benet LZ "Pharmacokinetics and metabolism of bepridil." Am J Cardiol 55 (1985):  c8-13|Kurosawa S, Kurosawa N, Owada E, et al. "Pharmacokinetics of diltiazem in patients with liver cirrhosis." Int J Clin Pharmacol Res 10 (1990):  311-8|Elliott HL, Meredith PA "The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine." Postgrad Med J 67 (1991):  s20-3|Stopher DA, Beresford AP, Macrae PV, Humphrey MJ "The metabolism and pharmacokinetics of amlodipine in humans and animals." J Cardiovasc Pharmacol 12 (1988):  s55-9|Kleinbloesem CH, van Harten J, Wilson JP, et al. "Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration." Clin Pharmacol Ther 40 (1986):  21-8|Raemsch KD, Sommer J "Pharmacokinetics and metabolism of nifedipine." Hypertension 5 (1983):  18-24|Ramsch KD, Graefe KH, Scherling D, et al. "Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine." Am J Nephrol 6 (1986):  73-80|Challenor VF, Waller DG, Renwick AG, et al. "The trans-hepatic extraction of nifedipine." Br J Clin Pharmacol 24 (1987):  473-7|Dunselman PH, Edgar B "Felodipine clinical pharmacokinetics." Clin Pharmacokinet 21 (1991):  418-30|Regardh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C "Pharmacokinetics of felodipine in patients with liver disease." Eur J Clin Pharmacol 36 (1989):  473-9|Cotting J, Reichen J, Kutz K, Laplanche R, Nuesch E "Pharmacokinetics of isradipine in patients with chronic liver disease." Eur J Clin Pharmacol 38 (1990):  599-603|Tse FL, Jaffe JM "Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man." Eur J Clin Pharmacol 32 (1987):  361-5|Graham D, Dow R, Hall D, Alexander O, Mroszczak E, Freedman A "The metabolism and pharmacokinetics of nicardipine hydrochloride in man." Br J Clin Pharmacol 20 (1985):  s23-8|Gengo FM, Fagan SC, Krol G, Bernhard H "Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls." Br J Clin Pharmacol 23 (1987):  47-53|Meredith P, Elliott H "Clinical pharmacokinetics of amlodipine." Clin Pharmacokinet 22 (1992):  22-31|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Johnson KE, Balderston SM, Pieper JA, Mann DE, Reiter MJ "Electrophysiologic effects of verapamil metabolites in the isolated heart." J Cardiovasc Pharmacol 17 (1991):  830-7|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Kumar KL, Colley CA "Verapamil-induced hepatotoxicity." West J Med 160 (1994):  485-6|Traverse JH, Swenson LJ, Mcbride JW "Acute hepatic injury after treatment with diltiazem." Am Heart J 127 (1994):  1636-9|Scherling D, Karl W, Ahr G, Ahr HJ, Wehinger E "Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man." Arzneimittelforschung 38 (1988):  1105-10|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57|"Product Information. Conjupri (levamlodipine)." CSPC Ouyi Pharmaceutical Co, Ltd  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51150, 25006, 'Felodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'Echizen H, Eichelbaum M "Clinical pharmacokinetics of verapamil, nifedipine and diltiazem." Clin Pharmacokinet 11 (1986):  425-49|Saracheck NS, London RL, Matulewicz TJ, et al. "Diltiazem and granulomatous hepatitis." Gastroenterology 88 (1985):  1260-2|Shallcross H, Padley SP, Glynn MJ, Gibbs DD "Fatal renal and hepatic toxicity after treatment with diltiazem." Br Med J 295 (1987):  1256-7|Colombo G, Zucchella G, Planca E, Grieco A "Intravenous diltiazem in the treatment of unstable angina: a study of efficacy and tolerance." Clin Ther 9 (1987):  536-47|Toft E, Vyberg M, Therkelsen K "Diltiazem-induced granulomatous hepatitis." Histopathology 18 (1991):  474-5|Abramson M, Littlejohn GO "Hepatic reactions to nifedipine." Med J Aust 142 (1985):  47-8|Toner M, White A, Moriarty J, Clancy L "Allergic urticarial eruption, leukocytosis and abnormal liver function tests following nifedipine administration." Chest 93 (1988):  1320-1|Babany G, Uzzan F, Larrey D, et al. "Alcoholic-like liver lesions induced by nifedipine." J Hepatol 9 (1989):  252-5|Brodsky SJ, Cutler SS, Weiner DA, Klein MD "Hepatotoxicity due to treatment with verapamil." Ann Intern Med 94 (1981):  490-1|Somogyi A, Albrecht M, Kliems G, et al. "Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis." Br J Clin Pharmacol 12 (1981):  51-60|Woodcock BG, Rietbrock I, Vohringer HF, Rietbrock N "Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships." Clin Pharmacol Ther 29 (1981):  27-34|Woodcock BG, Rietbrock N "Verapamil bioavailability and dosage in liver disease." Br J Clin Pharmacol 13 (1982):  240-1|Stern EH, Pitchon R, King BD, Wiener I "Possible hepatitis from verapamil." N Engl J Med 306 (1982):  612-3|Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|Hare DL, Horowitz JD "Verapamil hepatotoxicity: a hypersensitivity reaction." Am Heart J 111 (1986):  610-11|Guarascio P, D''Amato C, Sette P, et al. "Liver damage from verapamil." Br Med J 288 (1984):  362-3|Dow RJ, Graham DJM "A reveiw of the human metabolism and pharmacokinetics of nicardipine hydrochloride." Br J Clin Pharmacol 22 (1986):  s195-202|McAllister RG Jr, Hamann SR, Blouin RA "Pharmacokinetics of calcium-entry blockers." Am J Cardiol 55 (1985):  b30-40|Kates RE "Calcium antagonists: pharmacokinetic properties." Drugs 25 (1983):  113-24|Finucci GF, Padrini R, Piovan D, et al. "Verapamil pharmacokinetics and liver function in patients with cirrhosis." Int J Clin Pharmacol Res 8 (1988):  123-6|Giacomini KM, Massoud N, Wong FM, Giacomini JC "Decreased binding of verapamil to plasma proteins in patients with liver disease." J Cardiovasc Pharmacol 6 (1984):  924-8|Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Louis WJ "The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine." Clin Pharmacol Ther 47 (1990):  463-9|Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, Graham DJ "The metabolism of nicardipine hydrochloride in healthy male volunteers." Xenobiotica 16 (1986):  341-9|Benet LZ "Pharmacokinetics and metabolism of bepridil." Am J Cardiol 55 (1985):  c8-13|Kurosawa S, Kurosawa N, Owada E, et al. "Pharmacokinetics of diltiazem in patients with liver cirrhosis." Int J Clin Pharmacol Res 10 (1990):  311-8|Elliott HL, Meredith PA "The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine." Postgrad Med J 67 (1991):  s20-3|Stopher DA, Beresford AP, Macrae PV, Humphrey MJ "The metabolism and pharmacokinetics of amlodipine in humans and animals." J Cardiovasc Pharmacol 12 (1988):  s55-9|Kleinbloesem CH, van Harten J, Wilson JP, et al. "Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration." Clin Pharmacol Ther 40 (1986):  21-8|Raemsch KD, Sommer J "Pharmacokinetics and metabolism of nifedipine." Hypertension 5 (1983):  18-24|Ramsch KD, Graefe KH, Scherling D, et al. "Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine." Am J Nephrol 6 (1986):  73-80|Challenor VF, Waller DG, Renwick AG, et al. "The trans-hepatic extraction of nifedipine." Br J Clin Pharmacol 24 (1987):  473-7|Dunselman PH, Edgar B "Felodipine clinical pharmacokinetics." Clin Pharmacokinet 21 (1991):  418-30|Regardh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C "Pharmacokinetics of felodipine in patients with liver disease." Eur J Clin Pharmacol 36 (1989):  473-9|Cotting J, Reichen J, Kutz K, Laplanche R, Nuesch E "Pharmacokinetics of isradipine in patients with chronic liver disease." Eur J Clin Pharmacol 38 (1990):  599-603|Tse FL, Jaffe JM "Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man." Eur J Clin Pharmacol 32 (1987):  361-5|Graham D, Dow R, Hall D, Alexander O, Mroszczak E, Freedman A "The metabolism and pharmacokinetics of nicardipine hydrochloride in man." Br J Clin Pharmacol 20 (1985):  s23-8|Gengo FM, Fagan SC, Krol G, Bernhard H "Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls." Br J Clin Pharmacol 23 (1987):  47-53|Meredith P, Elliott H "Clinical pharmacokinetics of amlodipine." Clin Pharmacokinet 22 (1992):  22-31|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Johnson KE, Balderston SM, Pieper JA, Mann DE, Reiter MJ "Electrophysiologic effects of verapamil metabolites in the isolated heart." J Cardiovasc Pharmacol 17 (1991):  830-7|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Kumar KL, Colley CA "Verapamil-induced hepatotoxicity." West J Med 160 (1994):  485-6|Traverse JH, Swenson LJ, Mcbride JW "Acute hepatic injury after treatment with diltiazem." Am Heart J 127 (1994):  1636-9|Scherling D, Karl W, Ahr G, Ahr HJ, Wehinger E "Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man." Arzneimittelforschung 38 (1988):  1105-10|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57|"Product Information. Conjupri (levamlodipine)." CSPC Ouyi Pharmaceutical Co, Ltd  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51151, 25007, 'Felodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'Echizen H, Eichelbaum M "Clinical pharmacokinetics of verapamil, nifedipine and diltiazem." Clin Pharmacokinet 11 (1986):  425-49|Saracheck NS, London RL, Matulewicz TJ, et al. "Diltiazem and granulomatous hepatitis." Gastroenterology 88 (1985):  1260-2|Shallcross H, Padley SP, Glynn MJ, Gibbs DD "Fatal renal and hepatic toxicity after treatment with diltiazem." Br Med J 295 (1987):  1256-7|Colombo G, Zucchella G, Planca E, Grieco A "Intravenous diltiazem in the treatment of unstable angina: a study of efficacy and tolerance." Clin Ther 9 (1987):  536-47|Toft E, Vyberg M, Therkelsen K "Diltiazem-induced granulomatous hepatitis." Histopathology 18 (1991):  474-5|Abramson M, Littlejohn GO "Hepatic reactions to nifedipine." Med J Aust 142 (1985):  47-8|Toner M, White A, Moriarty J, Clancy L "Allergic urticarial eruption, leukocytosis and abnormal liver function tests following nifedipine administration." Chest 93 (1988):  1320-1|Babany G, Uzzan F, Larrey D, et al. "Alcoholic-like liver lesions induced by nifedipine." J Hepatol 9 (1989):  252-5|Brodsky SJ, Cutler SS, Weiner DA, Klein MD "Hepatotoxicity due to treatment with verapamil." Ann Intern Med 94 (1981):  490-1|Somogyi A, Albrecht M, Kliems G, et al. "Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis." Br J Clin Pharmacol 12 (1981):  51-60|Woodcock BG, Rietbrock I, Vohringer HF, Rietbrock N "Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships." Clin Pharmacol Ther 29 (1981):  27-34|Woodcock BG, Rietbrock N "Verapamil bioavailability and dosage in liver disease." Br J Clin Pharmacol 13 (1982):  240-1|Stern EH, Pitchon R, King BD, Wiener I "Possible hepatitis from verapamil." N Engl J Med 306 (1982):  612-3|Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|Hare DL, Horowitz JD "Verapamil hepatotoxicity: a hypersensitivity reaction." Am Heart J 111 (1986):  610-11|Guarascio P, D''Amato C, Sette P, et al. "Liver damage from verapamil." Br Med J 288 (1984):  362-3|Dow RJ, Graham DJM "A reveiw of the human metabolism and pharmacokinetics of nicardipine hydrochloride." Br J Clin Pharmacol 22 (1986):  s195-202|McAllister RG Jr, Hamann SR, Blouin RA "Pharmacokinetics of calcium-entry blockers." Am J Cardiol 55 (1985):  b30-40|Kates RE "Calcium antagonists: pharmacokinetic properties." Drugs 25 (1983):  113-24|Finucci GF, Padrini R, Piovan D, et al. "Verapamil pharmacokinetics and liver function in patients with cirrhosis." Int J Clin Pharmacol Res 8 (1988):  123-6|Giacomini KM, Massoud N, Wong FM, Giacomini JC "Decreased binding of verapamil to plasma proteins in patients with liver disease." J Cardiovasc Pharmacol 6 (1984):  924-8|Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Louis WJ "The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine." Clin Pharmacol Ther 47 (1990):  463-9|Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, Graham DJ "The metabolism of nicardipine hydrochloride in healthy male volunteers." Xenobiotica 16 (1986):  341-9|Benet LZ "Pharmacokinetics and metabolism of bepridil." Am J Cardiol 55 (1985):  c8-13|Kurosawa S, Kurosawa N, Owada E, et al. "Pharmacokinetics of diltiazem in patients with liver cirrhosis." Int J Clin Pharmacol Res 10 (1990):  311-8|Elliott HL, Meredith PA "The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine." Postgrad Med J 67 (1991):  s20-3|Stopher DA, Beresford AP, Macrae PV, Humphrey MJ "The metabolism and pharmacokinetics of amlodipine in humans and animals." J Cardiovasc Pharmacol 12 (1988):  s55-9|Kleinbloesem CH, van Harten J, Wilson JP, et al. "Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration." Clin Pharmacol Ther 40 (1986):  21-8|Raemsch KD, Sommer J "Pharmacokinetics and metabolism of nifedipine." Hypertension 5 (1983):  18-24|Ramsch KD, Graefe KH, Scherling D, et al. "Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine." Am J Nephrol 6 (1986):  73-80|Challenor VF, Waller DG, Renwick AG, et al. "The trans-hepatic extraction of nifedipine." Br J Clin Pharmacol 24 (1987):  473-7|Dunselman PH, Edgar B "Felodipine clinical pharmacokinetics." Clin Pharmacokinet 21 (1991):  418-30|Regardh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C "Pharmacokinetics of felodipine in patients with liver disease." Eur J Clin Pharmacol 36 (1989):  473-9|Cotting J, Reichen J, Kutz K, Laplanche R, Nuesch E "Pharmacokinetics of isradipine in patients with chronic liver disease." Eur J Clin Pharmacol 38 (1990):  599-603|Tse FL, Jaffe JM "Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man." Eur J Clin Pharmacol 32 (1987):  361-5|Graham D, Dow R, Hall D, Alexander O, Mroszczak E, Freedman A "The metabolism and pharmacokinetics of nicardipine hydrochloride in man." Br J Clin Pharmacol 20 (1985):  s23-8|Gengo FM, Fagan SC, Krol G, Bernhard H "Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls." Br J Clin Pharmacol 23 (1987):  47-53|Meredith P, Elliott H "Clinical pharmacokinetics of amlodipine." Clin Pharmacokinet 22 (1992):  22-31|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Johnson KE, Balderston SM, Pieper JA, Mann DE, Reiter MJ "Electrophysiologic effects of verapamil metabolites in the isolated heart." J Cardiovasc Pharmacol 17 (1991):  830-7|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Kumar KL, Colley CA "Verapamil-induced hepatotoxicity." West J Med 160 (1994):  485-6|Traverse JH, Swenson LJ, Mcbride JW "Acute hepatic injury after treatment with diltiazem." Am Heart J 127 (1994):  1636-9|Scherling D, Karl W, Ahr G, Ahr HJ, Wehinger E "Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man." Arzneimittelforschung 38 (1988):  1105-10|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57|"Product Information. Conjupri (levamlodipine)." CSPC Ouyi Pharmaceutical Co, Ltd  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51152, 25008, 'Felodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'Echizen H, Eichelbaum M "Clinical pharmacokinetics of verapamil, nifedipine and diltiazem." Clin Pharmacokinet 11 (1986):  425-49|Saracheck NS, London RL, Matulewicz TJ, et al. "Diltiazem and granulomatous hepatitis." Gastroenterology 88 (1985):  1260-2|Shallcross H, Padley SP, Glynn MJ, Gibbs DD "Fatal renal and hepatic toxicity after treatment with diltiazem." Br Med J 295 (1987):  1256-7|Colombo G, Zucchella G, Planca E, Grieco A "Intravenous diltiazem in the treatment of unstable angina: a study of efficacy and tolerance." Clin Ther 9 (1987):  536-47|Toft E, Vyberg M, Therkelsen K "Diltiazem-induced granulomatous hepatitis." Histopathology 18 (1991):  474-5|Abramson M, Littlejohn GO "Hepatic reactions to nifedipine." Med J Aust 142 (1985):  47-8|Toner M, White A, Moriarty J, Clancy L "Allergic urticarial eruption, leukocytosis and abnormal liver function tests following nifedipine administration." Chest 93 (1988):  1320-1|Babany G, Uzzan F, Larrey D, et al. "Alcoholic-like liver lesions induced by nifedipine." J Hepatol 9 (1989):  252-5|Brodsky SJ, Cutler SS, Weiner DA, Klein MD "Hepatotoxicity due to treatment with verapamil." Ann Intern Med 94 (1981):  490-1|Somogyi A, Albrecht M, Kliems G, et al. "Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis." Br J Clin Pharmacol 12 (1981):  51-60|Woodcock BG, Rietbrock I, Vohringer HF, Rietbrock N "Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships." Clin Pharmacol Ther 29 (1981):  27-34|Woodcock BG, Rietbrock N "Verapamil bioavailability and dosage in liver disease." Br J Clin Pharmacol 13 (1982):  240-1|Stern EH, Pitchon R, King BD, Wiener I "Possible hepatitis from verapamil." N Engl J Med 306 (1982):  612-3|Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|Hare DL, Horowitz JD "Verapamil hepatotoxicity: a hypersensitivity reaction." Am Heart J 111 (1986):  610-11|Guarascio P, D''Amato C, Sette P, et al. "Liver damage from verapamil." Br Med J 288 (1984):  362-3|Dow RJ, Graham DJM "A reveiw of the human metabolism and pharmacokinetics of nicardipine hydrochloride." Br J Clin Pharmacol 22 (1986):  s195-202|McAllister RG Jr, Hamann SR, Blouin RA "Pharmacokinetics of calcium-entry blockers." Am J Cardiol 55 (1985):  b30-40|Kates RE "Calcium antagonists: pharmacokinetic properties." Drugs 25 (1983):  113-24|Finucci GF, Padrini R, Piovan D, et al. "Verapamil pharmacokinetics and liver function in patients with cirrhosis." Int J Clin Pharmacol Res 8 (1988):  123-6|Giacomini KM, Massoud N, Wong FM, Giacomini JC "Decreased binding of verapamil to plasma proteins in patients with liver disease." J Cardiovasc Pharmacol 6 (1984):  924-8|Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Louis WJ "The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine." Clin Pharmacol Ther 47 (1990):  463-9|Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, Graham DJ "The metabolism of nicardipine hydrochloride in healthy male volunteers." Xenobiotica 16 (1986):  341-9|Benet LZ "Pharmacokinetics and metabolism of bepridil." Am J Cardiol 55 (1985):  c8-13|Kurosawa S, Kurosawa N, Owada E, et al. "Pharmacokinetics of diltiazem in patients with liver cirrhosis." Int J Clin Pharmacol Res 10 (1990):  311-8|Elliott HL, Meredith PA "The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine." Postgrad Med J 67 (1991):  s20-3|Stopher DA, Beresford AP, Macrae PV, Humphrey MJ "The metabolism and pharmacokinetics of amlodipine in humans and animals." J Cardiovasc Pharmacol 12 (1988):  s55-9|Kleinbloesem CH, van Harten J, Wilson JP, et al. "Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration." Clin Pharmacol Ther 40 (1986):  21-8|Raemsch KD, Sommer J "Pharmacokinetics and metabolism of nifedipine." Hypertension 5 (1983):  18-24|Ramsch KD, Graefe KH, Scherling D, et al. "Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine." Am J Nephrol 6 (1986):  73-80|Challenor VF, Waller DG, Renwick AG, et al. "The trans-hepatic extraction of nifedipine." Br J Clin Pharmacol 24 (1987):  473-7|Dunselman PH, Edgar B "Felodipine clinical pharmacokinetics." Clin Pharmacokinet 21 (1991):  418-30|Regardh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C "Pharmacokinetics of felodipine in patients with liver disease." Eur J Clin Pharmacol 36 (1989):  473-9|Cotting J, Reichen J, Kutz K, Laplanche R, Nuesch E "Pharmacokinetics of isradipine in patients with chronic liver disease." Eur J Clin Pharmacol 38 (1990):  599-603|Tse FL, Jaffe JM "Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man." Eur J Clin Pharmacol 32 (1987):  361-5|Graham D, Dow R, Hall D, Alexander O, Mroszczak E, Freedman A "The metabolism and pharmacokinetics of nicardipine hydrochloride in man." Br J Clin Pharmacol 20 (1985):  s23-8|Gengo FM, Fagan SC, Krol G, Bernhard H "Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls." Br J Clin Pharmacol 23 (1987):  47-53|Meredith P, Elliott H "Clinical pharmacokinetics of amlodipine." Clin Pharmacokinet 22 (1992):  22-31|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Johnson KE, Balderston SM, Pieper JA, Mann DE, Reiter MJ "Electrophysiologic effects of verapamil metabolites in the isolated heart." J Cardiovasc Pharmacol 17 (1991):  830-7|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Kumar KL, Colley CA "Verapamil-induced hepatotoxicity." West J Med 160 (1994):  485-6|Traverse JH, Swenson LJ, Mcbride JW "Acute hepatic injury after treatment with diltiazem." Am Heart J 127 (1994):  1636-9|Scherling D, Karl W, Ahr G, Ahr HJ, Wehinger E "Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man." Arzneimittelforschung 38 (1988):  1105-10|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57|"Product Information. Conjupri (levamlodipine)." CSPC Ouyi Pharmaceutical Co, Ltd  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51153, 18905, 'Felodipine', 'Heart Failure', 'Calcium channel blockers (CCBs) may have varying degrees of negative inotropic effect.  Congestive heart failure (CHF), worsening of CHF, and pulmonary edema have occurred in some patients treated with a CCB, primarily verapamil.  Some CCBs have also caused mild to moderate peripheral edema due to localized vasodilation of dependent arterioles and small blood vessels, which can be confused with the effects of increasing left ventricular dysfunction.  Although some CCBs have been used in the treatment of CHF, therapy with CCBs should be administered cautiously in patients with severe left ventricular dysfunction (e.g., ejection fraction < 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker.  Likewise, caution is advised in patients with acute myocardial infarction and pulmonary congestion documented by X-ray on admission, since associated heart failure may be acutely worsened by administration of a CCB.', '2', 'Gillmer DJ, Kark P "Pulmonary oedema precipitated by nifedipine." Br Med J 280 (1980):  1420-1|Batra AK, Segall PH, Ahmed T "Pulmonary edema with nifedipine in primary pulmonary hypertension." Respiration 47 (1985):  161-3|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Prigogine T, Waterlot Y, Gottignies P, et al. "Acute nonhemodynamic pulmonary edema with nifedipine in primary pulmonary hypertension." Chest 100 (1991):  563-4|Batlouni M, Armaganijan D, Ghorayeb N, Magliano MF "Clinical efficacy and tolerability of isradipine in the treatment of mild-to-moderate hypertension in young and elderly patients." J Cardiovasc Pharmacol 19 (1992):  s53-7|Scheidt S, LeWinter MM, Hermanovich J, Venkataraman K, Freedman D "Efficacy and safety of nicardipine for chronic, stable angina pectoris: a multicenter randomized trial." Am J Cardiol 58 (1986):  715-21|Taylor SH, Frais MA, Lee P, Verma SP, Jackson N, Reynolds G, Silke B "A study of the long-term efficacy and tolerability of oral nicardipine in hypertensive patients." Br J Clin Pharmacol 20 (1985):  s139-42|Dubois C, Blanchard D "Efficacy and safety of nicardipine in 29,104 patients with hypertension." Clin Ther 11 (1989):  452-60|Yedinak KC, Lopez LM "Felodipine: a new dihydropyridine calcium-channel antagonist." DICP 25 (1991):  1193-206|Lorimer AR, Pringle SD "The safety of felodipine." J Cardiovasc Pharmacol 15 (1990):  s85-9|Sundstedt CD, Ruegg PC, Keller A, Waite R "A multicenter evaluation of the safety, tolerability, and efficacy of isradipine in the treatment of essential hypertension." Am J Med 86 (1989):  98-102|Ruegg PC, Nelson DJ "Safety and efficacy of isradipine, alone and in combination, in the treatment of angina pectoris." Am J Med 86 (1989):  70-4|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Walton T, Symes LR "Felodipine and isradipine: new calcium-channel-blocking agents for the treatment of hypertension." Clin Pharm 12 (1993):  261-75|Fagan TC, Haggert BE, Liss C "Efficacy and tolerability of extended-release felodipine and extended-release nifedipine in patients with mild-to-moderate essential hypertension." Clin Ther 16 (1994):  634-46|Blecker D "Antihypertensive therapy with isradipine in patients with special safety concerns." Angiology 45 (1994):  997-1008|Brogden RN, Sorkin EM "Isradipine: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension." Drugs 49 (1995):  618-49|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Johnson BF, Eisner GM, Mcmahon FG, Jain AK, Rudd P, Sowers JR "A multicenter comparison of adverse reaction profiles of isradipine and enalapril at equipotent doses in patients with essential hypertension." J Clin Pharmacol 35 (1995):  484-92|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Sleight P "Calcium antagonists during and after myocardial infarction." Drugs 51 (1996):  216-25|Elkayam U "Calcium channel blockers in heart failure." Cardiology 89 (1998):  38-46|Schaefer RM, Aldons PM, Burgess ED, Tilvis R, Singh GP, Rehn L, Morgan TO "Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: A randomised, double-blind study in 535 patients, focusing on vasodilatory adverse events." Int J Clin Pract 52 (1998):  381|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51154, 18906, 'Felodipine', 'Heart Failure', 'Calcium channel blockers (CCBs) may have varying degrees of negative inotropic effect.  Congestive heart failure (CHF), worsening of CHF, and pulmonary edema have occurred in some patients treated with a CCB, primarily verapamil.  Some CCBs have also caused mild to moderate peripheral edema due to localized vasodilation of dependent arterioles and small blood vessels, which can be confused with the effects of increasing left ventricular dysfunction.  Although some CCBs have been used in the treatment of CHF, therapy with CCBs should be administered cautiously in patients with severe left ventricular dysfunction (e.g., ejection fraction < 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker.  Likewise, caution is advised in patients with acute myocardial infarction and pulmonary congestion documented by X-ray on admission, since associated heart failure may be acutely worsened by administration of a CCB.', '2', 'Gillmer DJ, Kark P "Pulmonary oedema precipitated by nifedipine." Br Med J 280 (1980):  1420-1|Batra AK, Segall PH, Ahmed T "Pulmonary edema with nifedipine in primary pulmonary hypertension." Respiration 47 (1985):  161-3|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Prigogine T, Waterlot Y, Gottignies P, et al. "Acute nonhemodynamic pulmonary edema with nifedipine in primary pulmonary hypertension." Chest 100 (1991):  563-4|Batlouni M, Armaganijan D, Ghorayeb N, Magliano MF "Clinical efficacy and tolerability of isradipine in the treatment of mild-to-moderate hypertension in young and elderly patients." J Cardiovasc Pharmacol 19 (1992):  s53-7|Scheidt S, LeWinter MM, Hermanovich J, Venkataraman K, Freedman D "Efficacy and safety of nicardipine for chronic, stable angina pectoris: a multicenter randomized trial." Am J Cardiol 58 (1986):  715-21|Taylor SH, Frais MA, Lee P, Verma SP, Jackson N, Reynolds G, Silke B "A study of the long-term efficacy and tolerability of oral nicardipine in hypertensive patients." Br J Clin Pharmacol 20 (1985):  s139-42|Dubois C, Blanchard D "Efficacy and safety of nicardipine in 29,104 patients with hypertension." Clin Ther 11 (1989):  452-60|Yedinak KC, Lopez LM "Felodipine: a new dihydropyridine calcium-channel antagonist." DICP 25 (1991):  1193-206|Lorimer AR, Pringle SD "The safety of felodipine." J Cardiovasc Pharmacol 15 (1990):  s85-9|Sundstedt CD, Ruegg PC, Keller A, Waite R "A multicenter evaluation of the safety, tolerability, and efficacy of isradipine in the treatment of essential hypertension." Am J Med 86 (1989):  98-102|Ruegg PC, Nelson DJ "Safety and efficacy of isradipine, alone and in combination, in the treatment of angina pectoris." Am J Med 86 (1989):  70-4|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Walton T, Symes LR "Felodipine and isradipine: new calcium-channel-blocking agents for the treatment of hypertension." Clin Pharm 12 (1993):  261-75|Fagan TC, Haggert BE, Liss C "Efficacy and tolerability of extended-release felodipine and extended-release nifedipine in patients with mild-to-moderate essential hypertension." Clin Ther 16 (1994):  634-46|Blecker D "Antihypertensive therapy with isradipine in patients with special safety concerns." Angiology 45 (1994):  997-1008|Brogden RN, Sorkin EM "Isradipine: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension." Drugs 49 (1995):  618-49|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Johnson BF, Eisner GM, Mcmahon FG, Jain AK, Rudd P, Sowers JR "A multicenter comparison of adverse reaction profiles of isradipine and enalapril at equipotent doses in patients with essential hypertension." J Clin Pharmacol 35 (1995):  484-92|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Sleight P "Calcium antagonists during and after myocardial infarction." Drugs 51 (1996):  216-25|Elkayam U "Calcium channel blockers in heart failure." Cardiology 89 (1998):  38-46|Schaefer RM, Aldons PM, Burgess ED, Tilvis R, Singh GP, Rehn L, Morgan TO "Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: A randomised, double-blind study in 535 patients, focusing on vasodilatory adverse events." Int J Clin Pract 52 (1998):  381|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51155, 18907, 'Felodipine', 'Heart Failure', 'Calcium channel blockers (CCBs) may have varying degrees of negative inotropic effect.  Congestive heart failure (CHF), worsening of CHF, and pulmonary edema have occurred in some patients treated with a CCB, primarily verapamil.  Some CCBs have also caused mild to moderate peripheral edema due to localized vasodilation of dependent arterioles and small blood vessels, which can be confused with the effects of increasing left ventricular dysfunction.  Although some CCBs have been used in the treatment of CHF, therapy with CCBs should be administered cautiously in patients with severe left ventricular dysfunction (e.g., ejection fraction < 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker.  Likewise, caution is advised in patients with acute myocardial infarction and pulmonary congestion documented by X-ray on admission, since associated heart failure may be acutely worsened by administration of a CCB.', '2', 'Gillmer DJ, Kark P "Pulmonary oedema precipitated by nifedipine." Br Med J 280 (1980):  1420-1|Batra AK, Segall PH, Ahmed T "Pulmonary edema with nifedipine in primary pulmonary hypertension." Respiration 47 (1985):  161-3|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Prigogine T, Waterlot Y, Gottignies P, et al. "Acute nonhemodynamic pulmonary edema with nifedipine in primary pulmonary hypertension." Chest 100 (1991):  563-4|Batlouni M, Armaganijan D, Ghorayeb N, Magliano MF "Clinical efficacy and tolerability of isradipine in the treatment of mild-to-moderate hypertension in young and elderly patients." J Cardiovasc Pharmacol 19 (1992):  s53-7|Scheidt S, LeWinter MM, Hermanovich J, Venkataraman K, Freedman D "Efficacy and safety of nicardipine for chronic, stable angina pectoris: a multicenter randomized trial." Am J Cardiol 58 (1986):  715-21|Taylor SH, Frais MA, Lee P, Verma SP, Jackson N, Reynolds G, Silke B "A study of the long-term efficacy and tolerability of oral nicardipine in hypertensive patients." Br J Clin Pharmacol 20 (1985):  s139-42|Dubois C, Blanchard D "Efficacy and safety of nicardipine in 29,104 patients with hypertension." Clin Ther 11 (1989):  452-60|Yedinak KC, Lopez LM "Felodipine: a new dihydropyridine calcium-channel antagonist." DICP 25 (1991):  1193-206|Lorimer AR, Pringle SD "The safety of felodipine." J Cardiovasc Pharmacol 15 (1990):  s85-9|Sundstedt CD, Ruegg PC, Keller A, Waite R "A multicenter evaluation of the safety, tolerability, and efficacy of isradipine in the treatment of essential hypertension." Am J Med 86 (1989):  98-102|Ruegg PC, Nelson DJ "Safety and efficacy of isradipine, alone and in combination, in the treatment of angina pectoris." Am J Med 86 (1989):  70-4|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Walton T, Symes LR "Felodipine and isradipine: new calcium-channel-blocking agents for the treatment of hypertension." Clin Pharm 12 (1993):  261-75|Fagan TC, Haggert BE, Liss C "Efficacy and tolerability of extended-release felodipine and extended-release nifedipine in patients with mild-to-moderate essential hypertension." Clin Ther 16 (1994):  634-46|Blecker D "Antihypertensive therapy with isradipine in patients with special safety concerns." Angiology 45 (1994):  997-1008|Brogden RN, Sorkin EM "Isradipine: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension." Drugs 49 (1995):  618-49|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Johnson BF, Eisner GM, Mcmahon FG, Jain AK, Rudd P, Sowers JR "A multicenter comparison of adverse reaction profiles of isradipine and enalapril at equipotent doses in patients with essential hypertension." J Clin Pharmacol 35 (1995):  484-92|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Sleight P "Calcium antagonists during and after myocardial infarction." Drugs 51 (1996):  216-25|Elkayam U "Calcium channel blockers in heart failure." Cardiology 89 (1998):  38-46|Schaefer RM, Aldons PM, Burgess ED, Tilvis R, Singh GP, Rehn L, Morgan TO "Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: A randomised, double-blind study in 535 patients, focusing on vasodilatory adverse events." Int J Clin Pract 52 (1998):  381|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51156, 18908, 'Felodipine', 'Heart Failure', 'Calcium channel blockers (CCBs) may have varying degrees of negative inotropic effect.  Congestive heart failure (CHF), worsening of CHF, and pulmonary edema have occurred in some patients treated with a CCB, primarily verapamil.  Some CCBs have also caused mild to moderate peripheral edema due to localized vasodilation of dependent arterioles and small blood vessels, which can be confused with the effects of increasing left ventricular dysfunction.  Although some CCBs have been used in the treatment of CHF, therapy with CCBs should be administered cautiously in patients with severe left ventricular dysfunction (e.g., ejection fraction < 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker.  Likewise, caution is advised in patients with acute myocardial infarction and pulmonary congestion documented by X-ray on admission, since associated heart failure may be acutely worsened by administration of a CCB.', '2', 'Gillmer DJ, Kark P "Pulmonary oedema precipitated by nifedipine." Br Med J 280 (1980):  1420-1|Batra AK, Segall PH, Ahmed T "Pulmonary edema with nifedipine in primary pulmonary hypertension." Respiration 47 (1985):  161-3|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Prigogine T, Waterlot Y, Gottignies P, et al. "Acute nonhemodynamic pulmonary edema with nifedipine in primary pulmonary hypertension." Chest 100 (1991):  563-4|Batlouni M, Armaganijan D, Ghorayeb N, Magliano MF "Clinical efficacy and tolerability of isradipine in the treatment of mild-to-moderate hypertension in young and elderly patients." J Cardiovasc Pharmacol 19 (1992):  s53-7|Scheidt S, LeWinter MM, Hermanovich J, Venkataraman K, Freedman D "Efficacy and safety of nicardipine for chronic, stable angina pectoris: a multicenter randomized trial." Am J Cardiol 58 (1986):  715-21|Taylor SH, Frais MA, Lee P, Verma SP, Jackson N, Reynolds G, Silke B "A study of the long-term efficacy and tolerability of oral nicardipine in hypertensive patients." Br J Clin Pharmacol 20 (1985):  s139-42|Dubois C, Blanchard D "Efficacy and safety of nicardipine in 29,104 patients with hypertension." Clin Ther 11 (1989):  452-60|Yedinak KC, Lopez LM "Felodipine: a new dihydropyridine calcium-channel antagonist." DICP 25 (1991):  1193-206|Lorimer AR, Pringle SD "The safety of felodipine." J Cardiovasc Pharmacol 15 (1990):  s85-9|Sundstedt CD, Ruegg PC, Keller A, Waite R "A multicenter evaluation of the safety, tolerability, and efficacy of isradipine in the treatment of essential hypertension." Am J Med 86 (1989):  98-102|Ruegg PC, Nelson DJ "Safety and efficacy of isradipine, alone and in combination, in the treatment of angina pectoris." Am J Med 86 (1989):  70-4|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Walton T, Symes LR "Felodipine and isradipine: new calcium-channel-blocking agents for the treatment of hypertension." Clin Pharm 12 (1993):  261-75|Fagan TC, Haggert BE, Liss C "Efficacy and tolerability of extended-release felodipine and extended-release nifedipine in patients with mild-to-moderate essential hypertension." Clin Ther 16 (1994):  634-46|Blecker D "Antihypertensive therapy with isradipine in patients with special safety concerns." Angiology 45 (1994):  997-1008|Brogden RN, Sorkin EM "Isradipine: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension." Drugs 49 (1995):  618-49|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Johnson BF, Eisner GM, Mcmahon FG, Jain AK, Rudd P, Sowers JR "A multicenter comparison of adverse reaction profiles of isradipine and enalapril at equipotent doses in patients with essential hypertension." J Clin Pharmacol 35 (1995):  484-92|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Sleight P "Calcium antagonists during and after myocardial infarction." Drugs 51 (1996):  216-25|Elkayam U "Calcium channel blockers in heart failure." Cardiology 89 (1998):  38-46|Schaefer RM, Aldons PM, Burgess ED, Tilvis R, Singh GP, Rehn L, Morgan TO "Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: A randomised, double-blind study in 535 patients, focusing on vasodilatory adverse events." Int J Clin Pract 52 (1998):  381|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51157, 18909, 'Felodipine', 'Heart Failure', 'Calcium channel blockers (CCBs) may have varying degrees of negative inotropic effect.  Congestive heart failure (CHF), worsening of CHF, and pulmonary edema have occurred in some patients treated with a CCB, primarily verapamil.  Some CCBs have also caused mild to moderate peripheral edema due to localized vasodilation of dependent arterioles and small blood vessels, which can be confused with the effects of increasing left ventricular dysfunction.  Although some CCBs have been used in the treatment of CHF, therapy with CCBs should be administered cautiously in patients with severe left ventricular dysfunction (e.g., ejection fraction < 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker.  Likewise, caution is advised in patients with acute myocardial infarction and pulmonary congestion documented by X-ray on admission, since associated heart failure may be acutely worsened by administration of a CCB.', '2', 'Gillmer DJ, Kark P "Pulmonary oedema precipitated by nifedipine." Br Med J 280 (1980):  1420-1|Batra AK, Segall PH, Ahmed T "Pulmonary edema with nifedipine in primary pulmonary hypertension." Respiration 47 (1985):  161-3|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Prigogine T, Waterlot Y, Gottignies P, et al. "Acute nonhemodynamic pulmonary edema with nifedipine in primary pulmonary hypertension." Chest 100 (1991):  563-4|Batlouni M, Armaganijan D, Ghorayeb N, Magliano MF "Clinical efficacy and tolerability of isradipine in the treatment of mild-to-moderate hypertension in young and elderly patients." J Cardiovasc Pharmacol 19 (1992):  s53-7|Scheidt S, LeWinter MM, Hermanovich J, Venkataraman K, Freedman D "Efficacy and safety of nicardipine for chronic, stable angina pectoris: a multicenter randomized trial." Am J Cardiol 58 (1986):  715-21|Taylor SH, Frais MA, Lee P, Verma SP, Jackson N, Reynolds G, Silke B "A study of the long-term efficacy and tolerability of oral nicardipine in hypertensive patients." Br J Clin Pharmacol 20 (1985):  s139-42|Dubois C, Blanchard D "Efficacy and safety of nicardipine in 29,104 patients with hypertension." Clin Ther 11 (1989):  452-60|Yedinak KC, Lopez LM "Felodipine: a new dihydropyridine calcium-channel antagonist." DICP 25 (1991):  1193-206|Lorimer AR, Pringle SD "The safety of felodipine." J Cardiovasc Pharmacol 15 (1990):  s85-9|Sundstedt CD, Ruegg PC, Keller A, Waite R "A multicenter evaluation of the safety, tolerability, and efficacy of isradipine in the treatment of essential hypertension." Am J Med 86 (1989):  98-102|Ruegg PC, Nelson DJ "Safety and efficacy of isradipine, alone and in combination, in the treatment of angina pectoris." Am J Med 86 (1989):  70-4|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Walton T, Symes LR "Felodipine and isradipine: new calcium-channel-blocking agents for the treatment of hypertension." Clin Pharm 12 (1993):  261-75|Fagan TC, Haggert BE, Liss C "Efficacy and tolerability of extended-release felodipine and extended-release nifedipine in patients with mild-to-moderate essential hypertension." Clin Ther 16 (1994):  634-46|Blecker D "Antihypertensive therapy with isradipine in patients with special safety concerns." Angiology 45 (1994):  997-1008|Brogden RN, Sorkin EM "Isradipine: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension." Drugs 49 (1995):  618-49|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Johnson BF, Eisner GM, Mcmahon FG, Jain AK, Rudd P, Sowers JR "A multicenter comparison of adverse reaction profiles of isradipine and enalapril at equipotent doses in patients with essential hypertension." J Clin Pharmacol 35 (1995):  484-92|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Sleight P "Calcium antagonists during and after myocardial infarction." Drugs 51 (1996):  216-25|Elkayam U "Calcium channel blockers in heart failure." Cardiology 89 (1998):  38-46|Schaefer RM, Aldons PM, Burgess ED, Tilvis R, Singh GP, Rehn L, Morgan TO "Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: A randomised, double-blind study in 535 patients, focusing on vasodilatory adverse events." Int J Clin Pract 52 (1998):  381|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51158, 18910, 'Felodipine', 'Heart Failure', 'Calcium channel blockers (CCBs) may have varying degrees of negative inotropic effect.  Congestive heart failure (CHF), worsening of CHF, and pulmonary edema have occurred in some patients treated with a CCB, primarily verapamil.  Some CCBs have also caused mild to moderate peripheral edema due to localized vasodilation of dependent arterioles and small blood vessels, which can be confused with the effects of increasing left ventricular dysfunction.  Although some CCBs have been used in the treatment of CHF, therapy with CCBs should be administered cautiously in patients with severe left ventricular dysfunction (e.g., ejection fraction < 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker.  Likewise, caution is advised in patients with acute myocardial infarction and pulmonary congestion documented by X-ray on admission, since associated heart failure may be acutely worsened by administration of a CCB.', '2', 'Gillmer DJ, Kark P "Pulmonary oedema precipitated by nifedipine." Br Med J 280 (1980):  1420-1|Batra AK, Segall PH, Ahmed T "Pulmonary edema with nifedipine in primary pulmonary hypertension." Respiration 47 (1985):  161-3|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Prigogine T, Waterlot Y, Gottignies P, et al. "Acute nonhemodynamic pulmonary edema with nifedipine in primary pulmonary hypertension." Chest 100 (1991):  563-4|Batlouni M, Armaganijan D, Ghorayeb N, Magliano MF "Clinical efficacy and tolerability of isradipine in the treatment of mild-to-moderate hypertension in young and elderly patients." J Cardiovasc Pharmacol 19 (1992):  s53-7|Scheidt S, LeWinter MM, Hermanovich J, Venkataraman K, Freedman D "Efficacy and safety of nicardipine for chronic, stable angina pectoris: a multicenter randomized trial." Am J Cardiol 58 (1986):  715-21|Taylor SH, Frais MA, Lee P, Verma SP, Jackson N, Reynolds G, Silke B "A study of the long-term efficacy and tolerability of oral nicardipine in hypertensive patients." Br J Clin Pharmacol 20 (1985):  s139-42|Dubois C, Blanchard D "Efficacy and safety of nicardipine in 29,104 patients with hypertension." Clin Ther 11 (1989):  452-60|Yedinak KC, Lopez LM "Felodipine: a new dihydropyridine calcium-channel antagonist." DICP 25 (1991):  1193-206|Lorimer AR, Pringle SD "The safety of felodipine." J Cardiovasc Pharmacol 15 (1990):  s85-9|Sundstedt CD, Ruegg PC, Keller A, Waite R "A multicenter evaluation of the safety, tolerability, and efficacy of isradipine in the treatment of essential hypertension." Am J Med 86 (1989):  98-102|Ruegg PC, Nelson DJ "Safety and efficacy of isradipine, alone and in combination, in the treatment of angina pectoris." Am J Med 86 (1989):  70-4|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Walton T, Symes LR "Felodipine and isradipine: new calcium-channel-blocking agents for the treatment of hypertension." Clin Pharm 12 (1993):  261-75|Fagan TC, Haggert BE, Liss C "Efficacy and tolerability of extended-release felodipine and extended-release nifedipine in patients with mild-to-moderate essential hypertension." Clin Ther 16 (1994):  634-46|Blecker D "Antihypertensive therapy with isradipine in patients with special safety concerns." Angiology 45 (1994):  997-1008|Brogden RN, Sorkin EM "Isradipine: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension." Drugs 49 (1995):  618-49|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Johnson BF, Eisner GM, Mcmahon FG, Jain AK, Rudd P, Sowers JR "A multicenter comparison of adverse reaction profiles of isradipine and enalapril at equipotent doses in patients with essential hypertension." J Clin Pharmacol 35 (1995):  484-92|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Sleight P "Calcium antagonists during and after myocardial infarction." Drugs 51 (1996):  216-25|Elkayam U "Calcium channel blockers in heart failure." Cardiology 89 (1998):  38-46|Schaefer RM, Aldons PM, Burgess ED, Tilvis R, Singh GP, Rehn L, Morgan TO "Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: A randomised, double-blind study in 535 patients, focusing on vasodilatory adverse events." Int J Clin Pract 52 (1998):  381|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51159, 20281, 'Felodipine', 'Heart Failure', 'Calcium channel blockers (CCBs) may have varying degrees of negative inotropic effect.  Congestive heart failure (CHF), worsening of CHF, and pulmonary edema have occurred in some patients treated with a CCB, primarily verapamil.  Some CCBs have also caused mild to moderate peripheral edema due to localized vasodilation of dependent arterioles and small blood vessels, which can be confused with the effects of increasing left ventricular dysfunction.  Although some CCBs have been used in the treatment of CHF, therapy with CCBs should be administered cautiously in patients with severe left ventricular dysfunction (e.g., ejection fraction < 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker.  Likewise, caution is advised in patients with acute myocardial infarction and pulmonary congestion documented by X-ray on admission, since associated heart failure may be acutely worsened by administration of a CCB.', '2', 'Gillmer DJ, Kark P "Pulmonary oedema precipitated by nifedipine." Br Med J 280 (1980):  1420-1|Batra AK, Segall PH, Ahmed T "Pulmonary edema with nifedipine in primary pulmonary hypertension." Respiration 47 (1985):  161-3|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Prigogine T, Waterlot Y, Gottignies P, et al. "Acute nonhemodynamic pulmonary edema with nifedipine in primary pulmonary hypertension." Chest 100 (1991):  563-4|Batlouni M, Armaganijan D, Ghorayeb N, Magliano MF "Clinical efficacy and tolerability of isradipine in the treatment of mild-to-moderate hypertension in young and elderly patients." J Cardiovasc Pharmacol 19 (1992):  s53-7|Scheidt S, LeWinter MM, Hermanovich J, Venkataraman K, Freedman D "Efficacy and safety of nicardipine for chronic, stable angina pectoris: a multicenter randomized trial." Am J Cardiol 58 (1986):  715-21|Taylor SH, Frais MA, Lee P, Verma SP, Jackson N, Reynolds G, Silke B "A study of the long-term efficacy and tolerability of oral nicardipine in hypertensive patients." Br J Clin Pharmacol 20 (1985):  s139-42|Dubois C, Blanchard D "Efficacy and safety of nicardipine in 29,104 patients with hypertension." Clin Ther 11 (1989):  452-60|Yedinak KC, Lopez LM "Felodipine: a new dihydropyridine calcium-channel antagonist." DICP 25 (1991):  1193-206|Lorimer AR, Pringle SD "The safety of felodipine." J Cardiovasc Pharmacol 15 (1990):  s85-9|Sundstedt CD, Ruegg PC, Keller A, Waite R "A multicenter evaluation of the safety, tolerability, and efficacy of isradipine in the treatment of essential hypertension." Am J Med 86 (1989):  98-102|Ruegg PC, Nelson DJ "Safety and efficacy of isradipine, alone and in combination, in the treatment of angina pectoris." Am J Med 86 (1989):  70-4|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Walton T, Symes LR "Felodipine and isradipine: new calcium-channel-blocking agents for the treatment of hypertension." Clin Pharm 12 (1993):  261-75|Fagan TC, Haggert BE, Liss C "Efficacy and tolerability of extended-release felodipine and extended-release nifedipine in patients with mild-to-moderate essential hypertension." Clin Ther 16 (1994):  634-46|Blecker D "Antihypertensive therapy with isradipine in patients with special safety concerns." Angiology 45 (1994):  997-1008|Brogden RN, Sorkin EM "Isradipine: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension." Drugs 49 (1995):  618-49|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Johnson BF, Eisner GM, Mcmahon FG, Jain AK, Rudd P, Sowers JR "A multicenter comparison of adverse reaction profiles of isradipine and enalapril at equipotent doses in patients with essential hypertension." J Clin Pharmacol 35 (1995):  484-92|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Sleight P "Calcium antagonists during and after myocardial infarction." Drugs 51 (1996):  216-25|Elkayam U "Calcium channel blockers in heart failure." Cardiology 89 (1998):  38-46|Schaefer RM, Aldons PM, Burgess ED, Tilvis R, Singh GP, Rehn L, Morgan TO "Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: A randomised, double-blind study in 535 patients, focusing on vasodilatory adverse events." Int J Clin Pract 52 (1998):  381|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51160, 25003, 'Felodipine', 'Heart Failure', 'Calcium channel blockers (CCBs) may have varying degrees of negative inotropic effect.  Congestive heart failure (CHF), worsening of CHF, and pulmonary edema have occurred in some patients treated with a CCB, primarily verapamil.  Some CCBs have also caused mild to moderate peripheral edema due to localized vasodilation of dependent arterioles and small blood vessels, which can be confused with the effects of increasing left ventricular dysfunction.  Although some CCBs have been used in the treatment of CHF, therapy with CCBs should be administered cautiously in patients with severe left ventricular dysfunction (e.g., ejection fraction < 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker.  Likewise, caution is advised in patients with acute myocardial infarction and pulmonary congestion documented by X-ray on admission, since associated heart failure may be acutely worsened by administration of a CCB.', '2', 'Gillmer DJ, Kark P "Pulmonary oedema precipitated by nifedipine." Br Med J 280 (1980):  1420-1|Batra AK, Segall PH, Ahmed T "Pulmonary edema with nifedipine in primary pulmonary hypertension." Respiration 47 (1985):  161-3|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Prigogine T, Waterlot Y, Gottignies P, et al. "Acute nonhemodynamic pulmonary edema with nifedipine in primary pulmonary hypertension." Chest 100 (1991):  563-4|Batlouni M, Armaganijan D, Ghorayeb N, Magliano MF "Clinical efficacy and tolerability of isradipine in the treatment of mild-to-moderate hypertension in young and elderly patients." J Cardiovasc Pharmacol 19 (1992):  s53-7|Scheidt S, LeWinter MM, Hermanovich J, Venkataraman K, Freedman D "Efficacy and safety of nicardipine for chronic, stable angina pectoris: a multicenter randomized trial." Am J Cardiol 58 (1986):  715-21|Taylor SH, Frais MA, Lee P, Verma SP, Jackson N, Reynolds G, Silke B "A study of the long-term efficacy and tolerability of oral nicardipine in hypertensive patients." Br J Clin Pharmacol 20 (1985):  s139-42|Dubois C, Blanchard D "Efficacy and safety of nicardipine in 29,104 patients with hypertension." Clin Ther 11 (1989):  452-60|Yedinak KC, Lopez LM "Felodipine: a new dihydropyridine calcium-channel antagonist." DICP 25 (1991):  1193-206|Lorimer AR, Pringle SD "The safety of felodipine." J Cardiovasc Pharmacol 15 (1990):  s85-9|Sundstedt CD, Ruegg PC, Keller A, Waite R "A multicenter evaluation of the safety, tolerability, and efficacy of isradipine in the treatment of essential hypertension." Am J Med 86 (1989):  98-102|Ruegg PC, Nelson DJ "Safety and efficacy of isradipine, alone and in combination, in the treatment of angina pectoris." Am J Med 86 (1989):  70-4|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Walton T, Symes LR "Felodipine and isradipine: new calcium-channel-blocking agents for the treatment of hypertension." Clin Pharm 12 (1993):  261-75|Fagan TC, Haggert BE, Liss C "Efficacy and tolerability of extended-release felodipine and extended-release nifedipine in patients with mild-to-moderate essential hypertension." Clin Ther 16 (1994):  634-46|Blecker D "Antihypertensive therapy with isradipine in patients with special safety concerns." Angiology 45 (1994):  997-1008|Brogden RN, Sorkin EM "Isradipine: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension." Drugs 49 (1995):  618-49|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Johnson BF, Eisner GM, Mcmahon FG, Jain AK, Rudd P, Sowers JR "A multicenter comparison of adverse reaction profiles of isradipine and enalapril at equipotent doses in patients with essential hypertension." J Clin Pharmacol 35 (1995):  484-92|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Sleight P "Calcium antagonists during and after myocardial infarction." Drugs 51 (1996):  216-25|Elkayam U "Calcium channel blockers in heart failure." Cardiology 89 (1998):  38-46|Schaefer RM, Aldons PM, Burgess ED, Tilvis R, Singh GP, Rehn L, Morgan TO "Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: A randomised, double-blind study in 535 patients, focusing on vasodilatory adverse events." Int J Clin Pract 52 (1998):  381|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51161, 25004, 'Felodipine', 'Heart Failure', 'Calcium channel blockers (CCBs) may have varying degrees of negative inotropic effect.  Congestive heart failure (CHF), worsening of CHF, and pulmonary edema have occurred in some patients treated with a CCB, primarily verapamil.  Some CCBs have also caused mild to moderate peripheral edema due to localized vasodilation of dependent arterioles and small blood vessels, which can be confused with the effects of increasing left ventricular dysfunction.  Although some CCBs have been used in the treatment of CHF, therapy with CCBs should be administered cautiously in patients with severe left ventricular dysfunction (e.g., ejection fraction < 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker.  Likewise, caution is advised in patients with acute myocardial infarction and pulmonary congestion documented by X-ray on admission, since associated heart failure may be acutely worsened by administration of a CCB.', '2', 'Gillmer DJ, Kark P "Pulmonary oedema precipitated by nifedipine." Br Med J 280 (1980):  1420-1|Batra AK, Segall PH, Ahmed T "Pulmonary edema with nifedipine in primary pulmonary hypertension." Respiration 47 (1985):  161-3|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Prigogine T, Waterlot Y, Gottignies P, et al. "Acute nonhemodynamic pulmonary edema with nifedipine in primary pulmonary hypertension." Chest 100 (1991):  563-4|Batlouni M, Armaganijan D, Ghorayeb N, Magliano MF "Clinical efficacy and tolerability of isradipine in the treatment of mild-to-moderate hypertension in young and elderly patients." J Cardiovasc Pharmacol 19 (1992):  s53-7|Scheidt S, LeWinter MM, Hermanovich J, Venkataraman K, Freedman D "Efficacy and safety of nicardipine for chronic, stable angina pectoris: a multicenter randomized trial." Am J Cardiol 58 (1986):  715-21|Taylor SH, Frais MA, Lee P, Verma SP, Jackson N, Reynolds G, Silke B "A study of the long-term efficacy and tolerability of oral nicardipine in hypertensive patients." Br J Clin Pharmacol 20 (1985):  s139-42|Dubois C, Blanchard D "Efficacy and safety of nicardipine in 29,104 patients with hypertension." Clin Ther 11 (1989):  452-60|Yedinak KC, Lopez LM "Felodipine: a new dihydropyridine calcium-channel antagonist." DICP 25 (1991):  1193-206|Lorimer AR, Pringle SD "The safety of felodipine." J Cardiovasc Pharmacol 15 (1990):  s85-9|Sundstedt CD, Ruegg PC, Keller A, Waite R "A multicenter evaluation of the safety, tolerability, and efficacy of isradipine in the treatment of essential hypertension." Am J Med 86 (1989):  98-102|Ruegg PC, Nelson DJ "Safety and efficacy of isradipine, alone and in combination, in the treatment of angina pectoris." Am J Med 86 (1989):  70-4|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Walton T, Symes LR "Felodipine and isradipine: new calcium-channel-blocking agents for the treatment of hypertension." Clin Pharm 12 (1993):  261-75|Fagan TC, Haggert BE, Liss C "Efficacy and tolerability of extended-release felodipine and extended-release nifedipine in patients with mild-to-moderate essential hypertension." Clin Ther 16 (1994):  634-46|Blecker D "Antihypertensive therapy with isradipine in patients with special safety concerns." Angiology 45 (1994):  997-1008|Brogden RN, Sorkin EM "Isradipine: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension." Drugs 49 (1995):  618-49|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Johnson BF, Eisner GM, Mcmahon FG, Jain AK, Rudd P, Sowers JR "A multicenter comparison of adverse reaction profiles of isradipine and enalapril at equipotent doses in patients with essential hypertension." J Clin Pharmacol 35 (1995):  484-92|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Sleight P "Calcium antagonists during and after myocardial infarction." Drugs 51 (1996):  216-25|Elkayam U "Calcium channel blockers in heart failure." Cardiology 89 (1998):  38-46|Schaefer RM, Aldons PM, Burgess ED, Tilvis R, Singh GP, Rehn L, Morgan TO "Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: A randomised, double-blind study in 535 patients, focusing on vasodilatory adverse events." Int J Clin Pract 52 (1998):  381|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51162, 25005, 'Felodipine', 'Heart Failure', 'Calcium channel blockers (CCBs) may have varying degrees of negative inotropic effect.  Congestive heart failure (CHF), worsening of CHF, and pulmonary edema have occurred in some patients treated with a CCB, primarily verapamil.  Some CCBs have also caused mild to moderate peripheral edema due to localized vasodilation of dependent arterioles and small blood vessels, which can be confused with the effects of increasing left ventricular dysfunction.  Although some CCBs have been used in the treatment of CHF, therapy with CCBs should be administered cautiously in patients with severe left ventricular dysfunction (e.g., ejection fraction < 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker.  Likewise, caution is advised in patients with acute myocardial infarction and pulmonary congestion documented by X-ray on admission, since associated heart failure may be acutely worsened by administration of a CCB.', '2', 'Gillmer DJ, Kark P "Pulmonary oedema precipitated by nifedipine." Br Med J 280 (1980):  1420-1|Batra AK, Segall PH, Ahmed T "Pulmonary edema with nifedipine in primary pulmonary hypertension." Respiration 47 (1985):  161-3|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Prigogine T, Waterlot Y, Gottignies P, et al. "Acute nonhemodynamic pulmonary edema with nifedipine in primary pulmonary hypertension." Chest 100 (1991):  563-4|Batlouni M, Armaganijan D, Ghorayeb N, Magliano MF "Clinical efficacy and tolerability of isradipine in the treatment of mild-to-moderate hypertension in young and elderly patients." J Cardiovasc Pharmacol 19 (1992):  s53-7|Scheidt S, LeWinter MM, Hermanovich J, Venkataraman K, Freedman D "Efficacy and safety of nicardipine for chronic, stable angina pectoris: a multicenter randomized trial." Am J Cardiol 58 (1986):  715-21|Taylor SH, Frais MA, Lee P, Verma SP, Jackson N, Reynolds G, Silke B "A study of the long-term efficacy and tolerability of oral nicardipine in hypertensive patients." Br J Clin Pharmacol 20 (1985):  s139-42|Dubois C, Blanchard D "Efficacy and safety of nicardipine in 29,104 patients with hypertension." Clin Ther 11 (1989):  452-60|Yedinak KC, Lopez LM "Felodipine: a new dihydropyridine calcium-channel antagonist." DICP 25 (1991):  1193-206|Lorimer AR, Pringle SD "The safety of felodipine." J Cardiovasc Pharmacol 15 (1990):  s85-9|Sundstedt CD, Ruegg PC, Keller A, Waite R "A multicenter evaluation of the safety, tolerability, and efficacy of isradipine in the treatment of essential hypertension." Am J Med 86 (1989):  98-102|Ruegg PC, Nelson DJ "Safety and efficacy of isradipine, alone and in combination, in the treatment of angina pectoris." Am J Med 86 (1989):  70-4|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Walton T, Symes LR "Felodipine and isradipine: new calcium-channel-blocking agents for the treatment of hypertension." Clin Pharm 12 (1993):  261-75|Fagan TC, Haggert BE, Liss C "Efficacy and tolerability of extended-release felodipine and extended-release nifedipine in patients with mild-to-moderate essential hypertension." Clin Ther 16 (1994):  634-46|Blecker D "Antihypertensive therapy with isradipine in patients with special safety concerns." Angiology 45 (1994):  997-1008|Brogden RN, Sorkin EM "Isradipine: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension." Drugs 49 (1995):  618-49|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Johnson BF, Eisner GM, Mcmahon FG, Jain AK, Rudd P, Sowers JR "A multicenter comparison of adverse reaction profiles of isradipine and enalapril at equipotent doses in patients with essential hypertension." J Clin Pharmacol 35 (1995):  484-92|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Sleight P "Calcium antagonists during and after myocardial infarction." Drugs 51 (1996):  216-25|Elkayam U "Calcium channel blockers in heart failure." Cardiology 89 (1998):  38-46|Schaefer RM, Aldons PM, Burgess ED, Tilvis R, Singh GP, Rehn L, Morgan TO "Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: A randomised, double-blind study in 535 patients, focusing on vasodilatory adverse events." Int J Clin Pract 52 (1998):  381|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51163, 25006, 'Felodipine', 'Heart Failure', 'Calcium channel blockers (CCBs) may have varying degrees of negative inotropic effect.  Congestive heart failure (CHF), worsening of CHF, and pulmonary edema have occurred in some patients treated with a CCB, primarily verapamil.  Some CCBs have also caused mild to moderate peripheral edema due to localized vasodilation of dependent arterioles and small blood vessels, which can be confused with the effects of increasing left ventricular dysfunction.  Although some CCBs have been used in the treatment of CHF, therapy with CCBs should be administered cautiously in patients with severe left ventricular dysfunction (e.g., ejection fraction < 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker.  Likewise, caution is advised in patients with acute myocardial infarction and pulmonary congestion documented by X-ray on admission, since associated heart failure may be acutely worsened by administration of a CCB.', '2', 'Gillmer DJ, Kark P "Pulmonary oedema precipitated by nifedipine." Br Med J 280 (1980):  1420-1|Batra AK, Segall PH, Ahmed T "Pulmonary edema with nifedipine in primary pulmonary hypertension." Respiration 47 (1985):  161-3|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Prigogine T, Waterlot Y, Gottignies P, et al. "Acute nonhemodynamic pulmonary edema with nifedipine in primary pulmonary hypertension." Chest 100 (1991):  563-4|Batlouni M, Armaganijan D, Ghorayeb N, Magliano MF "Clinical efficacy and tolerability of isradipine in the treatment of mild-to-moderate hypertension in young and elderly patients." J Cardiovasc Pharmacol 19 (1992):  s53-7|Scheidt S, LeWinter MM, Hermanovich J, Venkataraman K, Freedman D "Efficacy and safety of nicardipine for chronic, stable angina pectoris: a multicenter randomized trial." Am J Cardiol 58 (1986):  715-21|Taylor SH, Frais MA, Lee P, Verma SP, Jackson N, Reynolds G, Silke B "A study of the long-term efficacy and tolerability of oral nicardipine in hypertensive patients." Br J Clin Pharmacol 20 (1985):  s139-42|Dubois C, Blanchard D "Efficacy and safety of nicardipine in 29,104 patients with hypertension." Clin Ther 11 (1989):  452-60|Yedinak KC, Lopez LM "Felodipine: a new dihydropyridine calcium-channel antagonist." DICP 25 (1991):  1193-206|Lorimer AR, Pringle SD "The safety of felodipine." J Cardiovasc Pharmacol 15 (1990):  s85-9|Sundstedt CD, Ruegg PC, Keller A, Waite R "A multicenter evaluation of the safety, tolerability, and efficacy of isradipine in the treatment of essential hypertension." Am J Med 86 (1989):  98-102|Ruegg PC, Nelson DJ "Safety and efficacy of isradipine, alone and in combination, in the treatment of angina pectoris." Am J Med 86 (1989):  70-4|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Walton T, Symes LR "Felodipine and isradipine: new calcium-channel-blocking agents for the treatment of hypertension." Clin Pharm 12 (1993):  261-75|Fagan TC, Haggert BE, Liss C "Efficacy and tolerability of extended-release felodipine and extended-release nifedipine in patients with mild-to-moderate essential hypertension." Clin Ther 16 (1994):  634-46|Blecker D "Antihypertensive therapy with isradipine in patients with special safety concerns." Angiology 45 (1994):  997-1008|Brogden RN, Sorkin EM "Isradipine: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension." Drugs 49 (1995):  618-49|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Johnson BF, Eisner GM, Mcmahon FG, Jain AK, Rudd P, Sowers JR "A multicenter comparison of adverse reaction profiles of isradipine and enalapril at equipotent doses in patients with essential hypertension." J Clin Pharmacol 35 (1995):  484-92|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Sleight P "Calcium antagonists during and after myocardial infarction." Drugs 51 (1996):  216-25|Elkayam U "Calcium channel blockers in heart failure." Cardiology 89 (1998):  38-46|Schaefer RM, Aldons PM, Burgess ED, Tilvis R, Singh GP, Rehn L, Morgan TO "Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: A randomised, double-blind study in 535 patients, focusing on vasodilatory adverse events." Int J Clin Pract 52 (1998):  381|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51164, 25007, 'Felodipine', 'Heart Failure', 'Calcium channel blockers (CCBs) may have varying degrees of negative inotropic effect.  Congestive heart failure (CHF), worsening of CHF, and pulmonary edema have occurred in some patients treated with a CCB, primarily verapamil.  Some CCBs have also caused mild to moderate peripheral edema due to localized vasodilation of dependent arterioles and small blood vessels, which can be confused with the effects of increasing left ventricular dysfunction.  Although some CCBs have been used in the treatment of CHF, therapy with CCBs should be administered cautiously in patients with severe left ventricular dysfunction (e.g., ejection fraction < 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker.  Likewise, caution is advised in patients with acute myocardial infarction and pulmonary congestion documented by X-ray on admission, since associated heart failure may be acutely worsened by administration of a CCB.', '2', 'Gillmer DJ, Kark P "Pulmonary oedema precipitated by nifedipine." Br Med J 280 (1980):  1420-1|Batra AK, Segall PH, Ahmed T "Pulmonary edema with nifedipine in primary pulmonary hypertension." Respiration 47 (1985):  161-3|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Prigogine T, Waterlot Y, Gottignies P, et al. "Acute nonhemodynamic pulmonary edema with nifedipine in primary pulmonary hypertension." Chest 100 (1991):  563-4|Batlouni M, Armaganijan D, Ghorayeb N, Magliano MF "Clinical efficacy and tolerability of isradipine in the treatment of mild-to-moderate hypertension in young and elderly patients." J Cardiovasc Pharmacol 19 (1992):  s53-7|Scheidt S, LeWinter MM, Hermanovich J, Venkataraman K, Freedman D "Efficacy and safety of nicardipine for chronic, stable angina pectoris: a multicenter randomized trial." Am J Cardiol 58 (1986):  715-21|Taylor SH, Frais MA, Lee P, Verma SP, Jackson N, Reynolds G, Silke B "A study of the long-term efficacy and tolerability of oral nicardipine in hypertensive patients." Br J Clin Pharmacol 20 (1985):  s139-42|Dubois C, Blanchard D "Efficacy and safety of nicardipine in 29,104 patients with hypertension." Clin Ther 11 (1989):  452-60|Yedinak KC, Lopez LM "Felodipine: a new dihydropyridine calcium-channel antagonist." DICP 25 (1991):  1193-206|Lorimer AR, Pringle SD "The safety of felodipine." J Cardiovasc Pharmacol 15 (1990):  s85-9|Sundstedt CD, Ruegg PC, Keller A, Waite R "A multicenter evaluation of the safety, tolerability, and efficacy of isradipine in the treatment of essential hypertension." Am J Med 86 (1989):  98-102|Ruegg PC, Nelson DJ "Safety and efficacy of isradipine, alone and in combination, in the treatment of angina pectoris." Am J Med 86 (1989):  70-4|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Walton T, Symes LR "Felodipine and isradipine: new calcium-channel-blocking agents for the treatment of hypertension." Clin Pharm 12 (1993):  261-75|Fagan TC, Haggert BE, Liss C "Efficacy and tolerability of extended-release felodipine and extended-release nifedipine in patients with mild-to-moderate essential hypertension." Clin Ther 16 (1994):  634-46|Blecker D "Antihypertensive therapy with isradipine in patients with special safety concerns." Angiology 45 (1994):  997-1008|Brogden RN, Sorkin EM "Isradipine: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension." Drugs 49 (1995):  618-49|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Johnson BF, Eisner GM, Mcmahon FG, Jain AK, Rudd P, Sowers JR "A multicenter comparison of adverse reaction profiles of isradipine and enalapril at equipotent doses in patients with essential hypertension." J Clin Pharmacol 35 (1995):  484-92|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Sleight P "Calcium antagonists during and after myocardial infarction." Drugs 51 (1996):  216-25|Elkayam U "Calcium channel blockers in heart failure." Cardiology 89 (1998):  38-46|Schaefer RM, Aldons PM, Burgess ED, Tilvis R, Singh GP, Rehn L, Morgan TO "Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: A randomised, double-blind study in 535 patients, focusing on vasodilatory adverse events." Int J Clin Pract 52 (1998):  381|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51165, 25008, 'Felodipine', 'Heart Failure', 'Calcium channel blockers (CCBs) may have varying degrees of negative inotropic effect.  Congestive heart failure (CHF), worsening of CHF, and pulmonary edema have occurred in some patients treated with a CCB, primarily verapamil.  Some CCBs have also caused mild to moderate peripheral edema due to localized vasodilation of dependent arterioles and small blood vessels, which can be confused with the effects of increasing left ventricular dysfunction.  Although some CCBs have been used in the treatment of CHF, therapy with CCBs should be administered cautiously in patients with severe left ventricular dysfunction (e.g., ejection fraction < 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker.  Likewise, caution is advised in patients with acute myocardial infarction and pulmonary congestion documented by X-ray on admission, since associated heart failure may be acutely worsened by administration of a CCB.', '2', 'Gillmer DJ, Kark P "Pulmonary oedema precipitated by nifedipine." Br Med J 280 (1980):  1420-1|Batra AK, Segall PH, Ahmed T "Pulmonary edema with nifedipine in primary pulmonary hypertension." Respiration 47 (1985):  161-3|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Prigogine T, Waterlot Y, Gottignies P, et al. "Acute nonhemodynamic pulmonary edema with nifedipine in primary pulmonary hypertension." Chest 100 (1991):  563-4|Batlouni M, Armaganijan D, Ghorayeb N, Magliano MF "Clinical efficacy and tolerability of isradipine in the treatment of mild-to-moderate hypertension in young and elderly patients." J Cardiovasc Pharmacol 19 (1992):  s53-7|Scheidt S, LeWinter MM, Hermanovich J, Venkataraman K, Freedman D "Efficacy and safety of nicardipine for chronic, stable angina pectoris: a multicenter randomized trial." Am J Cardiol 58 (1986):  715-21|Taylor SH, Frais MA, Lee P, Verma SP, Jackson N, Reynolds G, Silke B "A study of the long-term efficacy and tolerability of oral nicardipine in hypertensive patients." Br J Clin Pharmacol 20 (1985):  s139-42|Dubois C, Blanchard D "Efficacy and safety of nicardipine in 29,104 patients with hypertension." Clin Ther 11 (1989):  452-60|Yedinak KC, Lopez LM "Felodipine: a new dihydropyridine calcium-channel antagonist." DICP 25 (1991):  1193-206|Lorimer AR, Pringle SD "The safety of felodipine." J Cardiovasc Pharmacol 15 (1990):  s85-9|Sundstedt CD, Ruegg PC, Keller A, Waite R "A multicenter evaluation of the safety, tolerability, and efficacy of isradipine in the treatment of essential hypertension." Am J Med 86 (1989):  98-102|Ruegg PC, Nelson DJ "Safety and efficacy of isradipine, alone and in combination, in the treatment of angina pectoris." Am J Med 86 (1989):  70-4|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Walton T, Symes LR "Felodipine and isradipine: new calcium-channel-blocking agents for the treatment of hypertension." Clin Pharm 12 (1993):  261-75|Fagan TC, Haggert BE, Liss C "Efficacy and tolerability of extended-release felodipine and extended-release nifedipine in patients with mild-to-moderate essential hypertension." Clin Ther 16 (1994):  634-46|Blecker D "Antihypertensive therapy with isradipine in patients with special safety concerns." Angiology 45 (1994):  997-1008|Brogden RN, Sorkin EM "Isradipine: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension." Drugs 49 (1995):  618-49|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Johnson BF, Eisner GM, Mcmahon FG, Jain AK, Rudd P, Sowers JR "A multicenter comparison of adverse reaction profiles of isradipine and enalapril at equipotent doses in patients with essential hypertension." J Clin Pharmacol 35 (1995):  484-92|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Sleight P "Calcium antagonists during and after myocardial infarction." Drugs 51 (1996):  216-25|Elkayam U "Calcium channel blockers in heart failure." Cardiology 89 (1998):  38-46|Schaefer RM, Aldons PM, Burgess ED, Tilvis R, Singh GP, Rehn L, Morgan TO "Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: A randomised, double-blind study in 535 patients, focusing on vasodilatory adverse events." Int J Clin Pract 52 (1998):  381|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51166, 17996, 'Famciclovir', 'Kidney Diseases', 'Penciclovir, the active antiviral metabolite of famciclovir, is primarily eliminated by the kidney.  Acute renal failure has been reported in patients with underlying renal disease who did not receive an appropriate dosage reduction.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl < 60 mL/min).', '3', 'Boike SC, Pue MA, Freed MI, Audet PR, Fairless A, Ilson BE, Zariffa N, Jorkasky DK "Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairment." Clin Pharmacol Ther 55 (1994):  418-26|"Product Information. Famvir (famciclovir)." SmithKline Beecham  (2001):|Gill KS, Wood MJ "The clinical pharmacokinetics of famciclovir." Clin Pharmacokinet 31 (1996):  1-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51167, 25359, 'Famciclovir', 'Kidney Diseases', 'Penciclovir, the active antiviral metabolite of famciclovir, is primarily eliminated by the kidney.  Acute renal failure has been reported in patients with underlying renal disease who did not receive an appropriate dosage reduction.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl < 60 mL/min).', '3', 'Boike SC, Pue MA, Freed MI, Audet PR, Fairless A, Ilson BE, Zariffa N, Jorkasky DK "Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairment." Clin Pharmacol Ther 55 (1994):  418-26|"Product Information. Famvir (famciclovir)." SmithKline Beecham  (2001):|Gill KS, Wood MJ "The clinical pharmacokinetics of famciclovir." Clin Pharmacokinet 31 (1996):  1-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51168, 25360, 'Famciclovir', 'Kidney Diseases', 'Penciclovir, the active antiviral metabolite of famciclovir, is primarily eliminated by the kidney.  Acute renal failure has been reported in patients with underlying renal disease who did not receive an appropriate dosage reduction.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl < 60 mL/min).', '3', 'Boike SC, Pue MA, Freed MI, Audet PR, Fairless A, Ilson BE, Zariffa N, Jorkasky DK "Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairment." Clin Pharmacol Ther 55 (1994):  418-26|"Product Information. Famvir (famciclovir)." SmithKline Beecham  (2001):|Gill KS, Wood MJ "The clinical pharmacokinetics of famciclovir." Clin Pharmacokinet 31 (1996):  1-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51169, 25361, 'Famciclovir', 'Kidney Diseases', 'Penciclovir, the active antiviral metabolite of famciclovir, is primarily eliminated by the kidney.  Acute renal failure has been reported in patients with underlying renal disease who did not receive an appropriate dosage reduction.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl < 60 mL/min).', '3', 'Boike SC, Pue MA, Freed MI, Audet PR, Fairless A, Ilson BE, Zariffa N, Jorkasky DK "Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairment." Clin Pharmacol Ther 55 (1994):  418-26|"Product Information. Famvir (famciclovir)." SmithKline Beecham  (2001):|Gill KS, Wood MJ "The clinical pharmacokinetics of famciclovir." Clin Pharmacokinet 31 (1996):  1-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51170, 17996, 'Famciclovir', 'Liver Diseases', 'Famciclovir is converted by the liver to the active antiviral metabolite, penciclovir.  The bioavailability of penciclovir following a dose of famciclovir was not affected in patients with well-compensated chronic liver disease.  However, there are no data on the pharmacokinetic disposition of famciclovir in patients with severe uncompensated liver disease.  Therapy with famciclovir should be administered cautiously in these patients, since the clinical significance of possible famciclovir accumulation is unknown.  Theoretically, famciclovir may also not be effective in these patients.', '2', '"Product Information. Famvir (famciclovir)." SmithKline Beecham  (2001):|Boike SC, Pue M, Audet PR, Freed MI, Fairless A, Ilson BE, Zariffa N, Jorkasky DK "Pharmacokinetics of famciclovir in subjects with chronic hepatic disease." J Clin Pharmacol 34 (1994):  1199-207|Perry CM, Wagstaff AJ "Famciclovir - a review of its pharmacological properties and therapeutic efficacy in herpesvirus infections." Drugs 50 (1995):  396-415|Gill KS, Wood MJ "The clinical pharmacokinetics of famciclovir." Clin Pharmacokinet 31 (1996):  1-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51171, 25359, 'Famciclovir', 'Liver Diseases', 'Famciclovir is converted by the liver to the active antiviral metabolite, penciclovir.  The bioavailability of penciclovir following a dose of famciclovir was not affected in patients with well-compensated chronic liver disease.  However, there are no data on the pharmacokinetic disposition of famciclovir in patients with severe uncompensated liver disease.  Therapy with famciclovir should be administered cautiously in these patients, since the clinical significance of possible famciclovir accumulation is unknown.  Theoretically, famciclovir may also not be effective in these patients.', '2', '"Product Information. Famvir (famciclovir)." SmithKline Beecham  (2001):|Boike SC, Pue M, Audet PR, Freed MI, Fairless A, Ilson BE, Zariffa N, Jorkasky DK "Pharmacokinetics of famciclovir in subjects with chronic hepatic disease." J Clin Pharmacol 34 (1994):  1199-207|Perry CM, Wagstaff AJ "Famciclovir - a review of its pharmacological properties and therapeutic efficacy in herpesvirus infections." Drugs 50 (1995):  396-415|Gill KS, Wood MJ "The clinical pharmacokinetics of famciclovir." Clin Pharmacokinet 31 (1996):  1-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51172, 25360, 'Famciclovir', 'Liver Diseases', 'Famciclovir is converted by the liver to the active antiviral metabolite, penciclovir.  The bioavailability of penciclovir following a dose of famciclovir was not affected in patients with well-compensated chronic liver disease.  However, there are no data on the pharmacokinetic disposition of famciclovir in patients with severe uncompensated liver disease.  Therapy with famciclovir should be administered cautiously in these patients, since the clinical significance of possible famciclovir accumulation is unknown.  Theoretically, famciclovir may also not be effective in these patients.', '2', '"Product Information. Famvir (famciclovir)." SmithKline Beecham  (2001):|Boike SC, Pue M, Audet PR, Freed MI, Fairless A, Ilson BE, Zariffa N, Jorkasky DK "Pharmacokinetics of famciclovir in subjects with chronic hepatic disease." J Clin Pharmacol 34 (1994):  1199-207|Perry CM, Wagstaff AJ "Famciclovir - a review of its pharmacological properties and therapeutic efficacy in herpesvirus infections." Drugs 50 (1995):  396-415|Gill KS, Wood MJ "The clinical pharmacokinetics of famciclovir." Clin Pharmacokinet 31 (1996):  1-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51173, 25361, 'Famciclovir', 'Liver Diseases', 'Famciclovir is converted by the liver to the active antiviral metabolite, penciclovir.  The bioavailability of penciclovir following a dose of famciclovir was not affected in patients with well-compensated chronic liver disease.  However, there are no data on the pharmacokinetic disposition of famciclovir in patients with severe uncompensated liver disease.  Therapy with famciclovir should be administered cautiously in these patients, since the clinical significance of possible famciclovir accumulation is unknown.  Theoretically, famciclovir may also not be effective in these patients.', '2', '"Product Information. Famvir (famciclovir)." SmithKline Beecham  (2001):|Boike SC, Pue M, Audet PR, Freed MI, Fairless A, Ilson BE, Zariffa N, Jorkasky DK "Pharmacokinetics of famciclovir in subjects with chronic hepatic disease." J Clin Pharmacol 34 (1994):  1199-207|Perry CM, Wagstaff AJ "Famciclovir - a review of its pharmacological properties and therapeutic efficacy in herpesvirus infections." Drugs 50 (1995):  396-415|Gill KS, Wood MJ "The clinical pharmacokinetics of famciclovir." Clin Pharmacokinet 31 (1996):  1-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51174, 4796, 'Fenofibrate', 'Liver Cirrhosis, Biliary', 'The use of fibric acid derivatives is contraindicated in patients with primary biliary cirrhosis.  These agents may further raise the already elevated cholesterol in these patients.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51175, 4870, 'Fenofibrate', 'Liver Cirrhosis, Biliary', 'The use of fibric acid derivatives is contraindicated in patients with primary biliary cirrhosis.  These agents may further raise the already elevated cholesterol in these patients.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51176, 7338, 'Fenofibrate', 'Liver Cirrhosis, Biliary', 'The use of fibric acid derivatives is contraindicated in patients with primary biliary cirrhosis.  These agents may further raise the already elevated cholesterol in these patients.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51177, 7341, 'Fenofibrate', 'Liver Cirrhosis, Biliary', 'The use of fibric acid derivatives is contraindicated in patients with primary biliary cirrhosis.  These agents may further raise the already elevated cholesterol in these patients.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51178, 7391, 'Fenofibrate', 'Liver Cirrhosis, Biliary', 'The use of fibric acid derivatives is contraindicated in patients with primary biliary cirrhosis.  These agents may further raise the already elevated cholesterol in these patients.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51179, 7393, 'Fenofibrate', 'Liver Cirrhosis, Biliary', 'The use of fibric acid derivatives is contraindicated in patients with primary biliary cirrhosis.  These agents may further raise the already elevated cholesterol in these patients.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51180, 18946, 'Fenofibrate', 'Liver Cirrhosis, Biliary', 'The use of fibric acid derivatives is contraindicated in patients with primary biliary cirrhosis.  These agents may further raise the already elevated cholesterol in these patients.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51181, 21293, 'Fenofibrate', 'Liver Cirrhosis, Biliary', 'The use of fibric acid derivatives is contraindicated in patients with primary biliary cirrhosis.  These agents may further raise the already elevated cholesterol in these patients.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51182, 21876, 'Fenofibrate', 'Liver Cirrhosis, Biliary', 'The use of fibric acid derivatives is contraindicated in patients with primary biliary cirrhosis.  These agents may further raise the already elevated cholesterol in these patients.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51183, 21902, 'Fenofibrate', 'Liver Cirrhosis, Biliary', 'The use of fibric acid derivatives is contraindicated in patients with primary biliary cirrhosis.  These agents may further raise the already elevated cholesterol in these patients.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51184, 21908, 'Fenofibrate', 'Liver Cirrhosis, Biliary', 'The use of fibric acid derivatives is contraindicated in patients with primary biliary cirrhosis.  These agents may further raise the already elevated cholesterol in these patients.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51185, 23677, 'Fenofibrate', 'Liver Cirrhosis, Biliary', 'The use of fibric acid derivatives is contraindicated in patients with primary biliary cirrhosis.  These agents may further raise the already elevated cholesterol in these patients.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51186, 23678, 'Fenofibrate', 'Liver Cirrhosis, Biliary', 'The use of fibric acid derivatives is contraindicated in patients with primary biliary cirrhosis.  These agents may further raise the already elevated cholesterol in these patients.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51187, 30829, 'Fenofibrate', 'Liver Cirrhosis, Biliary', 'The use of fibric acid derivatives is contraindicated in patients with primary biliary cirrhosis.  These agents may further raise the already elevated cholesterol in these patients.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51188, 4796, 'Fenofibrate', 'Cholelithiasis', 'The use of fibric acid derivatives is contraindicated in patients with gallbladder disease.  A significantly increased incidence of cholelithiasis has been observed in patients treated with the fibric acid derivative, clofibrate, presumably because of increased cholesterol excretion into the bile.  Based on two separate studies (the WHO study and the Coronary Drug Project study), clofibrate use was associated with twice the risk of developing cholelithiasis and cholecystitis requiring surgery.  Due to their structural and pharmacologic similarities, use of other fibric acid derivatives may be expected to carry the same risk.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Blane GF "Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives." Am J Med 83 (1987):  26-36|Roberts WC "Safety of fenofibrate--US and worldwide experience." Cardiology 76 (1989):  169-79|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51189, 4870, 'Fenofibrate', 'Cholelithiasis', 'The use of fibric acid derivatives is contraindicated in patients with gallbladder disease.  A significantly increased incidence of cholelithiasis has been observed in patients treated with the fibric acid derivative, clofibrate, presumably because of increased cholesterol excretion into the bile.  Based on two separate studies (the WHO study and the Coronary Drug Project study), clofibrate use was associated with twice the risk of developing cholelithiasis and cholecystitis requiring surgery.  Due to their structural and pharmacologic similarities, use of other fibric acid derivatives may be expected to carry the same risk.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Blane GF "Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives." Am J Med 83 (1987):  26-36|Roberts WC "Safety of fenofibrate--US and worldwide experience." Cardiology 76 (1989):  169-79|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51190, 7338, 'Fenofibrate', 'Cholelithiasis', 'The use of fibric acid derivatives is contraindicated in patients with gallbladder disease.  A significantly increased incidence of cholelithiasis has been observed in patients treated with the fibric acid derivative, clofibrate, presumably because of increased cholesterol excretion into the bile.  Based on two separate studies (the WHO study and the Coronary Drug Project study), clofibrate use was associated with twice the risk of developing cholelithiasis and cholecystitis requiring surgery.  Due to their structural and pharmacologic similarities, use of other fibric acid derivatives may be expected to carry the same risk.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Blane GF "Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives." Am J Med 83 (1987):  26-36|Roberts WC "Safety of fenofibrate--US and worldwide experience." Cardiology 76 (1989):  169-79|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51191, 7341, 'Fenofibrate', 'Cholelithiasis', 'The use of fibric acid derivatives is contraindicated in patients with gallbladder disease.  A significantly increased incidence of cholelithiasis has been observed in patients treated with the fibric acid derivative, clofibrate, presumably because of increased cholesterol excretion into the bile.  Based on two separate studies (the WHO study and the Coronary Drug Project study), clofibrate use was associated with twice the risk of developing cholelithiasis and cholecystitis requiring surgery.  Due to their structural and pharmacologic similarities, use of other fibric acid derivatives may be expected to carry the same risk.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Blane GF "Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives." Am J Med 83 (1987):  26-36|Roberts WC "Safety of fenofibrate--US and worldwide experience." Cardiology 76 (1989):  169-79|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51192, 7391, 'Fenofibrate', 'Cholelithiasis', 'The use of fibric acid derivatives is contraindicated in patients with gallbladder disease.  A significantly increased incidence of cholelithiasis has been observed in patients treated with the fibric acid derivative, clofibrate, presumably because of increased cholesterol excretion into the bile.  Based on two separate studies (the WHO study and the Coronary Drug Project study), clofibrate use was associated with twice the risk of developing cholelithiasis and cholecystitis requiring surgery.  Due to their structural and pharmacologic similarities, use of other fibric acid derivatives may be expected to carry the same risk.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Blane GF "Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives." Am J Med 83 (1987):  26-36|Roberts WC "Safety of fenofibrate--US and worldwide experience." Cardiology 76 (1989):  169-79|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51193, 7393, 'Fenofibrate', 'Cholelithiasis', 'The use of fibric acid derivatives is contraindicated in patients with gallbladder disease.  A significantly increased incidence of cholelithiasis has been observed in patients treated with the fibric acid derivative, clofibrate, presumably because of increased cholesterol excretion into the bile.  Based on two separate studies (the WHO study and the Coronary Drug Project study), clofibrate use was associated with twice the risk of developing cholelithiasis and cholecystitis requiring surgery.  Due to their structural and pharmacologic similarities, use of other fibric acid derivatives may be expected to carry the same risk.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Blane GF "Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives." Am J Med 83 (1987):  26-36|Roberts WC "Safety of fenofibrate--US and worldwide experience." Cardiology 76 (1989):  169-79|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51194, 18946, 'Fenofibrate', 'Cholelithiasis', 'The use of fibric acid derivatives is contraindicated in patients with gallbladder disease.  A significantly increased incidence of cholelithiasis has been observed in patients treated with the fibric acid derivative, clofibrate, presumably because of increased cholesterol excretion into the bile.  Based on two separate studies (the WHO study and the Coronary Drug Project study), clofibrate use was associated with twice the risk of developing cholelithiasis and cholecystitis requiring surgery.  Due to their structural and pharmacologic similarities, use of other fibric acid derivatives may be expected to carry the same risk.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Blane GF "Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives." Am J Med 83 (1987):  26-36|Roberts WC "Safety of fenofibrate--US and worldwide experience." Cardiology 76 (1989):  169-79|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51195, 21293, 'Fenofibrate', 'Cholelithiasis', 'The use of fibric acid derivatives is contraindicated in patients with gallbladder disease.  A significantly increased incidence of cholelithiasis has been observed in patients treated with the fibric acid derivative, clofibrate, presumably because of increased cholesterol excretion into the bile.  Based on two separate studies (the WHO study and the Coronary Drug Project study), clofibrate use was associated with twice the risk of developing cholelithiasis and cholecystitis requiring surgery.  Due to their structural and pharmacologic similarities, use of other fibric acid derivatives may be expected to carry the same risk.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Blane GF "Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives." Am J Med 83 (1987):  26-36|Roberts WC "Safety of fenofibrate--US and worldwide experience." Cardiology 76 (1989):  169-79|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51196, 21876, 'Fenofibrate', 'Cholelithiasis', 'The use of fibric acid derivatives is contraindicated in patients with gallbladder disease.  A significantly increased incidence of cholelithiasis has been observed in patients treated with the fibric acid derivative, clofibrate, presumably because of increased cholesterol excretion into the bile.  Based on two separate studies (the WHO study and the Coronary Drug Project study), clofibrate use was associated with twice the risk of developing cholelithiasis and cholecystitis requiring surgery.  Due to their structural and pharmacologic similarities, use of other fibric acid derivatives may be expected to carry the same risk.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Blane GF "Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives." Am J Med 83 (1987):  26-36|Roberts WC "Safety of fenofibrate--US and worldwide experience." Cardiology 76 (1989):  169-79|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51197, 21902, 'Fenofibrate', 'Cholelithiasis', 'The use of fibric acid derivatives is contraindicated in patients with gallbladder disease.  A significantly increased incidence of cholelithiasis has been observed in patients treated with the fibric acid derivative, clofibrate, presumably because of increased cholesterol excretion into the bile.  Based on two separate studies (the WHO study and the Coronary Drug Project study), clofibrate use was associated with twice the risk of developing cholelithiasis and cholecystitis requiring surgery.  Due to their structural and pharmacologic similarities, use of other fibric acid derivatives may be expected to carry the same risk.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Blane GF "Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives." Am J Med 83 (1987):  26-36|Roberts WC "Safety of fenofibrate--US and worldwide experience." Cardiology 76 (1989):  169-79|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51198, 21908, 'Fenofibrate', 'Cholelithiasis', 'The use of fibric acid derivatives is contraindicated in patients with gallbladder disease.  A significantly increased incidence of cholelithiasis has been observed in patients treated with the fibric acid derivative, clofibrate, presumably because of increased cholesterol excretion into the bile.  Based on two separate studies (the WHO study and the Coronary Drug Project study), clofibrate use was associated with twice the risk of developing cholelithiasis and cholecystitis requiring surgery.  Due to their structural and pharmacologic similarities, use of other fibric acid derivatives may be expected to carry the same risk.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Blane GF "Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives." Am J Med 83 (1987):  26-36|Roberts WC "Safety of fenofibrate--US and worldwide experience." Cardiology 76 (1989):  169-79|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51199, 23677, 'Fenofibrate', 'Cholelithiasis', 'The use of fibric acid derivatives is contraindicated in patients with gallbladder disease.  A significantly increased incidence of cholelithiasis has been observed in patients treated with the fibric acid derivative, clofibrate, presumably because of increased cholesterol excretion into the bile.  Based on two separate studies (the WHO study and the Coronary Drug Project study), clofibrate use was associated with twice the risk of developing cholelithiasis and cholecystitis requiring surgery.  Due to their structural and pharmacologic similarities, use of other fibric acid derivatives may be expected to carry the same risk.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Blane GF "Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives." Am J Med 83 (1987):  26-36|Roberts WC "Safety of fenofibrate--US and worldwide experience." Cardiology 76 (1989):  169-79|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51200, 23678, 'Fenofibrate', 'Cholelithiasis', 'The use of fibric acid derivatives is contraindicated in patients with gallbladder disease.  A significantly increased incidence of cholelithiasis has been observed in patients treated with the fibric acid derivative, clofibrate, presumably because of increased cholesterol excretion into the bile.  Based on two separate studies (the WHO study and the Coronary Drug Project study), clofibrate use was associated with twice the risk of developing cholelithiasis and cholecystitis requiring surgery.  Due to their structural and pharmacologic similarities, use of other fibric acid derivatives may be expected to carry the same risk.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Blane GF "Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives." Am J Med 83 (1987):  26-36|Roberts WC "Safety of fenofibrate--US and worldwide experience." Cardiology 76 (1989):  169-79|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51201, 30829, 'Fenofibrate', 'Cholelithiasis', 'The use of fibric acid derivatives is contraindicated in patients with gallbladder disease.  A significantly increased incidence of cholelithiasis has been observed in patients treated with the fibric acid derivative, clofibrate, presumably because of increased cholesterol excretion into the bile.  Based on two separate studies (the WHO study and the Coronary Drug Project study), clofibrate use was associated with twice the risk of developing cholelithiasis and cholecystitis requiring surgery.  Due to their structural and pharmacologic similarities, use of other fibric acid derivatives may be expected to carry the same risk.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Blane GF "Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives." Am J Med 83 (1987):  26-36|Roberts WC "Safety of fenofibrate--US and worldwide experience." Cardiology 76 (1989):  169-79|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51202, 4796, 'Fenofibrate', 'Hypolipoproteinemias', 'There have been reports of severe decreases in HDL cholesterol (HDL-C) levels (as low as 2 mg/dL) occurring in diabetic and non-diabetic patients initiated on fibric acid derivatives therapy.  The decrease has been reported to occur within 2 weeks to years after initiation of therapy.  It is recommended that HDL-C levels be checked within the first few months after initiation therapy and if a severely depressed HDL-C level is detected, therapy with these agents should be withdrawn.  Monitor HDL-C level until it has returned to baseline, and therapy with these agents should not be re-initiated in these patients.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51203, 4870, 'Fenofibrate', 'Hypolipoproteinemias', 'There have been reports of severe decreases in HDL cholesterol (HDL-C) levels (as low as 2 mg/dL) occurring in diabetic and non-diabetic patients initiated on fibric acid derivatives therapy.  The decrease has been reported to occur within 2 weeks to years after initiation of therapy.  It is recommended that HDL-C levels be checked within the first few months after initiation therapy and if a severely depressed HDL-C level is detected, therapy with these agents should be withdrawn.  Monitor HDL-C level until it has returned to baseline, and therapy with these agents should not be re-initiated in these patients.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51204, 7338, 'Fenofibrate', 'Hypolipoproteinemias', 'There have been reports of severe decreases in HDL cholesterol (HDL-C) levels (as low as 2 mg/dL) occurring in diabetic and non-diabetic patients initiated on fibric acid derivatives therapy.  The decrease has been reported to occur within 2 weeks to years after initiation of therapy.  It is recommended that HDL-C levels be checked within the first few months after initiation therapy and if a severely depressed HDL-C level is detected, therapy with these agents should be withdrawn.  Monitor HDL-C level until it has returned to baseline, and therapy with these agents should not be re-initiated in these patients.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51205, 7341, 'Fenofibrate', 'Hypolipoproteinemias', 'There have been reports of severe decreases in HDL cholesterol (HDL-C) levels (as low as 2 mg/dL) occurring in diabetic and non-diabetic patients initiated on fibric acid derivatives therapy.  The decrease has been reported to occur within 2 weeks to years after initiation of therapy.  It is recommended that HDL-C levels be checked within the first few months after initiation therapy and if a severely depressed HDL-C level is detected, therapy with these agents should be withdrawn.  Monitor HDL-C level until it has returned to baseline, and therapy with these agents should not be re-initiated in these patients.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51206, 7391, 'Fenofibrate', 'Hypolipoproteinemias', 'There have been reports of severe decreases in HDL cholesterol (HDL-C) levels (as low as 2 mg/dL) occurring in diabetic and non-diabetic patients initiated on fibric acid derivatives therapy.  The decrease has been reported to occur within 2 weeks to years after initiation of therapy.  It is recommended that HDL-C levels be checked within the first few months after initiation therapy and if a severely depressed HDL-C level is detected, therapy with these agents should be withdrawn.  Monitor HDL-C level until it has returned to baseline, and therapy with these agents should not be re-initiated in these patients.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51207, 7393, 'Fenofibrate', 'Hypolipoproteinemias', 'There have been reports of severe decreases in HDL cholesterol (HDL-C) levels (as low as 2 mg/dL) occurring in diabetic and non-diabetic patients initiated on fibric acid derivatives therapy.  The decrease has been reported to occur within 2 weeks to years after initiation of therapy.  It is recommended that HDL-C levels be checked within the first few months after initiation therapy and if a severely depressed HDL-C level is detected, therapy with these agents should be withdrawn.  Monitor HDL-C level until it has returned to baseline, and therapy with these agents should not be re-initiated in these patients.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51208, 18946, 'Fenofibrate', 'Hypolipoproteinemias', 'There have been reports of severe decreases in HDL cholesterol (HDL-C) levels (as low as 2 mg/dL) occurring in diabetic and non-diabetic patients initiated on fibric acid derivatives therapy.  The decrease has been reported to occur within 2 weeks to years after initiation of therapy.  It is recommended that HDL-C levels be checked within the first few months after initiation therapy and if a severely depressed HDL-C level is detected, therapy with these agents should be withdrawn.  Monitor HDL-C level until it has returned to baseline, and therapy with these agents should not be re-initiated in these patients.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51209, 21293, 'Fenofibrate', 'Hypolipoproteinemias', 'There have been reports of severe decreases in HDL cholesterol (HDL-C) levels (as low as 2 mg/dL) occurring in diabetic and non-diabetic patients initiated on fibric acid derivatives therapy.  The decrease has been reported to occur within 2 weeks to years after initiation of therapy.  It is recommended that HDL-C levels be checked within the first few months after initiation therapy and if a severely depressed HDL-C level is detected, therapy with these agents should be withdrawn.  Monitor HDL-C level until it has returned to baseline, and therapy with these agents should not be re-initiated in these patients.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51210, 21876, 'Fenofibrate', 'Hypolipoproteinemias', 'There have been reports of severe decreases in HDL cholesterol (HDL-C) levels (as low as 2 mg/dL) occurring in diabetic and non-diabetic patients initiated on fibric acid derivatives therapy.  The decrease has been reported to occur within 2 weeks to years after initiation of therapy.  It is recommended that HDL-C levels be checked within the first few months after initiation therapy and if a severely depressed HDL-C level is detected, therapy with these agents should be withdrawn.  Monitor HDL-C level until it has returned to baseline, and therapy with these agents should not be re-initiated in these patients.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51211, 21902, 'Fenofibrate', 'Hypolipoproteinemias', 'There have been reports of severe decreases in HDL cholesterol (HDL-C) levels (as low as 2 mg/dL) occurring in diabetic and non-diabetic patients initiated on fibric acid derivatives therapy.  The decrease has been reported to occur within 2 weeks to years after initiation of therapy.  It is recommended that HDL-C levels be checked within the first few months after initiation therapy and if a severely depressed HDL-C level is detected, therapy with these agents should be withdrawn.  Monitor HDL-C level until it has returned to baseline, and therapy with these agents should not be re-initiated in these patients.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51212, 21908, 'Fenofibrate', 'Hypolipoproteinemias', 'There have been reports of severe decreases in HDL cholesterol (HDL-C) levels (as low as 2 mg/dL) occurring in diabetic and non-diabetic patients initiated on fibric acid derivatives therapy.  The decrease has been reported to occur within 2 weeks to years after initiation of therapy.  It is recommended that HDL-C levels be checked within the first few months after initiation therapy and if a severely depressed HDL-C level is detected, therapy with these agents should be withdrawn.  Monitor HDL-C level until it has returned to baseline, and therapy with these agents should not be re-initiated in these patients.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51213, 23677, 'Fenofibrate', 'Hypolipoproteinemias', 'There have been reports of severe decreases in HDL cholesterol (HDL-C) levels (as low as 2 mg/dL) occurring in diabetic and non-diabetic patients initiated on fibric acid derivatives therapy.  The decrease has been reported to occur within 2 weeks to years after initiation of therapy.  It is recommended that HDL-C levels be checked within the first few months after initiation therapy and if a severely depressed HDL-C level is detected, therapy with these agents should be withdrawn.  Monitor HDL-C level until it has returned to baseline, and therapy with these agents should not be re-initiated in these patients.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51214, 23678, 'Fenofibrate', 'Hypolipoproteinemias', 'There have been reports of severe decreases in HDL cholesterol (HDL-C) levels (as low as 2 mg/dL) occurring in diabetic and non-diabetic patients initiated on fibric acid derivatives therapy.  The decrease has been reported to occur within 2 weeks to years after initiation of therapy.  It is recommended that HDL-C levels be checked within the first few months after initiation therapy and if a severely depressed HDL-C level is detected, therapy with these agents should be withdrawn.  Monitor HDL-C level until it has returned to baseline, and therapy with these agents should not be re-initiated in these patients.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51215, 30829, 'Fenofibrate', 'Hypolipoproteinemias', 'There have been reports of severe decreases in HDL cholesterol (HDL-C) levels (as low as 2 mg/dL) occurring in diabetic and non-diabetic patients initiated on fibric acid derivatives therapy.  The decrease has been reported to occur within 2 weeks to years after initiation of therapy.  It is recommended that HDL-C levels be checked within the first few months after initiation therapy and if a severely depressed HDL-C level is detected, therapy with these agents should be withdrawn.  Monitor HDL-C level until it has returned to baseline, and therapy with these agents should not be re-initiated in these patients.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51216, 4796, 'Fenofibrate', 'Liver Diseases', 'The use of fibric acid derivatives is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  Fibric acid derivatives therapy is associated with dose-related hepatotoxicity, including biochemical abnormalities of liver function, hepatitis (hepatocellular, chronic active, as well as cholestatic) and, rarely, cirrhosis.  Postmarketing cases of severe drug-induced liver injury, including liver transplantation and death, have been reported.  Therapy with these agents should be administered cautiously in patients with a history of liver disease and/or heavy alcohol use.  Liver function tests, including serum transaminase levels and total bilirubin, should be performed at baseline and periodically throughout the duration of therapy.  Therapy should be discontinued if signs or symptoms of liver injury develop or if elevated enzyme levels persist (ALT or AST greater than 3 times the upper limit of normal, or if accompanied by elevation of bilirubin).  Do not restart therapy if there is no alternative explanation for the liver injury.', '3', 'Cayen MN "Disposition, metabolism and pharmacokinetics of antihyperlipidemic agents in laboratory animals and man." Pharmacol Ther 29 (1985):  157-204|Chapman MJ "Pharmacology of fenofibrate." Am J Med 83 (1987):  21-5|Weil A, Caldwell J, Strolin-Benedetti M "The metabolism and disposition of 14C-fenofibrate in human volunteers." Drug Metab Dispos 18 (1990):  115-20|Balfour JA, McTavish D, Heel RC "Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia." Drugs 40 (1990):  260-90|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Adkins JC, Faulds D "Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia." Drugs 54 (1997):  615-33|Miller DB, Spence JD "Clinical pharmacokinetics of fibric acid derivatives (fibrates)." Clin Pharmacokinet 34 (1998):  155-62|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51217, 4870, 'Fenofibrate', 'Liver Diseases', 'The use of fibric acid derivatives is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  Fibric acid derivatives therapy is associated with dose-related hepatotoxicity, including biochemical abnormalities of liver function, hepatitis (hepatocellular, chronic active, as well as cholestatic) and, rarely, cirrhosis.  Postmarketing cases of severe drug-induced liver injury, including liver transplantation and death, have been reported.  Therapy with these agents should be administered cautiously in patients with a history of liver disease and/or heavy alcohol use.  Liver function tests, including serum transaminase levels and total bilirubin, should be performed at baseline and periodically throughout the duration of therapy.  Therapy should be discontinued if signs or symptoms of liver injury develop or if elevated enzyme levels persist (ALT or AST greater than 3 times the upper limit of normal, or if accompanied by elevation of bilirubin).  Do not restart therapy if there is no alternative explanation for the liver injury.', '3', 'Cayen MN "Disposition, metabolism and pharmacokinetics of antihyperlipidemic agents in laboratory animals and man." Pharmacol Ther 29 (1985):  157-204|Chapman MJ "Pharmacology of fenofibrate." Am J Med 83 (1987):  21-5|Weil A, Caldwell J, Strolin-Benedetti M "The metabolism and disposition of 14C-fenofibrate in human volunteers." Drug Metab Dispos 18 (1990):  115-20|Balfour JA, McTavish D, Heel RC "Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia." Drugs 40 (1990):  260-90|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Adkins JC, Faulds D "Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia." Drugs 54 (1997):  615-33|Miller DB, Spence JD "Clinical pharmacokinetics of fibric acid derivatives (fibrates)." Clin Pharmacokinet 34 (1998):  155-62|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51218, 7338, 'Fenofibrate', 'Liver Diseases', 'The use of fibric acid derivatives is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  Fibric acid derivatives therapy is associated with dose-related hepatotoxicity, including biochemical abnormalities of liver function, hepatitis (hepatocellular, chronic active, as well as cholestatic) and, rarely, cirrhosis.  Postmarketing cases of severe drug-induced liver injury, including liver transplantation and death, have been reported.  Therapy with these agents should be administered cautiously in patients with a history of liver disease and/or heavy alcohol use.  Liver function tests, including serum transaminase levels and total bilirubin, should be performed at baseline and periodically throughout the duration of therapy.  Therapy should be discontinued if signs or symptoms of liver injury develop or if elevated enzyme levels persist (ALT or AST greater than 3 times the upper limit of normal, or if accompanied by elevation of bilirubin).  Do not restart therapy if there is no alternative explanation for the liver injury.', '3', 'Cayen MN "Disposition, metabolism and pharmacokinetics of antihyperlipidemic agents in laboratory animals and man." Pharmacol Ther 29 (1985):  157-204|Chapman MJ "Pharmacology of fenofibrate." Am J Med 83 (1987):  21-5|Weil A, Caldwell J, Strolin-Benedetti M "The metabolism and disposition of 14C-fenofibrate in human volunteers." Drug Metab Dispos 18 (1990):  115-20|Balfour JA, McTavish D, Heel RC "Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia." Drugs 40 (1990):  260-90|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Adkins JC, Faulds D "Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia." Drugs 54 (1997):  615-33|Miller DB, Spence JD "Clinical pharmacokinetics of fibric acid derivatives (fibrates)." Clin Pharmacokinet 34 (1998):  155-62|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51219, 7341, 'Fenofibrate', 'Liver Diseases', 'The use of fibric acid derivatives is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  Fibric acid derivatives therapy is associated with dose-related hepatotoxicity, including biochemical abnormalities of liver function, hepatitis (hepatocellular, chronic active, as well as cholestatic) and, rarely, cirrhosis.  Postmarketing cases of severe drug-induced liver injury, including liver transplantation and death, have been reported.  Therapy with these agents should be administered cautiously in patients with a history of liver disease and/or heavy alcohol use.  Liver function tests, including serum transaminase levels and total bilirubin, should be performed at baseline and periodically throughout the duration of therapy.  Therapy should be discontinued if signs or symptoms of liver injury develop or if elevated enzyme levels persist (ALT or AST greater than 3 times the upper limit of normal, or if accompanied by elevation of bilirubin).  Do not restart therapy if there is no alternative explanation for the liver injury.', '3', 'Cayen MN "Disposition, metabolism and pharmacokinetics of antihyperlipidemic agents in laboratory animals and man." Pharmacol Ther 29 (1985):  157-204|Chapman MJ "Pharmacology of fenofibrate." Am J Med 83 (1987):  21-5|Weil A, Caldwell J, Strolin-Benedetti M "The metabolism and disposition of 14C-fenofibrate in human volunteers." Drug Metab Dispos 18 (1990):  115-20|Balfour JA, McTavish D, Heel RC "Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia." Drugs 40 (1990):  260-90|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Adkins JC, Faulds D "Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia." Drugs 54 (1997):  615-33|Miller DB, Spence JD "Clinical pharmacokinetics of fibric acid derivatives (fibrates)." Clin Pharmacokinet 34 (1998):  155-62|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51220, 7391, 'Fenofibrate', 'Liver Diseases', 'The use of fibric acid derivatives is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  Fibric acid derivatives therapy is associated with dose-related hepatotoxicity, including biochemical abnormalities of liver function, hepatitis (hepatocellular, chronic active, as well as cholestatic) and, rarely, cirrhosis.  Postmarketing cases of severe drug-induced liver injury, including liver transplantation and death, have been reported.  Therapy with these agents should be administered cautiously in patients with a history of liver disease and/or heavy alcohol use.  Liver function tests, including serum transaminase levels and total bilirubin, should be performed at baseline and periodically throughout the duration of therapy.  Therapy should be discontinued if signs or symptoms of liver injury develop or if elevated enzyme levels persist (ALT or AST greater than 3 times the upper limit of normal, or if accompanied by elevation of bilirubin).  Do not restart therapy if there is no alternative explanation for the liver injury.', '3', 'Cayen MN "Disposition, metabolism and pharmacokinetics of antihyperlipidemic agents in laboratory animals and man." Pharmacol Ther 29 (1985):  157-204|Chapman MJ "Pharmacology of fenofibrate." Am J Med 83 (1987):  21-5|Weil A, Caldwell J, Strolin-Benedetti M "The metabolism and disposition of 14C-fenofibrate in human volunteers." Drug Metab Dispos 18 (1990):  115-20|Balfour JA, McTavish D, Heel RC "Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia." Drugs 40 (1990):  260-90|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Adkins JC, Faulds D "Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia." Drugs 54 (1997):  615-33|Miller DB, Spence JD "Clinical pharmacokinetics of fibric acid derivatives (fibrates)." Clin Pharmacokinet 34 (1998):  155-62|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51221, 7393, 'Fenofibrate', 'Liver Diseases', 'The use of fibric acid derivatives is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  Fibric acid derivatives therapy is associated with dose-related hepatotoxicity, including biochemical abnormalities of liver function, hepatitis (hepatocellular, chronic active, as well as cholestatic) and, rarely, cirrhosis.  Postmarketing cases of severe drug-induced liver injury, including liver transplantation and death, have been reported.  Therapy with these agents should be administered cautiously in patients with a history of liver disease and/or heavy alcohol use.  Liver function tests, including serum transaminase levels and total bilirubin, should be performed at baseline and periodically throughout the duration of therapy.  Therapy should be discontinued if signs or symptoms of liver injury develop or if elevated enzyme levels persist (ALT or AST greater than 3 times the upper limit of normal, or if accompanied by elevation of bilirubin).  Do not restart therapy if there is no alternative explanation for the liver injury.', '3', 'Cayen MN "Disposition, metabolism and pharmacokinetics of antihyperlipidemic agents in laboratory animals and man." Pharmacol Ther 29 (1985):  157-204|Chapman MJ "Pharmacology of fenofibrate." Am J Med 83 (1987):  21-5|Weil A, Caldwell J, Strolin-Benedetti M "The metabolism and disposition of 14C-fenofibrate in human volunteers." Drug Metab Dispos 18 (1990):  115-20|Balfour JA, McTavish D, Heel RC "Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia." Drugs 40 (1990):  260-90|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Adkins JC, Faulds D "Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia." Drugs 54 (1997):  615-33|Miller DB, Spence JD "Clinical pharmacokinetics of fibric acid derivatives (fibrates)." Clin Pharmacokinet 34 (1998):  155-62|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51222, 18946, 'Fenofibrate', 'Liver Diseases', 'The use of fibric acid derivatives is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  Fibric acid derivatives therapy is associated with dose-related hepatotoxicity, including biochemical abnormalities of liver function, hepatitis (hepatocellular, chronic active, as well as cholestatic) and, rarely, cirrhosis.  Postmarketing cases of severe drug-induced liver injury, including liver transplantation and death, have been reported.  Therapy with these agents should be administered cautiously in patients with a history of liver disease and/or heavy alcohol use.  Liver function tests, including serum transaminase levels and total bilirubin, should be performed at baseline and periodically throughout the duration of therapy.  Therapy should be discontinued if signs or symptoms of liver injury develop or if elevated enzyme levels persist (ALT or AST greater than 3 times the upper limit of normal, or if accompanied by elevation of bilirubin).  Do not restart therapy if there is no alternative explanation for the liver injury.', '3', 'Cayen MN "Disposition, metabolism and pharmacokinetics of antihyperlipidemic agents in laboratory animals and man." Pharmacol Ther 29 (1985):  157-204|Chapman MJ "Pharmacology of fenofibrate." Am J Med 83 (1987):  21-5|Weil A, Caldwell J, Strolin-Benedetti M "The metabolism and disposition of 14C-fenofibrate in human volunteers." Drug Metab Dispos 18 (1990):  115-20|Balfour JA, McTavish D, Heel RC "Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia." Drugs 40 (1990):  260-90|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Adkins JC, Faulds D "Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia." Drugs 54 (1997):  615-33|Miller DB, Spence JD "Clinical pharmacokinetics of fibric acid derivatives (fibrates)." Clin Pharmacokinet 34 (1998):  155-62|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51223, 21293, 'Fenofibrate', 'Liver Diseases', 'The use of fibric acid derivatives is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  Fibric acid derivatives therapy is associated with dose-related hepatotoxicity, including biochemical abnormalities of liver function, hepatitis (hepatocellular, chronic active, as well as cholestatic) and, rarely, cirrhosis.  Postmarketing cases of severe drug-induced liver injury, including liver transplantation and death, have been reported.  Therapy with these agents should be administered cautiously in patients with a history of liver disease and/or heavy alcohol use.  Liver function tests, including serum transaminase levels and total bilirubin, should be performed at baseline and periodically throughout the duration of therapy.  Therapy should be discontinued if signs or symptoms of liver injury develop or if elevated enzyme levels persist (ALT or AST greater than 3 times the upper limit of normal, or if accompanied by elevation of bilirubin).  Do not restart therapy if there is no alternative explanation for the liver injury.', '3', 'Cayen MN "Disposition, metabolism and pharmacokinetics of antihyperlipidemic agents in laboratory animals and man." Pharmacol Ther 29 (1985):  157-204|Chapman MJ "Pharmacology of fenofibrate." Am J Med 83 (1987):  21-5|Weil A, Caldwell J, Strolin-Benedetti M "The metabolism and disposition of 14C-fenofibrate in human volunteers." Drug Metab Dispos 18 (1990):  115-20|Balfour JA, McTavish D, Heel RC "Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia." Drugs 40 (1990):  260-90|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Adkins JC, Faulds D "Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia." Drugs 54 (1997):  615-33|Miller DB, Spence JD "Clinical pharmacokinetics of fibric acid derivatives (fibrates)." Clin Pharmacokinet 34 (1998):  155-62|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51224, 21876, 'Fenofibrate', 'Liver Diseases', 'The use of fibric acid derivatives is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  Fibric acid derivatives therapy is associated with dose-related hepatotoxicity, including biochemical abnormalities of liver function, hepatitis (hepatocellular, chronic active, as well as cholestatic) and, rarely, cirrhosis.  Postmarketing cases of severe drug-induced liver injury, including liver transplantation and death, have been reported.  Therapy with these agents should be administered cautiously in patients with a history of liver disease and/or heavy alcohol use.  Liver function tests, including serum transaminase levels and total bilirubin, should be performed at baseline and periodically throughout the duration of therapy.  Therapy should be discontinued if signs or symptoms of liver injury develop or if elevated enzyme levels persist (ALT or AST greater than 3 times the upper limit of normal, or if accompanied by elevation of bilirubin).  Do not restart therapy if there is no alternative explanation for the liver injury.', '3', 'Cayen MN "Disposition, metabolism and pharmacokinetics of antihyperlipidemic agents in laboratory animals and man." Pharmacol Ther 29 (1985):  157-204|Chapman MJ "Pharmacology of fenofibrate." Am J Med 83 (1987):  21-5|Weil A, Caldwell J, Strolin-Benedetti M "The metabolism and disposition of 14C-fenofibrate in human volunteers." Drug Metab Dispos 18 (1990):  115-20|Balfour JA, McTavish D, Heel RC "Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia." Drugs 40 (1990):  260-90|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Adkins JC, Faulds D "Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia." Drugs 54 (1997):  615-33|Miller DB, Spence JD "Clinical pharmacokinetics of fibric acid derivatives (fibrates)." Clin Pharmacokinet 34 (1998):  155-62|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51225, 21902, 'Fenofibrate', 'Liver Diseases', 'The use of fibric acid derivatives is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  Fibric acid derivatives therapy is associated with dose-related hepatotoxicity, including biochemical abnormalities of liver function, hepatitis (hepatocellular, chronic active, as well as cholestatic) and, rarely, cirrhosis.  Postmarketing cases of severe drug-induced liver injury, including liver transplantation and death, have been reported.  Therapy with these agents should be administered cautiously in patients with a history of liver disease and/or heavy alcohol use.  Liver function tests, including serum transaminase levels and total bilirubin, should be performed at baseline and periodically throughout the duration of therapy.  Therapy should be discontinued if signs or symptoms of liver injury develop or if elevated enzyme levels persist (ALT or AST greater than 3 times the upper limit of normal, or if accompanied by elevation of bilirubin).  Do not restart therapy if there is no alternative explanation for the liver injury.', '3', 'Cayen MN "Disposition, metabolism and pharmacokinetics of antihyperlipidemic agents in laboratory animals and man." Pharmacol Ther 29 (1985):  157-204|Chapman MJ "Pharmacology of fenofibrate." Am J Med 83 (1987):  21-5|Weil A, Caldwell J, Strolin-Benedetti M "The metabolism and disposition of 14C-fenofibrate in human volunteers." Drug Metab Dispos 18 (1990):  115-20|Balfour JA, McTavish D, Heel RC "Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia." Drugs 40 (1990):  260-90|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Adkins JC, Faulds D "Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia." Drugs 54 (1997):  615-33|Miller DB, Spence JD "Clinical pharmacokinetics of fibric acid derivatives (fibrates)." Clin Pharmacokinet 34 (1998):  155-62|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51226, 21908, 'Fenofibrate', 'Liver Diseases', 'The use of fibric acid derivatives is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  Fibric acid derivatives therapy is associated with dose-related hepatotoxicity, including biochemical abnormalities of liver function, hepatitis (hepatocellular, chronic active, as well as cholestatic) and, rarely, cirrhosis.  Postmarketing cases of severe drug-induced liver injury, including liver transplantation and death, have been reported.  Therapy with these agents should be administered cautiously in patients with a history of liver disease and/or heavy alcohol use.  Liver function tests, including serum transaminase levels and total bilirubin, should be performed at baseline and periodically throughout the duration of therapy.  Therapy should be discontinued if signs or symptoms of liver injury develop or if elevated enzyme levels persist (ALT or AST greater than 3 times the upper limit of normal, or if accompanied by elevation of bilirubin).  Do not restart therapy if there is no alternative explanation for the liver injury.', '3', 'Cayen MN "Disposition, metabolism and pharmacokinetics of antihyperlipidemic agents in laboratory animals and man." Pharmacol Ther 29 (1985):  157-204|Chapman MJ "Pharmacology of fenofibrate." Am J Med 83 (1987):  21-5|Weil A, Caldwell J, Strolin-Benedetti M "The metabolism and disposition of 14C-fenofibrate in human volunteers." Drug Metab Dispos 18 (1990):  115-20|Balfour JA, McTavish D, Heel RC "Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia." Drugs 40 (1990):  260-90|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Adkins JC, Faulds D "Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia." Drugs 54 (1997):  615-33|Miller DB, Spence JD "Clinical pharmacokinetics of fibric acid derivatives (fibrates)." Clin Pharmacokinet 34 (1998):  155-62|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51227, 23677, 'Fenofibrate', 'Liver Diseases', 'The use of fibric acid derivatives is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  Fibric acid derivatives therapy is associated with dose-related hepatotoxicity, including biochemical abnormalities of liver function, hepatitis (hepatocellular, chronic active, as well as cholestatic) and, rarely, cirrhosis.  Postmarketing cases of severe drug-induced liver injury, including liver transplantation and death, have been reported.  Therapy with these agents should be administered cautiously in patients with a history of liver disease and/or heavy alcohol use.  Liver function tests, including serum transaminase levels and total bilirubin, should be performed at baseline and periodically throughout the duration of therapy.  Therapy should be discontinued if signs or symptoms of liver injury develop or if elevated enzyme levels persist (ALT or AST greater than 3 times the upper limit of normal, or if accompanied by elevation of bilirubin).  Do not restart therapy if there is no alternative explanation for the liver injury.', '3', 'Cayen MN "Disposition, metabolism and pharmacokinetics of antihyperlipidemic agents in laboratory animals and man." Pharmacol Ther 29 (1985):  157-204|Chapman MJ "Pharmacology of fenofibrate." Am J Med 83 (1987):  21-5|Weil A, Caldwell J, Strolin-Benedetti M "The metabolism and disposition of 14C-fenofibrate in human volunteers." Drug Metab Dispos 18 (1990):  115-20|Balfour JA, McTavish D, Heel RC "Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia." Drugs 40 (1990):  260-90|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Adkins JC, Faulds D "Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia." Drugs 54 (1997):  615-33|Miller DB, Spence JD "Clinical pharmacokinetics of fibric acid derivatives (fibrates)." Clin Pharmacokinet 34 (1998):  155-62|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51228, 23678, 'Fenofibrate', 'Liver Diseases', 'The use of fibric acid derivatives is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  Fibric acid derivatives therapy is associated with dose-related hepatotoxicity, including biochemical abnormalities of liver function, hepatitis (hepatocellular, chronic active, as well as cholestatic) and, rarely, cirrhosis.  Postmarketing cases of severe drug-induced liver injury, including liver transplantation and death, have been reported.  Therapy with these agents should be administered cautiously in patients with a history of liver disease and/or heavy alcohol use.  Liver function tests, including serum transaminase levels and total bilirubin, should be performed at baseline and periodically throughout the duration of therapy.  Therapy should be discontinued if signs or symptoms of liver injury develop or if elevated enzyme levels persist (ALT or AST greater than 3 times the upper limit of normal, or if accompanied by elevation of bilirubin).  Do not restart therapy if there is no alternative explanation for the liver injury.', '3', 'Cayen MN "Disposition, metabolism and pharmacokinetics of antihyperlipidemic agents in laboratory animals and man." Pharmacol Ther 29 (1985):  157-204|Chapman MJ "Pharmacology of fenofibrate." Am J Med 83 (1987):  21-5|Weil A, Caldwell J, Strolin-Benedetti M "The metabolism and disposition of 14C-fenofibrate in human volunteers." Drug Metab Dispos 18 (1990):  115-20|Balfour JA, McTavish D, Heel RC "Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia." Drugs 40 (1990):  260-90|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Adkins JC, Faulds D "Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia." Drugs 54 (1997):  615-33|Miller DB, Spence JD "Clinical pharmacokinetics of fibric acid derivatives (fibrates)." Clin Pharmacokinet 34 (1998):  155-62|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51229, 30829, 'Fenofibrate', 'Liver Diseases', 'The use of fibric acid derivatives is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  Fibric acid derivatives therapy is associated with dose-related hepatotoxicity, including biochemical abnormalities of liver function, hepatitis (hepatocellular, chronic active, as well as cholestatic) and, rarely, cirrhosis.  Postmarketing cases of severe drug-induced liver injury, including liver transplantation and death, have been reported.  Therapy with these agents should be administered cautiously in patients with a history of liver disease and/or heavy alcohol use.  Liver function tests, including serum transaminase levels and total bilirubin, should be performed at baseline and periodically throughout the duration of therapy.  Therapy should be discontinued if signs or symptoms of liver injury develop or if elevated enzyme levels persist (ALT or AST greater than 3 times the upper limit of normal, or if accompanied by elevation of bilirubin).  Do not restart therapy if there is no alternative explanation for the liver injury.', '3', 'Cayen MN "Disposition, metabolism and pharmacokinetics of antihyperlipidemic agents in laboratory animals and man." Pharmacol Ther 29 (1985):  157-204|Chapman MJ "Pharmacology of fenofibrate." Am J Med 83 (1987):  21-5|Weil A, Caldwell J, Strolin-Benedetti M "The metabolism and disposition of 14C-fenofibrate in human volunteers." Drug Metab Dispos 18 (1990):  115-20|Balfour JA, McTavish D, Heel RC "Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia." Drugs 40 (1990):  260-90|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Adkins JC, Faulds D "Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia." Drugs 54 (1997):  615-33|Miller DB, Spence JD "Clinical pharmacokinetics of fibric acid derivatives (fibrates)." Clin Pharmacokinet 34 (1998):  155-62|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51230, 4796, 'Fenofibrate', 'Kidney Diseases', 'The use of fibric acid derivatives is contraindicated in patients with significantly impaired renal function.  The rate of clearance of fenofibric acid has been shown to decrease substantially when CrCl is below 50 mL/min, with drug accumulation during chronic dosing.  Increased adverse effects, including rhabdomyolysis (with or without secondary renal failure) and severe hyperkalemia, have been associated with the use of fibric acid derivatives in patients with renal insufficiency.  Therapy with these agents should be administered cautiously in patients with mild or moderate renal impairment.  Close clinical monitoring is recommended during therapy.', '3', 'Pokroy N, Ress S, Gregory MC "Clofibrate-induced complications in renal disease: a case report." S Afr Med J 52 (1977):  806-8|Goldman JA, Fishman AB, Lee JE, Johnson RJ "The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis ." Arthritis Rheum 32 (1989):  358-9|Chapman MJ "Pharmacology of fenofibrate." Am J Med 83 (1987):  21-5|Weil A, Caldwell J, Strolin-Benedetti M "The metabolism and disposition of 14C-fenofibrate in human volunteers." Drug Metab Dispos 18 (1990):  115-20|Balfour JA, McTavish D, Heel RC "Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia." Drugs 40 (1990):  260-90|Dealava E, Sola JJ, Lozano MD, Pardomindan FJ "Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants." Nephron 66 (1994):  242-3|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Miller DB, Spence JD "Clinical pharmacokinetics of fibric acid derivatives (fibrates)." Clin Pharmacokinet 34 (1998):  155-62|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51231, 4870, 'Fenofibrate', 'Kidney Diseases', 'The use of fibric acid derivatives is contraindicated in patients with significantly impaired renal function.  The rate of clearance of fenofibric acid has been shown to decrease substantially when CrCl is below 50 mL/min, with drug accumulation during chronic dosing.  Increased adverse effects, including rhabdomyolysis (with or without secondary renal failure) and severe hyperkalemia, have been associated with the use of fibric acid derivatives in patients with renal insufficiency.  Therapy with these agents should be administered cautiously in patients with mild or moderate renal impairment.  Close clinical monitoring is recommended during therapy.', '3', 'Pokroy N, Ress S, Gregory MC "Clofibrate-induced complications in renal disease: a case report." S Afr Med J 52 (1977):  806-8|Goldman JA, Fishman AB, Lee JE, Johnson RJ "The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis ." Arthritis Rheum 32 (1989):  358-9|Chapman MJ "Pharmacology of fenofibrate." Am J Med 83 (1987):  21-5|Weil A, Caldwell J, Strolin-Benedetti M "The metabolism and disposition of 14C-fenofibrate in human volunteers." Drug Metab Dispos 18 (1990):  115-20|Balfour JA, McTavish D, Heel RC "Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia." Drugs 40 (1990):  260-90|Dealava E, Sola JJ, Lozano MD, Pardomindan FJ "Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants." Nephron 66 (1994):  242-3|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Miller DB, Spence JD "Clinical pharmacokinetics of fibric acid derivatives (fibrates)." Clin Pharmacokinet 34 (1998):  155-62|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51232, 7338, 'Fenofibrate', 'Kidney Diseases', 'The use of fibric acid derivatives is contraindicated in patients with significantly impaired renal function.  The rate of clearance of fenofibric acid has been shown to decrease substantially when CrCl is below 50 mL/min, with drug accumulation during chronic dosing.  Increased adverse effects, including rhabdomyolysis (with or without secondary renal failure) and severe hyperkalemia, have been associated with the use of fibric acid derivatives in patients with renal insufficiency.  Therapy with these agents should be administered cautiously in patients with mild or moderate renal impairment.  Close clinical monitoring is recommended during therapy.', '3', 'Pokroy N, Ress S, Gregory MC "Clofibrate-induced complications in renal disease: a case report." S Afr Med J 52 (1977):  806-8|Goldman JA, Fishman AB, Lee JE, Johnson RJ "The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis ." Arthritis Rheum 32 (1989):  358-9|Chapman MJ "Pharmacology of fenofibrate." Am J Med 83 (1987):  21-5|Weil A, Caldwell J, Strolin-Benedetti M "The metabolism and disposition of 14C-fenofibrate in human volunteers." Drug Metab Dispos 18 (1990):  115-20|Balfour JA, McTavish D, Heel RC "Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia." Drugs 40 (1990):  260-90|Dealava E, Sola JJ, Lozano MD, Pardomindan FJ "Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants." Nephron 66 (1994):  242-3|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Miller DB, Spence JD "Clinical pharmacokinetics of fibric acid derivatives (fibrates)." Clin Pharmacokinet 34 (1998):  155-62|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51233, 7341, 'Fenofibrate', 'Kidney Diseases', 'The use of fibric acid derivatives is contraindicated in patients with significantly impaired renal function.  The rate of clearance of fenofibric acid has been shown to decrease substantially when CrCl is below 50 mL/min, with drug accumulation during chronic dosing.  Increased adverse effects, including rhabdomyolysis (with or without secondary renal failure) and severe hyperkalemia, have been associated with the use of fibric acid derivatives in patients with renal insufficiency.  Therapy with these agents should be administered cautiously in patients with mild or moderate renal impairment.  Close clinical monitoring is recommended during therapy.', '3', 'Pokroy N, Ress S, Gregory MC "Clofibrate-induced complications in renal disease: a case report." S Afr Med J 52 (1977):  806-8|Goldman JA, Fishman AB, Lee JE, Johnson RJ "The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis ." Arthritis Rheum 32 (1989):  358-9|Chapman MJ "Pharmacology of fenofibrate." Am J Med 83 (1987):  21-5|Weil A, Caldwell J, Strolin-Benedetti M "The metabolism and disposition of 14C-fenofibrate in human volunteers." Drug Metab Dispos 18 (1990):  115-20|Balfour JA, McTavish D, Heel RC "Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia." Drugs 40 (1990):  260-90|Dealava E, Sola JJ, Lozano MD, Pardomindan FJ "Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants." Nephron 66 (1994):  242-3|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Miller DB, Spence JD "Clinical pharmacokinetics of fibric acid derivatives (fibrates)." Clin Pharmacokinet 34 (1998):  155-62|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51234, 7391, 'Fenofibrate', 'Kidney Diseases', 'The use of fibric acid derivatives is contraindicated in patients with significantly impaired renal function.  The rate of clearance of fenofibric acid has been shown to decrease substantially when CrCl is below 50 mL/min, with drug accumulation during chronic dosing.  Increased adverse effects, including rhabdomyolysis (with or without secondary renal failure) and severe hyperkalemia, have been associated with the use of fibric acid derivatives in patients with renal insufficiency.  Therapy with these agents should be administered cautiously in patients with mild or moderate renal impairment.  Close clinical monitoring is recommended during therapy.', '3', 'Pokroy N, Ress S, Gregory MC "Clofibrate-induced complications in renal disease: a case report." S Afr Med J 52 (1977):  806-8|Goldman JA, Fishman AB, Lee JE, Johnson RJ "The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis ." Arthritis Rheum 32 (1989):  358-9|Chapman MJ "Pharmacology of fenofibrate." Am J Med 83 (1987):  21-5|Weil A, Caldwell J, Strolin-Benedetti M "The metabolism and disposition of 14C-fenofibrate in human volunteers." Drug Metab Dispos 18 (1990):  115-20|Balfour JA, McTavish D, Heel RC "Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia." Drugs 40 (1990):  260-90|Dealava E, Sola JJ, Lozano MD, Pardomindan FJ "Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants." Nephron 66 (1994):  242-3|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Miller DB, Spence JD "Clinical pharmacokinetics of fibric acid derivatives (fibrates)." Clin Pharmacokinet 34 (1998):  155-62|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51235, 7393, 'Fenofibrate', 'Kidney Diseases', 'The use of fibric acid derivatives is contraindicated in patients with significantly impaired renal function.  The rate of clearance of fenofibric acid has been shown to decrease substantially when CrCl is below 50 mL/min, with drug accumulation during chronic dosing.  Increased adverse effects, including rhabdomyolysis (with or without secondary renal failure) and severe hyperkalemia, have been associated with the use of fibric acid derivatives in patients with renal insufficiency.  Therapy with these agents should be administered cautiously in patients with mild or moderate renal impairment.  Close clinical monitoring is recommended during therapy.', '3', 'Pokroy N, Ress S, Gregory MC "Clofibrate-induced complications in renal disease: a case report." S Afr Med J 52 (1977):  806-8|Goldman JA, Fishman AB, Lee JE, Johnson RJ "The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis ." Arthritis Rheum 32 (1989):  358-9|Chapman MJ "Pharmacology of fenofibrate." Am J Med 83 (1987):  21-5|Weil A, Caldwell J, Strolin-Benedetti M "The metabolism and disposition of 14C-fenofibrate in human volunteers." Drug Metab Dispos 18 (1990):  115-20|Balfour JA, McTavish D, Heel RC "Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia." Drugs 40 (1990):  260-90|Dealava E, Sola JJ, Lozano MD, Pardomindan FJ "Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants." Nephron 66 (1994):  242-3|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Miller DB, Spence JD "Clinical pharmacokinetics of fibric acid derivatives (fibrates)." Clin Pharmacokinet 34 (1998):  155-62|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51236, 18946, 'Fenofibrate', 'Kidney Diseases', 'The use of fibric acid derivatives is contraindicated in patients with significantly impaired renal function.  The rate of clearance of fenofibric acid has been shown to decrease substantially when CrCl is below 50 mL/min, with drug accumulation during chronic dosing.  Increased adverse effects, including rhabdomyolysis (with or without secondary renal failure) and severe hyperkalemia, have been associated with the use of fibric acid derivatives in patients with renal insufficiency.  Therapy with these agents should be administered cautiously in patients with mild or moderate renal impairment.  Close clinical monitoring is recommended during therapy.', '3', 'Pokroy N, Ress S, Gregory MC "Clofibrate-induced complications in renal disease: a case report." S Afr Med J 52 (1977):  806-8|Goldman JA, Fishman AB, Lee JE, Johnson RJ "The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis ." Arthritis Rheum 32 (1989):  358-9|Chapman MJ "Pharmacology of fenofibrate." Am J Med 83 (1987):  21-5|Weil A, Caldwell J, Strolin-Benedetti M "The metabolism and disposition of 14C-fenofibrate in human volunteers." Drug Metab Dispos 18 (1990):  115-20|Balfour JA, McTavish D, Heel RC "Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia." Drugs 40 (1990):  260-90|Dealava E, Sola JJ, Lozano MD, Pardomindan FJ "Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants." Nephron 66 (1994):  242-3|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Miller DB, Spence JD "Clinical pharmacokinetics of fibric acid derivatives (fibrates)." Clin Pharmacokinet 34 (1998):  155-62|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51237, 21293, 'Fenofibrate', 'Kidney Diseases', 'The use of fibric acid derivatives is contraindicated in patients with significantly impaired renal function.  The rate of clearance of fenofibric acid has been shown to decrease substantially when CrCl is below 50 mL/min, with drug accumulation during chronic dosing.  Increased adverse effects, including rhabdomyolysis (with or without secondary renal failure) and severe hyperkalemia, have been associated with the use of fibric acid derivatives in patients with renal insufficiency.  Therapy with these agents should be administered cautiously in patients with mild or moderate renal impairment.  Close clinical monitoring is recommended during therapy.', '3', 'Pokroy N, Ress S, Gregory MC "Clofibrate-induced complications in renal disease: a case report." S Afr Med J 52 (1977):  806-8|Goldman JA, Fishman AB, Lee JE, Johnson RJ "The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis ." Arthritis Rheum 32 (1989):  358-9|Chapman MJ "Pharmacology of fenofibrate." Am J Med 83 (1987):  21-5|Weil A, Caldwell J, Strolin-Benedetti M "The metabolism and disposition of 14C-fenofibrate in human volunteers." Drug Metab Dispos 18 (1990):  115-20|Balfour JA, McTavish D, Heel RC "Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia." Drugs 40 (1990):  260-90|Dealava E, Sola JJ, Lozano MD, Pardomindan FJ "Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants." Nephron 66 (1994):  242-3|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Miller DB, Spence JD "Clinical pharmacokinetics of fibric acid derivatives (fibrates)." Clin Pharmacokinet 34 (1998):  155-62|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51238, 21876, 'Fenofibrate', 'Kidney Diseases', 'The use of fibric acid derivatives is contraindicated in patients with significantly impaired renal function.  The rate of clearance of fenofibric acid has been shown to decrease substantially when CrCl is below 50 mL/min, with drug accumulation during chronic dosing.  Increased adverse effects, including rhabdomyolysis (with or without secondary renal failure) and severe hyperkalemia, have been associated with the use of fibric acid derivatives in patients with renal insufficiency.  Therapy with these agents should be administered cautiously in patients with mild or moderate renal impairment.  Close clinical monitoring is recommended during therapy.', '3', 'Pokroy N, Ress S, Gregory MC "Clofibrate-induced complications in renal disease: a case report." S Afr Med J 52 (1977):  806-8|Goldman JA, Fishman AB, Lee JE, Johnson RJ "The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis ." Arthritis Rheum 32 (1989):  358-9|Chapman MJ "Pharmacology of fenofibrate." Am J Med 83 (1987):  21-5|Weil A, Caldwell J, Strolin-Benedetti M "The metabolism and disposition of 14C-fenofibrate in human volunteers." Drug Metab Dispos 18 (1990):  115-20|Balfour JA, McTavish D, Heel RC "Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia." Drugs 40 (1990):  260-90|Dealava E, Sola JJ, Lozano MD, Pardomindan FJ "Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants." Nephron 66 (1994):  242-3|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Miller DB, Spence JD "Clinical pharmacokinetics of fibric acid derivatives (fibrates)." Clin Pharmacokinet 34 (1998):  155-62|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51239, 21902, 'Fenofibrate', 'Kidney Diseases', 'The use of fibric acid derivatives is contraindicated in patients with significantly impaired renal function.  The rate of clearance of fenofibric acid has been shown to decrease substantially when CrCl is below 50 mL/min, with drug accumulation during chronic dosing.  Increased adverse effects, including rhabdomyolysis (with or without secondary renal failure) and severe hyperkalemia, have been associated with the use of fibric acid derivatives in patients with renal insufficiency.  Therapy with these agents should be administered cautiously in patients with mild or moderate renal impairment.  Close clinical monitoring is recommended during therapy.', '3', 'Pokroy N, Ress S, Gregory MC "Clofibrate-induced complications in renal disease: a case report." S Afr Med J 52 (1977):  806-8|Goldman JA, Fishman AB, Lee JE, Johnson RJ "The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis ." Arthritis Rheum 32 (1989):  358-9|Chapman MJ "Pharmacology of fenofibrate." Am J Med 83 (1987):  21-5|Weil A, Caldwell J, Strolin-Benedetti M "The metabolism and disposition of 14C-fenofibrate in human volunteers." Drug Metab Dispos 18 (1990):  115-20|Balfour JA, McTavish D, Heel RC "Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia." Drugs 40 (1990):  260-90|Dealava E, Sola JJ, Lozano MD, Pardomindan FJ "Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants." Nephron 66 (1994):  242-3|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Miller DB, Spence JD "Clinical pharmacokinetics of fibric acid derivatives (fibrates)." Clin Pharmacokinet 34 (1998):  155-62|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51240, 21908, 'Fenofibrate', 'Kidney Diseases', 'The use of fibric acid derivatives is contraindicated in patients with significantly impaired renal function.  The rate of clearance of fenofibric acid has been shown to decrease substantially when CrCl is below 50 mL/min, with drug accumulation during chronic dosing.  Increased adverse effects, including rhabdomyolysis (with or without secondary renal failure) and severe hyperkalemia, have been associated with the use of fibric acid derivatives in patients with renal insufficiency.  Therapy with these agents should be administered cautiously in patients with mild or moderate renal impairment.  Close clinical monitoring is recommended during therapy.', '3', 'Pokroy N, Ress S, Gregory MC "Clofibrate-induced complications in renal disease: a case report." S Afr Med J 52 (1977):  806-8|Goldman JA, Fishman AB, Lee JE, Johnson RJ "The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis ." Arthritis Rheum 32 (1989):  358-9|Chapman MJ "Pharmacology of fenofibrate." Am J Med 83 (1987):  21-5|Weil A, Caldwell J, Strolin-Benedetti M "The metabolism and disposition of 14C-fenofibrate in human volunteers." Drug Metab Dispos 18 (1990):  115-20|Balfour JA, McTavish D, Heel RC "Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia." Drugs 40 (1990):  260-90|Dealava E, Sola JJ, Lozano MD, Pardomindan FJ "Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants." Nephron 66 (1994):  242-3|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Miller DB, Spence JD "Clinical pharmacokinetics of fibric acid derivatives (fibrates)." Clin Pharmacokinet 34 (1998):  155-62|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51241, 23677, 'Fenofibrate', 'Kidney Diseases', 'The use of fibric acid derivatives is contraindicated in patients with significantly impaired renal function.  The rate of clearance of fenofibric acid has been shown to decrease substantially when CrCl is below 50 mL/min, with drug accumulation during chronic dosing.  Increased adverse effects, including rhabdomyolysis (with or without secondary renal failure) and severe hyperkalemia, have been associated with the use of fibric acid derivatives in patients with renal insufficiency.  Therapy with these agents should be administered cautiously in patients with mild or moderate renal impairment.  Close clinical monitoring is recommended during therapy.', '3', 'Pokroy N, Ress S, Gregory MC "Clofibrate-induced complications in renal disease: a case report." S Afr Med J 52 (1977):  806-8|Goldman JA, Fishman AB, Lee JE, Johnson RJ "The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis ." Arthritis Rheum 32 (1989):  358-9|Chapman MJ "Pharmacology of fenofibrate." Am J Med 83 (1987):  21-5|Weil A, Caldwell J, Strolin-Benedetti M "The metabolism and disposition of 14C-fenofibrate in human volunteers." Drug Metab Dispos 18 (1990):  115-20|Balfour JA, McTavish D, Heel RC "Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia." Drugs 40 (1990):  260-90|Dealava E, Sola JJ, Lozano MD, Pardomindan FJ "Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants." Nephron 66 (1994):  242-3|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Miller DB, Spence JD "Clinical pharmacokinetics of fibric acid derivatives (fibrates)." Clin Pharmacokinet 34 (1998):  155-62|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51242, 23678, 'Fenofibrate', 'Kidney Diseases', 'The use of fibric acid derivatives is contraindicated in patients with significantly impaired renal function.  The rate of clearance of fenofibric acid has been shown to decrease substantially when CrCl is below 50 mL/min, with drug accumulation during chronic dosing.  Increased adverse effects, including rhabdomyolysis (with or without secondary renal failure) and severe hyperkalemia, have been associated with the use of fibric acid derivatives in patients with renal insufficiency.  Therapy with these agents should be administered cautiously in patients with mild or moderate renal impairment.  Close clinical monitoring is recommended during therapy.', '3', 'Pokroy N, Ress S, Gregory MC "Clofibrate-induced complications in renal disease: a case report." S Afr Med J 52 (1977):  806-8|Goldman JA, Fishman AB, Lee JE, Johnson RJ "The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis ." Arthritis Rheum 32 (1989):  358-9|Chapman MJ "Pharmacology of fenofibrate." Am J Med 83 (1987):  21-5|Weil A, Caldwell J, Strolin-Benedetti M "The metabolism and disposition of 14C-fenofibrate in human volunteers." Drug Metab Dispos 18 (1990):  115-20|Balfour JA, McTavish D, Heel RC "Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia." Drugs 40 (1990):  260-90|Dealava E, Sola JJ, Lozano MD, Pardomindan FJ "Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants." Nephron 66 (1994):  242-3|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Miller DB, Spence JD "Clinical pharmacokinetics of fibric acid derivatives (fibrates)." Clin Pharmacokinet 34 (1998):  155-62|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51243, 30829, 'Fenofibrate', 'Kidney Diseases', 'The use of fibric acid derivatives is contraindicated in patients with significantly impaired renal function.  The rate of clearance of fenofibric acid has been shown to decrease substantially when CrCl is below 50 mL/min, with drug accumulation during chronic dosing.  Increased adverse effects, including rhabdomyolysis (with or without secondary renal failure) and severe hyperkalemia, have been associated with the use of fibric acid derivatives in patients with renal insufficiency.  Therapy with these agents should be administered cautiously in patients with mild or moderate renal impairment.  Close clinical monitoring is recommended during therapy.', '3', 'Pokroy N, Ress S, Gregory MC "Clofibrate-induced complications in renal disease: a case report." S Afr Med J 52 (1977):  806-8|Goldman JA, Fishman AB, Lee JE, Johnson RJ "The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis ." Arthritis Rheum 32 (1989):  358-9|Chapman MJ "Pharmacology of fenofibrate." Am J Med 83 (1987):  21-5|Weil A, Caldwell J, Strolin-Benedetti M "The metabolism and disposition of 14C-fenofibrate in human volunteers." Drug Metab Dispos 18 (1990):  115-20|Balfour JA, McTavish D, Heel RC "Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia." Drugs 40 (1990):  260-90|Dealava E, Sola JJ, Lozano MD, Pardomindan FJ "Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants." Nephron 66 (1994):  242-3|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Miller DB, Spence JD "Clinical pharmacokinetics of fibric acid derivatives (fibrates)." Clin Pharmacokinet 34 (1998):  155-62|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51244, 4796, 'Fenofibrate', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of fibric acid derivatives.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with fibric acid derivatives should be administered cautiously in patients with preexisting myopathy or a myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  Therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', 'Pokroy N, Ress S, Gregory MC "Clofibrate-induced complications in renal disease: a case report." S Afr Med J 52 (1977):  806-8|Abourizk N, Khalil BA, Bahuth N, Afifi AK "Clofibrate-induced muscular syndrome. Report of a case with clinical, electromyographic and pathologic observations." J Neurol Sci 42 (1979):  1-9|Rush P, Baron M, Kapusta M "Clofibrate myopathy: a case report and a review of the literature." Semin Arthritis Rheum 15 (1986):  226-9|Goldman JA, Fishman AB, Lee JE, Johnson RJ "The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis ." Arthritis Rheum 32 (1989):  358-9|Fusella J, Strosberg JM "Polymyositis exacerbated by gemfibrozil ." J Rheumatol 17 (1990):  572-3|Pierce LR, Wysowski DK, Gross TP "Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy." JAMA 264 (1990):  71-5|Chow LT, Chow WH "Acute compartment syndrome: an unusual presentation of gemfibrozil induced myositis." Med J Aust 158 (1993):  48-9|"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Blane GF "Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives." Am J Med 83 (1987):  26-36|Roberts WC "Safety of fenofibrate--US and worldwide experience." Cardiology 76 (1989):  169-79|Dealava E, Sola JJ, Lozano MD, Pardomindan FJ "Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants." Nephron 66 (1994):  242-3|Shepherd J "Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety." Eur Heart J 16 (1995):  5-13|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Duell PB, Connor WE, Illingworth DR "Rhabdomyolysis after taking atorvastatin with gemfibrozil." Am J Cardiol 81 (1998):  368-9|Kirchgassler KU, Schmitz H, Bach G "Effectiveness and tolerability of 12-week treatment with micronised fenofibrate 200mg in a drug-monitoring programme involving 9884 patients with dyslipidaemia." Clin Drug Invest 15 (1998):  197-204|Iliadis EA, Rosenson RS "Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia." Clin Cardiol 22 (1999):  25-8|van Puijenbroek EP, Du Buf-Vereijken PW, Spooren PF, van Doormaal JJ "Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil." J Intern Med 240 (1996):  403-4|Pogson GW, Kindred LH, Carper BG "Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy." Am J Cardiol 83 (1999):  1146|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51245, 4870, 'Fenofibrate', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of fibric acid derivatives.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with fibric acid derivatives should be administered cautiously in patients with preexisting myopathy or a myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  Therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', 'Pokroy N, Ress S, Gregory MC "Clofibrate-induced complications in renal disease: a case report." S Afr Med J 52 (1977):  806-8|Abourizk N, Khalil BA, Bahuth N, Afifi AK "Clofibrate-induced muscular syndrome. Report of a case with clinical, electromyographic and pathologic observations." J Neurol Sci 42 (1979):  1-9|Rush P, Baron M, Kapusta M "Clofibrate myopathy: a case report and a review of the literature." Semin Arthritis Rheum 15 (1986):  226-9|Goldman JA, Fishman AB, Lee JE, Johnson RJ "The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis ." Arthritis Rheum 32 (1989):  358-9|Fusella J, Strosberg JM "Polymyositis exacerbated by gemfibrozil ." J Rheumatol 17 (1990):  572-3|Pierce LR, Wysowski DK, Gross TP "Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy." JAMA 264 (1990):  71-5|Chow LT, Chow WH "Acute compartment syndrome: an unusual presentation of gemfibrozil induced myositis." Med J Aust 158 (1993):  48-9|"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Blane GF "Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives." Am J Med 83 (1987):  26-36|Roberts WC "Safety of fenofibrate--US and worldwide experience." Cardiology 76 (1989):  169-79|Dealava E, Sola JJ, Lozano MD, Pardomindan FJ "Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants." Nephron 66 (1994):  242-3|Shepherd J "Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety." Eur Heart J 16 (1995):  5-13|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Duell PB, Connor WE, Illingworth DR "Rhabdomyolysis after taking atorvastatin with gemfibrozil." Am J Cardiol 81 (1998):  368-9|Kirchgassler KU, Schmitz H, Bach G "Effectiveness and tolerability of 12-week treatment with micronised fenofibrate 200mg in a drug-monitoring programme involving 9884 patients with dyslipidaemia." Clin Drug Invest 15 (1998):  197-204|Iliadis EA, Rosenson RS "Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia." Clin Cardiol 22 (1999):  25-8|van Puijenbroek EP, Du Buf-Vereijken PW, Spooren PF, van Doormaal JJ "Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil." J Intern Med 240 (1996):  403-4|Pogson GW, Kindred LH, Carper BG "Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy." Am J Cardiol 83 (1999):  1146|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51246, 7338, 'Fenofibrate', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of fibric acid derivatives.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with fibric acid derivatives should be administered cautiously in patients with preexisting myopathy or a myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  Therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', 'Pokroy N, Ress S, Gregory MC "Clofibrate-induced complications in renal disease: a case report." S Afr Med J 52 (1977):  806-8|Abourizk N, Khalil BA, Bahuth N, Afifi AK "Clofibrate-induced muscular syndrome. Report of a case with clinical, electromyographic and pathologic observations." J Neurol Sci 42 (1979):  1-9|Rush P, Baron M, Kapusta M "Clofibrate myopathy: a case report and a review of the literature." Semin Arthritis Rheum 15 (1986):  226-9|Goldman JA, Fishman AB, Lee JE, Johnson RJ "The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis ." Arthritis Rheum 32 (1989):  358-9|Fusella J, Strosberg JM "Polymyositis exacerbated by gemfibrozil ." J Rheumatol 17 (1990):  572-3|Pierce LR, Wysowski DK, Gross TP "Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy." JAMA 264 (1990):  71-5|Chow LT, Chow WH "Acute compartment syndrome: an unusual presentation of gemfibrozil induced myositis." Med J Aust 158 (1993):  48-9|"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Blane GF "Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives." Am J Med 83 (1987):  26-36|Roberts WC "Safety of fenofibrate--US and worldwide experience." Cardiology 76 (1989):  169-79|Dealava E, Sola JJ, Lozano MD, Pardomindan FJ "Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants." Nephron 66 (1994):  242-3|Shepherd J "Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety." Eur Heart J 16 (1995):  5-13|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Duell PB, Connor WE, Illingworth DR "Rhabdomyolysis after taking atorvastatin with gemfibrozil." Am J Cardiol 81 (1998):  368-9|Kirchgassler KU, Schmitz H, Bach G "Effectiveness and tolerability of 12-week treatment with micronised fenofibrate 200mg in a drug-monitoring programme involving 9884 patients with dyslipidaemia." Clin Drug Invest 15 (1998):  197-204|Iliadis EA, Rosenson RS "Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia." Clin Cardiol 22 (1999):  25-8|van Puijenbroek EP, Du Buf-Vereijken PW, Spooren PF, van Doormaal JJ "Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil." J Intern Med 240 (1996):  403-4|Pogson GW, Kindred LH, Carper BG "Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy." Am J Cardiol 83 (1999):  1146|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51247, 7341, 'Fenofibrate', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of fibric acid derivatives.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with fibric acid derivatives should be administered cautiously in patients with preexisting myopathy or a myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  Therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', 'Pokroy N, Ress S, Gregory MC "Clofibrate-induced complications in renal disease: a case report." S Afr Med J 52 (1977):  806-8|Abourizk N, Khalil BA, Bahuth N, Afifi AK "Clofibrate-induced muscular syndrome. Report of a case with clinical, electromyographic and pathologic observations." J Neurol Sci 42 (1979):  1-9|Rush P, Baron M, Kapusta M "Clofibrate myopathy: a case report and a review of the literature." Semin Arthritis Rheum 15 (1986):  226-9|Goldman JA, Fishman AB, Lee JE, Johnson RJ "The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis ." Arthritis Rheum 32 (1989):  358-9|Fusella J, Strosberg JM "Polymyositis exacerbated by gemfibrozil ." J Rheumatol 17 (1990):  572-3|Pierce LR, Wysowski DK, Gross TP "Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy." JAMA 264 (1990):  71-5|Chow LT, Chow WH "Acute compartment syndrome: an unusual presentation of gemfibrozil induced myositis." Med J Aust 158 (1993):  48-9|"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Blane GF "Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives." Am J Med 83 (1987):  26-36|Roberts WC "Safety of fenofibrate--US and worldwide experience." Cardiology 76 (1989):  169-79|Dealava E, Sola JJ, Lozano MD, Pardomindan FJ "Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants." Nephron 66 (1994):  242-3|Shepherd J "Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety." Eur Heart J 16 (1995):  5-13|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Duell PB, Connor WE, Illingworth DR "Rhabdomyolysis after taking atorvastatin with gemfibrozil." Am J Cardiol 81 (1998):  368-9|Kirchgassler KU, Schmitz H, Bach G "Effectiveness and tolerability of 12-week treatment with micronised fenofibrate 200mg in a drug-monitoring programme involving 9884 patients with dyslipidaemia." Clin Drug Invest 15 (1998):  197-204|Iliadis EA, Rosenson RS "Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia." Clin Cardiol 22 (1999):  25-8|van Puijenbroek EP, Du Buf-Vereijken PW, Spooren PF, van Doormaal JJ "Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil." J Intern Med 240 (1996):  403-4|Pogson GW, Kindred LH, Carper BG "Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy." Am J Cardiol 83 (1999):  1146|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51248, 7391, 'Fenofibrate', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of fibric acid derivatives.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with fibric acid derivatives should be administered cautiously in patients with preexisting myopathy or a myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  Therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', 'Pokroy N, Ress S, Gregory MC "Clofibrate-induced complications in renal disease: a case report." S Afr Med J 52 (1977):  806-8|Abourizk N, Khalil BA, Bahuth N, Afifi AK "Clofibrate-induced muscular syndrome. Report of a case with clinical, electromyographic and pathologic observations." J Neurol Sci 42 (1979):  1-9|Rush P, Baron M, Kapusta M "Clofibrate myopathy: a case report and a review of the literature." Semin Arthritis Rheum 15 (1986):  226-9|Goldman JA, Fishman AB, Lee JE, Johnson RJ "The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis ." Arthritis Rheum 32 (1989):  358-9|Fusella J, Strosberg JM "Polymyositis exacerbated by gemfibrozil ." J Rheumatol 17 (1990):  572-3|Pierce LR, Wysowski DK, Gross TP "Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy." JAMA 264 (1990):  71-5|Chow LT, Chow WH "Acute compartment syndrome: an unusual presentation of gemfibrozil induced myositis." Med J Aust 158 (1993):  48-9|"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Blane GF "Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives." Am J Med 83 (1987):  26-36|Roberts WC "Safety of fenofibrate--US and worldwide experience." Cardiology 76 (1989):  169-79|Dealava E, Sola JJ, Lozano MD, Pardomindan FJ "Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants." Nephron 66 (1994):  242-3|Shepherd J "Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety." Eur Heart J 16 (1995):  5-13|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Duell PB, Connor WE, Illingworth DR "Rhabdomyolysis after taking atorvastatin with gemfibrozil." Am J Cardiol 81 (1998):  368-9|Kirchgassler KU, Schmitz H, Bach G "Effectiveness and tolerability of 12-week treatment with micronised fenofibrate 200mg in a drug-monitoring programme involving 9884 patients with dyslipidaemia." Clin Drug Invest 15 (1998):  197-204|Iliadis EA, Rosenson RS "Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia." Clin Cardiol 22 (1999):  25-8|van Puijenbroek EP, Du Buf-Vereijken PW, Spooren PF, van Doormaal JJ "Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil." J Intern Med 240 (1996):  403-4|Pogson GW, Kindred LH, Carper BG "Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy." Am J Cardiol 83 (1999):  1146|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51249, 7393, 'Fenofibrate', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of fibric acid derivatives.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with fibric acid derivatives should be administered cautiously in patients with preexisting myopathy or a myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  Therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', 'Pokroy N, Ress S, Gregory MC "Clofibrate-induced complications in renal disease: a case report." S Afr Med J 52 (1977):  806-8|Abourizk N, Khalil BA, Bahuth N, Afifi AK "Clofibrate-induced muscular syndrome. Report of a case with clinical, electromyographic and pathologic observations." J Neurol Sci 42 (1979):  1-9|Rush P, Baron M, Kapusta M "Clofibrate myopathy: a case report and a review of the literature." Semin Arthritis Rheum 15 (1986):  226-9|Goldman JA, Fishman AB, Lee JE, Johnson RJ "The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis ." Arthritis Rheum 32 (1989):  358-9|Fusella J, Strosberg JM "Polymyositis exacerbated by gemfibrozil ." J Rheumatol 17 (1990):  572-3|Pierce LR, Wysowski DK, Gross TP "Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy." JAMA 264 (1990):  71-5|Chow LT, Chow WH "Acute compartment syndrome: an unusual presentation of gemfibrozil induced myositis." Med J Aust 158 (1993):  48-9|"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Blane GF "Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives." Am J Med 83 (1987):  26-36|Roberts WC "Safety of fenofibrate--US and worldwide experience." Cardiology 76 (1989):  169-79|Dealava E, Sola JJ, Lozano MD, Pardomindan FJ "Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants." Nephron 66 (1994):  242-3|Shepherd J "Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety." Eur Heart J 16 (1995):  5-13|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Duell PB, Connor WE, Illingworth DR "Rhabdomyolysis after taking atorvastatin with gemfibrozil." Am J Cardiol 81 (1998):  368-9|Kirchgassler KU, Schmitz H, Bach G "Effectiveness and tolerability of 12-week treatment with micronised fenofibrate 200mg in a drug-monitoring programme involving 9884 patients with dyslipidaemia." Clin Drug Invest 15 (1998):  197-204|Iliadis EA, Rosenson RS "Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia." Clin Cardiol 22 (1999):  25-8|van Puijenbroek EP, Du Buf-Vereijken PW, Spooren PF, van Doormaal JJ "Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil." J Intern Med 240 (1996):  403-4|Pogson GW, Kindred LH, Carper BG "Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy." Am J Cardiol 83 (1999):  1146|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51250, 18946, 'Fenofibrate', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of fibric acid derivatives.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with fibric acid derivatives should be administered cautiously in patients with preexisting myopathy or a myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  Therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', 'Pokroy N, Ress S, Gregory MC "Clofibrate-induced complications in renal disease: a case report." S Afr Med J 52 (1977):  806-8|Abourizk N, Khalil BA, Bahuth N, Afifi AK "Clofibrate-induced muscular syndrome. Report of a case with clinical, electromyographic and pathologic observations." J Neurol Sci 42 (1979):  1-9|Rush P, Baron M, Kapusta M "Clofibrate myopathy: a case report and a review of the literature." Semin Arthritis Rheum 15 (1986):  226-9|Goldman JA, Fishman AB, Lee JE, Johnson RJ "The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis ." Arthritis Rheum 32 (1989):  358-9|Fusella J, Strosberg JM "Polymyositis exacerbated by gemfibrozil ." J Rheumatol 17 (1990):  572-3|Pierce LR, Wysowski DK, Gross TP "Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy." JAMA 264 (1990):  71-5|Chow LT, Chow WH "Acute compartment syndrome: an unusual presentation of gemfibrozil induced myositis." Med J Aust 158 (1993):  48-9|"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Blane GF "Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives." Am J Med 83 (1987):  26-36|Roberts WC "Safety of fenofibrate--US and worldwide experience." Cardiology 76 (1989):  169-79|Dealava E, Sola JJ, Lozano MD, Pardomindan FJ "Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants." Nephron 66 (1994):  242-3|Shepherd J "Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety." Eur Heart J 16 (1995):  5-13|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Duell PB, Connor WE, Illingworth DR "Rhabdomyolysis after taking atorvastatin with gemfibrozil." Am J Cardiol 81 (1998):  368-9|Kirchgassler KU, Schmitz H, Bach G "Effectiveness and tolerability of 12-week treatment with micronised fenofibrate 200mg in a drug-monitoring programme involving 9884 patients with dyslipidaemia." Clin Drug Invest 15 (1998):  197-204|Iliadis EA, Rosenson RS "Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia." Clin Cardiol 22 (1999):  25-8|van Puijenbroek EP, Du Buf-Vereijken PW, Spooren PF, van Doormaal JJ "Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil." J Intern Med 240 (1996):  403-4|Pogson GW, Kindred LH, Carper BG "Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy." Am J Cardiol 83 (1999):  1146|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51251, 21293, 'Fenofibrate', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of fibric acid derivatives.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with fibric acid derivatives should be administered cautiously in patients with preexisting myopathy or a myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  Therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', 'Pokroy N, Ress S, Gregory MC "Clofibrate-induced complications in renal disease: a case report." S Afr Med J 52 (1977):  806-8|Abourizk N, Khalil BA, Bahuth N, Afifi AK "Clofibrate-induced muscular syndrome. Report of a case with clinical, electromyographic and pathologic observations." J Neurol Sci 42 (1979):  1-9|Rush P, Baron M, Kapusta M "Clofibrate myopathy: a case report and a review of the literature." Semin Arthritis Rheum 15 (1986):  226-9|Goldman JA, Fishman AB, Lee JE, Johnson RJ "The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis ." Arthritis Rheum 32 (1989):  358-9|Fusella J, Strosberg JM "Polymyositis exacerbated by gemfibrozil ." J Rheumatol 17 (1990):  572-3|Pierce LR, Wysowski DK, Gross TP "Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy." JAMA 264 (1990):  71-5|Chow LT, Chow WH "Acute compartment syndrome: an unusual presentation of gemfibrozil induced myositis." Med J Aust 158 (1993):  48-9|"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Blane GF "Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives." Am J Med 83 (1987):  26-36|Roberts WC "Safety of fenofibrate--US and worldwide experience." Cardiology 76 (1989):  169-79|Dealava E, Sola JJ, Lozano MD, Pardomindan FJ "Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants." Nephron 66 (1994):  242-3|Shepherd J "Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety." Eur Heart J 16 (1995):  5-13|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Duell PB, Connor WE, Illingworth DR "Rhabdomyolysis after taking atorvastatin with gemfibrozil." Am J Cardiol 81 (1998):  368-9|Kirchgassler KU, Schmitz H, Bach G "Effectiveness and tolerability of 12-week treatment with micronised fenofibrate 200mg in a drug-monitoring programme involving 9884 patients with dyslipidaemia." Clin Drug Invest 15 (1998):  197-204|Iliadis EA, Rosenson RS "Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia." Clin Cardiol 22 (1999):  25-8|van Puijenbroek EP, Du Buf-Vereijken PW, Spooren PF, van Doormaal JJ "Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil." J Intern Med 240 (1996):  403-4|Pogson GW, Kindred LH, Carper BG "Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy." Am J Cardiol 83 (1999):  1146|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51252, 21876, 'Fenofibrate', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of fibric acid derivatives.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with fibric acid derivatives should be administered cautiously in patients with preexisting myopathy or a myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  Therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', 'Pokroy N, Ress S, Gregory MC "Clofibrate-induced complications in renal disease: a case report." S Afr Med J 52 (1977):  806-8|Abourizk N, Khalil BA, Bahuth N, Afifi AK "Clofibrate-induced muscular syndrome. Report of a case with clinical, electromyographic and pathologic observations." J Neurol Sci 42 (1979):  1-9|Rush P, Baron M, Kapusta M "Clofibrate myopathy: a case report and a review of the literature." Semin Arthritis Rheum 15 (1986):  226-9|Goldman JA, Fishman AB, Lee JE, Johnson RJ "The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis ." Arthritis Rheum 32 (1989):  358-9|Fusella J, Strosberg JM "Polymyositis exacerbated by gemfibrozil ." J Rheumatol 17 (1990):  572-3|Pierce LR, Wysowski DK, Gross TP "Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy." JAMA 264 (1990):  71-5|Chow LT, Chow WH "Acute compartment syndrome: an unusual presentation of gemfibrozil induced myositis." Med J Aust 158 (1993):  48-9|"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Blane GF "Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives." Am J Med 83 (1987):  26-36|Roberts WC "Safety of fenofibrate--US and worldwide experience." Cardiology 76 (1989):  169-79|Dealava E, Sola JJ, Lozano MD, Pardomindan FJ "Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants." Nephron 66 (1994):  242-3|Shepherd J "Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety." Eur Heart J 16 (1995):  5-13|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Duell PB, Connor WE, Illingworth DR "Rhabdomyolysis after taking atorvastatin with gemfibrozil." Am J Cardiol 81 (1998):  368-9|Kirchgassler KU, Schmitz H, Bach G "Effectiveness and tolerability of 12-week treatment with micronised fenofibrate 200mg in a drug-monitoring programme involving 9884 patients with dyslipidaemia." Clin Drug Invest 15 (1998):  197-204|Iliadis EA, Rosenson RS "Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia." Clin Cardiol 22 (1999):  25-8|van Puijenbroek EP, Du Buf-Vereijken PW, Spooren PF, van Doormaal JJ "Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil." J Intern Med 240 (1996):  403-4|Pogson GW, Kindred LH, Carper BG "Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy." Am J Cardiol 83 (1999):  1146|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51253, 21902, 'Fenofibrate', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of fibric acid derivatives.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with fibric acid derivatives should be administered cautiously in patients with preexisting myopathy or a myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  Therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', 'Pokroy N, Ress S, Gregory MC "Clofibrate-induced complications in renal disease: a case report." S Afr Med J 52 (1977):  806-8|Abourizk N, Khalil BA, Bahuth N, Afifi AK "Clofibrate-induced muscular syndrome. Report of a case with clinical, electromyographic and pathologic observations." J Neurol Sci 42 (1979):  1-9|Rush P, Baron M, Kapusta M "Clofibrate myopathy: a case report and a review of the literature." Semin Arthritis Rheum 15 (1986):  226-9|Goldman JA, Fishman AB, Lee JE, Johnson RJ "The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis ." Arthritis Rheum 32 (1989):  358-9|Fusella J, Strosberg JM "Polymyositis exacerbated by gemfibrozil ." J Rheumatol 17 (1990):  572-3|Pierce LR, Wysowski DK, Gross TP "Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy." JAMA 264 (1990):  71-5|Chow LT, Chow WH "Acute compartment syndrome: an unusual presentation of gemfibrozil induced myositis." Med J Aust 158 (1993):  48-9|"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Blane GF "Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives." Am J Med 83 (1987):  26-36|Roberts WC "Safety of fenofibrate--US and worldwide experience." Cardiology 76 (1989):  169-79|Dealava E, Sola JJ, Lozano MD, Pardomindan FJ "Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants." Nephron 66 (1994):  242-3|Shepherd J "Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety." Eur Heart J 16 (1995):  5-13|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Duell PB, Connor WE, Illingworth DR "Rhabdomyolysis after taking atorvastatin with gemfibrozil." Am J Cardiol 81 (1998):  368-9|Kirchgassler KU, Schmitz H, Bach G "Effectiveness and tolerability of 12-week treatment with micronised fenofibrate 200mg in a drug-monitoring programme involving 9884 patients with dyslipidaemia." Clin Drug Invest 15 (1998):  197-204|Iliadis EA, Rosenson RS "Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia." Clin Cardiol 22 (1999):  25-8|van Puijenbroek EP, Du Buf-Vereijken PW, Spooren PF, van Doormaal JJ "Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil." J Intern Med 240 (1996):  403-4|Pogson GW, Kindred LH, Carper BG "Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy." Am J Cardiol 83 (1999):  1146|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51254, 21908, 'Fenofibrate', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of fibric acid derivatives.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with fibric acid derivatives should be administered cautiously in patients with preexisting myopathy or a myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  Therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', 'Pokroy N, Ress S, Gregory MC "Clofibrate-induced complications in renal disease: a case report." S Afr Med J 52 (1977):  806-8|Abourizk N, Khalil BA, Bahuth N, Afifi AK "Clofibrate-induced muscular syndrome. Report of a case with clinical, electromyographic and pathologic observations." J Neurol Sci 42 (1979):  1-9|Rush P, Baron M, Kapusta M "Clofibrate myopathy: a case report and a review of the literature." Semin Arthritis Rheum 15 (1986):  226-9|Goldman JA, Fishman AB, Lee JE, Johnson RJ "The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis ." Arthritis Rheum 32 (1989):  358-9|Fusella J, Strosberg JM "Polymyositis exacerbated by gemfibrozil ." J Rheumatol 17 (1990):  572-3|Pierce LR, Wysowski DK, Gross TP "Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy." JAMA 264 (1990):  71-5|Chow LT, Chow WH "Acute compartment syndrome: an unusual presentation of gemfibrozil induced myositis." Med J Aust 158 (1993):  48-9|"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Blane GF "Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives." Am J Med 83 (1987):  26-36|Roberts WC "Safety of fenofibrate--US and worldwide experience." Cardiology 76 (1989):  169-79|Dealava E, Sola JJ, Lozano MD, Pardomindan FJ "Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants." Nephron 66 (1994):  242-3|Shepherd J "Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety." Eur Heart J 16 (1995):  5-13|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Duell PB, Connor WE, Illingworth DR "Rhabdomyolysis after taking atorvastatin with gemfibrozil." Am J Cardiol 81 (1998):  368-9|Kirchgassler KU, Schmitz H, Bach G "Effectiveness and tolerability of 12-week treatment with micronised fenofibrate 200mg in a drug-monitoring programme involving 9884 patients with dyslipidaemia." Clin Drug Invest 15 (1998):  197-204|Iliadis EA, Rosenson RS "Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia." Clin Cardiol 22 (1999):  25-8|van Puijenbroek EP, Du Buf-Vereijken PW, Spooren PF, van Doormaal JJ "Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil." J Intern Med 240 (1996):  403-4|Pogson GW, Kindred LH, Carper BG "Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy." Am J Cardiol 83 (1999):  1146|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51255, 23677, 'Fenofibrate', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of fibric acid derivatives.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with fibric acid derivatives should be administered cautiously in patients with preexisting myopathy or a myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  Therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', 'Pokroy N, Ress S, Gregory MC "Clofibrate-induced complications in renal disease: a case report." S Afr Med J 52 (1977):  806-8|Abourizk N, Khalil BA, Bahuth N, Afifi AK "Clofibrate-induced muscular syndrome. Report of a case with clinical, electromyographic and pathologic observations." J Neurol Sci 42 (1979):  1-9|Rush P, Baron M, Kapusta M "Clofibrate myopathy: a case report and a review of the literature." Semin Arthritis Rheum 15 (1986):  226-9|Goldman JA, Fishman AB, Lee JE, Johnson RJ "The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis ." Arthritis Rheum 32 (1989):  358-9|Fusella J, Strosberg JM "Polymyositis exacerbated by gemfibrozil ." J Rheumatol 17 (1990):  572-3|Pierce LR, Wysowski DK, Gross TP "Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy." JAMA 264 (1990):  71-5|Chow LT, Chow WH "Acute compartment syndrome: an unusual presentation of gemfibrozil induced myositis." Med J Aust 158 (1993):  48-9|"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Blane GF "Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives." Am J Med 83 (1987):  26-36|Roberts WC "Safety of fenofibrate--US and worldwide experience." Cardiology 76 (1989):  169-79|Dealava E, Sola JJ, Lozano MD, Pardomindan FJ "Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants." Nephron 66 (1994):  242-3|Shepherd J "Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety." Eur Heart J 16 (1995):  5-13|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Duell PB, Connor WE, Illingworth DR "Rhabdomyolysis after taking atorvastatin with gemfibrozil." Am J Cardiol 81 (1998):  368-9|Kirchgassler KU, Schmitz H, Bach G "Effectiveness and tolerability of 12-week treatment with micronised fenofibrate 200mg in a drug-monitoring programme involving 9884 patients with dyslipidaemia." Clin Drug Invest 15 (1998):  197-204|Iliadis EA, Rosenson RS "Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia." Clin Cardiol 22 (1999):  25-8|van Puijenbroek EP, Du Buf-Vereijken PW, Spooren PF, van Doormaal JJ "Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil." J Intern Med 240 (1996):  403-4|Pogson GW, Kindred LH, Carper BG "Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy." Am J Cardiol 83 (1999):  1146|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51256, 23678, 'Fenofibrate', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of fibric acid derivatives.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with fibric acid derivatives should be administered cautiously in patients with preexisting myopathy or a myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  Therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', 'Pokroy N, Ress S, Gregory MC "Clofibrate-induced complications in renal disease: a case report." S Afr Med J 52 (1977):  806-8|Abourizk N, Khalil BA, Bahuth N, Afifi AK "Clofibrate-induced muscular syndrome. Report of a case with clinical, electromyographic and pathologic observations." J Neurol Sci 42 (1979):  1-9|Rush P, Baron M, Kapusta M "Clofibrate myopathy: a case report and a review of the literature." Semin Arthritis Rheum 15 (1986):  226-9|Goldman JA, Fishman AB, Lee JE, Johnson RJ "The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis ." Arthritis Rheum 32 (1989):  358-9|Fusella J, Strosberg JM "Polymyositis exacerbated by gemfibrozil ." J Rheumatol 17 (1990):  572-3|Pierce LR, Wysowski DK, Gross TP "Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy." JAMA 264 (1990):  71-5|Chow LT, Chow WH "Acute compartment syndrome: an unusual presentation of gemfibrozil induced myositis." Med J Aust 158 (1993):  48-9|"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Blane GF "Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives." Am J Med 83 (1987):  26-36|Roberts WC "Safety of fenofibrate--US and worldwide experience." Cardiology 76 (1989):  169-79|Dealava E, Sola JJ, Lozano MD, Pardomindan FJ "Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants." Nephron 66 (1994):  242-3|Shepherd J "Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety." Eur Heart J 16 (1995):  5-13|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Duell PB, Connor WE, Illingworth DR "Rhabdomyolysis after taking atorvastatin with gemfibrozil." Am J Cardiol 81 (1998):  368-9|Kirchgassler KU, Schmitz H, Bach G "Effectiveness and tolerability of 12-week treatment with micronised fenofibrate 200mg in a drug-monitoring programme involving 9884 patients with dyslipidaemia." Clin Drug Invest 15 (1998):  197-204|Iliadis EA, Rosenson RS "Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia." Clin Cardiol 22 (1999):  25-8|van Puijenbroek EP, Du Buf-Vereijken PW, Spooren PF, van Doormaal JJ "Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil." J Intern Med 240 (1996):  403-4|Pogson GW, Kindred LH, Carper BG "Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy." Am J Cardiol 83 (1999):  1146|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51257, 30829, 'Fenofibrate', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of fibric acid derivatives.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with fibric acid derivatives should be administered cautiously in patients with preexisting myopathy or a myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  Therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', 'Pokroy N, Ress S, Gregory MC "Clofibrate-induced complications in renal disease: a case report." S Afr Med J 52 (1977):  806-8|Abourizk N, Khalil BA, Bahuth N, Afifi AK "Clofibrate-induced muscular syndrome. Report of a case with clinical, electromyographic and pathologic observations." J Neurol Sci 42 (1979):  1-9|Rush P, Baron M, Kapusta M "Clofibrate myopathy: a case report and a review of the literature." Semin Arthritis Rheum 15 (1986):  226-9|Goldman JA, Fishman AB, Lee JE, Johnson RJ "The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis ." Arthritis Rheum 32 (1989):  358-9|Fusella J, Strosberg JM "Polymyositis exacerbated by gemfibrozil ." J Rheumatol 17 (1990):  572-3|Pierce LR, Wysowski DK, Gross TP "Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy." JAMA 264 (1990):  71-5|Chow LT, Chow WH "Acute compartment syndrome: an unusual presentation of gemfibrozil induced myositis." Med J Aust 158 (1993):  48-9|"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Blane GF "Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives." Am J Med 83 (1987):  26-36|Roberts WC "Safety of fenofibrate--US and worldwide experience." Cardiology 76 (1989):  169-79|Dealava E, Sola JJ, Lozano MD, Pardomindan FJ "Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants." Nephron 66 (1994):  242-3|Shepherd J "Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety." Eur Heart J 16 (1995):  5-13|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Duell PB, Connor WE, Illingworth DR "Rhabdomyolysis after taking atorvastatin with gemfibrozil." Am J Cardiol 81 (1998):  368-9|Kirchgassler KU, Schmitz H, Bach G "Effectiveness and tolerability of 12-week treatment with micronised fenofibrate 200mg in a drug-monitoring programme involving 9884 patients with dyslipidaemia." Clin Drug Invest 15 (1998):  197-204|Iliadis EA, Rosenson RS "Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia." Clin Cardiol 22 (1999):  25-8|van Puijenbroek EP, Du Buf-Vereijken PW, Spooren PF, van Doormaal JJ "Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil." J Intern Med 240 (1996):  403-4|Pogson GW, Kindred LH, Carper BG "Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy." Am J Cardiol 83 (1999):  1146|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51258, 4796, 'Fenofibrate', 'Hematologic Diseases', 'Mild to moderate hemoglobin, hematocrit and white blood cell decreases have been observed in patients following initiation of fibric acid derivatives therapy.  However, these levels stabilize during long-term administration.  Thrombocytopenia and agranulocytosis have been reported in individuals treated with these agents.  Caution is recommended when treating patients predisposed to hematologic changes.  Periodic monitoring of red and white blood cell counts is recommended during the first 12 months of therapy.', '2', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51259, 4870, 'Fenofibrate', 'Hematologic Diseases', 'Mild to moderate hemoglobin, hematocrit and white blood cell decreases have been observed in patients following initiation of fibric acid derivatives therapy.  However, these levels stabilize during long-term administration.  Thrombocytopenia and agranulocytosis have been reported in individuals treated with these agents.  Caution is recommended when treating patients predisposed to hematologic changes.  Periodic monitoring of red and white blood cell counts is recommended during the first 12 months of therapy.', '2', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51260, 7338, 'Fenofibrate', 'Hematologic Diseases', 'Mild to moderate hemoglobin, hematocrit and white blood cell decreases have been observed in patients following initiation of fibric acid derivatives therapy.  However, these levels stabilize during long-term administration.  Thrombocytopenia and agranulocytosis have been reported in individuals treated with these agents.  Caution is recommended when treating patients predisposed to hematologic changes.  Periodic monitoring of red and white blood cell counts is recommended during the first 12 months of therapy.', '2', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51261, 7341, 'Fenofibrate', 'Hematologic Diseases', 'Mild to moderate hemoglobin, hematocrit and white blood cell decreases have been observed in patients following initiation of fibric acid derivatives therapy.  However, these levels stabilize during long-term administration.  Thrombocytopenia and agranulocytosis have been reported in individuals treated with these agents.  Caution is recommended when treating patients predisposed to hematologic changes.  Periodic monitoring of red and white blood cell counts is recommended during the first 12 months of therapy.', '2', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51262, 7391, 'Fenofibrate', 'Hematologic Diseases', 'Mild to moderate hemoglobin, hematocrit and white blood cell decreases have been observed in patients following initiation of fibric acid derivatives therapy.  However, these levels stabilize during long-term administration.  Thrombocytopenia and agranulocytosis have been reported in individuals treated with these agents.  Caution is recommended when treating patients predisposed to hematologic changes.  Periodic monitoring of red and white blood cell counts is recommended during the first 12 months of therapy.', '2', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51263, 7393, 'Fenofibrate', 'Hematologic Diseases', 'Mild to moderate hemoglobin, hematocrit and white blood cell decreases have been observed in patients following initiation of fibric acid derivatives therapy.  However, these levels stabilize during long-term administration.  Thrombocytopenia and agranulocytosis have been reported in individuals treated with these agents.  Caution is recommended when treating patients predisposed to hematologic changes.  Periodic monitoring of red and white blood cell counts is recommended during the first 12 months of therapy.', '2', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51264, 18946, 'Fenofibrate', 'Hematologic Diseases', 'Mild to moderate hemoglobin, hematocrit and white blood cell decreases have been observed in patients following initiation of fibric acid derivatives therapy.  However, these levels stabilize during long-term administration.  Thrombocytopenia and agranulocytosis have been reported in individuals treated with these agents.  Caution is recommended when treating patients predisposed to hematologic changes.  Periodic monitoring of red and white blood cell counts is recommended during the first 12 months of therapy.', '2', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51265, 21293, 'Fenofibrate', 'Hematologic Diseases', 'Mild to moderate hemoglobin, hematocrit and white blood cell decreases have been observed in patients following initiation of fibric acid derivatives therapy.  However, these levels stabilize during long-term administration.  Thrombocytopenia and agranulocytosis have been reported in individuals treated with these agents.  Caution is recommended when treating patients predisposed to hematologic changes.  Periodic monitoring of red and white blood cell counts is recommended during the first 12 months of therapy.', '2', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51266, 21876, 'Fenofibrate', 'Hematologic Diseases', 'Mild to moderate hemoglobin, hematocrit and white blood cell decreases have been observed in patients following initiation of fibric acid derivatives therapy.  However, these levels stabilize during long-term administration.  Thrombocytopenia and agranulocytosis have been reported in individuals treated with these agents.  Caution is recommended when treating patients predisposed to hematologic changes.  Periodic monitoring of red and white blood cell counts is recommended during the first 12 months of therapy.', '2', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51267, 21902, 'Fenofibrate', 'Hematologic Diseases', 'Mild to moderate hemoglobin, hematocrit and white blood cell decreases have been observed in patients following initiation of fibric acid derivatives therapy.  However, these levels stabilize during long-term administration.  Thrombocytopenia and agranulocytosis have been reported in individuals treated with these agents.  Caution is recommended when treating patients predisposed to hematologic changes.  Periodic monitoring of red and white blood cell counts is recommended during the first 12 months of therapy.', '2', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51268, 21908, 'Fenofibrate', 'Hematologic Diseases', 'Mild to moderate hemoglobin, hematocrit and white blood cell decreases have been observed in patients following initiation of fibric acid derivatives therapy.  However, these levels stabilize during long-term administration.  Thrombocytopenia and agranulocytosis have been reported in individuals treated with these agents.  Caution is recommended when treating patients predisposed to hematologic changes.  Periodic monitoring of red and white blood cell counts is recommended during the first 12 months of therapy.', '2', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51269, 23677, 'Fenofibrate', 'Hematologic Diseases', 'Mild to moderate hemoglobin, hematocrit and white blood cell decreases have been observed in patients following initiation of fibric acid derivatives therapy.  However, these levels stabilize during long-term administration.  Thrombocytopenia and agranulocytosis have been reported in individuals treated with these agents.  Caution is recommended when treating patients predisposed to hematologic changes.  Periodic monitoring of red and white blood cell counts is recommended during the first 12 months of therapy.', '2', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51270, 23678, 'Fenofibrate', 'Hematologic Diseases', 'Mild to moderate hemoglobin, hematocrit and white blood cell decreases have been observed in patients following initiation of fibric acid derivatives therapy.  However, these levels stabilize during long-term administration.  Thrombocytopenia and agranulocytosis have been reported in individuals treated with these agents.  Caution is recommended when treating patients predisposed to hematologic changes.  Periodic monitoring of red and white blood cell counts is recommended during the first 12 months of therapy.', '2', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51271, 30829, 'Fenofibrate', 'Hematologic Diseases', 'Mild to moderate hemoglobin, hematocrit and white blood cell decreases have been observed in patients following initiation of fibric acid derivatives therapy.  However, these levels stabilize during long-term administration.  Thrombocytopenia and agranulocytosis have been reported in individuals treated with these agents.  Caution is recommended when treating patients predisposed to hematologic changes.  Periodic monitoring of red and white blood cell counts is recommended during the first 12 months of therapy.', '2', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51272, 0, 'Felbamate', 'Anemia, Aplastic', 'The use of felbamate is contraindicated in patients with bone marrow suppression or a current or prior history of blood dyscrasias.  A marked increase in the incidence of aplastic anemia has been associated with the use of felbamate, reportedly exceeding 100 times the incidence observed in the general population (2 to 5 per million persons per year).  In the few cases that have been reported in felbamate patients, the onset of clinical manifestations of aplastic anemia ranged from 5 to 30 weeks.  However, the injury to bone marrow stem cells that is believed to be ultimately responsible for the anemia may occur much earlier.  Currently, it is not known whether the risk is related to dose, duration of exposure, and/or concomitant use of other antiepileptic or myelotoxic drugs.  Expert hematologic consultation should be available for all patients treated with felbamate.  Since aplastic anemia typically develops without premonitory clinical or laboratory signs, it should be borne in mind that routine blood testing may not be reliably used to prevent development of the syndrome.  However, in some cases, it may allow the detection of hematologic changes before the condition is full-blown.  Felbamate therapy should be withdrawn if evidence of bone marrow depression is observed.  Patients who are discontinued from the drug may remain at risk for developing anemia for a variable and unknown period afterwards and should be monitored accordingly.', '3', 'Palmer KJ, McTavish D "Felbamate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in epilepsy." Drugs 45 (1993):  1041-65|"Product Information. Felbatol (felbamate)." Wallace Laboratories  (2001):|Ney GC, Schaul N, Loughlin J, Rai K, Chandra V "Thrombocytopenia in association with adjunctive felbamate use." Neurology 44 (1994):  980-1|Werble CP, ed. "Carter-Wallace felbatol discontinued use recommended due to aplastic anemia; felbamate loss could mean three C-W products off market in a year." F-D-C Reports -- "The Pink Sheet" 56 (1994):  6-7|Ahmad SR "Felbamate and aplastic anaemia." Lancet 344 (1994):  465|Nightengale SL "Recommendation to immediately withdraw patients from treatment with felbamate." JAMA 272 (1994):  995', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51273, 0, 'Felbamate', 'Liver Diseases', 'The use of felbamate is contraindicated in patients with a history of hepatic impairment.  A marked increase in the incidence of hepatic failure, some resulting in fatality, has been associated with the use of felbamate relative to that expected in the general population (approximately 2000 cases per year).  Currently, it is not known whether the risk is related to dose, duration of exposure, and/or concomitant use of other antiepileptic or hepatotoxic drugs.  All patients treated with felbamate should have serum transaminase and bilirubin levels checked prior to initiating therapy and at 1- to 2-week intervals while treatment continues.  Felbamate therapy should be withdrawn if abnormal liver function tests occur.', '3', 'Palmer KJ, McTavish D "Felbamate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in epilepsy." Drugs 45 (1993):  1041-65|"Product Information. Felbatol (felbamate)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51274, 0, 'Felbamate', 'Kidney Diseases', 'Felbamate is partially eliminated by the kidney as unchanged drug (approximately 40% to 50% of absorbed dose).  The plasma clearance of felbamate may be decreased and the half-life prolonged in patients with impaired renal function.  Therapy with felbamate should be administered cautiously in patients with renal impairment.', '3', 'Wilensky AJ, Friel PN, Ojemann LM, Kupferberg HJ, Levy RH "Pharmacokinetics of W-554 (ADD 03055) in epileptic patients." Epilepsia 26 (1985):  602-6|"Product Information. Felbatol (felbamate)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51275, 0, 'Felbamate', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Klonopin (clonazepam)." Roche Laboratories  (2001):|"Product Information. Dilantin (phenytoin)." Parke-Davis  (2001):|"Product Information. Cerebyx (fosphenytoin)." Parke-Davis  (2001):|"Product Information. Mysoline (primidone)." Elan Pharmaceuticals  (2001):|"Product Information. Lyrica (pregabalin)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Sabril (vigabatrin)." Lundbeck Inc  (2009):|"Product Information. Potiga (ezogabine)." GlaxoSmithKline  (2011):|"Product Information. Qsymia (phentermine-topiramate)." Vivus Inc  (2012):|"Product Information. Fycompa (perampanel)." Eisai Inc  (2012):|"Product Information. Briviact (brivaracetam)." UCB Pharma Inc  (2016):|"Product Information. Diacomit (stiripentol)." Biocodex USA  (2018):|"Product Information. Epidiolex (cannabidiol)." Greenwich Biosciences LLC  (2018):|"Product Information. Xcopri (cenobamate)." SK Life Science, Inc.  (2020):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):|"Product Information. Ztalmy (ganaxolone)." Marinus Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51276, 29046, 'Fenofibric acid', 'Liver Cirrhosis, Biliary', 'The use of fibric acid derivatives is contraindicated in patients with primary biliary cirrhosis.  These agents may further raise the already elevated cholesterol in these patients.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51277, 29047, 'Fenofibric acid', 'Liver Cirrhosis, Biliary', 'The use of fibric acid derivatives is contraindicated in patients with primary biliary cirrhosis.  These agents may further raise the already elevated cholesterol in these patients.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51278, 29046, 'Fenofibric acid', 'Cholelithiasis', 'The use of fibric acid derivatives is contraindicated in patients with gallbladder disease.  A significantly increased incidence of cholelithiasis has been observed in patients treated with the fibric acid derivative, clofibrate, presumably because of increased cholesterol excretion into the bile.  Based on two separate studies (the WHO study and the Coronary Drug Project study), clofibrate use was associated with twice the risk of developing cholelithiasis and cholecystitis requiring surgery.  Due to their structural and pharmacologic similarities, use of other fibric acid derivatives may be expected to carry the same risk.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Blane GF "Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives." Am J Med 83 (1987):  26-36|Roberts WC "Safety of fenofibrate--US and worldwide experience." Cardiology 76 (1989):  169-79|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51279, 29047, 'Fenofibric acid', 'Cholelithiasis', 'The use of fibric acid derivatives is contraindicated in patients with gallbladder disease.  A significantly increased incidence of cholelithiasis has been observed in patients treated with the fibric acid derivative, clofibrate, presumably because of increased cholesterol excretion into the bile.  Based on two separate studies (the WHO study and the Coronary Drug Project study), clofibrate use was associated with twice the risk of developing cholelithiasis and cholecystitis requiring surgery.  Due to their structural and pharmacologic similarities, use of other fibric acid derivatives may be expected to carry the same risk.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Blane GF "Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives." Am J Med 83 (1987):  26-36|Roberts WC "Safety of fenofibrate--US and worldwide experience." Cardiology 76 (1989):  169-79|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51280, 29046, 'Fenofibric acid', 'Hypolipoproteinemias', 'There have been reports of severe decreases in HDL cholesterol (HDL-C) levels (as low as 2 mg/dL) occurring in diabetic and non-diabetic patients initiated on fibric acid derivatives therapy.  The decrease has been reported to occur within 2 weeks to years after initiation of therapy.  It is recommended that HDL-C levels be checked within the first few months after initiation therapy and if a severely depressed HDL-C level is detected, therapy with these agents should be withdrawn.  Monitor HDL-C level until it has returned to baseline, and therapy with these agents should not be re-initiated in these patients.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51281, 29047, 'Fenofibric acid', 'Hypolipoproteinemias', 'There have been reports of severe decreases in HDL cholesterol (HDL-C) levels (as low as 2 mg/dL) occurring in diabetic and non-diabetic patients initiated on fibric acid derivatives therapy.  The decrease has been reported to occur within 2 weeks to years after initiation of therapy.  It is recommended that HDL-C levels be checked within the first few months after initiation therapy and if a severely depressed HDL-C level is detected, therapy with these agents should be withdrawn.  Monitor HDL-C level until it has returned to baseline, and therapy with these agents should not be re-initiated in these patients.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51282, 29046, 'Fenofibric acid', 'Liver Diseases', 'The use of fibric acid derivatives is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  Fibric acid derivatives therapy is associated with dose-related hepatotoxicity, including biochemical abnormalities of liver function, hepatitis (hepatocellular, chronic active, as well as cholestatic) and, rarely, cirrhosis.  Postmarketing cases of severe drug-induced liver injury, including liver transplantation and death, have been reported.  Therapy with these agents should be administered cautiously in patients with a history of liver disease and/or heavy alcohol use.  Liver function tests, including serum transaminase levels and total bilirubin, should be performed at baseline and periodically throughout the duration of therapy.  Therapy should be discontinued if signs or symptoms of liver injury develop or if elevated enzyme levels persist (ALT or AST greater than 3 times the upper limit of normal, or if accompanied by elevation of bilirubin).  Do not restart therapy if there is no alternative explanation for the liver injury.', '3', 'Cayen MN "Disposition, metabolism and pharmacokinetics of antihyperlipidemic agents in laboratory animals and man." Pharmacol Ther 29 (1985):  157-204|Chapman MJ "Pharmacology of fenofibrate." Am J Med 83 (1987):  21-5|Weil A, Caldwell J, Strolin-Benedetti M "The metabolism and disposition of 14C-fenofibrate in human volunteers." Drug Metab Dispos 18 (1990):  115-20|Balfour JA, McTavish D, Heel RC "Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia." Drugs 40 (1990):  260-90|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Adkins JC, Faulds D "Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia." Drugs 54 (1997):  615-33|Miller DB, Spence JD "Clinical pharmacokinetics of fibric acid derivatives (fibrates)." Clin Pharmacokinet 34 (1998):  155-62|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51283, 29047, 'Fenofibric acid', 'Liver Diseases', 'The use of fibric acid derivatives is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  Fibric acid derivatives therapy is associated with dose-related hepatotoxicity, including biochemical abnormalities of liver function, hepatitis (hepatocellular, chronic active, as well as cholestatic) and, rarely, cirrhosis.  Postmarketing cases of severe drug-induced liver injury, including liver transplantation and death, have been reported.  Therapy with these agents should be administered cautiously in patients with a history of liver disease and/or heavy alcohol use.  Liver function tests, including serum transaminase levels and total bilirubin, should be performed at baseline and periodically throughout the duration of therapy.  Therapy should be discontinued if signs or symptoms of liver injury develop or if elevated enzyme levels persist (ALT or AST greater than 3 times the upper limit of normal, or if accompanied by elevation of bilirubin).  Do not restart therapy if there is no alternative explanation for the liver injury.', '3', 'Cayen MN "Disposition, metabolism and pharmacokinetics of antihyperlipidemic agents in laboratory animals and man." Pharmacol Ther 29 (1985):  157-204|Chapman MJ "Pharmacology of fenofibrate." Am J Med 83 (1987):  21-5|Weil A, Caldwell J, Strolin-Benedetti M "The metabolism and disposition of 14C-fenofibrate in human volunteers." Drug Metab Dispos 18 (1990):  115-20|Balfour JA, McTavish D, Heel RC "Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia." Drugs 40 (1990):  260-90|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Adkins JC, Faulds D "Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia." Drugs 54 (1997):  615-33|Miller DB, Spence JD "Clinical pharmacokinetics of fibric acid derivatives (fibrates)." Clin Pharmacokinet 34 (1998):  155-62|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51284, 29046, 'Fenofibric acid', 'Kidney Diseases', 'The use of fibric acid derivatives is contraindicated in patients with significantly impaired renal function.  The rate of clearance of fenofibric acid has been shown to decrease substantially when CrCl is below 50 mL/min, with drug accumulation during chronic dosing.  Increased adverse effects, including rhabdomyolysis (with or without secondary renal failure) and severe hyperkalemia, have been associated with the use of fibric acid derivatives in patients with renal insufficiency.  Therapy with these agents should be administered cautiously in patients with mild or moderate renal impairment.  Close clinical monitoring is recommended during therapy.', '3', 'Pokroy N, Ress S, Gregory MC "Clofibrate-induced complications in renal disease: a case report." S Afr Med J 52 (1977):  806-8|Goldman JA, Fishman AB, Lee JE, Johnson RJ "The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis ." Arthritis Rheum 32 (1989):  358-9|Chapman MJ "Pharmacology of fenofibrate." Am J Med 83 (1987):  21-5|Weil A, Caldwell J, Strolin-Benedetti M "The metabolism and disposition of 14C-fenofibrate in human volunteers." Drug Metab Dispos 18 (1990):  115-20|Balfour JA, McTavish D, Heel RC "Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia." Drugs 40 (1990):  260-90|Dealava E, Sola JJ, Lozano MD, Pardomindan FJ "Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants." Nephron 66 (1994):  242-3|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Miller DB, Spence JD "Clinical pharmacokinetics of fibric acid derivatives (fibrates)." Clin Pharmacokinet 34 (1998):  155-62|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51285, 29047, 'Fenofibric acid', 'Kidney Diseases', 'The use of fibric acid derivatives is contraindicated in patients with significantly impaired renal function.  The rate of clearance of fenofibric acid has been shown to decrease substantially when CrCl is below 50 mL/min, with drug accumulation during chronic dosing.  Increased adverse effects, including rhabdomyolysis (with or without secondary renal failure) and severe hyperkalemia, have been associated with the use of fibric acid derivatives in patients with renal insufficiency.  Therapy with these agents should be administered cautiously in patients with mild or moderate renal impairment.  Close clinical monitoring is recommended during therapy.', '3', 'Pokroy N, Ress S, Gregory MC "Clofibrate-induced complications in renal disease: a case report." S Afr Med J 52 (1977):  806-8|Goldman JA, Fishman AB, Lee JE, Johnson RJ "The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis ." Arthritis Rheum 32 (1989):  358-9|Chapman MJ "Pharmacology of fenofibrate." Am J Med 83 (1987):  21-5|Weil A, Caldwell J, Strolin-Benedetti M "The metabolism and disposition of 14C-fenofibrate in human volunteers." Drug Metab Dispos 18 (1990):  115-20|Balfour JA, McTavish D, Heel RC "Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia." Drugs 40 (1990):  260-90|Dealava E, Sola JJ, Lozano MD, Pardomindan FJ "Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants." Nephron 66 (1994):  242-3|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Miller DB, Spence JD "Clinical pharmacokinetics of fibric acid derivatives (fibrates)." Clin Pharmacokinet 34 (1998):  155-62|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51286, 29046, 'Fenofibric acid', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of fibric acid derivatives.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with fibric acid derivatives should be administered cautiously in patients with preexisting myopathy or a myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  Therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', 'Pokroy N, Ress S, Gregory MC "Clofibrate-induced complications in renal disease: a case report." S Afr Med J 52 (1977):  806-8|Abourizk N, Khalil BA, Bahuth N, Afifi AK "Clofibrate-induced muscular syndrome. Report of a case with clinical, electromyographic and pathologic observations." J Neurol Sci 42 (1979):  1-9|Rush P, Baron M, Kapusta M "Clofibrate myopathy: a case report and a review of the literature." Semin Arthritis Rheum 15 (1986):  226-9|Goldman JA, Fishman AB, Lee JE, Johnson RJ "The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis ." Arthritis Rheum 32 (1989):  358-9|Fusella J, Strosberg JM "Polymyositis exacerbated by gemfibrozil ." J Rheumatol 17 (1990):  572-3|Pierce LR, Wysowski DK, Gross TP "Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy." JAMA 264 (1990):  71-5|Chow LT, Chow WH "Acute compartment syndrome: an unusual presentation of gemfibrozil induced myositis." Med J Aust 158 (1993):  48-9|"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Blane GF "Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives." Am J Med 83 (1987):  26-36|Roberts WC "Safety of fenofibrate--US and worldwide experience." Cardiology 76 (1989):  169-79|Dealava E, Sola JJ, Lozano MD, Pardomindan FJ "Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants." Nephron 66 (1994):  242-3|Shepherd J "Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety." Eur Heart J 16 (1995):  5-13|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Duell PB, Connor WE, Illingworth DR "Rhabdomyolysis after taking atorvastatin with gemfibrozil." Am J Cardiol 81 (1998):  368-9|Kirchgassler KU, Schmitz H, Bach G "Effectiveness and tolerability of 12-week treatment with micronised fenofibrate 200mg in a drug-monitoring programme involving 9884 patients with dyslipidaemia." Clin Drug Invest 15 (1998):  197-204|Iliadis EA, Rosenson RS "Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia." Clin Cardiol 22 (1999):  25-8|van Puijenbroek EP, Du Buf-Vereijken PW, Spooren PF, van Doormaal JJ "Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil." J Intern Med 240 (1996):  403-4|Pogson GW, Kindred LH, Carper BG "Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy." Am J Cardiol 83 (1999):  1146|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51287, 29047, 'Fenofibric acid', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of fibric acid derivatives.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with fibric acid derivatives should be administered cautiously in patients with preexisting myopathy or a myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  Therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', 'Pokroy N, Ress S, Gregory MC "Clofibrate-induced complications in renal disease: a case report." S Afr Med J 52 (1977):  806-8|Abourizk N, Khalil BA, Bahuth N, Afifi AK "Clofibrate-induced muscular syndrome. Report of a case with clinical, electromyographic and pathologic observations." J Neurol Sci 42 (1979):  1-9|Rush P, Baron M, Kapusta M "Clofibrate myopathy: a case report and a review of the literature." Semin Arthritis Rheum 15 (1986):  226-9|Goldman JA, Fishman AB, Lee JE, Johnson RJ "The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis ." Arthritis Rheum 32 (1989):  358-9|Fusella J, Strosberg JM "Polymyositis exacerbated by gemfibrozil ." J Rheumatol 17 (1990):  572-3|Pierce LR, Wysowski DK, Gross TP "Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy." JAMA 264 (1990):  71-5|Chow LT, Chow WH "Acute compartment syndrome: an unusual presentation of gemfibrozil induced myositis." Med J Aust 158 (1993):  48-9|"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Blane GF "Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives." Am J Med 83 (1987):  26-36|Roberts WC "Safety of fenofibrate--US and worldwide experience." Cardiology 76 (1989):  169-79|Dealava E, Sola JJ, Lozano MD, Pardomindan FJ "Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants." Nephron 66 (1994):  242-3|Shepherd J "Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety." Eur Heart J 16 (1995):  5-13|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Duell PB, Connor WE, Illingworth DR "Rhabdomyolysis after taking atorvastatin with gemfibrozil." Am J Cardiol 81 (1998):  368-9|Kirchgassler KU, Schmitz H, Bach G "Effectiveness and tolerability of 12-week treatment with micronised fenofibrate 200mg in a drug-monitoring programme involving 9884 patients with dyslipidaemia." Clin Drug Invest 15 (1998):  197-204|Iliadis EA, Rosenson RS "Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia." Clin Cardiol 22 (1999):  25-8|van Puijenbroek EP, Du Buf-Vereijken PW, Spooren PF, van Doormaal JJ "Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil." J Intern Med 240 (1996):  403-4|Pogson GW, Kindred LH, Carper BG "Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy." Am J Cardiol 83 (1999):  1146|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51288, 29046, 'Fenofibric acid', 'Hematologic Diseases', 'Mild to moderate hemoglobin, hematocrit and white blood cell decreases have been observed in patients following initiation of fibric acid derivatives therapy.  However, these levels stabilize during long-term administration.  Thrombocytopenia and agranulocytosis have been reported in individuals treated with these agents.  Caution is recommended when treating patients predisposed to hematologic changes.  Periodic monitoring of red and white blood cell counts is recommended during the first 12 months of therapy.', '2', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51289, 29047, 'Fenofibric acid', 'Hematologic Diseases', 'Mild to moderate hemoglobin, hematocrit and white blood cell decreases have been observed in patients following initiation of fibric acid derivatives therapy.  However, these levels stabilize during long-term administration.  Thrombocytopenia and agranulocytosis have been reported in individuals treated with these agents.  Caution is recommended when treating patients predisposed to hematologic changes.  Periodic monitoring of red and white blood cell counts is recommended during the first 12 months of therapy.', '2', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51290, 0, 'Fenoldopam', 'Heart Failure', 'Fenoldopam causes a dose-related fall in blood pressure that may worsen congestive heart failure.  Therapy with fenoldopam should be administered cautiously in patients with heart failure.  Monitoring blood pressure at regular intervals is recommended.', '3', 'Panacek EA, Bednarczyk EM, Dunbar LM, Foulke GE, Holcslaw TL "Randomized, prospective trial of fenoldopam vs sodium nitroprusside in the treatment of acute severe hypertension. Fenoldopam Study Group." Acad Emerg Med 2 (1995):  959-65|Ventura HO, Messerli FH, Frohlich ED, Kobrin I, Oigman W, Dunn FG, Carey RM "Immediate hemodynamic effects of a dopamine-receptor agonist (fenoldopam) in patients with essential hypertension." Circulation 69 (1984):  1142-5|Gluck Z, Jossen L, Weidmann P, Gnadinger MP, Peheim E "Cardiovascular and renal profile of acute peripheral dopamine1- receptor agonism with fenoldopam." Hypertension 10 (1987):  43-54|"Product Information. Corlopam (fenoldopam)." Neurex  (2001):|Brogden RN, Markham A "Fenoldopam: a review of its pharmacodynamic and pharmacokinetic properties and intravenous clinical potential in the management of hypertensive urgencies and emergencies." Drugs 54 (1997):  634-50', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51291, 0, 'Fenoldopam', 'Glaucoma', 'Fenoldopam causes a dose-dependent increase in intraocular pressure.  Therapy with fenoldopam should be administered cautiously in patients with glaucoma or intraocular hypertension.  Intraocular pressure may return to baseline in 2 hours following discontinuation of fenoldopam.', '3', 'Everitt DE, Boike SC, Piltz-Seymour JR, VanCoevorden R, Audet P, Zariffa N, Jorkasky D "Effect of intravenous fenoldopam on intraocular pressure in ocular hypertension." J Clin Pharmacol 37 (1997):  312-20|"Product Information. Corlopam (fenoldopam)." Neurex  (2001):|Brogden RN, Markham A "Fenoldopam: a review of its pharmacodynamic and pharmacokinetic properties and intravenous clinical potential in the management of hypertensive urgencies and emergencies." Drugs 54 (1997):  634-50', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51292, 0, 'Fenoldopam', 'Hypokalemia', 'The use of fenoldopam is associated with hypokalemia (less than 3 mEq/L after 6 hours of infusion).  Therapy with fenoldopam should be administered cautiously in patients with preexisting hypokalemia.  Monitoring serum electrolytes and potassium replacement as required is recommended.', '3', 'Panacek EA, Bednarczyk EM, Dunbar LM, Foulke GE, Holcslaw TL "Randomized, prospective trial of fenoldopam vs sodium nitroprusside in the treatment of acute severe hypertension. Fenoldopam Study Group." Acad Emerg Med 2 (1995):  959-65|Nichols AJ, Ruffolo RR Jr, Brooks DP "The pharmacology of fenoldopam." Am J Hypertens 3 (1990):  s116-9|Ruilope LM, Robles RG, Miranda B, Tovar J, Alcazar JM, Sancho J, Rodicio JL, Martinez A, Astorga A, Beck T "Renal effects of fenoldopam in refractory hypertension." J Hypertens 6 (1988):  665-9|Girbes AR, Smit AJ, Meijer S, Reitsma WD "Renal and endocrine effects of fenoldopam and metoclopramide in normal man." Nephron 56 (1990):  179-85|"Product Information. Corlopam (fenoldopam)." Neurex  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51293, 0, 'Fenoldopam', 'Hypotension', 'Fenoldopam may cause symptomatic hypotension that may exacerbate cerebral infarction or hemorrhage.  Monitoring blood pressure closely during administration is recommended.', '3', 'White WB, Radford MJ, Gonzalez FM, Weed SG, McCabe EJ, Katz AM "Selective dopamine-1 agonist therapy in severe hypertension: effects of intravenous fenoldopam." J Am Coll Cardiol 11 (1988):  1118-23|Panacek EA, Bednarczyk EM, Dunbar LM, Foulke GE, Holcslaw TL "Randomized, prospective trial of fenoldopam vs sodium nitroprusside in the treatment of acute severe hypertension. Fenoldopam Study Group." Acad Emerg Med 2 (1995):  959-65|Ventura HO, Messerli FH, Frohlich ED, Kobrin I, Oigman W, Dunn FG, Carey RM "Immediate hemodynamic effects of a dopamine-receptor agonist (fenoldopam) in patients with essential hypertension." Circulation 69 (1984):  1142-5|Munger MA, Rutherford WF, Anderson L, Hakki AI, Gonzalez FM, Bednarczyk EM, Emmanuel G, Weed SG, Panacek EA, Green JA "Assessment of intravenous fenoldopam mesylate in the management of severe systemic hypertension." Crit Care Med 18 (1990):  502-4|Gluck Z, Jossen L, Weidmann P, Gnadinger MP, Peheim E "Cardiovascular and renal profile of acute peripheral dopamine1- receptor agonism with fenoldopam." Hypertension 10 (1987):  43-54|"Product Information. Corlopam (fenoldopam)." Neurex  (2001):|Brogden RN, Markham A "Fenoldopam: a review of its pharmacodynamic and pharmacokinetic properties and intravenous clinical potential in the management of hypertensive urgencies and emergencies." Drugs 54 (1997):  634-50', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51294, 0, 'Fenoldopam', 'Tachycardia', 'The use of fenoldopam is associated with producing dose-related compensatory tachycardia, particularly with infusion rates greater than 0.1 mcg/kg/min in adults and >0.8 mcg/kg/min in pediatric patients.  Tachycardia may diminish over time, but remains substantial at higher doses.  Care should be exercised when using this agent in patients at risk.', '3', 'Panacek EA, Bednarczyk EM, Dunbar LM, Foulke GE, Holcslaw TL "Randomized, prospective trial of fenoldopam vs sodium nitroprusside in the treatment of acute severe hypertension. Fenoldopam Study Group." Acad Emerg Med 2 (1995):  959-65|Ventura HO, Messerli FH, Frohlich ED, Kobrin I, Oigman W, Dunn FG, Carey RM "Immediate hemodynamic effects of a dopamine-receptor agonist (fenoldopam) in patients with essential hypertension." Circulation 69 (1984):  1142-5|Gluck Z, Jossen L, Weidmann P, Gnadinger MP, Peheim E "Cardiovascular and renal profile of acute peripheral dopamine1- receptor agonism with fenoldopam." Hypertension 10 (1987):  43-54|Holcslaw TL, Beck TR "Clinical experience with intravenous fenoldopam." Am J Hypertens 3 (1990):  s120-5|"Product Information. Corlopam (fenoldopam)." Neurex  (2001):|Brogden RN, Markham A "Fenoldopam: a review of its pharmacodynamic and pharmacokinetic properties and intravenous clinical potential in the management of hypertensive urgencies and emergencies." Drugs 54 (1997):  634-50', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51295, 8544, 'Fenoprofen', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51296, 8545, 'Fenoprofen', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51297, 18948, 'Fenoprofen', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51298, 8544, 'Fenoprofen', 'Water-Electrolyte Imbalance', 'Fluid retention and edema have been reported in association with the use of nonsteroidal anti-inflammatory drugs (NSAIDs).  Therapy with NSAIDs should be administered cautiously in patients with preexisting fluid retention, hypertension, or a history of heart failure.  Blood pressure and cardiovascular status should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Anaprox (naproxen)." Roche Laboratories  (2006):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51299, 8545, 'Fenoprofen', 'Water-Electrolyte Imbalance', 'Fluid retention and edema have been reported in association with the use of nonsteroidal anti-inflammatory drugs (NSAIDs).  Therapy with NSAIDs should be administered cautiously in patients with preexisting fluid retention, hypertension, or a history of heart failure.  Blood pressure and cardiovascular status should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Anaprox (naproxen)." Roche Laboratories  (2006):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51300, 18948, 'Fenoprofen', 'Water-Electrolyte Imbalance', 'Fluid retention and edema have been reported in association with the use of nonsteroidal anti-inflammatory drugs (NSAIDs).  Therapy with NSAIDs should be administered cautiously in patients with preexisting fluid retention, hypertension, or a history of heart failure.  Blood pressure and cardiovascular status should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Anaprox (naproxen)." Roche Laboratories  (2006):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51301, 8544, 'Fenoprofen', 'Peptic Ulcer', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal.  These serious adverse events can develop at any time, with or without warning symptoms.  Only 1 in 5 patients who develop a serious upper GI side effect on NSAIDs is symptomatic.  NSAIDs should be used with caution in patients with history of peptic ulcer disease and/or GI bleeding, as these patients had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors.  Caution is also advised if NSAIDs are prescribed to patients with other factors that increase risk of GI bleeding, such as:  prolonged NSAID therapy; concomitant use of oral corticosteroids, antiplatelet agents (e.g., aspirin), anticoagulants, selective serotonin reuptake inhibitors; alcohol use; smoking; history of gastrointestinal surgery or anastomosis, older age; poor general health status; and advanced liver disease and/or coagulopathy.  Particular vigilance is necessary when treating elderly or debilitated patients since most postmarketing reports of fatal GI events occurred in these patients.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51302, 8545, 'Fenoprofen', 'Peptic Ulcer', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal.  These serious adverse events can develop at any time, with or without warning symptoms.  Only 1 in 5 patients who develop a serious upper GI side effect on NSAIDs is symptomatic.  NSAIDs should be used with caution in patients with history of peptic ulcer disease and/or GI bleeding, as these patients had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors.  Caution is also advised if NSAIDs are prescribed to patients with other factors that increase risk of GI bleeding, such as:  prolonged NSAID therapy; concomitant use of oral corticosteroids, antiplatelet agents (e.g., aspirin), anticoagulants, selective serotonin reuptake inhibitors; alcohol use; smoking; history of gastrointestinal surgery or anastomosis, older age; poor general health status; and advanced liver disease and/or coagulopathy.  Particular vigilance is necessary when treating elderly or debilitated patients since most postmarketing reports of fatal GI events occurred in these patients.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51303, 18948, 'Fenoprofen', 'Peptic Ulcer', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal.  These serious adverse events can develop at any time, with or without warning symptoms.  Only 1 in 5 patients who develop a serious upper GI side effect on NSAIDs is symptomatic.  NSAIDs should be used with caution in patients with history of peptic ulcer disease and/or GI bleeding, as these patients had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors.  Caution is also advised if NSAIDs are prescribed to patients with other factors that increase risk of GI bleeding, such as:  prolonged NSAID therapy; concomitant use of oral corticosteroids, antiplatelet agents (e.g., aspirin), anticoagulants, selective serotonin reuptake inhibitors; alcohol use; smoking; history of gastrointestinal surgery or anastomosis, older age; poor general health status; and advanced liver disease and/or coagulopathy.  Particular vigilance is necessary when treating elderly or debilitated patients since most postmarketing reports of fatal GI events occurred in these patients.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51304, 8544, 'Fenoprofen', 'Exanthema', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious skin adverse reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, and exfoliative dermatitis), which can be fatal.  These serious events may occur without warning.  Patients should be advised to discontinue the NSAID and seek medical attention promptly at the first sign of skin rash or any other sign of hypersensitivity.  NSAIDs are contraindicated in patients with previous serious skin reactions to these drugs.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51305, 8545, 'Fenoprofen', 'Exanthema', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious skin adverse reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, and exfoliative dermatitis), which can be fatal.  These serious events may occur without warning.  Patients should be advised to discontinue the NSAID and seek medical attention promptly at the first sign of skin rash or any other sign of hypersensitivity.  NSAIDs are contraindicated in patients with previous serious skin reactions to these drugs.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51306, 18948, 'Fenoprofen', 'Exanthema', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious skin adverse reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, and exfoliative dermatitis), which can be fatal.  These serious events may occur without warning.  Patients should be advised to discontinue the NSAID and seek medical attention promptly at the first sign of skin rash or any other sign of hypersensitivity.  NSAIDs are contraindicated in patients with previous serious skin reactions to these drugs.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51307, 8544, 'Fenoprofen', 'Kidney Diseases', 'Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) has resulted in renal papillary necrosis and other renal injury.  Renal toxicity has been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion:  in such patients, NSAIDs may cause a dose-dependent reduction in prostaglandin synthesis and, secondarily, in renal blood flow, which may precipitate overt renal decompensation.  Patients at greatest risk for this reaction include the elderly, those with impaired renal function, dehydration, hypovolemia, heart failure, or liver dysfunction, and those taking diuretics, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers; discontinuation of NSAID therapy will usually lead to recovery to the pretreatment state.  No information is available regarding use NSAIDs in patients with advanced renal disease; the renal effects of NSAIDs may hasten the progression of renal dysfunction in patients with preexisting renal disease.  Volume status should be corrected in dehydrated or hypovolemic patients prior to initiating treatment.  Renal function should be monitored during therapy in patients with renal or liver dysfunction, heart failure, dehydration, or hypovolemia.  NSAIDs should be avoided in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function; if an NSAID is used in such patients, they should be monitored for signs of worsening renal function.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51308, 8545, 'Fenoprofen', 'Kidney Diseases', 'Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) has resulted in renal papillary necrosis and other renal injury.  Renal toxicity has been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion:  in such patients, NSAIDs may cause a dose-dependent reduction in prostaglandin synthesis and, secondarily, in renal blood flow, which may precipitate overt renal decompensation.  Patients at greatest risk for this reaction include the elderly, those with impaired renal function, dehydration, hypovolemia, heart failure, or liver dysfunction, and those taking diuretics, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers; discontinuation of NSAID therapy will usually lead to recovery to the pretreatment state.  No information is available regarding use NSAIDs in patients with advanced renal disease; the renal effects of NSAIDs may hasten the progression of renal dysfunction in patients with preexisting renal disease.  Volume status should be corrected in dehydrated or hypovolemic patients prior to initiating treatment.  Renal function should be monitored during therapy in patients with renal or liver dysfunction, heart failure, dehydration, or hypovolemia.  NSAIDs should be avoided in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function; if an NSAID is used in such patients, they should be monitored for signs of worsening renal function.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51309, 18948, 'Fenoprofen', 'Kidney Diseases', 'Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) has resulted in renal papillary necrosis and other renal injury.  Renal toxicity has been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion:  in such patients, NSAIDs may cause a dose-dependent reduction in prostaglandin synthesis and, secondarily, in renal blood flow, which may precipitate overt renal decompensation.  Patients at greatest risk for this reaction include the elderly, those with impaired renal function, dehydration, hypovolemia, heart failure, or liver dysfunction, and those taking diuretics, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers; discontinuation of NSAID therapy will usually lead to recovery to the pretreatment state.  No information is available regarding use NSAIDs in patients with advanced renal disease; the renal effects of NSAIDs may hasten the progression of renal dysfunction in patients with preexisting renal disease.  Volume status should be corrected in dehydrated or hypovolemic patients prior to initiating treatment.  Renal function should be monitored during therapy in patients with renal or liver dysfunction, heart failure, dehydration, or hypovolemia.  NSAIDs should be avoided in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function; if an NSAID is used in such patients, they should be monitored for signs of worsening renal function.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51310, 8544, 'Fenoprofen', 'Thrombosis', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.  This risk may occur early in treatment and may increase with duration of use.  Clinical trials of several cyclooxygenase-2 (COX-2) selective and nonselective NSAIDs of up to 3 years duration have supported this increased risk.  It is unclear from available data if the risk for cardiovascular thrombotic events is similar for all NSAIDs.  Therapy with NSAIDs should be administered cautiously in patients with a history of cardiovascular or cerebrovascular disease.  Patients should be treated with the lowest effective dosage for the shortest duration necessary.  Appropriate antiplatelet therapy should be administered to patients requiring cardioprotection; however, there is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious cardiovascular thrombotic events associated with NSAID use, while the risk of serious gastrointestinal events is increased.  Physicians and patients should remain alert for the development of adverse cardiovascular events throughout the entire duration of therapy, even without prior cardiovascular symptoms.  Patients should be advised to promptly seek medical attention if they experience symptoms of cardiovascular thrombotic events (including chest pain, shortness of breath, weakness, or slurring of speech).NSAIDs are contraindicated in the setting of coronary artery bypass graft (CABG) surgery.  Two large clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10 to 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke.The use of NSAIDs should be avoided in patients with a recent myocardial infarction unless the benefits are expected to outweigh the risk of recurrent cardiovascular thrombotic events.  If an NSAID is used in patients with a recent myocardial infarction, they should be monitored for signs of cardiac ischemia.', '3', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Ponstel (mefenamic acid)." Pfizer U.S. Pharmaceuticals Group  (2006):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51311, 8545, 'Fenoprofen', 'Thrombosis', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.  This risk may occur early in treatment and may increase with duration of use.  Clinical trials of several cyclooxygenase-2 (COX-2) selective and nonselective NSAIDs of up to 3 years duration have supported this increased risk.  It is unclear from available data if the risk for cardiovascular thrombotic events is similar for all NSAIDs.  Therapy with NSAIDs should be administered cautiously in patients with a history of cardiovascular or cerebrovascular disease.  Patients should be treated with the lowest effective dosage for the shortest duration necessary.  Appropriate antiplatelet therapy should be administered to patients requiring cardioprotection; however, there is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious cardiovascular thrombotic events associated with NSAID use, while the risk of serious gastrointestinal events is increased.  Physicians and patients should remain alert for the development of adverse cardiovascular events throughout the entire duration of therapy, even without prior cardiovascular symptoms.  Patients should be advised to promptly seek medical attention if they experience symptoms of cardiovascular thrombotic events (including chest pain, shortness of breath, weakness, or slurring of speech).NSAIDs are contraindicated in the setting of coronary artery bypass graft (CABG) surgery.  Two large clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10 to 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke.The use of NSAIDs should be avoided in patients with a recent myocardial infarction unless the benefits are expected to outweigh the risk of recurrent cardiovascular thrombotic events.  If an NSAID is used in patients with a recent myocardial infarction, they should be monitored for signs of cardiac ischemia.', '3', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Ponstel (mefenamic acid)." Pfizer U.S. Pharmaceuticals Group  (2006):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51312, 18948, 'Fenoprofen', 'Thrombosis', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.  This risk may occur early in treatment and may increase with duration of use.  Clinical trials of several cyclooxygenase-2 (COX-2) selective and nonselective NSAIDs of up to 3 years duration have supported this increased risk.  It is unclear from available data if the risk for cardiovascular thrombotic events is similar for all NSAIDs.  Therapy with NSAIDs should be administered cautiously in patients with a history of cardiovascular or cerebrovascular disease.  Patients should be treated with the lowest effective dosage for the shortest duration necessary.  Appropriate antiplatelet therapy should be administered to patients requiring cardioprotection; however, there is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious cardiovascular thrombotic events associated with NSAID use, while the risk of serious gastrointestinal events is increased.  Physicians and patients should remain alert for the development of adverse cardiovascular events throughout the entire duration of therapy, even without prior cardiovascular symptoms.  Patients should be advised to promptly seek medical attention if they experience symptoms of cardiovascular thrombotic events (including chest pain, shortness of breath, weakness, or slurring of speech).NSAIDs are contraindicated in the setting of coronary artery bypass graft (CABG) surgery.  Two large clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10 to 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke.The use of NSAIDs should be avoided in patients with a recent myocardial infarction unless the benefits are expected to outweigh the risk of recurrent cardiovascular thrombotic events.  If an NSAID is used in patients with a recent myocardial infarction, they should be monitored for signs of cardiac ischemia.', '3', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Ponstel (mefenamic acid)." Pfizer U.S. Pharmaceuticals Group  (2006):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51313, 8544, 'Fenoprofen', 'Anemia', 'Anemia has been reported in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  This may be due to fluid retention, occult/gross blood loss, or an incompletely described effect on erythropoiesis.  Hemoglobin or hematocrit should be monitored in patients with any signs/symptoms of anemia or blood loss, especially during long-term therapy.  NSAIDs may increase risk of bleeding events; comorbid conditions (e.g., coagulation disorders; concomitant use of warfarin/other anticoagulants, antiplatelet agents, serotonin/serotonin norepinephrine reuptake inhibitors) may increase this risk, and patients with these conditions should be monitored for signs of bleeding.  Therapy with NSAIDs should be administered cautiously in patients with or predisposed to anemia.  Clinical monitoring of hematopoietic function may be appropriate, particularly during chronic therapy.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Toradol (ketorolac)." Roche Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51314, 8545, 'Fenoprofen', 'Anemia', 'Anemia has been reported in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  This may be due to fluid retention, occult/gross blood loss, or an incompletely described effect on erythropoiesis.  Hemoglobin or hematocrit should be monitored in patients with any signs/symptoms of anemia or blood loss, especially during long-term therapy.  NSAIDs may increase risk of bleeding events; comorbid conditions (e.g., coagulation disorders; concomitant use of warfarin/other anticoagulants, antiplatelet agents, serotonin/serotonin norepinephrine reuptake inhibitors) may increase this risk, and patients with these conditions should be monitored for signs of bleeding.  Therapy with NSAIDs should be administered cautiously in patients with or predisposed to anemia.  Clinical monitoring of hematopoietic function may be appropriate, particularly during chronic therapy.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Toradol (ketorolac)." Roche Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51315, 18948, 'Fenoprofen', 'Anemia', 'Anemia has been reported in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  This may be due to fluid retention, occult/gross blood loss, or an incompletely described effect on erythropoiesis.  Hemoglobin or hematocrit should be monitored in patients with any signs/symptoms of anemia or blood loss, especially during long-term therapy.  NSAIDs may increase risk of bleeding events; comorbid conditions (e.g., coagulation disorders; concomitant use of warfarin/other anticoagulants, antiplatelet agents, serotonin/serotonin norepinephrine reuptake inhibitors) may increase this risk, and patients with these conditions should be monitored for signs of bleeding.  Therapy with NSAIDs should be administered cautiously in patients with or predisposed to anemia.  Clinical monitoring of hematopoietic function may be appropriate, particularly during chronic therapy.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Toradol (ketorolac)." Roche Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51316, 8544, 'Fenoprofen', 'Heart Failure', 'Fluid retention and edema have been observed in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs), including some topical formulations.  These drugs should be avoided in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure.  If an NSAID is used in patients with severe heart failure, they should be monitored for signs of worsening heart failure.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51317, 8545, 'Fenoprofen', 'Heart Failure', 'Fluid retention and edema have been observed in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs), including some topical formulations.  These drugs should be avoided in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure.  If an NSAID is used in patients with severe heart failure, they should be monitored for signs of worsening heart failure.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51318, 18948, 'Fenoprofen', 'Heart Failure', 'Fluid retention and edema have been observed in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs), including some topical formulations.  These drugs should be avoided in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure.  If an NSAID is used in patients with severe heart failure, they should be monitored for signs of worsening heart failure.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51319, 8544, 'Fenoprofen', 'Liver Diseases', 'Borderline elevations of 1 or more liver tests may occur in up to 15% of patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  These laboratory abnormalities may progress, remain unchanged, or regress with continuing therapy.  Elevations of ALT or AST (at least 3 times the upper limit of normal) have been reported in about 1% of patients in clinical trials.  In addition, rare (sometimes fatal) cases of severe hepatotoxicity, including liver necrosis, hepatic failure, jaundice, and fulminant hepatitis have been reported.  Therapy with NSAIDs should be administered cautiously in patients with preexisting liver disease.  Periodic monitoring of liver function is recommended during prolonged therapy.  NSAIDs are also highly protein-bound and some are extensively metabolized by the liver.  Metabolic activity and/or plasma protein binding may be altered in patients with hepatic impairment.  A dosage reduction may be required in some cases.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Toradol (ketorolac)." Roche Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51320, 8545, 'Fenoprofen', 'Liver Diseases', 'Borderline elevations of 1 or more liver tests may occur in up to 15% of patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  These laboratory abnormalities may progress, remain unchanged, or regress with continuing therapy.  Elevations of ALT or AST (at least 3 times the upper limit of normal) have been reported in about 1% of patients in clinical trials.  In addition, rare (sometimes fatal) cases of severe hepatotoxicity, including liver necrosis, hepatic failure, jaundice, and fulminant hepatitis have been reported.  Therapy with NSAIDs should be administered cautiously in patients with preexisting liver disease.  Periodic monitoring of liver function is recommended during prolonged therapy.  NSAIDs are also highly protein-bound and some are extensively metabolized by the liver.  Metabolic activity and/or plasma protein binding may be altered in patients with hepatic impairment.  A dosage reduction may be required in some cases.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Toradol (ketorolac)." Roche Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51321, 18948, 'Fenoprofen', 'Liver Diseases', 'Borderline elevations of 1 or more liver tests may occur in up to 15% of patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  These laboratory abnormalities may progress, remain unchanged, or regress with continuing therapy.  Elevations of ALT or AST (at least 3 times the upper limit of normal) have been reported in about 1% of patients in clinical trials.  In addition, rare (sometimes fatal) cases of severe hepatotoxicity, including liver necrosis, hepatic failure, jaundice, and fulminant hepatitis have been reported.  Therapy with NSAIDs should be administered cautiously in patients with preexisting liver disease.  Periodic monitoring of liver function is recommended during prolonged therapy.  NSAIDs are also highly protein-bound and some are extensively metabolized by the liver.  Metabolic activity and/or plasma protein binding may be altered in patients with hepatic impairment.  A dosage reduction may be required in some cases.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Toradol (ketorolac)." Roche Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51322, 8544, 'Fenoprofen', 'Hyperkalemia', 'Increases in serum potassium concentration (including hyperkalemia) have been reported with use of nonsteroidal anti-inflammatory drugs (NSAIDs), even in some patients without renal impairment.  In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.  Caution is advised in patients with hyperkalemia.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51323, 8545, 'Fenoprofen', 'Hyperkalemia', 'Increases in serum potassium concentration (including hyperkalemia) have been reported with use of nonsteroidal anti-inflammatory drugs (NSAIDs), even in some patients without renal impairment.  In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.  Caution is advised in patients with hyperkalemia.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51324, 18948, 'Fenoprofen', 'Hyperkalemia', 'Increases in serum potassium concentration (including hyperkalemia) have been reported with use of nonsteroidal anti-inflammatory drugs (NSAIDs), even in some patients without renal impairment.  In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.  Caution is advised in patients with hyperkalemia.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51325, 8544, 'Fenoprofen', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51326, 8545, 'Fenoprofen', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51327, 18948, 'Fenoprofen', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51328, 8544, 'Fenoprofen', 'Blood Platelet Disorders', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) reversibly inhibit platelet adhesion and aggregation and may prolong bleeding time in some patients.  With the exception of aspirin, the platelet effects seen with most NSAIDs at usual recommended dosages are generally slight and of relatively short duration but may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  NSAIDs that selectively inhibit cyclooxygenase-2 (i.e., COX-2 inhibitors) do not appear to affect platelet function or bleeding time at indicated dosages and may be preferable if risk of bleeding is a concern.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51329, 8545, 'Fenoprofen', 'Blood Platelet Disorders', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) reversibly inhibit platelet adhesion and aggregation and may prolong bleeding time in some patients.  With the exception of aspirin, the platelet effects seen with most NSAIDs at usual recommended dosages are generally slight and of relatively short duration but may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  NSAIDs that selectively inhibit cyclooxygenase-2 (i.e., COX-2 inhibitors) do not appear to affect platelet function or bleeding time at indicated dosages and may be preferable if risk of bleeding is a concern.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51330, 18948, 'Fenoprofen', 'Blood Platelet Disorders', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) reversibly inhibit platelet adhesion and aggregation and may prolong bleeding time in some patients.  With the exception of aspirin, the platelet effects seen with most NSAIDs at usual recommended dosages are generally slight and of relatively short duration but may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  NSAIDs that selectively inhibit cyclooxygenase-2 (i.e., COX-2 inhibitors) do not appear to affect platelet function or bleeding time at indicated dosages and may be preferable if risk of bleeding is a concern.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51331, 4802, 'Fentanyl', 'Gastrointestinal Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the gastrointestinal tract and decrease peristalsis, which can lead to elevated intraluminal pressure, spasm, and constipation following prolonged use.  In patients with severe or acute inflammatory bowel disease, the decrease in colonic motility may induce toxic megacolon.  Therapy with opioids should be administered cautiously in patients with gastrointestinal obstruction, constipation, inflammatory bowel disease, or recent gastrointestinal tract surgery.  Gastrointestinal effects appear to be the most pronounced with morphine.', '3', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|White MJ, Berghausen EJ, Dumont SW, Tsueda K, Schroeder JA, Vogel RL, Heine MF, Huang KC "Side effects during continuous epidural infusion of morphine and fentanyl." Can J Anaesth 39 (1992):  576-82|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Thorn SE, Wattwil M, Kallander A "Effects of epidural morphine and epidural bupivacaine on gastroduodenal motility during the fasted state and after food intake." Acta Anaesthesiol Scand 38 (1994):  57-62|Bennett MWR, Shah MV, Bembridge JL "A comparison of the effect on gastric emptying of alfentanil or morphine given during anaesthesia for minor surgery." Anaesthesia 49 (1994):  155-6|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51332, 13291, 'Fentanyl', 'Gastrointestinal Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the gastrointestinal tract and decrease peristalsis, which can lead to elevated intraluminal pressure, spasm, and constipation following prolonged use.  In patients with severe or acute inflammatory bowel disease, the decrease in colonic motility may induce toxic megacolon.  Therapy with opioids should be administered cautiously in patients with gastrointestinal obstruction, constipation, inflammatory bowel disease, or recent gastrointestinal tract surgery.  Gastrointestinal effects appear to be the most pronounced with morphine.', '3', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|White MJ, Berghausen EJ, Dumont SW, Tsueda K, Schroeder JA, Vogel RL, Heine MF, Huang KC "Side effects during continuous epidural infusion of morphine and fentanyl." Can J Anaesth 39 (1992):  576-82|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Thorn SE, Wattwil M, Kallander A "Effects of epidural morphine and epidural bupivacaine on gastroduodenal motility during the fasted state and after food intake." Acta Anaesthesiol Scand 38 (1994):  57-62|Bennett MWR, Shah MV, Bembridge JL "A comparison of the effect on gastric emptying of alfentanil or morphine given during anaesthesia for minor surgery." Anaesthesia 49 (1994):  155-6|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51333, 13292, 'Fentanyl', 'Gastrointestinal Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the gastrointestinal tract and decrease peristalsis, which can lead to elevated intraluminal pressure, spasm, and constipation following prolonged use.  In patients with severe or acute inflammatory bowel disease, the decrease in colonic motility may induce toxic megacolon.  Therapy with opioids should be administered cautiously in patients with gastrointestinal obstruction, constipation, inflammatory bowel disease, or recent gastrointestinal tract surgery.  Gastrointestinal effects appear to be the most pronounced with morphine.', '3', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|White MJ, Berghausen EJ, Dumont SW, Tsueda K, Schroeder JA, Vogel RL, Heine MF, Huang KC "Side effects during continuous epidural infusion of morphine and fentanyl." Can J Anaesth 39 (1992):  576-82|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Thorn SE, Wattwil M, Kallander A "Effects of epidural morphine and epidural bupivacaine on gastroduodenal motility during the fasted state and after food intake." Acta Anaesthesiol Scand 38 (1994):  57-62|Bennett MWR, Shah MV, Bembridge JL "A comparison of the effect on gastric emptying of alfentanil or morphine given during anaesthesia for minor surgery." Anaesthesia 49 (1994):  155-6|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51334, 17981, 'Fentanyl', 'Gastrointestinal Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the gastrointestinal tract and decrease peristalsis, which can lead to elevated intraluminal pressure, spasm, and constipation following prolonged use.  In patients with severe or acute inflammatory bowel disease, the decrease in colonic motility may induce toxic megacolon.  Therapy with opioids should be administered cautiously in patients with gastrointestinal obstruction, constipation, inflammatory bowel disease, or recent gastrointestinal tract surgery.  Gastrointestinal effects appear to be the most pronounced with morphine.', '3', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|White MJ, Berghausen EJ, Dumont SW, Tsueda K, Schroeder JA, Vogel RL, Heine MF, Huang KC "Side effects during continuous epidural infusion of morphine and fentanyl." Can J Anaesth 39 (1992):  576-82|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Thorn SE, Wattwil M, Kallander A "Effects of epidural morphine and epidural bupivacaine on gastroduodenal motility during the fasted state and after food intake." Acta Anaesthesiol Scand 38 (1994):  57-62|Bennett MWR, Shah MV, Bembridge JL "A comparison of the effect on gastric emptying of alfentanil or morphine given during anaesthesia for minor surgery." Anaesthesia 49 (1994):  155-6|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51335, 17982, 'Fentanyl', 'Gastrointestinal Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the gastrointestinal tract and decrease peristalsis, which can lead to elevated intraluminal pressure, spasm, and constipation following prolonged use.  In patients with severe or acute inflammatory bowel disease, the decrease in colonic motility may induce toxic megacolon.  Therapy with opioids should be administered cautiously in patients with gastrointestinal obstruction, constipation, inflammatory bowel disease, or recent gastrointestinal tract surgery.  Gastrointestinal effects appear to be the most pronounced with morphine.', '3', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|White MJ, Berghausen EJ, Dumont SW, Tsueda K, Schroeder JA, Vogel RL, Heine MF, Huang KC "Side effects during continuous epidural infusion of morphine and fentanyl." Can J Anaesth 39 (1992):  576-82|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Thorn SE, Wattwil M, Kallander A "Effects of epidural morphine and epidural bupivacaine on gastroduodenal motility during the fasted state and after food intake." Acta Anaesthesiol Scand 38 (1994):  57-62|Bennett MWR, Shah MV, Bembridge JL "A comparison of the effect on gastric emptying of alfentanil or morphine given during anaesthesia for minor surgery." Anaesthesia 49 (1994):  155-6|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51336, 17983, 'Fentanyl', 'Gastrointestinal Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the gastrointestinal tract and decrease peristalsis, which can lead to elevated intraluminal pressure, spasm, and constipation following prolonged use.  In patients with severe or acute inflammatory bowel disease, the decrease in colonic motility may induce toxic megacolon.  Therapy with opioids should be administered cautiously in patients with gastrointestinal obstruction, constipation, inflammatory bowel disease, or recent gastrointestinal tract surgery.  Gastrointestinal effects appear to be the most pronounced with morphine.', '3', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|White MJ, Berghausen EJ, Dumont SW, Tsueda K, Schroeder JA, Vogel RL, Heine MF, Huang KC "Side effects during continuous epidural infusion of morphine and fentanyl." Can J Anaesth 39 (1992):  576-82|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Thorn SE, Wattwil M, Kallander A "Effects of epidural morphine and epidural bupivacaine on gastroduodenal motility during the fasted state and after food intake." Acta Anaesthesiol Scand 38 (1994):  57-62|Bennett MWR, Shah MV, Bembridge JL "A comparison of the effect on gastric emptying of alfentanil or morphine given during anaesthesia for minor surgery." Anaesthesia 49 (1994):  155-6|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51337, 17984, 'Fentanyl', 'Gastrointestinal Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the gastrointestinal tract and decrease peristalsis, which can lead to elevated intraluminal pressure, spasm, and constipation following prolonged use.  In patients with severe or acute inflammatory bowel disease, the decrease in colonic motility may induce toxic megacolon.  Therapy with opioids should be administered cautiously in patients with gastrointestinal obstruction, constipation, inflammatory bowel disease, or recent gastrointestinal tract surgery.  Gastrointestinal effects appear to be the most pronounced with morphine.', '3', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|White MJ, Berghausen EJ, Dumont SW, Tsueda K, Schroeder JA, Vogel RL, Heine MF, Huang KC "Side effects during continuous epidural infusion of morphine and fentanyl." Can J Anaesth 39 (1992):  576-82|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Thorn SE, Wattwil M, Kallander A "Effects of epidural morphine and epidural bupivacaine on gastroduodenal motility during the fasted state and after food intake." Acta Anaesthesiol Scand 38 (1994):  57-62|Bennett MWR, Shah MV, Bembridge JL "A comparison of the effect on gastric emptying of alfentanil or morphine given during anaesthesia for minor surgery." Anaesthesia 49 (1994):  155-6|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51338, 17985, 'Fentanyl', 'Gastrointestinal Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the gastrointestinal tract and decrease peristalsis, which can lead to elevated intraluminal pressure, spasm, and constipation following prolonged use.  In patients with severe or acute inflammatory bowel disease, the decrease in colonic motility may induce toxic megacolon.  Therapy with opioids should be administered cautiously in patients with gastrointestinal obstruction, constipation, inflammatory bowel disease, or recent gastrointestinal tract surgery.  Gastrointestinal effects appear to be the most pronounced with morphine.', '3', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|White MJ, Berghausen EJ, Dumont SW, Tsueda K, Schroeder JA, Vogel RL, Heine MF, Huang KC "Side effects during continuous epidural infusion of morphine and fentanyl." Can J Anaesth 39 (1992):  576-82|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Thorn SE, Wattwil M, Kallander A "Effects of epidural morphine and epidural bupivacaine on gastroduodenal motility during the fasted state and after food intake." Acta Anaesthesiol Scand 38 (1994):  57-62|Bennett MWR, Shah MV, Bembridge JL "A comparison of the effect on gastric emptying of alfentanil or morphine given during anaesthesia for minor surgery." Anaesthesia 49 (1994):  155-6|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51339, 18952, 'Fentanyl', 'Gastrointestinal Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the gastrointestinal tract and decrease peristalsis, which can lead to elevated intraluminal pressure, spasm, and constipation following prolonged use.  In patients with severe or acute inflammatory bowel disease, the decrease in colonic motility may induce toxic megacolon.  Therapy with opioids should be administered cautiously in patients with gastrointestinal obstruction, constipation, inflammatory bowel disease, or recent gastrointestinal tract surgery.  Gastrointestinal effects appear to be the most pronounced with morphine.', '3', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|White MJ, Berghausen EJ, Dumont SW, Tsueda K, Schroeder JA, Vogel RL, Heine MF, Huang KC "Side effects during continuous epidural infusion of morphine and fentanyl." Can J Anaesth 39 (1992):  576-82|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Thorn SE, Wattwil M, Kallander A "Effects of epidural morphine and epidural bupivacaine on gastroduodenal motility during the fasted state and after food intake." Acta Anaesthesiol Scand 38 (1994):  57-62|Bennett MWR, Shah MV, Bembridge JL "A comparison of the effect on gastric emptying of alfentanil or morphine given during anaesthesia for minor surgery." Anaesthesia 49 (1994):  155-6|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51340, 18953, 'Fentanyl', 'Gastrointestinal Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the gastrointestinal tract and decrease peristalsis, which can lead to elevated intraluminal pressure, spasm, and constipation following prolonged use.  In patients with severe or acute inflammatory bowel disease, the decrease in colonic motility may induce toxic megacolon.  Therapy with opioids should be administered cautiously in patients with gastrointestinal obstruction, constipation, inflammatory bowel disease, or recent gastrointestinal tract surgery.  Gastrointestinal effects appear to be the most pronounced with morphine.', '3', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|White MJ, Berghausen EJ, Dumont SW, Tsueda K, Schroeder JA, Vogel RL, Heine MF, Huang KC "Side effects during continuous epidural infusion of morphine and fentanyl." Can J Anaesth 39 (1992):  576-82|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Thorn SE, Wattwil M, Kallander A "Effects of epidural morphine and epidural bupivacaine on gastroduodenal motility during the fasted state and after food intake." Acta Anaesthesiol Scand 38 (1994):  57-62|Bennett MWR, Shah MV, Bembridge JL "A comparison of the effect on gastric emptying of alfentanil or morphine given during anaesthesia for minor surgery." Anaesthesia 49 (1994):  155-6|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51341, 18955, 'Fentanyl', 'Gastrointestinal Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the gastrointestinal tract and decrease peristalsis, which can lead to elevated intraluminal pressure, spasm, and constipation following prolonged use.  In patients with severe or acute inflammatory bowel disease, the decrease in colonic motility may induce toxic megacolon.  Therapy with opioids should be administered cautiously in patients with gastrointestinal obstruction, constipation, inflammatory bowel disease, or recent gastrointestinal tract surgery.  Gastrointestinal effects appear to be the most pronounced with morphine.', '3', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|White MJ, Berghausen EJ, Dumont SW, Tsueda K, Schroeder JA, Vogel RL, Heine MF, Huang KC "Side effects during continuous epidural infusion of morphine and fentanyl." Can J Anaesth 39 (1992):  576-82|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Thorn SE, Wattwil M, Kallander A "Effects of epidural morphine and epidural bupivacaine on gastroduodenal motility during the fasted state and after food intake." Acta Anaesthesiol Scand 38 (1994):  57-62|Bennett MWR, Shah MV, Bembridge JL "A comparison of the effect on gastric emptying of alfentanil or morphine given during anaesthesia for minor surgery." Anaesthesia 49 (1994):  155-6|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51342, 30532, 'Fentanyl', 'Gastrointestinal Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the gastrointestinal tract and decrease peristalsis, which can lead to elevated intraluminal pressure, spasm, and constipation following prolonged use.  In patients with severe or acute inflammatory bowel disease, the decrease in colonic motility may induce toxic megacolon.  Therapy with opioids should be administered cautiously in patients with gastrointestinal obstruction, constipation, inflammatory bowel disease, or recent gastrointestinal tract surgery.  Gastrointestinal effects appear to be the most pronounced with morphine.', '3', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|White MJ, Berghausen EJ, Dumont SW, Tsueda K, Schroeder JA, Vogel RL, Heine MF, Huang KC "Side effects during continuous epidural infusion of morphine and fentanyl." Can J Anaesth 39 (1992):  576-82|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Thorn SE, Wattwil M, Kallander A "Effects of epidural morphine and epidural bupivacaine on gastroduodenal motility during the fasted state and after food intake." Acta Anaesthesiol Scand 38 (1994):  57-62|Bennett MWR, Shah MV, Bembridge JL "A comparison of the effect on gastric emptying of alfentanil or morphine given during anaesthesia for minor surgery." Anaesthesia 49 (1994):  155-6|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51343, 4802, 'Fentanyl', 'Dysentery', 'Narcotic (opioid) analgesic agents may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella, Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  These agents decrease gastrointestinal motility, which may delay the excretion of infective gastroenteric organisms and/or their toxins.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  Therapy with opioids should be avoided or administered cautiously in patients with infectious diarrhea, particularly that due to pseudomembranous enterocolitis or enterotoxin-producing bacteria or if accompanied by high fever, pus, or blood in the stool.', '3', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|White MJ, Berghausen EJ, Dumont SW, Tsueda K, Schroeder JA, Vogel RL, Heine MF, Huang KC "Side effects during continuous epidural infusion of morphine and fentanyl." Can J Anaesth 39 (1992):  576-82|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Thorn SE, Wattwil M, Kallander A "Effects of epidural morphine and epidural bupivacaine on gastroduodenal motility during the fasted state and after food intake." Acta Anaesthesiol Scand 38 (1994):  57-62|Bennett MWR, Shah MV, Bembridge JL "A comparison of the effect on gastric emptying of alfentanil or morphine given during anaesthesia for minor surgery." Anaesthesia 49 (1994):  155-6|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51344, 13291, 'Fentanyl', 'Dysentery', 'Narcotic (opioid) analgesic agents may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella, Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  These agents decrease gastrointestinal motility, which may delay the excretion of infective gastroenteric organisms and/or their toxins.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  Therapy with opioids should be avoided or administered cautiously in patients with infectious diarrhea, particularly that due to pseudomembranous enterocolitis or enterotoxin-producing bacteria or if accompanied by high fever, pus, or blood in the stool.', '3', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|White MJ, Berghausen EJ, Dumont SW, Tsueda K, Schroeder JA, Vogel RL, Heine MF, Huang KC "Side effects during continuous epidural infusion of morphine and fentanyl." Can J Anaesth 39 (1992):  576-82|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Thorn SE, Wattwil M, Kallander A "Effects of epidural morphine and epidural bupivacaine on gastroduodenal motility during the fasted state and after food intake." Acta Anaesthesiol Scand 38 (1994):  57-62|Bennett MWR, Shah MV, Bembridge JL "A comparison of the effect on gastric emptying of alfentanil or morphine given during anaesthesia for minor surgery." Anaesthesia 49 (1994):  155-6|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51345, 13292, 'Fentanyl', 'Dysentery', 'Narcotic (opioid) analgesic agents may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella, Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  These agents decrease gastrointestinal motility, which may delay the excretion of infective gastroenteric organisms and/or their toxins.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  Therapy with opioids should be avoided or administered cautiously in patients with infectious diarrhea, particularly that due to pseudomembranous enterocolitis or enterotoxin-producing bacteria or if accompanied by high fever, pus, or blood in the stool.', '3', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|White MJ, Berghausen EJ, Dumont SW, Tsueda K, Schroeder JA, Vogel RL, Heine MF, Huang KC "Side effects during continuous epidural infusion of morphine and fentanyl." Can J Anaesth 39 (1992):  576-82|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Thorn SE, Wattwil M, Kallander A "Effects of epidural morphine and epidural bupivacaine on gastroduodenal motility during the fasted state and after food intake." Acta Anaesthesiol Scand 38 (1994):  57-62|Bennett MWR, Shah MV, Bembridge JL "A comparison of the effect on gastric emptying of alfentanil or morphine given during anaesthesia for minor surgery." Anaesthesia 49 (1994):  155-6|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51346, 17981, 'Fentanyl', 'Dysentery', 'Narcotic (opioid) analgesic agents may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella, Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  These agents decrease gastrointestinal motility, which may delay the excretion of infective gastroenteric organisms and/or their toxins.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  Therapy with opioids should be avoided or administered cautiously in patients with infectious diarrhea, particularly that due to pseudomembranous enterocolitis or enterotoxin-producing bacteria or if accompanied by high fever, pus, or blood in the stool.', '3', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|White MJ, Berghausen EJ, Dumont SW, Tsueda K, Schroeder JA, Vogel RL, Heine MF, Huang KC "Side effects during continuous epidural infusion of morphine and fentanyl." Can J Anaesth 39 (1992):  576-82|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Thorn SE, Wattwil M, Kallander A "Effects of epidural morphine and epidural bupivacaine on gastroduodenal motility during the fasted state and after food intake." Acta Anaesthesiol Scand 38 (1994):  57-62|Bennett MWR, Shah MV, Bembridge JL "A comparison of the effect on gastric emptying of alfentanil or morphine given during anaesthesia for minor surgery." Anaesthesia 49 (1994):  155-6|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51347, 17982, 'Fentanyl', 'Dysentery', 'Narcotic (opioid) analgesic agents may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella, Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  These agents decrease gastrointestinal motility, which may delay the excretion of infective gastroenteric organisms and/or their toxins.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  Therapy with opioids should be avoided or administered cautiously in patients with infectious diarrhea, particularly that due to pseudomembranous enterocolitis or enterotoxin-producing bacteria or if accompanied by high fever, pus, or blood in the stool.', '3', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|White MJ, Berghausen EJ, Dumont SW, Tsueda K, Schroeder JA, Vogel RL, Heine MF, Huang KC "Side effects during continuous epidural infusion of morphine and fentanyl." Can J Anaesth 39 (1992):  576-82|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Thorn SE, Wattwil M, Kallander A "Effects of epidural morphine and epidural bupivacaine on gastroduodenal motility during the fasted state and after food intake." Acta Anaesthesiol Scand 38 (1994):  57-62|Bennett MWR, Shah MV, Bembridge JL "A comparison of the effect on gastric emptying of alfentanil or morphine given during anaesthesia for minor surgery." Anaesthesia 49 (1994):  155-6|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51348, 17983, 'Fentanyl', 'Dysentery', 'Narcotic (opioid) analgesic agents may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella, Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  These agents decrease gastrointestinal motility, which may delay the excretion of infective gastroenteric organisms and/or their toxins.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  Therapy with opioids should be avoided or administered cautiously in patients with infectious diarrhea, particularly that due to pseudomembranous enterocolitis or enterotoxin-producing bacteria or if accompanied by high fever, pus, or blood in the stool.', '3', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|White MJ, Berghausen EJ, Dumont SW, Tsueda K, Schroeder JA, Vogel RL, Heine MF, Huang KC "Side effects during continuous epidural infusion of morphine and fentanyl." Can J Anaesth 39 (1992):  576-82|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Thorn SE, Wattwil M, Kallander A "Effects of epidural morphine and epidural bupivacaine on gastroduodenal motility during the fasted state and after food intake." Acta Anaesthesiol Scand 38 (1994):  57-62|Bennett MWR, Shah MV, Bembridge JL "A comparison of the effect on gastric emptying of alfentanil or morphine given during anaesthesia for minor surgery." Anaesthesia 49 (1994):  155-6|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51349, 17984, 'Fentanyl', 'Dysentery', 'Narcotic (opioid) analgesic agents may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella, Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  These agents decrease gastrointestinal motility, which may delay the excretion of infective gastroenteric organisms and/or their toxins.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  Therapy with opioids should be avoided or administered cautiously in patients with infectious diarrhea, particularly that due to pseudomembranous enterocolitis or enterotoxin-producing bacteria or if accompanied by high fever, pus, or blood in the stool.', '3', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|White MJ, Berghausen EJ, Dumont SW, Tsueda K, Schroeder JA, Vogel RL, Heine MF, Huang KC "Side effects during continuous epidural infusion of morphine and fentanyl." Can J Anaesth 39 (1992):  576-82|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Thorn SE, Wattwil M, Kallander A "Effects of epidural morphine and epidural bupivacaine on gastroduodenal motility during the fasted state and after food intake." Acta Anaesthesiol Scand 38 (1994):  57-62|Bennett MWR, Shah MV, Bembridge JL "A comparison of the effect on gastric emptying of alfentanil or morphine given during anaesthesia for minor surgery." Anaesthesia 49 (1994):  155-6|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51350, 17985, 'Fentanyl', 'Dysentery', 'Narcotic (opioid) analgesic agents may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella, Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  These agents decrease gastrointestinal motility, which may delay the excretion of infective gastroenteric organisms and/or their toxins.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  Therapy with opioids should be avoided or administered cautiously in patients with infectious diarrhea, particularly that due to pseudomembranous enterocolitis or enterotoxin-producing bacteria or if accompanied by high fever, pus, or blood in the stool.', '3', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|White MJ, Berghausen EJ, Dumont SW, Tsueda K, Schroeder JA, Vogel RL, Heine MF, Huang KC "Side effects during continuous epidural infusion of morphine and fentanyl." Can J Anaesth 39 (1992):  576-82|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Thorn SE, Wattwil M, Kallander A "Effects of epidural morphine and epidural bupivacaine on gastroduodenal motility during the fasted state and after food intake." Acta Anaesthesiol Scand 38 (1994):  57-62|Bennett MWR, Shah MV, Bembridge JL "A comparison of the effect on gastric emptying of alfentanil or morphine given during anaesthesia for minor surgery." Anaesthesia 49 (1994):  155-6|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51351, 18952, 'Fentanyl', 'Dysentery', 'Narcotic (opioid) analgesic agents may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella, Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  These agents decrease gastrointestinal motility, which may delay the excretion of infective gastroenteric organisms and/or their toxins.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  Therapy with opioids should be avoided or administered cautiously in patients with infectious diarrhea, particularly that due to pseudomembranous enterocolitis or enterotoxin-producing bacteria or if accompanied by high fever, pus, or blood in the stool.', '3', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|White MJ, Berghausen EJ, Dumont SW, Tsueda K, Schroeder JA, Vogel RL, Heine MF, Huang KC "Side effects during continuous epidural infusion of morphine and fentanyl." Can J Anaesth 39 (1992):  576-82|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Thorn SE, Wattwil M, Kallander A "Effects of epidural morphine and epidural bupivacaine on gastroduodenal motility during the fasted state and after food intake." Acta Anaesthesiol Scand 38 (1994):  57-62|Bennett MWR, Shah MV, Bembridge JL "A comparison of the effect on gastric emptying of alfentanil or morphine given during anaesthesia for minor surgery." Anaesthesia 49 (1994):  155-6|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51352, 18953, 'Fentanyl', 'Dysentery', 'Narcotic (opioid) analgesic agents may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella, Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  These agents decrease gastrointestinal motility, which may delay the excretion of infective gastroenteric organisms and/or their toxins.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  Therapy with opioids should be avoided or administered cautiously in patients with infectious diarrhea, particularly that due to pseudomembranous enterocolitis or enterotoxin-producing bacteria or if accompanied by high fever, pus, or blood in the stool.', '3', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|White MJ, Berghausen EJ, Dumont SW, Tsueda K, Schroeder JA, Vogel RL, Heine MF, Huang KC "Side effects during continuous epidural infusion of morphine and fentanyl." Can J Anaesth 39 (1992):  576-82|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Thorn SE, Wattwil M, Kallander A "Effects of epidural morphine and epidural bupivacaine on gastroduodenal motility during the fasted state and after food intake." Acta Anaesthesiol Scand 38 (1994):  57-62|Bennett MWR, Shah MV, Bembridge JL "A comparison of the effect on gastric emptying of alfentanil or morphine given during anaesthesia for minor surgery." Anaesthesia 49 (1994):  155-6|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51353, 18955, 'Fentanyl', 'Dysentery', 'Narcotic (opioid) analgesic agents may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella, Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  These agents decrease gastrointestinal motility, which may delay the excretion of infective gastroenteric organisms and/or their toxins.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  Therapy with opioids should be avoided or administered cautiously in patients with infectious diarrhea, particularly that due to pseudomembranous enterocolitis or enterotoxin-producing bacteria or if accompanied by high fever, pus, or blood in the stool.', '3', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|White MJ, Berghausen EJ, Dumont SW, Tsueda K, Schroeder JA, Vogel RL, Heine MF, Huang KC "Side effects during continuous epidural infusion of morphine and fentanyl." Can J Anaesth 39 (1992):  576-82|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Thorn SE, Wattwil M, Kallander A "Effects of epidural morphine and epidural bupivacaine on gastroduodenal motility during the fasted state and after food intake." Acta Anaesthesiol Scand 38 (1994):  57-62|Bennett MWR, Shah MV, Bembridge JL "A comparison of the effect on gastric emptying of alfentanil or morphine given during anaesthesia for minor surgery." Anaesthesia 49 (1994):  155-6|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51354, 30532, 'Fentanyl', 'Dysentery', 'Narcotic (opioid) analgesic agents may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella, Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  These agents decrease gastrointestinal motility, which may delay the excretion of infective gastroenteric organisms and/or their toxins.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  Therapy with opioids should be avoided or administered cautiously in patients with infectious diarrhea, particularly that due to pseudomembranous enterocolitis or enterotoxin-producing bacteria or if accompanied by high fever, pus, or blood in the stool.', '3', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|White MJ, Berghausen EJ, Dumont SW, Tsueda K, Schroeder JA, Vogel RL, Heine MF, Huang KC "Side effects during continuous epidural infusion of morphine and fentanyl." Can J Anaesth 39 (1992):  576-82|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Thorn SE, Wattwil M, Kallander A "Effects of epidural morphine and epidural bupivacaine on gastroduodenal motility during the fasted state and after food intake." Acta Anaesthesiol Scand 38 (1994):  57-62|Bennett MWR, Shah MV, Bembridge JL "A comparison of the effect on gastric emptying of alfentanil or morphine given during anaesthesia for minor surgery." Anaesthesia 49 (1994):  155-6|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51355, 4802, 'Fentanyl', 'Liver Diseases', 'Narcotic (opioid) analgesic agents are extensively metabolized by the liver, and several of them (e.g., codeine, hydrocodone, meperidine, methadone, morphine, propoxyphene) have active metabolites that are further converted to inactive substances.  The serum concentrations of these agents and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with liver disease.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '3', 'Yue QY, Hasselstrom J, Svensson JO, Sawe J "Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine." Br J Clin Pharmacol 31 (1991):  635-42|Pond SM, Tong T, Benowitz NL, et al. "Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects." Clin Pharmacol Ther 30 (1981):  183-8|Neal EA, Meffin PJ, Gregory PB, Blaschke TF "Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis." Gastroenterology 77 (1979):  96-102|Bower S, Sear JW, Roy RC, Carter RF "Effects of different hepatic pathologies on disposition of alfentanil in anaesthetized patients." Br J Anaesth 68 (1992):  462-5|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Mazoit J-X, Sandouk P, Zetlaoui P, Scherrmann J-M "Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects." Anesth Analg 66 (1987):  293-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Osborne R, Joel S, Trew D, Slevin M "Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucoronide." Clin Pharmacol Ther 47 (1990):  12-9|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Yun CH, Wood M, Wood AJ, Guengerich FP "Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4: an explanation of the variable elimination clearance." Anesthesiology 77 (1992):  467-74|Cone EJ, Darwin WD, Gorodetzky CW "Comparative metabolism of codeine in man, rat, dog, guinea-pig and rabbit: identification of four new metabolites." J Pharm Pharmacol 31 (1979):  314-7|McHorse TS, Klotz U, Wilkinson G, Schenker S "Impaired elimination of meperidine in patients with liver disease." Trans Assoc Am Physicians 87 (1974):  281-7|Hasselstrom J, Eriksson S, Persson A, Rane A, Svensson JO, Sawe J "The metabolism and bioavailability of morphine in patients with severe liver cirrhosis." Br J Clin Pharmacol 29 (1990):  289-97|Novick DM, Kreek MJ, Arns PA, et al. "Effect of severe alcoholic liver disease on the disposition of methadone in maintenance patients." Alcohol Clin Exp Res 9 (1985):  349|Kreek MJ, Fanizza AM, et al. "Methadone disposition in patients with chronic liver disease." Clin Pharmacol Ther 30 (1981):  353-62|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|Goromaru T, Matsuura H, Yoshimura N, Miyawaki T, Sameshima T, Miyao J, Furuta T, Baba S "Identification and quantitative determination of fentanyl metabolites in patients by gas chromatography--mass spectrometry." Anesthesiology 61 (1984):  73-7|Haberer JP, Schoeffler P, Couderc E, Duvaldestin P "Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis." Br J Anaesth 54 (1982):  1267-70|McClain DA, Hug CC, Jr "Intravenous fentanyl kinetics." Clin Pharmacol Ther 28 (1980):  106-14|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM "CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone." Clin Pharmacol Ther 54 (1993):  463-72|Cone EJ, Darwin WD, Gorodetzky CW, Tan T "Comparative metabolism of hydrocodone in man, rat, guinea pig, rabbit, and dog." Drug Metab Dispos 6 (1978):  488-93|Hasselstrom J, Sawe J "Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations." Clin Pharmacokinet 24 (1993):  344-54|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Giacomini KM, Giacomini JC, Gibson TP, Levy G "Propoxyphene and norpropoxyphene plasma concentrations after oral propoxyphene in cirrhotic patients with and without surgically constructed portacaval shunt." Clin Pharmacol Ther 28 (1980):  417-24|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Chen ZR, Somogy AA, Reynolds G, Bochner F "Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers." Br J Clin Pharmacol 31 (1991):  381-90|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Hagen N, Thirlwell MP, Dhaliwal HS, Babul N, Harsanyi Z, Darke AC "Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone." J Clin Pharmacol 35 (1995):  37-44|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Beckett AH, Vaughan DP, Essien EE "N-Oxidation--an important route in the metabolism of methadone in man." J Pharm Pharmacol 24 (1972):  244|Beckett AH, Taylor JF, Casy AF, Hassan MM "The biotransformation of methadone in man: synthesis and identification of a major metabolite." J Pharm Pharmacol 20 (1968):  754-62|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|Dershwitz M, Randel GI, Rosow CE, Fragen RJ, Connors PM, Librojo ES, Shaw DL, Peng AW, Jamerson BD "Initial clinical experience with remifentanil, a new opioid metabolized by esterases." Anesth Analg 81 (1995):  619-23|Dershwitz M, Hoke JF, Rosow CE, Michalowski P, Connors PM, Muir KT, Dienstag JL "Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease." Anesthesiology 84 (1996):  812-20|Westmoreland CL, Hoke JF, Sebel PS, Hug CC Jr, Muir KT "Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery." Anesthesiology 79 (1993):  893-903|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51356, 13291, 'Fentanyl', 'Liver Diseases', 'Narcotic (opioid) analgesic agents are extensively metabolized by the liver, and several of them (e.g., codeine, hydrocodone, meperidine, methadone, morphine, propoxyphene) have active metabolites that are further converted to inactive substances.  The serum concentrations of these agents and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with liver disease.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '3', 'Yue QY, Hasselstrom J, Svensson JO, Sawe J "Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine." Br J Clin Pharmacol 31 (1991):  635-42|Pond SM, Tong T, Benowitz NL, et al. "Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects." Clin Pharmacol Ther 30 (1981):  183-8|Neal EA, Meffin PJ, Gregory PB, Blaschke TF "Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis." Gastroenterology 77 (1979):  96-102|Bower S, Sear JW, Roy RC, Carter RF "Effects of different hepatic pathologies on disposition of alfentanil in anaesthetized patients." Br J Anaesth 68 (1992):  462-5|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Mazoit J-X, Sandouk P, Zetlaoui P, Scherrmann J-M "Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects." Anesth Analg 66 (1987):  293-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Osborne R, Joel S, Trew D, Slevin M "Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucoronide." Clin Pharmacol Ther 47 (1990):  12-9|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Yun CH, Wood M, Wood AJ, Guengerich FP "Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4: an explanation of the variable elimination clearance." Anesthesiology 77 (1992):  467-74|Cone EJ, Darwin WD, Gorodetzky CW "Comparative metabolism of codeine in man, rat, dog, guinea-pig and rabbit: identification of four new metabolites." J Pharm Pharmacol 31 (1979):  314-7|McHorse TS, Klotz U, Wilkinson G, Schenker S "Impaired elimination of meperidine in patients with liver disease." Trans Assoc Am Physicians 87 (1974):  281-7|Hasselstrom J, Eriksson S, Persson A, Rane A, Svensson JO, Sawe J "The metabolism and bioavailability of morphine in patients with severe liver cirrhosis." Br J Clin Pharmacol 29 (1990):  289-97|Novick DM, Kreek MJ, Arns PA, et al. "Effect of severe alcoholic liver disease on the disposition of methadone in maintenance patients." Alcohol Clin Exp Res 9 (1985):  349|Kreek MJ, Fanizza AM, et al. "Methadone disposition in patients with chronic liver disease." Clin Pharmacol Ther 30 (1981):  353-62|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|Goromaru T, Matsuura H, Yoshimura N, Miyawaki T, Sameshima T, Miyao J, Furuta T, Baba S "Identification and quantitative determination of fentanyl metabolites in patients by gas chromatography--mass spectrometry." Anesthesiology 61 (1984):  73-7|Haberer JP, Schoeffler P, Couderc E, Duvaldestin P "Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis." Br J Anaesth 54 (1982):  1267-70|McClain DA, Hug CC, Jr "Intravenous fentanyl kinetics." Clin Pharmacol Ther 28 (1980):  106-14|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM "CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone." Clin Pharmacol Ther 54 (1993):  463-72|Cone EJ, Darwin WD, Gorodetzky CW, Tan T "Comparative metabolism of hydrocodone in man, rat, guinea pig, rabbit, and dog." Drug Metab Dispos 6 (1978):  488-93|Hasselstrom J, Sawe J "Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations." Clin Pharmacokinet 24 (1993):  344-54|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Giacomini KM, Giacomini JC, Gibson TP, Levy G "Propoxyphene and norpropoxyphene plasma concentrations after oral propoxyphene in cirrhotic patients with and without surgically constructed portacaval shunt." Clin Pharmacol Ther 28 (1980):  417-24|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Chen ZR, Somogy AA, Reynolds G, Bochner F "Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers." Br J Clin Pharmacol 31 (1991):  381-90|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Hagen N, Thirlwell MP, Dhaliwal HS, Babul N, Harsanyi Z, Darke AC "Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone." J Clin Pharmacol 35 (1995):  37-44|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Beckett AH, Vaughan DP, Essien EE "N-Oxidation--an important route in the metabolism of methadone in man." J Pharm Pharmacol 24 (1972):  244|Beckett AH, Taylor JF, Casy AF, Hassan MM "The biotransformation of methadone in man: synthesis and identification of a major metabolite." J Pharm Pharmacol 20 (1968):  754-62|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|Dershwitz M, Randel GI, Rosow CE, Fragen RJ, Connors PM, Librojo ES, Shaw DL, Peng AW, Jamerson BD "Initial clinical experience with remifentanil, a new opioid metabolized by esterases." Anesth Analg 81 (1995):  619-23|Dershwitz M, Hoke JF, Rosow CE, Michalowski P, Connors PM, Muir KT, Dienstag JL "Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease." Anesthesiology 84 (1996):  812-20|Westmoreland CL, Hoke JF, Sebel PS, Hug CC Jr, Muir KT "Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery." Anesthesiology 79 (1993):  893-903|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51357, 13292, 'Fentanyl', 'Liver Diseases', 'Narcotic (opioid) analgesic agents are extensively metabolized by the liver, and several of them (e.g., codeine, hydrocodone, meperidine, methadone, morphine, propoxyphene) have active metabolites that are further converted to inactive substances.  The serum concentrations of these agents and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with liver disease.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '3', 'Yue QY, Hasselstrom J, Svensson JO, Sawe J "Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine." Br J Clin Pharmacol 31 (1991):  635-42|Pond SM, Tong T, Benowitz NL, et al. "Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects." Clin Pharmacol Ther 30 (1981):  183-8|Neal EA, Meffin PJ, Gregory PB, Blaschke TF "Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis." Gastroenterology 77 (1979):  96-102|Bower S, Sear JW, Roy RC, Carter RF "Effects of different hepatic pathologies on disposition of alfentanil in anaesthetized patients." Br J Anaesth 68 (1992):  462-5|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Mazoit J-X, Sandouk P, Zetlaoui P, Scherrmann J-M "Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects." Anesth Analg 66 (1987):  293-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Osborne R, Joel S, Trew D, Slevin M "Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucoronide." Clin Pharmacol Ther 47 (1990):  12-9|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Yun CH, Wood M, Wood AJ, Guengerich FP "Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4: an explanation of the variable elimination clearance." Anesthesiology 77 (1992):  467-74|Cone EJ, Darwin WD, Gorodetzky CW "Comparative metabolism of codeine in man, rat, dog, guinea-pig and rabbit: identification of four new metabolites." J Pharm Pharmacol 31 (1979):  314-7|McHorse TS, Klotz U, Wilkinson G, Schenker S "Impaired elimination of meperidine in patients with liver disease." Trans Assoc Am Physicians 87 (1974):  281-7|Hasselstrom J, Eriksson S, Persson A, Rane A, Svensson JO, Sawe J "The metabolism and bioavailability of morphine in patients with severe liver cirrhosis." Br J Clin Pharmacol 29 (1990):  289-97|Novick DM, Kreek MJ, Arns PA, et al. "Effect of severe alcoholic liver disease on the disposition of methadone in maintenance patients." Alcohol Clin Exp Res 9 (1985):  349|Kreek MJ, Fanizza AM, et al. "Methadone disposition in patients with chronic liver disease." Clin Pharmacol Ther 30 (1981):  353-62|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|Goromaru T, Matsuura H, Yoshimura N, Miyawaki T, Sameshima T, Miyao J, Furuta T, Baba S "Identification and quantitative determination of fentanyl metabolites in patients by gas chromatography--mass spectrometry." Anesthesiology 61 (1984):  73-7|Haberer JP, Schoeffler P, Couderc E, Duvaldestin P "Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis." Br J Anaesth 54 (1982):  1267-70|McClain DA, Hug CC, Jr "Intravenous fentanyl kinetics." Clin Pharmacol Ther 28 (1980):  106-14|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM "CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone." Clin Pharmacol Ther 54 (1993):  463-72|Cone EJ, Darwin WD, Gorodetzky CW, Tan T "Comparative metabolism of hydrocodone in man, rat, guinea pig, rabbit, and dog." Drug Metab Dispos 6 (1978):  488-93|Hasselstrom J, Sawe J "Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations." Clin Pharmacokinet 24 (1993):  344-54|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Giacomini KM, Giacomini JC, Gibson TP, Levy G "Propoxyphene and norpropoxyphene plasma concentrations after oral propoxyphene in cirrhotic patients with and without surgically constructed portacaval shunt." Clin Pharmacol Ther 28 (1980):  417-24|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Chen ZR, Somogy AA, Reynolds G, Bochner F "Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers." Br J Clin Pharmacol 31 (1991):  381-90|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Hagen N, Thirlwell MP, Dhaliwal HS, Babul N, Harsanyi Z, Darke AC "Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone." J Clin Pharmacol 35 (1995):  37-44|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Beckett AH, Vaughan DP, Essien EE "N-Oxidation--an important route in the metabolism of methadone in man." J Pharm Pharmacol 24 (1972):  244|Beckett AH, Taylor JF, Casy AF, Hassan MM "The biotransformation of methadone in man: synthesis and identification of a major metabolite." J Pharm Pharmacol 20 (1968):  754-62|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|Dershwitz M, Randel GI, Rosow CE, Fragen RJ, Connors PM, Librojo ES, Shaw DL, Peng AW, Jamerson BD "Initial clinical experience with remifentanil, a new opioid metabolized by esterases." Anesth Analg 81 (1995):  619-23|Dershwitz M, Hoke JF, Rosow CE, Michalowski P, Connors PM, Muir KT, Dienstag JL "Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease." Anesthesiology 84 (1996):  812-20|Westmoreland CL, Hoke JF, Sebel PS, Hug CC Jr, Muir KT "Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery." Anesthesiology 79 (1993):  893-903|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51358, 17981, 'Fentanyl', 'Liver Diseases', 'Narcotic (opioid) analgesic agents are extensively metabolized by the liver, and several of them (e.g., codeine, hydrocodone, meperidine, methadone, morphine, propoxyphene) have active metabolites that are further converted to inactive substances.  The serum concentrations of these agents and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with liver disease.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '3', 'Yue QY, Hasselstrom J, Svensson JO, Sawe J "Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine." Br J Clin Pharmacol 31 (1991):  635-42|Pond SM, Tong T, Benowitz NL, et al. "Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects." Clin Pharmacol Ther 30 (1981):  183-8|Neal EA, Meffin PJ, Gregory PB, Blaschke TF "Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis." Gastroenterology 77 (1979):  96-102|Bower S, Sear JW, Roy RC, Carter RF "Effects of different hepatic pathologies on disposition of alfentanil in anaesthetized patients." Br J Anaesth 68 (1992):  462-5|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Mazoit J-X, Sandouk P, Zetlaoui P, Scherrmann J-M "Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects." Anesth Analg 66 (1987):  293-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Osborne R, Joel S, Trew D, Slevin M "Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucoronide." Clin Pharmacol Ther 47 (1990):  12-9|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Yun CH, Wood M, Wood AJ, Guengerich FP "Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4: an explanation of the variable elimination clearance." Anesthesiology 77 (1992):  467-74|Cone EJ, Darwin WD, Gorodetzky CW "Comparative metabolism of codeine in man, rat, dog, guinea-pig and rabbit: identification of four new metabolites." J Pharm Pharmacol 31 (1979):  314-7|McHorse TS, Klotz U, Wilkinson G, Schenker S "Impaired elimination of meperidine in patients with liver disease." Trans Assoc Am Physicians 87 (1974):  281-7|Hasselstrom J, Eriksson S, Persson A, Rane A, Svensson JO, Sawe J "The metabolism and bioavailability of morphine in patients with severe liver cirrhosis." Br J Clin Pharmacol 29 (1990):  289-97|Novick DM, Kreek MJ, Arns PA, et al. "Effect of severe alcoholic liver disease on the disposition of methadone in maintenance patients." Alcohol Clin Exp Res 9 (1985):  349|Kreek MJ, Fanizza AM, et al. "Methadone disposition in patients with chronic liver disease." Clin Pharmacol Ther 30 (1981):  353-62|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|Goromaru T, Matsuura H, Yoshimura N, Miyawaki T, Sameshima T, Miyao J, Furuta T, Baba S "Identification and quantitative determination of fentanyl metabolites in patients by gas chromatography--mass spectrometry." Anesthesiology 61 (1984):  73-7|Haberer JP, Schoeffler P, Couderc E, Duvaldestin P "Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis." Br J Anaesth 54 (1982):  1267-70|McClain DA, Hug CC, Jr "Intravenous fentanyl kinetics." Clin Pharmacol Ther 28 (1980):  106-14|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM "CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone." Clin Pharmacol Ther 54 (1993):  463-72|Cone EJ, Darwin WD, Gorodetzky CW, Tan T "Comparative metabolism of hydrocodone in man, rat, guinea pig, rabbit, and dog." Drug Metab Dispos 6 (1978):  488-93|Hasselstrom J, Sawe J "Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations." Clin Pharmacokinet 24 (1993):  344-54|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Giacomini KM, Giacomini JC, Gibson TP, Levy G "Propoxyphene and norpropoxyphene plasma concentrations after oral propoxyphene in cirrhotic patients with and without surgically constructed portacaval shunt." Clin Pharmacol Ther 28 (1980):  417-24|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Chen ZR, Somogy AA, Reynolds G, Bochner F "Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers." Br J Clin Pharmacol 31 (1991):  381-90|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Hagen N, Thirlwell MP, Dhaliwal HS, Babul N, Harsanyi Z, Darke AC "Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone." J Clin Pharmacol 35 (1995):  37-44|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Beckett AH, Vaughan DP, Essien EE "N-Oxidation--an important route in the metabolism of methadone in man." J Pharm Pharmacol 24 (1972):  244|Beckett AH, Taylor JF, Casy AF, Hassan MM "The biotransformation of methadone in man: synthesis and identification of a major metabolite." J Pharm Pharmacol 20 (1968):  754-62|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|Dershwitz M, Randel GI, Rosow CE, Fragen RJ, Connors PM, Librojo ES, Shaw DL, Peng AW, Jamerson BD "Initial clinical experience with remifentanil, a new opioid metabolized by esterases." Anesth Analg 81 (1995):  619-23|Dershwitz M, Hoke JF, Rosow CE, Michalowski P, Connors PM, Muir KT, Dienstag JL "Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease." Anesthesiology 84 (1996):  812-20|Westmoreland CL, Hoke JF, Sebel PS, Hug CC Jr, Muir KT "Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery." Anesthesiology 79 (1993):  893-903|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51359, 17982, 'Fentanyl', 'Liver Diseases', 'Narcotic (opioid) analgesic agents are extensively metabolized by the liver, and several of them (e.g., codeine, hydrocodone, meperidine, methadone, morphine, propoxyphene) have active metabolites that are further converted to inactive substances.  The serum concentrations of these agents and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with liver disease.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '3', 'Yue QY, Hasselstrom J, Svensson JO, Sawe J "Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine." Br J Clin Pharmacol 31 (1991):  635-42|Pond SM, Tong T, Benowitz NL, et al. "Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects." Clin Pharmacol Ther 30 (1981):  183-8|Neal EA, Meffin PJ, Gregory PB, Blaschke TF "Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis." Gastroenterology 77 (1979):  96-102|Bower S, Sear JW, Roy RC, Carter RF "Effects of different hepatic pathologies on disposition of alfentanil in anaesthetized patients." Br J Anaesth 68 (1992):  462-5|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Mazoit J-X, Sandouk P, Zetlaoui P, Scherrmann J-M "Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects." Anesth Analg 66 (1987):  293-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Osborne R, Joel S, Trew D, Slevin M "Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucoronide." Clin Pharmacol Ther 47 (1990):  12-9|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Yun CH, Wood M, Wood AJ, Guengerich FP "Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4: an explanation of the variable elimination clearance." Anesthesiology 77 (1992):  467-74|Cone EJ, Darwin WD, Gorodetzky CW "Comparative metabolism of codeine in man, rat, dog, guinea-pig and rabbit: identification of four new metabolites." J Pharm Pharmacol 31 (1979):  314-7|McHorse TS, Klotz U, Wilkinson G, Schenker S "Impaired elimination of meperidine in patients with liver disease." Trans Assoc Am Physicians 87 (1974):  281-7|Hasselstrom J, Eriksson S, Persson A, Rane A, Svensson JO, Sawe J "The metabolism and bioavailability of morphine in patients with severe liver cirrhosis." Br J Clin Pharmacol 29 (1990):  289-97|Novick DM, Kreek MJ, Arns PA, et al. "Effect of severe alcoholic liver disease on the disposition of methadone in maintenance patients." Alcohol Clin Exp Res 9 (1985):  349|Kreek MJ, Fanizza AM, et al. "Methadone disposition in patients with chronic liver disease." Clin Pharmacol Ther 30 (1981):  353-62|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|Goromaru T, Matsuura H, Yoshimura N, Miyawaki T, Sameshima T, Miyao J, Furuta T, Baba S "Identification and quantitative determination of fentanyl metabolites in patients by gas chromatography--mass spectrometry." Anesthesiology 61 (1984):  73-7|Haberer JP, Schoeffler P, Couderc E, Duvaldestin P "Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis." Br J Anaesth 54 (1982):  1267-70|McClain DA, Hug CC, Jr "Intravenous fentanyl kinetics." Clin Pharmacol Ther 28 (1980):  106-14|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM "CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone." Clin Pharmacol Ther 54 (1993):  463-72|Cone EJ, Darwin WD, Gorodetzky CW, Tan T "Comparative metabolism of hydrocodone in man, rat, guinea pig, rabbit, and dog." Drug Metab Dispos 6 (1978):  488-93|Hasselstrom J, Sawe J "Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations." Clin Pharmacokinet 24 (1993):  344-54|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Giacomini KM, Giacomini JC, Gibson TP, Levy G "Propoxyphene and norpropoxyphene plasma concentrations after oral propoxyphene in cirrhotic patients with and without surgically constructed portacaval shunt." Clin Pharmacol Ther 28 (1980):  417-24|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Chen ZR, Somogy AA, Reynolds G, Bochner F "Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers." Br J Clin Pharmacol 31 (1991):  381-90|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Hagen N, Thirlwell MP, Dhaliwal HS, Babul N, Harsanyi Z, Darke AC "Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone." J Clin Pharmacol 35 (1995):  37-44|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Beckett AH, Vaughan DP, Essien EE "N-Oxidation--an important route in the metabolism of methadone in man." J Pharm Pharmacol 24 (1972):  244|Beckett AH, Taylor JF, Casy AF, Hassan MM "The biotransformation of methadone in man: synthesis and identification of a major metabolite." J Pharm Pharmacol 20 (1968):  754-62|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|Dershwitz M, Randel GI, Rosow CE, Fragen RJ, Connors PM, Librojo ES, Shaw DL, Peng AW, Jamerson BD "Initial clinical experience with remifentanil, a new opioid metabolized by esterases." Anesth Analg 81 (1995):  619-23|Dershwitz M, Hoke JF, Rosow CE, Michalowski P, Connors PM, Muir KT, Dienstag JL "Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease." Anesthesiology 84 (1996):  812-20|Westmoreland CL, Hoke JF, Sebel PS, Hug CC Jr, Muir KT "Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery." Anesthesiology 79 (1993):  893-903|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51360, 17983, 'Fentanyl', 'Liver Diseases', 'Narcotic (opioid) analgesic agents are extensively metabolized by the liver, and several of them (e.g., codeine, hydrocodone, meperidine, methadone, morphine, propoxyphene) have active metabolites that are further converted to inactive substances.  The serum concentrations of these agents and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with liver disease.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '3', 'Yue QY, Hasselstrom J, Svensson JO, Sawe J "Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine." Br J Clin Pharmacol 31 (1991):  635-42|Pond SM, Tong T, Benowitz NL, et al. "Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects." Clin Pharmacol Ther 30 (1981):  183-8|Neal EA, Meffin PJ, Gregory PB, Blaschke TF "Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis." Gastroenterology 77 (1979):  96-102|Bower S, Sear JW, Roy RC, Carter RF "Effects of different hepatic pathologies on disposition of alfentanil in anaesthetized patients." Br J Anaesth 68 (1992):  462-5|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Mazoit J-X, Sandouk P, Zetlaoui P, Scherrmann J-M "Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects." Anesth Analg 66 (1987):  293-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Osborne R, Joel S, Trew D, Slevin M "Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucoronide." Clin Pharmacol Ther 47 (1990):  12-9|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Yun CH, Wood M, Wood AJ, Guengerich FP "Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4: an explanation of the variable elimination clearance." Anesthesiology 77 (1992):  467-74|Cone EJ, Darwin WD, Gorodetzky CW "Comparative metabolism of codeine in man, rat, dog, guinea-pig and rabbit: identification of four new metabolites." J Pharm Pharmacol 31 (1979):  314-7|McHorse TS, Klotz U, Wilkinson G, Schenker S "Impaired elimination of meperidine in patients with liver disease." Trans Assoc Am Physicians 87 (1974):  281-7|Hasselstrom J, Eriksson S, Persson A, Rane A, Svensson JO, Sawe J "The metabolism and bioavailability of morphine in patients with severe liver cirrhosis." Br J Clin Pharmacol 29 (1990):  289-97|Novick DM, Kreek MJ, Arns PA, et al. "Effect of severe alcoholic liver disease on the disposition of methadone in maintenance patients." Alcohol Clin Exp Res 9 (1985):  349|Kreek MJ, Fanizza AM, et al. "Methadone disposition in patients with chronic liver disease." Clin Pharmacol Ther 30 (1981):  353-62|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|Goromaru T, Matsuura H, Yoshimura N, Miyawaki T, Sameshima T, Miyao J, Furuta T, Baba S "Identification and quantitative determination of fentanyl metabolites in patients by gas chromatography--mass spectrometry." Anesthesiology 61 (1984):  73-7|Haberer JP, Schoeffler P, Couderc E, Duvaldestin P "Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis." Br J Anaesth 54 (1982):  1267-70|McClain DA, Hug CC, Jr "Intravenous fentanyl kinetics." Clin Pharmacol Ther 28 (1980):  106-14|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM "CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone." Clin Pharmacol Ther 54 (1993):  463-72|Cone EJ, Darwin WD, Gorodetzky CW, Tan T "Comparative metabolism of hydrocodone in man, rat, guinea pig, rabbit, and dog." Drug Metab Dispos 6 (1978):  488-93|Hasselstrom J, Sawe J "Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations." Clin Pharmacokinet 24 (1993):  344-54|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Giacomini KM, Giacomini JC, Gibson TP, Levy G "Propoxyphene and norpropoxyphene plasma concentrations after oral propoxyphene in cirrhotic patients with and without surgically constructed portacaval shunt." Clin Pharmacol Ther 28 (1980):  417-24|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Chen ZR, Somogy AA, Reynolds G, Bochner F "Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers." Br J Clin Pharmacol 31 (1991):  381-90|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Hagen N, Thirlwell MP, Dhaliwal HS, Babul N, Harsanyi Z, Darke AC "Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone." J Clin Pharmacol 35 (1995):  37-44|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Beckett AH, Vaughan DP, Essien EE "N-Oxidation--an important route in the metabolism of methadone in man." J Pharm Pharmacol 24 (1972):  244|Beckett AH, Taylor JF, Casy AF, Hassan MM "The biotransformation of methadone in man: synthesis and identification of a major metabolite." J Pharm Pharmacol 20 (1968):  754-62|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|Dershwitz M, Randel GI, Rosow CE, Fragen RJ, Connors PM, Librojo ES, Shaw DL, Peng AW, Jamerson BD "Initial clinical experience with remifentanil, a new opioid metabolized by esterases." Anesth Analg 81 (1995):  619-23|Dershwitz M, Hoke JF, Rosow CE, Michalowski P, Connors PM, Muir KT, Dienstag JL "Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease." Anesthesiology 84 (1996):  812-20|Westmoreland CL, Hoke JF, Sebel PS, Hug CC Jr, Muir KT "Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery." Anesthesiology 79 (1993):  893-903|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51361, 17984, 'Fentanyl', 'Liver Diseases', 'Narcotic (opioid) analgesic agents are extensively metabolized by the liver, and several of them (e.g., codeine, hydrocodone, meperidine, methadone, morphine, propoxyphene) have active metabolites that are further converted to inactive substances.  The serum concentrations of these agents and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with liver disease.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '3', 'Yue QY, Hasselstrom J, Svensson JO, Sawe J "Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine." Br J Clin Pharmacol 31 (1991):  635-42|Pond SM, Tong T, Benowitz NL, et al. "Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects." Clin Pharmacol Ther 30 (1981):  183-8|Neal EA, Meffin PJ, Gregory PB, Blaschke TF "Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis." Gastroenterology 77 (1979):  96-102|Bower S, Sear JW, Roy RC, Carter RF "Effects of different hepatic pathologies on disposition of alfentanil in anaesthetized patients." Br J Anaesth 68 (1992):  462-5|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Mazoit J-X, Sandouk P, Zetlaoui P, Scherrmann J-M "Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects." Anesth Analg 66 (1987):  293-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Osborne R, Joel S, Trew D, Slevin M "Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucoronide." Clin Pharmacol Ther 47 (1990):  12-9|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Yun CH, Wood M, Wood AJ, Guengerich FP "Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4: an explanation of the variable elimination clearance." Anesthesiology 77 (1992):  467-74|Cone EJ, Darwin WD, Gorodetzky CW "Comparative metabolism of codeine in man, rat, dog, guinea-pig and rabbit: identification of four new metabolites." J Pharm Pharmacol 31 (1979):  314-7|McHorse TS, Klotz U, Wilkinson G, Schenker S "Impaired elimination of meperidine in patients with liver disease." Trans Assoc Am Physicians 87 (1974):  281-7|Hasselstrom J, Eriksson S, Persson A, Rane A, Svensson JO, Sawe J "The metabolism and bioavailability of morphine in patients with severe liver cirrhosis." Br J Clin Pharmacol 29 (1990):  289-97|Novick DM, Kreek MJ, Arns PA, et al. "Effect of severe alcoholic liver disease on the disposition of methadone in maintenance patients." Alcohol Clin Exp Res 9 (1985):  349|Kreek MJ, Fanizza AM, et al. "Methadone disposition in patients with chronic liver disease." Clin Pharmacol Ther 30 (1981):  353-62|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|Goromaru T, Matsuura H, Yoshimura N, Miyawaki T, Sameshima T, Miyao J, Furuta T, Baba S "Identification and quantitative determination of fentanyl metabolites in patients by gas chromatography--mass spectrometry." Anesthesiology 61 (1984):  73-7|Haberer JP, Schoeffler P, Couderc E, Duvaldestin P "Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis." Br J Anaesth 54 (1982):  1267-70|McClain DA, Hug CC, Jr "Intravenous fentanyl kinetics." Clin Pharmacol Ther 28 (1980):  106-14|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM "CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone." Clin Pharmacol Ther 54 (1993):  463-72|Cone EJ, Darwin WD, Gorodetzky CW, Tan T "Comparative metabolism of hydrocodone in man, rat, guinea pig, rabbit, and dog." Drug Metab Dispos 6 (1978):  488-93|Hasselstrom J, Sawe J "Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations." Clin Pharmacokinet 24 (1993):  344-54|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Giacomini KM, Giacomini JC, Gibson TP, Levy G "Propoxyphene and norpropoxyphene plasma concentrations after oral propoxyphene in cirrhotic patients with and without surgically constructed portacaval shunt." Clin Pharmacol Ther 28 (1980):  417-24|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Chen ZR, Somogy AA, Reynolds G, Bochner F "Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers." Br J Clin Pharmacol 31 (1991):  381-90|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Hagen N, Thirlwell MP, Dhaliwal HS, Babul N, Harsanyi Z, Darke AC "Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone." J Clin Pharmacol 35 (1995):  37-44|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Beckett AH, Vaughan DP, Essien EE "N-Oxidation--an important route in the metabolism of methadone in man." J Pharm Pharmacol 24 (1972):  244|Beckett AH, Taylor JF, Casy AF, Hassan MM "The biotransformation of methadone in man: synthesis and identification of a major metabolite." J Pharm Pharmacol 20 (1968):  754-62|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|Dershwitz M, Randel GI, Rosow CE, Fragen RJ, Connors PM, Librojo ES, Shaw DL, Peng AW, Jamerson BD "Initial clinical experience with remifentanil, a new opioid metabolized by esterases." Anesth Analg 81 (1995):  619-23|Dershwitz M, Hoke JF, Rosow CE, Michalowski P, Connors PM, Muir KT, Dienstag JL "Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease." Anesthesiology 84 (1996):  812-20|Westmoreland CL, Hoke JF, Sebel PS, Hug CC Jr, Muir KT "Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery." Anesthesiology 79 (1993):  893-903|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51362, 17985, 'Fentanyl', 'Liver Diseases', 'Narcotic (opioid) analgesic agents are extensively metabolized by the liver, and several of them (e.g., codeine, hydrocodone, meperidine, methadone, morphine, propoxyphene) have active metabolites that are further converted to inactive substances.  The serum concentrations of these agents and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with liver disease.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '3', 'Yue QY, Hasselstrom J, Svensson JO, Sawe J "Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine." Br J Clin Pharmacol 31 (1991):  635-42|Pond SM, Tong T, Benowitz NL, et al. "Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects." Clin Pharmacol Ther 30 (1981):  183-8|Neal EA, Meffin PJ, Gregory PB, Blaschke TF "Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis." Gastroenterology 77 (1979):  96-102|Bower S, Sear JW, Roy RC, Carter RF "Effects of different hepatic pathologies on disposition of alfentanil in anaesthetized patients." Br J Anaesth 68 (1992):  462-5|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Mazoit J-X, Sandouk P, Zetlaoui P, Scherrmann J-M "Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects." Anesth Analg 66 (1987):  293-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Osborne R, Joel S, Trew D, Slevin M "Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucoronide." Clin Pharmacol Ther 47 (1990):  12-9|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Yun CH, Wood M, Wood AJ, Guengerich FP "Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4: an explanation of the variable elimination clearance." Anesthesiology 77 (1992):  467-74|Cone EJ, Darwin WD, Gorodetzky CW "Comparative metabolism of codeine in man, rat, dog, guinea-pig and rabbit: identification of four new metabolites." J Pharm Pharmacol 31 (1979):  314-7|McHorse TS, Klotz U, Wilkinson G, Schenker S "Impaired elimination of meperidine in patients with liver disease." Trans Assoc Am Physicians 87 (1974):  281-7|Hasselstrom J, Eriksson S, Persson A, Rane A, Svensson JO, Sawe J "The metabolism and bioavailability of morphine in patients with severe liver cirrhosis." Br J Clin Pharmacol 29 (1990):  289-97|Novick DM, Kreek MJ, Arns PA, et al. "Effect of severe alcoholic liver disease on the disposition of methadone in maintenance patients." Alcohol Clin Exp Res 9 (1985):  349|Kreek MJ, Fanizza AM, et al. "Methadone disposition in patients with chronic liver disease." Clin Pharmacol Ther 30 (1981):  353-62|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|Goromaru T, Matsuura H, Yoshimura N, Miyawaki T, Sameshima T, Miyao J, Furuta T, Baba S "Identification and quantitative determination of fentanyl metabolites in patients by gas chromatography--mass spectrometry." Anesthesiology 61 (1984):  73-7|Haberer JP, Schoeffler P, Couderc E, Duvaldestin P "Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis." Br J Anaesth 54 (1982):  1267-70|McClain DA, Hug CC, Jr "Intravenous fentanyl kinetics." Clin Pharmacol Ther 28 (1980):  106-14|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM "CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone." Clin Pharmacol Ther 54 (1993):  463-72|Cone EJ, Darwin WD, Gorodetzky CW, Tan T "Comparative metabolism of hydrocodone in man, rat, guinea pig, rabbit, and dog." Drug Metab Dispos 6 (1978):  488-93|Hasselstrom J, Sawe J "Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations." Clin Pharmacokinet 24 (1993):  344-54|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Giacomini KM, Giacomini JC, Gibson TP, Levy G "Propoxyphene and norpropoxyphene plasma concentrations after oral propoxyphene in cirrhotic patients with and without surgically constructed portacaval shunt." Clin Pharmacol Ther 28 (1980):  417-24|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Chen ZR, Somogy AA, Reynolds G, Bochner F "Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers." Br J Clin Pharmacol 31 (1991):  381-90|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Hagen N, Thirlwell MP, Dhaliwal HS, Babul N, Harsanyi Z, Darke AC "Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone." J Clin Pharmacol 35 (1995):  37-44|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Beckett AH, Vaughan DP, Essien EE "N-Oxidation--an important route in the metabolism of methadone in man." J Pharm Pharmacol 24 (1972):  244|Beckett AH, Taylor JF, Casy AF, Hassan MM "The biotransformation of methadone in man: synthesis and identification of a major metabolite." J Pharm Pharmacol 20 (1968):  754-62|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|Dershwitz M, Randel GI, Rosow CE, Fragen RJ, Connors PM, Librojo ES, Shaw DL, Peng AW, Jamerson BD "Initial clinical experience with remifentanil, a new opioid metabolized by esterases." Anesth Analg 81 (1995):  619-23|Dershwitz M, Hoke JF, Rosow CE, Michalowski P, Connors PM, Muir KT, Dienstag JL "Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease." Anesthesiology 84 (1996):  812-20|Westmoreland CL, Hoke JF, Sebel PS, Hug CC Jr, Muir KT "Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery." Anesthesiology 79 (1993):  893-903|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51363, 18952, 'Fentanyl', 'Liver Diseases', 'Narcotic (opioid) analgesic agents are extensively metabolized by the liver, and several of them (e.g., codeine, hydrocodone, meperidine, methadone, morphine, propoxyphene) have active metabolites that are further converted to inactive substances.  The serum concentrations of these agents and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with liver disease.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '3', 'Yue QY, Hasselstrom J, Svensson JO, Sawe J "Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine." Br J Clin Pharmacol 31 (1991):  635-42|Pond SM, Tong T, Benowitz NL, et al. "Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects." Clin Pharmacol Ther 30 (1981):  183-8|Neal EA, Meffin PJ, Gregory PB, Blaschke TF "Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis." Gastroenterology 77 (1979):  96-102|Bower S, Sear JW, Roy RC, Carter RF "Effects of different hepatic pathologies on disposition of alfentanil in anaesthetized patients." Br J Anaesth 68 (1992):  462-5|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Mazoit J-X, Sandouk P, Zetlaoui P, Scherrmann J-M "Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects." Anesth Analg 66 (1987):  293-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Osborne R, Joel S, Trew D, Slevin M "Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucoronide." Clin Pharmacol Ther 47 (1990):  12-9|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Yun CH, Wood M, Wood AJ, Guengerich FP "Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4: an explanation of the variable elimination clearance." Anesthesiology 77 (1992):  467-74|Cone EJ, Darwin WD, Gorodetzky CW "Comparative metabolism of codeine in man, rat, dog, guinea-pig and rabbit: identification of four new metabolites." J Pharm Pharmacol 31 (1979):  314-7|McHorse TS, Klotz U, Wilkinson G, Schenker S "Impaired elimination of meperidine in patients with liver disease." Trans Assoc Am Physicians 87 (1974):  281-7|Hasselstrom J, Eriksson S, Persson A, Rane A, Svensson JO, Sawe J "The metabolism and bioavailability of morphine in patients with severe liver cirrhosis." Br J Clin Pharmacol 29 (1990):  289-97|Novick DM, Kreek MJ, Arns PA, et al. "Effect of severe alcoholic liver disease on the disposition of methadone in maintenance patients." Alcohol Clin Exp Res 9 (1985):  349|Kreek MJ, Fanizza AM, et al. "Methadone disposition in patients with chronic liver disease." Clin Pharmacol Ther 30 (1981):  353-62|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|Goromaru T, Matsuura H, Yoshimura N, Miyawaki T, Sameshima T, Miyao J, Furuta T, Baba S "Identification and quantitative determination of fentanyl metabolites in patients by gas chromatography--mass spectrometry." Anesthesiology 61 (1984):  73-7|Haberer JP, Schoeffler P, Couderc E, Duvaldestin P "Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis." Br J Anaesth 54 (1982):  1267-70|McClain DA, Hug CC, Jr "Intravenous fentanyl kinetics." Clin Pharmacol Ther 28 (1980):  106-14|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM "CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone." Clin Pharmacol Ther 54 (1993):  463-72|Cone EJ, Darwin WD, Gorodetzky CW, Tan T "Comparative metabolism of hydrocodone in man, rat, guinea pig, rabbit, and dog." Drug Metab Dispos 6 (1978):  488-93|Hasselstrom J, Sawe J "Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations." Clin Pharmacokinet 24 (1993):  344-54|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Giacomini KM, Giacomini JC, Gibson TP, Levy G "Propoxyphene and norpropoxyphene plasma concentrations after oral propoxyphene in cirrhotic patients with and without surgically constructed portacaval shunt." Clin Pharmacol Ther 28 (1980):  417-24|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Chen ZR, Somogy AA, Reynolds G, Bochner F "Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers." Br J Clin Pharmacol 31 (1991):  381-90|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Hagen N, Thirlwell MP, Dhaliwal HS, Babul N, Harsanyi Z, Darke AC "Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone." J Clin Pharmacol 35 (1995):  37-44|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Beckett AH, Vaughan DP, Essien EE "N-Oxidation--an important route in the metabolism of methadone in man." J Pharm Pharmacol 24 (1972):  244|Beckett AH, Taylor JF, Casy AF, Hassan MM "The biotransformation of methadone in man: synthesis and identification of a major metabolite." J Pharm Pharmacol 20 (1968):  754-62|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|Dershwitz M, Randel GI, Rosow CE, Fragen RJ, Connors PM, Librojo ES, Shaw DL, Peng AW, Jamerson BD "Initial clinical experience with remifentanil, a new opioid metabolized by esterases." Anesth Analg 81 (1995):  619-23|Dershwitz M, Hoke JF, Rosow CE, Michalowski P, Connors PM, Muir KT, Dienstag JL "Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease." Anesthesiology 84 (1996):  812-20|Westmoreland CL, Hoke JF, Sebel PS, Hug CC Jr, Muir KT "Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery." Anesthesiology 79 (1993):  893-903|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51364, 18953, 'Fentanyl', 'Liver Diseases', 'Narcotic (opioid) analgesic agents are extensively metabolized by the liver, and several of them (e.g., codeine, hydrocodone, meperidine, methadone, morphine, propoxyphene) have active metabolites that are further converted to inactive substances.  The serum concentrations of these agents and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with liver disease.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '3', 'Yue QY, Hasselstrom J, Svensson JO, Sawe J "Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine." Br J Clin Pharmacol 31 (1991):  635-42|Pond SM, Tong T, Benowitz NL, et al. "Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects." Clin Pharmacol Ther 30 (1981):  183-8|Neal EA, Meffin PJ, Gregory PB, Blaschke TF "Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis." Gastroenterology 77 (1979):  96-102|Bower S, Sear JW, Roy RC, Carter RF "Effects of different hepatic pathologies on disposition of alfentanil in anaesthetized patients." Br J Anaesth 68 (1992):  462-5|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Mazoit J-X, Sandouk P, Zetlaoui P, Scherrmann J-M "Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects." Anesth Analg 66 (1987):  293-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Osborne R, Joel S, Trew D, Slevin M "Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucoronide." Clin Pharmacol Ther 47 (1990):  12-9|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Yun CH, Wood M, Wood AJ, Guengerich FP "Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4: an explanation of the variable elimination clearance." Anesthesiology 77 (1992):  467-74|Cone EJ, Darwin WD, Gorodetzky CW "Comparative metabolism of codeine in man, rat, dog, guinea-pig and rabbit: identification of four new metabolites." J Pharm Pharmacol 31 (1979):  314-7|McHorse TS, Klotz U, Wilkinson G, Schenker S "Impaired elimination of meperidine in patients with liver disease." Trans Assoc Am Physicians 87 (1974):  281-7|Hasselstrom J, Eriksson S, Persson A, Rane A, Svensson JO, Sawe J "The metabolism and bioavailability of morphine in patients with severe liver cirrhosis." Br J Clin Pharmacol 29 (1990):  289-97|Novick DM, Kreek MJ, Arns PA, et al. "Effect of severe alcoholic liver disease on the disposition of methadone in maintenance patients." Alcohol Clin Exp Res 9 (1985):  349|Kreek MJ, Fanizza AM, et al. "Methadone disposition in patients with chronic liver disease." Clin Pharmacol Ther 30 (1981):  353-62|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|Goromaru T, Matsuura H, Yoshimura N, Miyawaki T, Sameshima T, Miyao J, Furuta T, Baba S "Identification and quantitative determination of fentanyl metabolites in patients by gas chromatography--mass spectrometry." Anesthesiology 61 (1984):  73-7|Haberer JP, Schoeffler P, Couderc E, Duvaldestin P "Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis." Br J Anaesth 54 (1982):  1267-70|McClain DA, Hug CC, Jr "Intravenous fentanyl kinetics." Clin Pharmacol Ther 28 (1980):  106-14|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM "CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone." Clin Pharmacol Ther 54 (1993):  463-72|Cone EJ, Darwin WD, Gorodetzky CW, Tan T "Comparative metabolism of hydrocodone in man, rat, guinea pig, rabbit, and dog." Drug Metab Dispos 6 (1978):  488-93|Hasselstrom J, Sawe J "Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations." Clin Pharmacokinet 24 (1993):  344-54|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Giacomini KM, Giacomini JC, Gibson TP, Levy G "Propoxyphene and norpropoxyphene plasma concentrations after oral propoxyphene in cirrhotic patients with and without surgically constructed portacaval shunt." Clin Pharmacol Ther 28 (1980):  417-24|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Chen ZR, Somogy AA, Reynolds G, Bochner F "Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers." Br J Clin Pharmacol 31 (1991):  381-90|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Hagen N, Thirlwell MP, Dhaliwal HS, Babul N, Harsanyi Z, Darke AC "Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone." J Clin Pharmacol 35 (1995):  37-44|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Beckett AH, Vaughan DP, Essien EE "N-Oxidation--an important route in the metabolism of methadone in man." J Pharm Pharmacol 24 (1972):  244|Beckett AH, Taylor JF, Casy AF, Hassan MM "The biotransformation of methadone in man: synthesis and identification of a major metabolite." J Pharm Pharmacol 20 (1968):  754-62|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|Dershwitz M, Randel GI, Rosow CE, Fragen RJ, Connors PM, Librojo ES, Shaw DL, Peng AW, Jamerson BD "Initial clinical experience with remifentanil, a new opioid metabolized by esterases." Anesth Analg 81 (1995):  619-23|Dershwitz M, Hoke JF, Rosow CE, Michalowski P, Connors PM, Muir KT, Dienstag JL "Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease." Anesthesiology 84 (1996):  812-20|Westmoreland CL, Hoke JF, Sebel PS, Hug CC Jr, Muir KT "Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery." Anesthesiology 79 (1993):  893-903|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51365, 18955, 'Fentanyl', 'Liver Diseases', 'Narcotic (opioid) analgesic agents are extensively metabolized by the liver, and several of them (e.g., codeine, hydrocodone, meperidine, methadone, morphine, propoxyphene) have active metabolites that are further converted to inactive substances.  The serum concentrations of these agents and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with liver disease.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '3', 'Yue QY, Hasselstrom J, Svensson JO, Sawe J "Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine." Br J Clin Pharmacol 31 (1991):  635-42|Pond SM, Tong T, Benowitz NL, et al. "Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects." Clin Pharmacol Ther 30 (1981):  183-8|Neal EA, Meffin PJ, Gregory PB, Blaschke TF "Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis." Gastroenterology 77 (1979):  96-102|Bower S, Sear JW, Roy RC, Carter RF "Effects of different hepatic pathologies on disposition of alfentanil in anaesthetized patients." Br J Anaesth 68 (1992):  462-5|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Mazoit J-X, Sandouk P, Zetlaoui P, Scherrmann J-M "Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects." Anesth Analg 66 (1987):  293-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Osborne R, Joel S, Trew D, Slevin M "Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucoronide." Clin Pharmacol Ther 47 (1990):  12-9|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Yun CH, Wood M, Wood AJ, Guengerich FP "Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4: an explanation of the variable elimination clearance." Anesthesiology 77 (1992):  467-74|Cone EJ, Darwin WD, Gorodetzky CW "Comparative metabolism of codeine in man, rat, dog, guinea-pig and rabbit: identification of four new metabolites." J Pharm Pharmacol 31 (1979):  314-7|McHorse TS, Klotz U, Wilkinson G, Schenker S "Impaired elimination of meperidine in patients with liver disease." Trans Assoc Am Physicians 87 (1974):  281-7|Hasselstrom J, Eriksson S, Persson A, Rane A, Svensson JO, Sawe J "The metabolism and bioavailability of morphine in patients with severe liver cirrhosis." Br J Clin Pharmacol 29 (1990):  289-97|Novick DM, Kreek MJ, Arns PA, et al. "Effect of severe alcoholic liver disease on the disposition of methadone in maintenance patients." Alcohol Clin Exp Res 9 (1985):  349|Kreek MJ, Fanizza AM, et al. "Methadone disposition in patients with chronic liver disease." Clin Pharmacol Ther 30 (1981):  353-62|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|Goromaru T, Matsuura H, Yoshimura N, Miyawaki T, Sameshima T, Miyao J, Furuta T, Baba S "Identification and quantitative determination of fentanyl metabolites in patients by gas chromatography--mass spectrometry." Anesthesiology 61 (1984):  73-7|Haberer JP, Schoeffler P, Couderc E, Duvaldestin P "Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis." Br J Anaesth 54 (1982):  1267-70|McClain DA, Hug CC, Jr "Intravenous fentanyl kinetics." Clin Pharmacol Ther 28 (1980):  106-14|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM "CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone." Clin Pharmacol Ther 54 (1993):  463-72|Cone EJ, Darwin WD, Gorodetzky CW, Tan T "Comparative metabolism of hydrocodone in man, rat, guinea pig, rabbit, and dog." Drug Metab Dispos 6 (1978):  488-93|Hasselstrom J, Sawe J "Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations." Clin Pharmacokinet 24 (1993):  344-54|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Giacomini KM, Giacomini JC, Gibson TP, Levy G "Propoxyphene and norpropoxyphene plasma concentrations after oral propoxyphene in cirrhotic patients with and without surgically constructed portacaval shunt." Clin Pharmacol Ther 28 (1980):  417-24|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Chen ZR, Somogy AA, Reynolds G, Bochner F "Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers." Br J Clin Pharmacol 31 (1991):  381-90|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Hagen N, Thirlwell MP, Dhaliwal HS, Babul N, Harsanyi Z, Darke AC "Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone." J Clin Pharmacol 35 (1995):  37-44|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Beckett AH, Vaughan DP, Essien EE "N-Oxidation--an important route in the metabolism of methadone in man." J Pharm Pharmacol 24 (1972):  244|Beckett AH, Taylor JF, Casy AF, Hassan MM "The biotransformation of methadone in man: synthesis and identification of a major metabolite." J Pharm Pharmacol 20 (1968):  754-62|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|Dershwitz M, Randel GI, Rosow CE, Fragen RJ, Connors PM, Librojo ES, Shaw DL, Peng AW, Jamerson BD "Initial clinical experience with remifentanil, a new opioid metabolized by esterases." Anesth Analg 81 (1995):  619-23|Dershwitz M, Hoke JF, Rosow CE, Michalowski P, Connors PM, Muir KT, Dienstag JL "Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease." Anesthesiology 84 (1996):  812-20|Westmoreland CL, Hoke JF, Sebel PS, Hug CC Jr, Muir KT "Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery." Anesthesiology 79 (1993):  893-903|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51366, 30532, 'Fentanyl', 'Liver Diseases', 'Narcotic (opioid) analgesic agents are extensively metabolized by the liver, and several of them (e.g., codeine, hydrocodone, meperidine, methadone, morphine, propoxyphene) have active metabolites that are further converted to inactive substances.  The serum concentrations of these agents and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with liver disease.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '3', 'Yue QY, Hasselstrom J, Svensson JO, Sawe J "Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine." Br J Clin Pharmacol 31 (1991):  635-42|Pond SM, Tong T, Benowitz NL, et al. "Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects." Clin Pharmacol Ther 30 (1981):  183-8|Neal EA, Meffin PJ, Gregory PB, Blaschke TF "Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis." Gastroenterology 77 (1979):  96-102|Bower S, Sear JW, Roy RC, Carter RF "Effects of different hepatic pathologies on disposition of alfentanil in anaesthetized patients." Br J Anaesth 68 (1992):  462-5|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Mazoit J-X, Sandouk P, Zetlaoui P, Scherrmann J-M "Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects." Anesth Analg 66 (1987):  293-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Osborne R, Joel S, Trew D, Slevin M "Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucoronide." Clin Pharmacol Ther 47 (1990):  12-9|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Yun CH, Wood M, Wood AJ, Guengerich FP "Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4: an explanation of the variable elimination clearance." Anesthesiology 77 (1992):  467-74|Cone EJ, Darwin WD, Gorodetzky CW "Comparative metabolism of codeine in man, rat, dog, guinea-pig and rabbit: identification of four new metabolites." J Pharm Pharmacol 31 (1979):  314-7|McHorse TS, Klotz U, Wilkinson G, Schenker S "Impaired elimination of meperidine in patients with liver disease." Trans Assoc Am Physicians 87 (1974):  281-7|Hasselstrom J, Eriksson S, Persson A, Rane A, Svensson JO, Sawe J "The metabolism and bioavailability of morphine in patients with severe liver cirrhosis." Br J Clin Pharmacol 29 (1990):  289-97|Novick DM, Kreek MJ, Arns PA, et al. "Effect of severe alcoholic liver disease on the disposition of methadone in maintenance patients." Alcohol Clin Exp Res 9 (1985):  349|Kreek MJ, Fanizza AM, et al. "Methadone disposition in patients with chronic liver disease." Clin Pharmacol Ther 30 (1981):  353-62|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|Goromaru T, Matsuura H, Yoshimura N, Miyawaki T, Sameshima T, Miyao J, Furuta T, Baba S "Identification and quantitative determination of fentanyl metabolites in patients by gas chromatography--mass spectrometry." Anesthesiology 61 (1984):  73-7|Haberer JP, Schoeffler P, Couderc E, Duvaldestin P "Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis." Br J Anaesth 54 (1982):  1267-70|McClain DA, Hug CC, Jr "Intravenous fentanyl kinetics." Clin Pharmacol Ther 28 (1980):  106-14|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM "CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone." Clin Pharmacol Ther 54 (1993):  463-72|Cone EJ, Darwin WD, Gorodetzky CW, Tan T "Comparative metabolism of hydrocodone in man, rat, guinea pig, rabbit, and dog." Drug Metab Dispos 6 (1978):  488-93|Hasselstrom J, Sawe J "Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations." Clin Pharmacokinet 24 (1993):  344-54|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Giacomini KM, Giacomini JC, Gibson TP, Levy G "Propoxyphene and norpropoxyphene plasma concentrations after oral propoxyphene in cirrhotic patients with and without surgically constructed portacaval shunt." Clin Pharmacol Ther 28 (1980):  417-24|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Chen ZR, Somogy AA, Reynolds G, Bochner F "Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers." Br J Clin Pharmacol 31 (1991):  381-90|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Hagen N, Thirlwell MP, Dhaliwal HS, Babul N, Harsanyi Z, Darke AC "Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone." J Clin Pharmacol 35 (1995):  37-44|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Beckett AH, Vaughan DP, Essien EE "N-Oxidation--an important route in the metabolism of methadone in man." J Pharm Pharmacol 24 (1972):  244|Beckett AH, Taylor JF, Casy AF, Hassan MM "The biotransformation of methadone in man: synthesis and identification of a major metabolite." J Pharm Pharmacol 20 (1968):  754-62|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|Dershwitz M, Randel GI, Rosow CE, Fragen RJ, Connors PM, Librojo ES, Shaw DL, Peng AW, Jamerson BD "Initial clinical experience with remifentanil, a new opioid metabolized by esterases." Anesth Analg 81 (1995):  619-23|Dershwitz M, Hoke JF, Rosow CE, Michalowski P, Connors PM, Muir KT, Dienstag JL "Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease." Anesthesiology 84 (1996):  812-20|Westmoreland CL, Hoke JF, Sebel PS, Hug CC Jr, Muir KT "Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery." Anesthesiology 79 (1993):  893-903|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51367, 4802, 'Fentanyl', 'Premature Birth', 'The use of narcotic (opioid) analgesic agents is contraindicated in premature infants.  These agents may cross the immature blood-brain barrier to a greater extent than in adults, resulting in disproportionate respiratory depression.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Multum Information Services, Inc. Expert Review Panel"', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51368, 13291, 'Fentanyl', 'Premature Birth', 'The use of narcotic (opioid) analgesic agents is contraindicated in premature infants.  These agents may cross the immature blood-brain barrier to a greater extent than in adults, resulting in disproportionate respiratory depression.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Multum Information Services, Inc. Expert Review Panel"', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51369, 13292, 'Fentanyl', 'Premature Birth', 'The use of narcotic (opioid) analgesic agents is contraindicated in premature infants.  These agents may cross the immature blood-brain barrier to a greater extent than in adults, resulting in disproportionate respiratory depression.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Multum Information Services, Inc. Expert Review Panel"', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51370, 17981, 'Fentanyl', 'Premature Birth', 'The use of narcotic (opioid) analgesic agents is contraindicated in premature infants.  These agents may cross the immature blood-brain barrier to a greater extent than in adults, resulting in disproportionate respiratory depression.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Multum Information Services, Inc. Expert Review Panel"', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51371, 17982, 'Fentanyl', 'Premature Birth', 'The use of narcotic (opioid) analgesic agents is contraindicated in premature infants.  These agents may cross the immature blood-brain barrier to a greater extent than in adults, resulting in disproportionate respiratory depression.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Multum Information Services, Inc. Expert Review Panel"', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51372, 17983, 'Fentanyl', 'Premature Birth', 'The use of narcotic (opioid) analgesic agents is contraindicated in premature infants.  These agents may cross the immature blood-brain barrier to a greater extent than in adults, resulting in disproportionate respiratory depression.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Multum Information Services, Inc. Expert Review Panel"', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51373, 17984, 'Fentanyl', 'Premature Birth', 'The use of narcotic (opioid) analgesic agents is contraindicated in premature infants.  These agents may cross the immature blood-brain barrier to a greater extent than in adults, resulting in disproportionate respiratory depression.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Multum Information Services, Inc. Expert Review Panel"', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51374, 17985, 'Fentanyl', 'Premature Birth', 'The use of narcotic (opioid) analgesic agents is contraindicated in premature infants.  These agents may cross the immature blood-brain barrier to a greater extent than in adults, resulting in disproportionate respiratory depression.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Multum Information Services, Inc. Expert Review Panel"', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51375, 18952, 'Fentanyl', 'Premature Birth', 'The use of narcotic (opioid) analgesic agents is contraindicated in premature infants.  These agents may cross the immature blood-brain barrier to a greater extent than in adults, resulting in disproportionate respiratory depression.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Multum Information Services, Inc. Expert Review Panel"', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51376, 18953, 'Fentanyl', 'Premature Birth', 'The use of narcotic (opioid) analgesic agents is contraindicated in premature infants.  These agents may cross the immature blood-brain barrier to a greater extent than in adults, resulting in disproportionate respiratory depression.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Multum Information Services, Inc. Expert Review Panel"', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51377, 18955, 'Fentanyl', 'Premature Birth', 'The use of narcotic (opioid) analgesic agents is contraindicated in premature infants.  These agents may cross the immature blood-brain barrier to a greater extent than in adults, resulting in disproportionate respiratory depression.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Multum Information Services, Inc. Expert Review Panel"', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51378, 30532, 'Fentanyl', 'Premature Birth', 'The use of narcotic (opioid) analgesic agents is contraindicated in premature infants.  These agents may cross the immature blood-brain barrier to a greater extent than in adults, resulting in disproportionate respiratory depression.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Multum Information Services, Inc. Expert Review Panel"', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51379, 4802, 'Fentanyl', 'Alcoholic Intoxication', 'The use of opiate agonists is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of opiate agonists may be additive with those of alcohol.  Severe respiratory depression and death may occur.  Therapy with opiate agonists should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51380, 13291, 'Fentanyl', 'Alcoholic Intoxication', 'The use of opiate agonists is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of opiate agonists may be additive with those of alcohol.  Severe respiratory depression and death may occur.  Therapy with opiate agonists should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51381, 13292, 'Fentanyl', 'Alcoholic Intoxication', 'The use of opiate agonists is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of opiate agonists may be additive with those of alcohol.  Severe respiratory depression and death may occur.  Therapy with opiate agonists should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51382, 17981, 'Fentanyl', 'Alcoholic Intoxication', 'The use of opiate agonists is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of opiate agonists may be additive with those of alcohol.  Severe respiratory depression and death may occur.  Therapy with opiate agonists should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51383, 17982, 'Fentanyl', 'Alcoholic Intoxication', 'The use of opiate agonists is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of opiate agonists may be additive with those of alcohol.  Severe respiratory depression and death may occur.  Therapy with opiate agonists should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51384, 17983, 'Fentanyl', 'Alcoholic Intoxication', 'The use of opiate agonists is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of opiate agonists may be additive with those of alcohol.  Severe respiratory depression and death may occur.  Therapy with opiate agonists should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51385, 17984, 'Fentanyl', 'Alcoholic Intoxication', 'The use of opiate agonists is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of opiate agonists may be additive with those of alcohol.  Severe respiratory depression and death may occur.  Therapy with opiate agonists should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51386, 17985, 'Fentanyl', 'Alcoholic Intoxication', 'The use of opiate agonists is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of opiate agonists may be additive with those of alcohol.  Severe respiratory depression and death may occur.  Therapy with opiate agonists should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51387, 18952, 'Fentanyl', 'Alcoholic Intoxication', 'The use of opiate agonists is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of opiate agonists may be additive with those of alcohol.  Severe respiratory depression and death may occur.  Therapy with opiate agonists should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51388, 18953, 'Fentanyl', 'Alcoholic Intoxication', 'The use of opiate agonists is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of opiate agonists may be additive with those of alcohol.  Severe respiratory depression and death may occur.  Therapy with opiate agonists should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51389, 18955, 'Fentanyl', 'Alcoholic Intoxication', 'The use of opiate agonists is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of opiate agonists may be additive with those of alcohol.  Severe respiratory depression and death may occur.  Therapy with opiate agonists should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51390, 30532, 'Fentanyl', 'Alcoholic Intoxication', 'The use of opiate agonists is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of opiate agonists may be additive with those of alcohol.  Severe respiratory depression and death may occur.  Therapy with opiate agonists should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51391, 4802, 'Fentanyl', 'Substance-Related Disorders', 'Opiate agonists have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop after prolonged use.  Abrupt cessation, reduction in dosage, or administration of an opiate antagonist such as naloxone may precipitate withdrawal symptoms.  In patients who have developed tolerance to an opiate agonist, overdosage can still produce respiratory depression and death, and cross-tolerance usually will occur with other agents in the class.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with opiate agonists.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of opiate therapy should be undertaken gradually using a dosage-tapering schedule.', '3', 'Fishbain DA, Goldberg M, Rosomoff RS, Rosomoff H "Atypical withdrawal syndrome (organic delusional syndrome) secondary to oxycodone detoxification ." J Clin Psychopharmacol 8 (1988):  441-2|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Miser AW, Chayt KJ, Sandlund JT, Cohen PS, Dothage JA, Miser JS "Narcotic withdrawal syndrome in young adults after the therapeutic use of opiates." Am J Dis Child 140 (1986):  603-4|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Morrison AB "Toxicity and abuse of hydrocodone bitartrate." Can Med Assoc J 120 (1979):  1338|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Azorlosa JL, Stitzer ML, Greenwald MK "Opioid physical dependence development - effects of single versus repeated morphine pretreatments and of subjects opioid exposure history." Psychopharmacology (Berl) 114 (1994):  71-80|Strode SW "Propoxyphene dependence and withdrawal." Am Fam Physician 32 (1985):  105-8|Wall R, Linford SM, Akhter MI "Addiction to Distalgesic (dextropropoxyphene)." Br Med J 280 (1980):  1213-4|Salguero CH, Villarreal JE, Hug CC Jr, Domino EF "Propoxyphene dependence." JAMA 210 (1969):  135-6|Claghorn JL, Schoolar JC "Propoxyphene hydrochloride, a drug of abuse." JAMA 196 (1966):  1089-91|Whittington RM "Dextropropoxyphene addiction." Lancet 2 (1979):  743-4|Collins GB, Kiefer KS "Propoxyphene dependence: an update." Postgrad Med 70 (1981):  57-61|Ng B, Alvear M "Dextropropoxyphene addiction--a drug of primary abuse." Am J Drug Alcohol Abuse 19 (1993):  153-8|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|Hedenmalm K "A case of severe withdrawal syndrome due to dextropropoxyphene." Ann Intern Med 123 (1995):  473|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51392, 13291, 'Fentanyl', 'Substance-Related Disorders', 'Opiate agonists have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop after prolonged use.  Abrupt cessation, reduction in dosage, or administration of an opiate antagonist such as naloxone may precipitate withdrawal symptoms.  In patients who have developed tolerance to an opiate agonist, overdosage can still produce respiratory depression and death, and cross-tolerance usually will occur with other agents in the class.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with opiate agonists.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of opiate therapy should be undertaken gradually using a dosage-tapering schedule.', '3', 'Fishbain DA, Goldberg M, Rosomoff RS, Rosomoff H "Atypical withdrawal syndrome (organic delusional syndrome) secondary to oxycodone detoxification ." J Clin Psychopharmacol 8 (1988):  441-2|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Miser AW, Chayt KJ, Sandlund JT, Cohen PS, Dothage JA, Miser JS "Narcotic withdrawal syndrome in young adults after the therapeutic use of opiates." Am J Dis Child 140 (1986):  603-4|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Morrison AB "Toxicity and abuse of hydrocodone bitartrate." Can Med Assoc J 120 (1979):  1338|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Azorlosa JL, Stitzer ML, Greenwald MK "Opioid physical dependence development - effects of single versus repeated morphine pretreatments and of subjects opioid exposure history." Psychopharmacology (Berl) 114 (1994):  71-80|Strode SW "Propoxyphene dependence and withdrawal." Am Fam Physician 32 (1985):  105-8|Wall R, Linford SM, Akhter MI "Addiction to Distalgesic (dextropropoxyphene)." Br Med J 280 (1980):  1213-4|Salguero CH, Villarreal JE, Hug CC Jr, Domino EF "Propoxyphene dependence." JAMA 210 (1969):  135-6|Claghorn JL, Schoolar JC "Propoxyphene hydrochloride, a drug of abuse." JAMA 196 (1966):  1089-91|Whittington RM "Dextropropoxyphene addiction." Lancet 2 (1979):  743-4|Collins GB, Kiefer KS "Propoxyphene dependence: an update." Postgrad Med 70 (1981):  57-61|Ng B, Alvear M "Dextropropoxyphene addiction--a drug of primary abuse." Am J Drug Alcohol Abuse 19 (1993):  153-8|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|Hedenmalm K "A case of severe withdrawal syndrome due to dextropropoxyphene." Ann Intern Med 123 (1995):  473|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51393, 13292, 'Fentanyl', 'Substance-Related Disorders', 'Opiate agonists have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop after prolonged use.  Abrupt cessation, reduction in dosage, or administration of an opiate antagonist such as naloxone may precipitate withdrawal symptoms.  In patients who have developed tolerance to an opiate agonist, overdosage can still produce respiratory depression and death, and cross-tolerance usually will occur with other agents in the class.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with opiate agonists.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of opiate therapy should be undertaken gradually using a dosage-tapering schedule.', '3', 'Fishbain DA, Goldberg M, Rosomoff RS, Rosomoff H "Atypical withdrawal syndrome (organic delusional syndrome) secondary to oxycodone detoxification ." J Clin Psychopharmacol 8 (1988):  441-2|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Miser AW, Chayt KJ, Sandlund JT, Cohen PS, Dothage JA, Miser JS "Narcotic withdrawal syndrome in young adults after the therapeutic use of opiates." Am J Dis Child 140 (1986):  603-4|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Morrison AB "Toxicity and abuse of hydrocodone bitartrate." Can Med Assoc J 120 (1979):  1338|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Azorlosa JL, Stitzer ML, Greenwald MK "Opioid physical dependence development - effects of single versus repeated morphine pretreatments and of subjects opioid exposure history." Psychopharmacology (Berl) 114 (1994):  71-80|Strode SW "Propoxyphene dependence and withdrawal." Am Fam Physician 32 (1985):  105-8|Wall R, Linford SM, Akhter MI "Addiction to Distalgesic (dextropropoxyphene)." Br Med J 280 (1980):  1213-4|Salguero CH, Villarreal JE, Hug CC Jr, Domino EF "Propoxyphene dependence." JAMA 210 (1969):  135-6|Claghorn JL, Schoolar JC "Propoxyphene hydrochloride, a drug of abuse." JAMA 196 (1966):  1089-91|Whittington RM "Dextropropoxyphene addiction." Lancet 2 (1979):  743-4|Collins GB, Kiefer KS "Propoxyphene dependence: an update." Postgrad Med 70 (1981):  57-61|Ng B, Alvear M "Dextropropoxyphene addiction--a drug of primary abuse." Am J Drug Alcohol Abuse 19 (1993):  153-8|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|Hedenmalm K "A case of severe withdrawal syndrome due to dextropropoxyphene." Ann Intern Med 123 (1995):  473|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51394, 17981, 'Fentanyl', 'Substance-Related Disorders', 'Opiate agonists have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop after prolonged use.  Abrupt cessation, reduction in dosage, or administration of an opiate antagonist such as naloxone may precipitate withdrawal symptoms.  In patients who have developed tolerance to an opiate agonist, overdosage can still produce respiratory depression and death, and cross-tolerance usually will occur with other agents in the class.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with opiate agonists.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of opiate therapy should be undertaken gradually using a dosage-tapering schedule.', '3', 'Fishbain DA, Goldberg M, Rosomoff RS, Rosomoff H "Atypical withdrawal syndrome (organic delusional syndrome) secondary to oxycodone detoxification ." J Clin Psychopharmacol 8 (1988):  441-2|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Miser AW, Chayt KJ, Sandlund JT, Cohen PS, Dothage JA, Miser JS "Narcotic withdrawal syndrome in young adults after the therapeutic use of opiates." Am J Dis Child 140 (1986):  603-4|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Morrison AB "Toxicity and abuse of hydrocodone bitartrate." Can Med Assoc J 120 (1979):  1338|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Azorlosa JL, Stitzer ML, Greenwald MK "Opioid physical dependence development - effects of single versus repeated morphine pretreatments and of subjects opioid exposure history." Psychopharmacology (Berl) 114 (1994):  71-80|Strode SW "Propoxyphene dependence and withdrawal." Am Fam Physician 32 (1985):  105-8|Wall R, Linford SM, Akhter MI "Addiction to Distalgesic (dextropropoxyphene)." Br Med J 280 (1980):  1213-4|Salguero CH, Villarreal JE, Hug CC Jr, Domino EF "Propoxyphene dependence." JAMA 210 (1969):  135-6|Claghorn JL, Schoolar JC "Propoxyphene hydrochloride, a drug of abuse." JAMA 196 (1966):  1089-91|Whittington RM "Dextropropoxyphene addiction." Lancet 2 (1979):  743-4|Collins GB, Kiefer KS "Propoxyphene dependence: an update." Postgrad Med 70 (1981):  57-61|Ng B, Alvear M "Dextropropoxyphene addiction--a drug of primary abuse." Am J Drug Alcohol Abuse 19 (1993):  153-8|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|Hedenmalm K "A case of severe withdrawal syndrome due to dextropropoxyphene." Ann Intern Med 123 (1995):  473|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51395, 17982, 'Fentanyl', 'Substance-Related Disorders', 'Opiate agonists have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop after prolonged use.  Abrupt cessation, reduction in dosage, or administration of an opiate antagonist such as naloxone may precipitate withdrawal symptoms.  In patients who have developed tolerance to an opiate agonist, overdosage can still produce respiratory depression and death, and cross-tolerance usually will occur with other agents in the class.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with opiate agonists.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of opiate therapy should be undertaken gradually using a dosage-tapering schedule.', '3', 'Fishbain DA, Goldberg M, Rosomoff RS, Rosomoff H "Atypical withdrawal syndrome (organic delusional syndrome) secondary to oxycodone detoxification ." J Clin Psychopharmacol 8 (1988):  441-2|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Miser AW, Chayt KJ, Sandlund JT, Cohen PS, Dothage JA, Miser JS "Narcotic withdrawal syndrome in young adults after the therapeutic use of opiates." Am J Dis Child 140 (1986):  603-4|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Morrison AB "Toxicity and abuse of hydrocodone bitartrate." Can Med Assoc J 120 (1979):  1338|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Azorlosa JL, Stitzer ML, Greenwald MK "Opioid physical dependence development - effects of single versus repeated morphine pretreatments and of subjects opioid exposure history." Psychopharmacology (Berl) 114 (1994):  71-80|Strode SW "Propoxyphene dependence and withdrawal." Am Fam Physician 32 (1985):  105-8|Wall R, Linford SM, Akhter MI "Addiction to Distalgesic (dextropropoxyphene)." Br Med J 280 (1980):  1213-4|Salguero CH, Villarreal JE, Hug CC Jr, Domino EF "Propoxyphene dependence." JAMA 210 (1969):  135-6|Claghorn JL, Schoolar JC "Propoxyphene hydrochloride, a drug of abuse." JAMA 196 (1966):  1089-91|Whittington RM "Dextropropoxyphene addiction." Lancet 2 (1979):  743-4|Collins GB, Kiefer KS "Propoxyphene dependence: an update." Postgrad Med 70 (1981):  57-61|Ng B, Alvear M "Dextropropoxyphene addiction--a drug of primary abuse." Am J Drug Alcohol Abuse 19 (1993):  153-8|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|Hedenmalm K "A case of severe withdrawal syndrome due to dextropropoxyphene." Ann Intern Med 123 (1995):  473|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51396, 17983, 'Fentanyl', 'Substance-Related Disorders', 'Opiate agonists have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop after prolonged use.  Abrupt cessation, reduction in dosage, or administration of an opiate antagonist such as naloxone may precipitate withdrawal symptoms.  In patients who have developed tolerance to an opiate agonist, overdosage can still produce respiratory depression and death, and cross-tolerance usually will occur with other agents in the class.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with opiate agonists.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of opiate therapy should be undertaken gradually using a dosage-tapering schedule.', '3', 'Fishbain DA, Goldberg M, Rosomoff RS, Rosomoff H "Atypical withdrawal syndrome (organic delusional syndrome) secondary to oxycodone detoxification ." J Clin Psychopharmacol 8 (1988):  441-2|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Miser AW, Chayt KJ, Sandlund JT, Cohen PS, Dothage JA, Miser JS "Narcotic withdrawal syndrome in young adults after the therapeutic use of opiates." Am J Dis Child 140 (1986):  603-4|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Morrison AB "Toxicity and abuse of hydrocodone bitartrate." Can Med Assoc J 120 (1979):  1338|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Azorlosa JL, Stitzer ML, Greenwald MK "Opioid physical dependence development - effects of single versus repeated morphine pretreatments and of subjects opioid exposure history." Psychopharmacology (Berl) 114 (1994):  71-80|Strode SW "Propoxyphene dependence and withdrawal." Am Fam Physician 32 (1985):  105-8|Wall R, Linford SM, Akhter MI "Addiction to Distalgesic (dextropropoxyphene)." Br Med J 280 (1980):  1213-4|Salguero CH, Villarreal JE, Hug CC Jr, Domino EF "Propoxyphene dependence." JAMA 210 (1969):  135-6|Claghorn JL, Schoolar JC "Propoxyphene hydrochloride, a drug of abuse." JAMA 196 (1966):  1089-91|Whittington RM "Dextropropoxyphene addiction." Lancet 2 (1979):  743-4|Collins GB, Kiefer KS "Propoxyphene dependence: an update." Postgrad Med 70 (1981):  57-61|Ng B, Alvear M "Dextropropoxyphene addiction--a drug of primary abuse." Am J Drug Alcohol Abuse 19 (1993):  153-8|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|Hedenmalm K "A case of severe withdrawal syndrome due to dextropropoxyphene." Ann Intern Med 123 (1995):  473|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51397, 17984, 'Fentanyl', 'Substance-Related Disorders', 'Opiate agonists have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop after prolonged use.  Abrupt cessation, reduction in dosage, or administration of an opiate antagonist such as naloxone may precipitate withdrawal symptoms.  In patients who have developed tolerance to an opiate agonist, overdosage can still produce respiratory depression and death, and cross-tolerance usually will occur with other agents in the class.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with opiate agonists.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of opiate therapy should be undertaken gradually using a dosage-tapering schedule.', '3', 'Fishbain DA, Goldberg M, Rosomoff RS, Rosomoff H "Atypical withdrawal syndrome (organic delusional syndrome) secondary to oxycodone detoxification ." J Clin Psychopharmacol 8 (1988):  441-2|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Miser AW, Chayt KJ, Sandlund JT, Cohen PS, Dothage JA, Miser JS "Narcotic withdrawal syndrome in young adults after the therapeutic use of opiates." Am J Dis Child 140 (1986):  603-4|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Morrison AB "Toxicity and abuse of hydrocodone bitartrate." Can Med Assoc J 120 (1979):  1338|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Azorlosa JL, Stitzer ML, Greenwald MK "Opioid physical dependence development - effects of single versus repeated morphine pretreatments and of subjects opioid exposure history." Psychopharmacology (Berl) 114 (1994):  71-80|Strode SW "Propoxyphene dependence and withdrawal." Am Fam Physician 32 (1985):  105-8|Wall R, Linford SM, Akhter MI "Addiction to Distalgesic (dextropropoxyphene)." Br Med J 280 (1980):  1213-4|Salguero CH, Villarreal JE, Hug CC Jr, Domino EF "Propoxyphene dependence." JAMA 210 (1969):  135-6|Claghorn JL, Schoolar JC "Propoxyphene hydrochloride, a drug of abuse." JAMA 196 (1966):  1089-91|Whittington RM "Dextropropoxyphene addiction." Lancet 2 (1979):  743-4|Collins GB, Kiefer KS "Propoxyphene dependence: an update." Postgrad Med 70 (1981):  57-61|Ng B, Alvear M "Dextropropoxyphene addiction--a drug of primary abuse." Am J Drug Alcohol Abuse 19 (1993):  153-8|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|Hedenmalm K "A case of severe withdrawal syndrome due to dextropropoxyphene." Ann Intern Med 123 (1995):  473|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51398, 17985, 'Fentanyl', 'Substance-Related Disorders', 'Opiate agonists have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop after prolonged use.  Abrupt cessation, reduction in dosage, or administration of an opiate antagonist such as naloxone may precipitate withdrawal symptoms.  In patients who have developed tolerance to an opiate agonist, overdosage can still produce respiratory depression and death, and cross-tolerance usually will occur with other agents in the class.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with opiate agonists.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of opiate therapy should be undertaken gradually using a dosage-tapering schedule.', '3', 'Fishbain DA, Goldberg M, Rosomoff RS, Rosomoff H "Atypical withdrawal syndrome (organic delusional syndrome) secondary to oxycodone detoxification ." J Clin Psychopharmacol 8 (1988):  441-2|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Miser AW, Chayt KJ, Sandlund JT, Cohen PS, Dothage JA, Miser JS "Narcotic withdrawal syndrome in young adults after the therapeutic use of opiates." Am J Dis Child 140 (1986):  603-4|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Morrison AB "Toxicity and abuse of hydrocodone bitartrate." Can Med Assoc J 120 (1979):  1338|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Azorlosa JL, Stitzer ML, Greenwald MK "Opioid physical dependence development - effects of single versus repeated morphine pretreatments and of subjects opioid exposure history." Psychopharmacology (Berl) 114 (1994):  71-80|Strode SW "Propoxyphene dependence and withdrawal." Am Fam Physician 32 (1985):  105-8|Wall R, Linford SM, Akhter MI "Addiction to Distalgesic (dextropropoxyphene)." Br Med J 280 (1980):  1213-4|Salguero CH, Villarreal JE, Hug CC Jr, Domino EF "Propoxyphene dependence." JAMA 210 (1969):  135-6|Claghorn JL, Schoolar JC "Propoxyphene hydrochloride, a drug of abuse." JAMA 196 (1966):  1089-91|Whittington RM "Dextropropoxyphene addiction." Lancet 2 (1979):  743-4|Collins GB, Kiefer KS "Propoxyphene dependence: an update." Postgrad Med 70 (1981):  57-61|Ng B, Alvear M "Dextropropoxyphene addiction--a drug of primary abuse." Am J Drug Alcohol Abuse 19 (1993):  153-8|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|Hedenmalm K "A case of severe withdrawal syndrome due to dextropropoxyphene." Ann Intern Med 123 (1995):  473|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51399, 18952, 'Fentanyl', 'Substance-Related Disorders', 'Opiate agonists have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop after prolonged use.  Abrupt cessation, reduction in dosage, or administration of an opiate antagonist such as naloxone may precipitate withdrawal symptoms.  In patients who have developed tolerance to an opiate agonist, overdosage can still produce respiratory depression and death, and cross-tolerance usually will occur with other agents in the class.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with opiate agonists.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of opiate therapy should be undertaken gradually using a dosage-tapering schedule.', '3', 'Fishbain DA, Goldberg M, Rosomoff RS, Rosomoff H "Atypical withdrawal syndrome (organic delusional syndrome) secondary to oxycodone detoxification ." J Clin Psychopharmacol 8 (1988):  441-2|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Miser AW, Chayt KJ, Sandlund JT, Cohen PS, Dothage JA, Miser JS "Narcotic withdrawal syndrome in young adults after the therapeutic use of opiates." Am J Dis Child 140 (1986):  603-4|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Morrison AB "Toxicity and abuse of hydrocodone bitartrate." Can Med Assoc J 120 (1979):  1338|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Azorlosa JL, Stitzer ML, Greenwald MK "Opioid physical dependence development - effects of single versus repeated morphine pretreatments and of subjects opioid exposure history." Psychopharmacology (Berl) 114 (1994):  71-80|Strode SW "Propoxyphene dependence and withdrawal." Am Fam Physician 32 (1985):  105-8|Wall R, Linford SM, Akhter MI "Addiction to Distalgesic (dextropropoxyphene)." Br Med J 280 (1980):  1213-4|Salguero CH, Villarreal JE, Hug CC Jr, Domino EF "Propoxyphene dependence." JAMA 210 (1969):  135-6|Claghorn JL, Schoolar JC "Propoxyphene hydrochloride, a drug of abuse." JAMA 196 (1966):  1089-91|Whittington RM "Dextropropoxyphene addiction." Lancet 2 (1979):  743-4|Collins GB, Kiefer KS "Propoxyphene dependence: an update." Postgrad Med 70 (1981):  57-61|Ng B, Alvear M "Dextropropoxyphene addiction--a drug of primary abuse." Am J Drug Alcohol Abuse 19 (1993):  153-8|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|Hedenmalm K "A case of severe withdrawal syndrome due to dextropropoxyphene." Ann Intern Med 123 (1995):  473|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51400, 18953, 'Fentanyl', 'Substance-Related Disorders', 'Opiate agonists have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop after prolonged use.  Abrupt cessation, reduction in dosage, or administration of an opiate antagonist such as naloxone may precipitate withdrawal symptoms.  In patients who have developed tolerance to an opiate agonist, overdosage can still produce respiratory depression and death, and cross-tolerance usually will occur with other agents in the class.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with opiate agonists.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of opiate therapy should be undertaken gradually using a dosage-tapering schedule.', '3', 'Fishbain DA, Goldberg M, Rosomoff RS, Rosomoff H "Atypical withdrawal syndrome (organic delusional syndrome) secondary to oxycodone detoxification ." J Clin Psychopharmacol 8 (1988):  441-2|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Miser AW, Chayt KJ, Sandlund JT, Cohen PS, Dothage JA, Miser JS "Narcotic withdrawal syndrome in young adults after the therapeutic use of opiates." Am J Dis Child 140 (1986):  603-4|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Morrison AB "Toxicity and abuse of hydrocodone bitartrate." Can Med Assoc J 120 (1979):  1338|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Azorlosa JL, Stitzer ML, Greenwald MK "Opioid physical dependence development - effects of single versus repeated morphine pretreatments and of subjects opioid exposure history." Psychopharmacology (Berl) 114 (1994):  71-80|Strode SW "Propoxyphene dependence and withdrawal." Am Fam Physician 32 (1985):  105-8|Wall R, Linford SM, Akhter MI "Addiction to Distalgesic (dextropropoxyphene)." Br Med J 280 (1980):  1213-4|Salguero CH, Villarreal JE, Hug CC Jr, Domino EF "Propoxyphene dependence." JAMA 210 (1969):  135-6|Claghorn JL, Schoolar JC "Propoxyphene hydrochloride, a drug of abuse." JAMA 196 (1966):  1089-91|Whittington RM "Dextropropoxyphene addiction." Lancet 2 (1979):  743-4|Collins GB, Kiefer KS "Propoxyphene dependence: an update." Postgrad Med 70 (1981):  57-61|Ng B, Alvear M "Dextropropoxyphene addiction--a drug of primary abuse." Am J Drug Alcohol Abuse 19 (1993):  153-8|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|Hedenmalm K "A case of severe withdrawal syndrome due to dextropropoxyphene." Ann Intern Med 123 (1995):  473|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51401, 18955, 'Fentanyl', 'Substance-Related Disorders', 'Opiate agonists have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop after prolonged use.  Abrupt cessation, reduction in dosage, or administration of an opiate antagonist such as naloxone may precipitate withdrawal symptoms.  In patients who have developed tolerance to an opiate agonist, overdosage can still produce respiratory depression and death, and cross-tolerance usually will occur with other agents in the class.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with opiate agonists.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of opiate therapy should be undertaken gradually using a dosage-tapering schedule.', '3', 'Fishbain DA, Goldberg M, Rosomoff RS, Rosomoff H "Atypical withdrawal syndrome (organic delusional syndrome) secondary to oxycodone detoxification ." J Clin Psychopharmacol 8 (1988):  441-2|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Miser AW, Chayt KJ, Sandlund JT, Cohen PS, Dothage JA, Miser JS "Narcotic withdrawal syndrome in young adults after the therapeutic use of opiates." Am J Dis Child 140 (1986):  603-4|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Morrison AB "Toxicity and abuse of hydrocodone bitartrate." Can Med Assoc J 120 (1979):  1338|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Azorlosa JL, Stitzer ML, Greenwald MK "Opioid physical dependence development - effects of single versus repeated morphine pretreatments and of subjects opioid exposure history." Psychopharmacology (Berl) 114 (1994):  71-80|Strode SW "Propoxyphene dependence and withdrawal." Am Fam Physician 32 (1985):  105-8|Wall R, Linford SM, Akhter MI "Addiction to Distalgesic (dextropropoxyphene)." Br Med J 280 (1980):  1213-4|Salguero CH, Villarreal JE, Hug CC Jr, Domino EF "Propoxyphene dependence." JAMA 210 (1969):  135-6|Claghorn JL, Schoolar JC "Propoxyphene hydrochloride, a drug of abuse." JAMA 196 (1966):  1089-91|Whittington RM "Dextropropoxyphene addiction." Lancet 2 (1979):  743-4|Collins GB, Kiefer KS "Propoxyphene dependence: an update." Postgrad Med 70 (1981):  57-61|Ng B, Alvear M "Dextropropoxyphene addiction--a drug of primary abuse." Am J Drug Alcohol Abuse 19 (1993):  153-8|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|Hedenmalm K "A case of severe withdrawal syndrome due to dextropropoxyphene." Ann Intern Med 123 (1995):  473|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51402, 30532, 'Fentanyl', 'Substance-Related Disorders', 'Opiate agonists have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop after prolonged use.  Abrupt cessation, reduction in dosage, or administration of an opiate antagonist such as naloxone may precipitate withdrawal symptoms.  In patients who have developed tolerance to an opiate agonist, overdosage can still produce respiratory depression and death, and cross-tolerance usually will occur with other agents in the class.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with opiate agonists.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of opiate therapy should be undertaken gradually using a dosage-tapering schedule.', '3', 'Fishbain DA, Goldberg M, Rosomoff RS, Rosomoff H "Atypical withdrawal syndrome (organic delusional syndrome) secondary to oxycodone detoxification ." J Clin Psychopharmacol 8 (1988):  441-2|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Miser AW, Chayt KJ, Sandlund JT, Cohen PS, Dothage JA, Miser JS "Narcotic withdrawal syndrome in young adults after the therapeutic use of opiates." Am J Dis Child 140 (1986):  603-4|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Morrison AB "Toxicity and abuse of hydrocodone bitartrate." Can Med Assoc J 120 (1979):  1338|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Azorlosa JL, Stitzer ML, Greenwald MK "Opioid physical dependence development - effects of single versus repeated morphine pretreatments and of subjects opioid exposure history." Psychopharmacology (Berl) 114 (1994):  71-80|Strode SW "Propoxyphene dependence and withdrawal." Am Fam Physician 32 (1985):  105-8|Wall R, Linford SM, Akhter MI "Addiction to Distalgesic (dextropropoxyphene)." Br Med J 280 (1980):  1213-4|Salguero CH, Villarreal JE, Hug CC Jr, Domino EF "Propoxyphene dependence." JAMA 210 (1969):  135-6|Claghorn JL, Schoolar JC "Propoxyphene hydrochloride, a drug of abuse." JAMA 196 (1966):  1089-91|Whittington RM "Dextropropoxyphene addiction." Lancet 2 (1979):  743-4|Collins GB, Kiefer KS "Propoxyphene dependence: an update." Postgrad Med 70 (1981):  57-61|Ng B, Alvear M "Dextropropoxyphene addiction--a drug of primary abuse." Am J Drug Alcohol Abuse 19 (1993):  153-8|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|Hedenmalm K "A case of severe withdrawal syndrome due to dextropropoxyphene." Ann Intern Med 123 (1995):  473|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51403, 4802, 'Fentanyl', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51404, 13291, 'Fentanyl', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51405, 13292, 'Fentanyl', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51406, 17981, 'Fentanyl', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51407, 17982, 'Fentanyl', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51408, 17983, 'Fentanyl', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51409, 17984, 'Fentanyl', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51410, 17985, 'Fentanyl', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51411, 18952, 'Fentanyl', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51412, 18953, 'Fentanyl', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51413, 18955, 'Fentanyl', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51414, 30532, 'Fentanyl', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51415, 4802, 'Fentanyl', 'Hypotension', 'Opiate agonists can induce vasodilation and significant hypotension, particularly when given in high dosages and/or by rapid intravenous administration.  Opiate analgesics cause vasodilatation that may exacerbate hypotension and hypoperfusion and, therefore, are contraindicated in circulatory shock.  At therapeutic analgesic dosages, ambulatory patients are more likely to experience dizziness and hypotension than patients who are confined to bed.  However, orthostatic hypotension may occur in supine patients upon rising.  Therapy with opiate agonists should be administered cautiously and initiated at reduced dosages in patients with hypovolemia, or a predisposition to hypotension.  When given by intramuscular or subcutaneous administration, clinicians should also be aware that impaired perfusion in these patients may prevent complete absorption of the drug.  With repeated injections, an excessive amount may be absorbed suddenly if normal circulation is reestablished.', '3', 'Parke TJ, Nandi PR, Bird KJ, Jewkes DA "Profound hypotension following intravenous codeine phosphate: three case reports and some recommendations." Anaesthesia 47 (1992):  852-4|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982):  308-15|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Cox RG "Hypoxaemia and hypotension after intravenous codeine phosphate." Can J Anaesth 41 (1994):  1211-3|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51416, 13291, 'Fentanyl', 'Hypotension', 'Opiate agonists can induce vasodilation and significant hypotension, particularly when given in high dosages and/or by rapid intravenous administration.  Opiate analgesics cause vasodilatation that may exacerbate hypotension and hypoperfusion and, therefore, are contraindicated in circulatory shock.  At therapeutic analgesic dosages, ambulatory patients are more likely to experience dizziness and hypotension than patients who are confined to bed.  However, orthostatic hypotension may occur in supine patients upon rising.  Therapy with opiate agonists should be administered cautiously and initiated at reduced dosages in patients with hypovolemia, or a predisposition to hypotension.  When given by intramuscular or subcutaneous administration, clinicians should also be aware that impaired perfusion in these patients may prevent complete absorption of the drug.  With repeated injections, an excessive amount may be absorbed suddenly if normal circulation is reestablished.', '3', 'Parke TJ, Nandi PR, Bird KJ, Jewkes DA "Profound hypotension following intravenous codeine phosphate: three case reports and some recommendations." Anaesthesia 47 (1992):  852-4|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982):  308-15|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Cox RG "Hypoxaemia and hypotension after intravenous codeine phosphate." Can J Anaesth 41 (1994):  1211-3|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51417, 13292, 'Fentanyl', 'Hypotension', 'Opiate agonists can induce vasodilation and significant hypotension, particularly when given in high dosages and/or by rapid intravenous administration.  Opiate analgesics cause vasodilatation that may exacerbate hypotension and hypoperfusion and, therefore, are contraindicated in circulatory shock.  At therapeutic analgesic dosages, ambulatory patients are more likely to experience dizziness and hypotension than patients who are confined to bed.  However, orthostatic hypotension may occur in supine patients upon rising.  Therapy with opiate agonists should be administered cautiously and initiated at reduced dosages in patients with hypovolemia, or a predisposition to hypotension.  When given by intramuscular or subcutaneous administration, clinicians should also be aware that impaired perfusion in these patients may prevent complete absorption of the drug.  With repeated injections, an excessive amount may be absorbed suddenly if normal circulation is reestablished.', '3', 'Parke TJ, Nandi PR, Bird KJ, Jewkes DA "Profound hypotension following intravenous codeine phosphate: three case reports and some recommendations." Anaesthesia 47 (1992):  852-4|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982):  308-15|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Cox RG "Hypoxaemia and hypotension after intravenous codeine phosphate." Can J Anaesth 41 (1994):  1211-3|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51418, 17981, 'Fentanyl', 'Hypotension', 'Opiate agonists can induce vasodilation and significant hypotension, particularly when given in high dosages and/or by rapid intravenous administration.  Opiate analgesics cause vasodilatation that may exacerbate hypotension and hypoperfusion and, therefore, are contraindicated in circulatory shock.  At therapeutic analgesic dosages, ambulatory patients are more likely to experience dizziness and hypotension than patients who are confined to bed.  However, orthostatic hypotension may occur in supine patients upon rising.  Therapy with opiate agonists should be administered cautiously and initiated at reduced dosages in patients with hypovolemia, or a predisposition to hypotension.  When given by intramuscular or subcutaneous administration, clinicians should also be aware that impaired perfusion in these patients may prevent complete absorption of the drug.  With repeated injections, an excessive amount may be absorbed suddenly if normal circulation is reestablished.', '3', 'Parke TJ, Nandi PR, Bird KJ, Jewkes DA "Profound hypotension following intravenous codeine phosphate: three case reports and some recommendations." Anaesthesia 47 (1992):  852-4|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982):  308-15|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Cox RG "Hypoxaemia and hypotension after intravenous codeine phosphate." Can J Anaesth 41 (1994):  1211-3|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51419, 17982, 'Fentanyl', 'Hypotension', 'Opiate agonists can induce vasodilation and significant hypotension, particularly when given in high dosages and/or by rapid intravenous administration.  Opiate analgesics cause vasodilatation that may exacerbate hypotension and hypoperfusion and, therefore, are contraindicated in circulatory shock.  At therapeutic analgesic dosages, ambulatory patients are more likely to experience dizziness and hypotension than patients who are confined to bed.  However, orthostatic hypotension may occur in supine patients upon rising.  Therapy with opiate agonists should be administered cautiously and initiated at reduced dosages in patients with hypovolemia, or a predisposition to hypotension.  When given by intramuscular or subcutaneous administration, clinicians should also be aware that impaired perfusion in these patients may prevent complete absorption of the drug.  With repeated injections, an excessive amount may be absorbed suddenly if normal circulation is reestablished.', '3', 'Parke TJ, Nandi PR, Bird KJ, Jewkes DA "Profound hypotension following intravenous codeine phosphate: three case reports and some recommendations." Anaesthesia 47 (1992):  852-4|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982):  308-15|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Cox RG "Hypoxaemia and hypotension after intravenous codeine phosphate." Can J Anaesth 41 (1994):  1211-3|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51420, 17983, 'Fentanyl', 'Hypotension', 'Opiate agonists can induce vasodilation and significant hypotension, particularly when given in high dosages and/or by rapid intravenous administration.  Opiate analgesics cause vasodilatation that may exacerbate hypotension and hypoperfusion and, therefore, are contraindicated in circulatory shock.  At therapeutic analgesic dosages, ambulatory patients are more likely to experience dizziness and hypotension than patients who are confined to bed.  However, orthostatic hypotension may occur in supine patients upon rising.  Therapy with opiate agonists should be administered cautiously and initiated at reduced dosages in patients with hypovolemia, or a predisposition to hypotension.  When given by intramuscular or subcutaneous administration, clinicians should also be aware that impaired perfusion in these patients may prevent complete absorption of the drug.  With repeated injections, an excessive amount may be absorbed suddenly if normal circulation is reestablished.', '3', 'Parke TJ, Nandi PR, Bird KJ, Jewkes DA "Profound hypotension following intravenous codeine phosphate: three case reports and some recommendations." Anaesthesia 47 (1992):  852-4|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982):  308-15|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Cox RG "Hypoxaemia and hypotension after intravenous codeine phosphate." Can J Anaesth 41 (1994):  1211-3|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51421, 17984, 'Fentanyl', 'Hypotension', 'Opiate agonists can induce vasodilation and significant hypotension, particularly when given in high dosages and/or by rapid intravenous administration.  Opiate analgesics cause vasodilatation that may exacerbate hypotension and hypoperfusion and, therefore, are contraindicated in circulatory shock.  At therapeutic analgesic dosages, ambulatory patients are more likely to experience dizziness and hypotension than patients who are confined to bed.  However, orthostatic hypotension may occur in supine patients upon rising.  Therapy with opiate agonists should be administered cautiously and initiated at reduced dosages in patients with hypovolemia, or a predisposition to hypotension.  When given by intramuscular or subcutaneous administration, clinicians should also be aware that impaired perfusion in these patients may prevent complete absorption of the drug.  With repeated injections, an excessive amount may be absorbed suddenly if normal circulation is reestablished.', '3', 'Parke TJ, Nandi PR, Bird KJ, Jewkes DA "Profound hypotension following intravenous codeine phosphate: three case reports and some recommendations." Anaesthesia 47 (1992):  852-4|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982):  308-15|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Cox RG "Hypoxaemia and hypotension after intravenous codeine phosphate." Can J Anaesth 41 (1994):  1211-3|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51422, 17985, 'Fentanyl', 'Hypotension', 'Opiate agonists can induce vasodilation and significant hypotension, particularly when given in high dosages and/or by rapid intravenous administration.  Opiate analgesics cause vasodilatation that may exacerbate hypotension and hypoperfusion and, therefore, are contraindicated in circulatory shock.  At therapeutic analgesic dosages, ambulatory patients are more likely to experience dizziness and hypotension than patients who are confined to bed.  However, orthostatic hypotension may occur in supine patients upon rising.  Therapy with opiate agonists should be administered cautiously and initiated at reduced dosages in patients with hypovolemia, or a predisposition to hypotension.  When given by intramuscular or subcutaneous administration, clinicians should also be aware that impaired perfusion in these patients may prevent complete absorption of the drug.  With repeated injections, an excessive amount may be absorbed suddenly if normal circulation is reestablished.', '3', 'Parke TJ, Nandi PR, Bird KJ, Jewkes DA "Profound hypotension following intravenous codeine phosphate: three case reports and some recommendations." Anaesthesia 47 (1992):  852-4|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982):  308-15|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Cox RG "Hypoxaemia and hypotension after intravenous codeine phosphate." Can J Anaesth 41 (1994):  1211-3|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51423, 18952, 'Fentanyl', 'Hypotension', 'Opiate agonists can induce vasodilation and significant hypotension, particularly when given in high dosages and/or by rapid intravenous administration.  Opiate analgesics cause vasodilatation that may exacerbate hypotension and hypoperfusion and, therefore, are contraindicated in circulatory shock.  At therapeutic analgesic dosages, ambulatory patients are more likely to experience dizziness and hypotension than patients who are confined to bed.  However, orthostatic hypotension may occur in supine patients upon rising.  Therapy with opiate agonists should be administered cautiously and initiated at reduced dosages in patients with hypovolemia, or a predisposition to hypotension.  When given by intramuscular or subcutaneous administration, clinicians should also be aware that impaired perfusion in these patients may prevent complete absorption of the drug.  With repeated injections, an excessive amount may be absorbed suddenly if normal circulation is reestablished.', '3', 'Parke TJ, Nandi PR, Bird KJ, Jewkes DA "Profound hypotension following intravenous codeine phosphate: three case reports and some recommendations." Anaesthesia 47 (1992):  852-4|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982):  308-15|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Cox RG "Hypoxaemia and hypotension after intravenous codeine phosphate." Can J Anaesth 41 (1994):  1211-3|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51424, 18953, 'Fentanyl', 'Hypotension', 'Opiate agonists can induce vasodilation and significant hypotension, particularly when given in high dosages and/or by rapid intravenous administration.  Opiate analgesics cause vasodilatation that may exacerbate hypotension and hypoperfusion and, therefore, are contraindicated in circulatory shock.  At therapeutic analgesic dosages, ambulatory patients are more likely to experience dizziness and hypotension than patients who are confined to bed.  However, orthostatic hypotension may occur in supine patients upon rising.  Therapy with opiate agonists should be administered cautiously and initiated at reduced dosages in patients with hypovolemia, or a predisposition to hypotension.  When given by intramuscular or subcutaneous administration, clinicians should also be aware that impaired perfusion in these patients may prevent complete absorption of the drug.  With repeated injections, an excessive amount may be absorbed suddenly if normal circulation is reestablished.', '3', 'Parke TJ, Nandi PR, Bird KJ, Jewkes DA "Profound hypotension following intravenous codeine phosphate: three case reports and some recommendations." Anaesthesia 47 (1992):  852-4|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982):  308-15|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Cox RG "Hypoxaemia and hypotension after intravenous codeine phosphate." Can J Anaesth 41 (1994):  1211-3|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51425, 18955, 'Fentanyl', 'Hypotension', 'Opiate agonists can induce vasodilation and significant hypotension, particularly when given in high dosages and/or by rapid intravenous administration.  Opiate analgesics cause vasodilatation that may exacerbate hypotension and hypoperfusion and, therefore, are contraindicated in circulatory shock.  At therapeutic analgesic dosages, ambulatory patients are more likely to experience dizziness and hypotension than patients who are confined to bed.  However, orthostatic hypotension may occur in supine patients upon rising.  Therapy with opiate agonists should be administered cautiously and initiated at reduced dosages in patients with hypovolemia, or a predisposition to hypotension.  When given by intramuscular or subcutaneous administration, clinicians should also be aware that impaired perfusion in these patients may prevent complete absorption of the drug.  With repeated injections, an excessive amount may be absorbed suddenly if normal circulation is reestablished.', '3', 'Parke TJ, Nandi PR, Bird KJ, Jewkes DA "Profound hypotension following intravenous codeine phosphate: three case reports and some recommendations." Anaesthesia 47 (1992):  852-4|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982):  308-15|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Cox RG "Hypoxaemia and hypotension after intravenous codeine phosphate." Can J Anaesth 41 (1994):  1211-3|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51426, 30532, 'Fentanyl', 'Hypotension', 'Opiate agonists can induce vasodilation and significant hypotension, particularly when given in high dosages and/or by rapid intravenous administration.  Opiate analgesics cause vasodilatation that may exacerbate hypotension and hypoperfusion and, therefore, are contraindicated in circulatory shock.  At therapeutic analgesic dosages, ambulatory patients are more likely to experience dizziness and hypotension than patients who are confined to bed.  However, orthostatic hypotension may occur in supine patients upon rising.  Therapy with opiate agonists should be administered cautiously and initiated at reduced dosages in patients with hypovolemia, or a predisposition to hypotension.  When given by intramuscular or subcutaneous administration, clinicians should also be aware that impaired perfusion in these patients may prevent complete absorption of the drug.  With repeated injections, an excessive amount may be absorbed suddenly if normal circulation is reestablished.', '3', 'Parke TJ, Nandi PR, Bird KJ, Jewkes DA "Profound hypotension following intravenous codeine phosphate: three case reports and some recommendations." Anaesthesia 47 (1992):  852-4|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982):  308-15|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Cox RG "Hypoxaemia and hypotension after intravenous codeine phosphate." Can J Anaesth 41 (1994):  1211-3|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51427, 4802, 'Fentanyl', 'Intracranial Hypertension', 'The hypoventilation associated with administration of opiate agonists, particularly by the intravenous route, can induce cerebral hypoxia and vasodilatation with resultant increase in intracranial pressure.  Opiate agonists should not be used in patients with suspected or known head injury or increased intracranial pressure.  Also, clinicians treating such patients should be aware that opiate agonists may interfere with the evaluation of CNS function, especially with respect to consciousness levels, respiratory status, and pupillary changes.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51428, 13291, 'Fentanyl', 'Intracranial Hypertension', 'The hypoventilation associated with administration of opiate agonists, particularly by the intravenous route, can induce cerebral hypoxia and vasodilatation with resultant increase in intracranial pressure.  Opiate agonists should not be used in patients with suspected or known head injury or increased intracranial pressure.  Also, clinicians treating such patients should be aware that opiate agonists may interfere with the evaluation of CNS function, especially with respect to consciousness levels, respiratory status, and pupillary changes.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51429, 13292, 'Fentanyl', 'Intracranial Hypertension', 'The hypoventilation associated with administration of opiate agonists, particularly by the intravenous route, can induce cerebral hypoxia and vasodilatation with resultant increase in intracranial pressure.  Opiate agonists should not be used in patients with suspected or known head injury or increased intracranial pressure.  Also, clinicians treating such patients should be aware that opiate agonists may interfere with the evaluation of CNS function, especially with respect to consciousness levels, respiratory status, and pupillary changes.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51430, 17981, 'Fentanyl', 'Intracranial Hypertension', 'The hypoventilation associated with administration of opiate agonists, particularly by the intravenous route, can induce cerebral hypoxia and vasodilatation with resultant increase in intracranial pressure.  Opiate agonists should not be used in patients with suspected or known head injury or increased intracranial pressure.  Also, clinicians treating such patients should be aware that opiate agonists may interfere with the evaluation of CNS function, especially with respect to consciousness levels, respiratory status, and pupillary changes.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51431, 17982, 'Fentanyl', 'Intracranial Hypertension', 'The hypoventilation associated with administration of opiate agonists, particularly by the intravenous route, can induce cerebral hypoxia and vasodilatation with resultant increase in intracranial pressure.  Opiate agonists should not be used in patients with suspected or known head injury or increased intracranial pressure.  Also, clinicians treating such patients should be aware that opiate agonists may interfere with the evaluation of CNS function, especially with respect to consciousness levels, respiratory status, and pupillary changes.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51432, 17983, 'Fentanyl', 'Intracranial Hypertension', 'The hypoventilation associated with administration of opiate agonists, particularly by the intravenous route, can induce cerebral hypoxia and vasodilatation with resultant increase in intracranial pressure.  Opiate agonists should not be used in patients with suspected or known head injury or increased intracranial pressure.  Also, clinicians treating such patients should be aware that opiate agonists may interfere with the evaluation of CNS function, especially with respect to consciousness levels, respiratory status, and pupillary changes.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51433, 17984, 'Fentanyl', 'Intracranial Hypertension', 'The hypoventilation associated with administration of opiate agonists, particularly by the intravenous route, can induce cerebral hypoxia and vasodilatation with resultant increase in intracranial pressure.  Opiate agonists should not be used in patients with suspected or known head injury or increased intracranial pressure.  Also, clinicians treating such patients should be aware that opiate agonists may interfere with the evaluation of CNS function, especially with respect to consciousness levels, respiratory status, and pupillary changes.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51434, 17985, 'Fentanyl', 'Intracranial Hypertension', 'The hypoventilation associated with administration of opiate agonists, particularly by the intravenous route, can induce cerebral hypoxia and vasodilatation with resultant increase in intracranial pressure.  Opiate agonists should not be used in patients with suspected or known head injury or increased intracranial pressure.  Also, clinicians treating such patients should be aware that opiate agonists may interfere with the evaluation of CNS function, especially with respect to consciousness levels, respiratory status, and pupillary changes.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51435, 18952, 'Fentanyl', 'Intracranial Hypertension', 'The hypoventilation associated with administration of opiate agonists, particularly by the intravenous route, can induce cerebral hypoxia and vasodilatation with resultant increase in intracranial pressure.  Opiate agonists should not be used in patients with suspected or known head injury or increased intracranial pressure.  Also, clinicians treating such patients should be aware that opiate agonists may interfere with the evaluation of CNS function, especially with respect to consciousness levels, respiratory status, and pupillary changes.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51436, 18953, 'Fentanyl', 'Intracranial Hypertension', 'The hypoventilation associated with administration of opiate agonists, particularly by the intravenous route, can induce cerebral hypoxia and vasodilatation with resultant increase in intracranial pressure.  Opiate agonists should not be used in patients with suspected or known head injury or increased intracranial pressure.  Also, clinicians treating such patients should be aware that opiate agonists may interfere with the evaluation of CNS function, especially with respect to consciousness levels, respiratory status, and pupillary changes.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51437, 18955, 'Fentanyl', 'Intracranial Hypertension', 'The hypoventilation associated with administration of opiate agonists, particularly by the intravenous route, can induce cerebral hypoxia and vasodilatation with resultant increase in intracranial pressure.  Opiate agonists should not be used in patients with suspected or known head injury or increased intracranial pressure.  Also, clinicians treating such patients should be aware that opiate agonists may interfere with the evaluation of CNS function, especially with respect to consciousness levels, respiratory status, and pupillary changes.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51438, 30532, 'Fentanyl', 'Intracranial Hypertension', 'The hypoventilation associated with administration of opiate agonists, particularly by the intravenous route, can induce cerebral hypoxia and vasodilatation with resultant increase in intracranial pressure.  Opiate agonists should not be used in patients with suspected or known head injury or increased intracranial pressure.  Also, clinicians treating such patients should be aware that opiate agonists may interfere with the evaluation of CNS function, especially with respect to consciousness levels, respiratory status, and pupillary changes.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51439, 4802, 'Fentanyl', 'Respiratory Insufficiency', 'Opiate agonists may produce significant central nervous system and respiratory depression of varying duration, particularly when given in high dosages and/or by rapid intravenous administration.  Apnea may result from decreased respiratory drive as well as increased airway resistance, and rigidity of respiratory muscles may occur during rapid IV administration or when these agents are used in the induction of anesthesia.  At therapeutic analgesic dosages, the respiratory effects are usually not clinically important except in patients with preexisting pulmonary impairment.  Therapy with opiate agonists should be avoided or administered with extreme caution and initiated at reduced dosages in patients with severe CNS depression; sleep apnea; hypoxia, anoxia, or hypercapnia; upper airway obstruction; chronic pulmonary insufficiency; a limited ventilatory reserve; or other respiratory disorders.  In the presence of excessive respiratory secretions, the use of opiate agonists may also be problematic because they decrease ciliary activity and reduce the cough reflex.  Caution is also advised in patients who may be at increased risk for respiratory depression, such as comatose patients or those with head injury, intracranial lesions, or intracranial hypertension.  Clinical monitoring of pulmonary function is recommended, and equipment for resuscitation should be immediately available if parenteral or neuraxial routes are used.  Naloxone may be administered to reverse clinically significant respiratory depression, which may be prolonged depending on the opioid agent, cumulative dose, and route of administration.', '3', 'Redpath JB, Pleuvry BJ "Double-blind comparison of the respiratory and sedative effects of codeine phosphate and (+/-)-glaucine phosphate in human volunteers." Br J Clin Pharmacol 14 (1982):  555-8|Rigg JR, Ilsley AH, Vedig AE "Relationship of ventilatory depression to steady-state blood pethidine concentrations." Br J Anaesth 53 (1981):  613-9|Samuels SI, Rabinov W "Difficulty reversing drug-induced coma in a patient with sleep apnea." Anesth Analg 65 (1986):  1222-4|Elloway R, Sherman S, Maas L, et al. "Meperidine-induced bronchospasm." Gastrointest Endosc 38 (1992):  93|Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|Bigler D, Eriksen J, Christensen CB "Prolonged respiratory depression caused by slow release morphine." Lancet 06/30/84 (1984):  1477|Covington EC, Gonsalves-Ebrahim L, Currie KO, et al. "Severe respiratory depression from patient-controlled analgesia in renal failure." Psychosomatics 30 (1989):  226-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sackner MA "Effects of hydrocodone bitartrate on breathing pattern of patients with chronic obstructive pulmonary disease and restrictive lung disease." Mt Sinai J Med 51 (1984):  222-6|Comstock MK, Carter JG, Moyers JR, Stevens WC "Rigidity and hypercarbia associated with high dose fentanyl induction of anesthesia." Anesth Analg 60 (1981):  362-3|Eisenach JC "Respiratory depression following intrathecal opioids." Anesthesiology 75 (1991):  712|Palmer CM "Early respiratory depression following intrathecal fentanyl-morphine combination." Anesthesiology 74 (1991):  1153-5|Brockway MS, Noble DW, Sharwood-Smith GH, McClure JH "Profound respiratory depression after extradural fentanyl." Br J Anaesth 64 (1990):  243-5|Harper MH, Hickey RF, Cromwell TH, Linwood S "The magnitude and duration of respiratory depression produced by fentanyl and fentanyl plus droperidol in man." J Pharmacol Exp Ther 199 (1976):  464-8|Varrassi G, Celleno D, Capogna G, et al. "Ventilatory effects of subarachnoid fentanyl in the elderly." Anaesthesia 47 (1992):  558-62|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Ogawa K, Iranami H, Yoshiyama T, Maeda H, Hatano Y "Severe respiratory depression after epidural morphine in a patient with myotonic dystrophy." Can J Anaesth 40 (1993):  968-70|Noble DW, Morrison LM, Brockway MS, Mcclure JH "Respiratory depression after extradural fentanyl." Br J Anaesth 72 (1994):  251|Houghton IT, Aun CST, Wong YC, Chan K, Lau JTF, Oh TE "The respiratory depressant effect of morphine - a comparative study in three ethnic groups." Anaesthesia 49 (1994):  197-201|Jackson FW "Fentanyl and the wooden chest." Gastroenterology 106 (1994):  820-1|Etches RC "Respiratory depression associated with patient-controlled analgesia - a review of eight cases." Can J Anaesth 41 (1994):  125-32|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Sandler AN, Baxter AD, Katz J, Samson B, Friedlander M, Norman P, Koren G, Roger S, Hull K, Klein J "A double-blind, placebo-controlled trial of transdermal fentanyl after abdominal hysterectomy: analgesic, respiratory, and pharmacokinetic effects." Anesthesiology 81 (1994):  1169-80|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Hudson RJ "Apnoea and unconsciousness after apparent recovery from alfentanil- supplemented anaesthesia." Can J Anaesth 37 (1990):  255-7|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|Morley AD "Profound respiratory depression with morphine patient-controlled analgesia in an elderly patient." Anaesth Intensive Care 24 (1996):  287|Amin HM, Sopchak AM, Esposito BF, Henson LG, Batenhorst RL, Fox AW, Camporesi EM "Naloxone-induced and spontaneous reversal of depressed ventilatory responses to hypoxia during and after continuous infusion of remifentanil or alfentanil." J Pharmacol Exp Ther 274 (1995):  34-9|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51440, 13291, 'Fentanyl', 'Respiratory Insufficiency', 'Opiate agonists may produce significant central nervous system and respiratory depression of varying duration, particularly when given in high dosages and/or by rapid intravenous administration.  Apnea may result from decreased respiratory drive as well as increased airway resistance, and rigidity of respiratory muscles may occur during rapid IV administration or when these agents are used in the induction of anesthesia.  At therapeutic analgesic dosages, the respiratory effects are usually not clinically important except in patients with preexisting pulmonary impairment.  Therapy with opiate agonists should be avoided or administered with extreme caution and initiated at reduced dosages in patients with severe CNS depression; sleep apnea; hypoxia, anoxia, or hypercapnia; upper airway obstruction; chronic pulmonary insufficiency; a limited ventilatory reserve; or other respiratory disorders.  In the presence of excessive respiratory secretions, the use of opiate agonists may also be problematic because they decrease ciliary activity and reduce the cough reflex.  Caution is also advised in patients who may be at increased risk for respiratory depression, such as comatose patients or those with head injury, intracranial lesions, or intracranial hypertension.  Clinical monitoring of pulmonary function is recommended, and equipment for resuscitation should be immediately available if parenteral or neuraxial routes are used.  Naloxone may be administered to reverse clinically significant respiratory depression, which may be prolonged depending on the opioid agent, cumulative dose, and route of administration.', '3', 'Redpath JB, Pleuvry BJ "Double-blind comparison of the respiratory and sedative effects of codeine phosphate and (+/-)-glaucine phosphate in human volunteers." Br J Clin Pharmacol 14 (1982):  555-8|Rigg JR, Ilsley AH, Vedig AE "Relationship of ventilatory depression to steady-state blood pethidine concentrations." Br J Anaesth 53 (1981):  613-9|Samuels SI, Rabinov W "Difficulty reversing drug-induced coma in a patient with sleep apnea." Anesth Analg 65 (1986):  1222-4|Elloway R, Sherman S, Maas L, et al. "Meperidine-induced bronchospasm." Gastrointest Endosc 38 (1992):  93|Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|Bigler D, Eriksen J, Christensen CB "Prolonged respiratory depression caused by slow release morphine." Lancet 06/30/84 (1984):  1477|Covington EC, Gonsalves-Ebrahim L, Currie KO, et al. "Severe respiratory depression from patient-controlled analgesia in renal failure." Psychosomatics 30 (1989):  226-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sackner MA "Effects of hydrocodone bitartrate on breathing pattern of patients with chronic obstructive pulmonary disease and restrictive lung disease." Mt Sinai J Med 51 (1984):  222-6|Comstock MK, Carter JG, Moyers JR, Stevens WC "Rigidity and hypercarbia associated with high dose fentanyl induction of anesthesia." Anesth Analg 60 (1981):  362-3|Eisenach JC "Respiratory depression following intrathecal opioids." Anesthesiology 75 (1991):  712|Palmer CM "Early respiratory depression following intrathecal fentanyl-morphine combination." Anesthesiology 74 (1991):  1153-5|Brockway MS, Noble DW, Sharwood-Smith GH, McClure JH "Profound respiratory depression after extradural fentanyl." Br J Anaesth 64 (1990):  243-5|Harper MH, Hickey RF, Cromwell TH, Linwood S "The magnitude and duration of respiratory depression produced by fentanyl and fentanyl plus droperidol in man." J Pharmacol Exp Ther 199 (1976):  464-8|Varrassi G, Celleno D, Capogna G, et al. "Ventilatory effects of subarachnoid fentanyl in the elderly." Anaesthesia 47 (1992):  558-62|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Ogawa K, Iranami H, Yoshiyama T, Maeda H, Hatano Y "Severe respiratory depression after epidural morphine in a patient with myotonic dystrophy." Can J Anaesth 40 (1993):  968-70|Noble DW, Morrison LM, Brockway MS, Mcclure JH "Respiratory depression after extradural fentanyl." Br J Anaesth 72 (1994):  251|Houghton IT, Aun CST, Wong YC, Chan K, Lau JTF, Oh TE "The respiratory depressant effect of morphine - a comparative study in three ethnic groups." Anaesthesia 49 (1994):  197-201|Jackson FW "Fentanyl and the wooden chest." Gastroenterology 106 (1994):  820-1|Etches RC "Respiratory depression associated with patient-controlled analgesia - a review of eight cases." Can J Anaesth 41 (1994):  125-32|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Sandler AN, Baxter AD, Katz J, Samson B, Friedlander M, Norman P, Koren G, Roger S, Hull K, Klein J "A double-blind, placebo-controlled trial of transdermal fentanyl after abdominal hysterectomy: analgesic, respiratory, and pharmacokinetic effects." Anesthesiology 81 (1994):  1169-80|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Hudson RJ "Apnoea and unconsciousness after apparent recovery from alfentanil- supplemented anaesthesia." Can J Anaesth 37 (1990):  255-7|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|Morley AD "Profound respiratory depression with morphine patient-controlled analgesia in an elderly patient." Anaesth Intensive Care 24 (1996):  287|Amin HM, Sopchak AM, Esposito BF, Henson LG, Batenhorst RL, Fox AW, Camporesi EM "Naloxone-induced and spontaneous reversal of depressed ventilatory responses to hypoxia during and after continuous infusion of remifentanil or alfentanil." J Pharmacol Exp Ther 274 (1995):  34-9|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51441, 13292, 'Fentanyl', 'Respiratory Insufficiency', 'Opiate agonists may produce significant central nervous system and respiratory depression of varying duration, particularly when given in high dosages and/or by rapid intravenous administration.  Apnea may result from decreased respiratory drive as well as increased airway resistance, and rigidity of respiratory muscles may occur during rapid IV administration or when these agents are used in the induction of anesthesia.  At therapeutic analgesic dosages, the respiratory effects are usually not clinically important except in patients with preexisting pulmonary impairment.  Therapy with opiate agonists should be avoided or administered with extreme caution and initiated at reduced dosages in patients with severe CNS depression; sleep apnea; hypoxia, anoxia, or hypercapnia; upper airway obstruction; chronic pulmonary insufficiency; a limited ventilatory reserve; or other respiratory disorders.  In the presence of excessive respiratory secretions, the use of opiate agonists may also be problematic because they decrease ciliary activity and reduce the cough reflex.  Caution is also advised in patients who may be at increased risk for respiratory depression, such as comatose patients or those with head injury, intracranial lesions, or intracranial hypertension.  Clinical monitoring of pulmonary function is recommended, and equipment for resuscitation should be immediately available if parenteral or neuraxial routes are used.  Naloxone may be administered to reverse clinically significant respiratory depression, which may be prolonged depending on the opioid agent, cumulative dose, and route of administration.', '3', 'Redpath JB, Pleuvry BJ "Double-blind comparison of the respiratory and sedative effects of codeine phosphate and (+/-)-glaucine phosphate in human volunteers." Br J Clin Pharmacol 14 (1982):  555-8|Rigg JR, Ilsley AH, Vedig AE "Relationship of ventilatory depression to steady-state blood pethidine concentrations." Br J Anaesth 53 (1981):  613-9|Samuels SI, Rabinov W "Difficulty reversing drug-induced coma in a patient with sleep apnea." Anesth Analg 65 (1986):  1222-4|Elloway R, Sherman S, Maas L, et al. "Meperidine-induced bronchospasm." Gastrointest Endosc 38 (1992):  93|Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|Bigler D, Eriksen J, Christensen CB "Prolonged respiratory depression caused by slow release morphine." Lancet 06/30/84 (1984):  1477|Covington EC, Gonsalves-Ebrahim L, Currie KO, et al. "Severe respiratory depression from patient-controlled analgesia in renal failure." Psychosomatics 30 (1989):  226-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sackner MA "Effects of hydrocodone bitartrate on breathing pattern of patients with chronic obstructive pulmonary disease and restrictive lung disease." Mt Sinai J Med 51 (1984):  222-6|Comstock MK, Carter JG, Moyers JR, Stevens WC "Rigidity and hypercarbia associated with high dose fentanyl induction of anesthesia." Anesth Analg 60 (1981):  362-3|Eisenach JC "Respiratory depression following intrathecal opioids." Anesthesiology 75 (1991):  712|Palmer CM "Early respiratory depression following intrathecal fentanyl-morphine combination." Anesthesiology 74 (1991):  1153-5|Brockway MS, Noble DW, Sharwood-Smith GH, McClure JH "Profound respiratory depression after extradural fentanyl." Br J Anaesth 64 (1990):  243-5|Harper MH, Hickey RF, Cromwell TH, Linwood S "The magnitude and duration of respiratory depression produced by fentanyl and fentanyl plus droperidol in man." J Pharmacol Exp Ther 199 (1976):  464-8|Varrassi G, Celleno D, Capogna G, et al. "Ventilatory effects of subarachnoid fentanyl in the elderly." Anaesthesia 47 (1992):  558-62|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Ogawa K, Iranami H, Yoshiyama T, Maeda H, Hatano Y "Severe respiratory depression after epidural morphine in a patient with myotonic dystrophy." Can J Anaesth 40 (1993):  968-70|Noble DW, Morrison LM, Brockway MS, Mcclure JH "Respiratory depression after extradural fentanyl." Br J Anaesth 72 (1994):  251|Houghton IT, Aun CST, Wong YC, Chan K, Lau JTF, Oh TE "The respiratory depressant effect of morphine - a comparative study in three ethnic groups." Anaesthesia 49 (1994):  197-201|Jackson FW "Fentanyl and the wooden chest." Gastroenterology 106 (1994):  820-1|Etches RC "Respiratory depression associated with patient-controlled analgesia - a review of eight cases." Can J Anaesth 41 (1994):  125-32|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Sandler AN, Baxter AD, Katz J, Samson B, Friedlander M, Norman P, Koren G, Roger S, Hull K, Klein J "A double-blind, placebo-controlled trial of transdermal fentanyl after abdominal hysterectomy: analgesic, respiratory, and pharmacokinetic effects." Anesthesiology 81 (1994):  1169-80|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Hudson RJ "Apnoea and unconsciousness after apparent recovery from alfentanil- supplemented anaesthesia." Can J Anaesth 37 (1990):  255-7|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|Morley AD "Profound respiratory depression with morphine patient-controlled analgesia in an elderly patient." Anaesth Intensive Care 24 (1996):  287|Amin HM, Sopchak AM, Esposito BF, Henson LG, Batenhorst RL, Fox AW, Camporesi EM "Naloxone-induced and spontaneous reversal of depressed ventilatory responses to hypoxia during and after continuous infusion of remifentanil or alfentanil." J Pharmacol Exp Ther 274 (1995):  34-9|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51442, 17981, 'Fentanyl', 'Respiratory Insufficiency', 'Opiate agonists may produce significant central nervous system and respiratory depression of varying duration, particularly when given in high dosages and/or by rapid intravenous administration.  Apnea may result from decreased respiratory drive as well as increased airway resistance, and rigidity of respiratory muscles may occur during rapid IV administration or when these agents are used in the induction of anesthesia.  At therapeutic analgesic dosages, the respiratory effects are usually not clinically important except in patients with preexisting pulmonary impairment.  Therapy with opiate agonists should be avoided or administered with extreme caution and initiated at reduced dosages in patients with severe CNS depression; sleep apnea; hypoxia, anoxia, or hypercapnia; upper airway obstruction; chronic pulmonary insufficiency; a limited ventilatory reserve; or other respiratory disorders.  In the presence of excessive respiratory secretions, the use of opiate agonists may also be problematic because they decrease ciliary activity and reduce the cough reflex.  Caution is also advised in patients who may be at increased risk for respiratory depression, such as comatose patients or those with head injury, intracranial lesions, or intracranial hypertension.  Clinical monitoring of pulmonary function is recommended, and equipment for resuscitation should be immediately available if parenteral or neuraxial routes are used.  Naloxone may be administered to reverse clinically significant respiratory depression, which may be prolonged depending on the opioid agent, cumulative dose, and route of administration.', '3', 'Redpath JB, Pleuvry BJ "Double-blind comparison of the respiratory and sedative effects of codeine phosphate and (+/-)-glaucine phosphate in human volunteers." Br J Clin Pharmacol 14 (1982):  555-8|Rigg JR, Ilsley AH, Vedig AE "Relationship of ventilatory depression to steady-state blood pethidine concentrations." Br J Anaesth 53 (1981):  613-9|Samuels SI, Rabinov W "Difficulty reversing drug-induced coma in a patient with sleep apnea." Anesth Analg 65 (1986):  1222-4|Elloway R, Sherman S, Maas L, et al. "Meperidine-induced bronchospasm." Gastrointest Endosc 38 (1992):  93|Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|Bigler D, Eriksen J, Christensen CB "Prolonged respiratory depression caused by slow release morphine." Lancet 06/30/84 (1984):  1477|Covington EC, Gonsalves-Ebrahim L, Currie KO, et al. "Severe respiratory depression from patient-controlled analgesia in renal failure." Psychosomatics 30 (1989):  226-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sackner MA "Effects of hydrocodone bitartrate on breathing pattern of patients with chronic obstructive pulmonary disease and restrictive lung disease." Mt Sinai J Med 51 (1984):  222-6|Comstock MK, Carter JG, Moyers JR, Stevens WC "Rigidity and hypercarbia associated with high dose fentanyl induction of anesthesia." Anesth Analg 60 (1981):  362-3|Eisenach JC "Respiratory depression following intrathecal opioids." Anesthesiology 75 (1991):  712|Palmer CM "Early respiratory depression following intrathecal fentanyl-morphine combination." Anesthesiology 74 (1991):  1153-5|Brockway MS, Noble DW, Sharwood-Smith GH, McClure JH "Profound respiratory depression after extradural fentanyl." Br J Anaesth 64 (1990):  243-5|Harper MH, Hickey RF, Cromwell TH, Linwood S "The magnitude and duration of respiratory depression produced by fentanyl and fentanyl plus droperidol in man." J Pharmacol Exp Ther 199 (1976):  464-8|Varrassi G, Celleno D, Capogna G, et al. "Ventilatory effects of subarachnoid fentanyl in the elderly." Anaesthesia 47 (1992):  558-62|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Ogawa K, Iranami H, Yoshiyama T, Maeda H, Hatano Y "Severe respiratory depression after epidural morphine in a patient with myotonic dystrophy." Can J Anaesth 40 (1993):  968-70|Noble DW, Morrison LM, Brockway MS, Mcclure JH "Respiratory depression after extradural fentanyl." Br J Anaesth 72 (1994):  251|Houghton IT, Aun CST, Wong YC, Chan K, Lau JTF, Oh TE "The respiratory depressant effect of morphine - a comparative study in three ethnic groups." Anaesthesia 49 (1994):  197-201|Jackson FW "Fentanyl and the wooden chest." Gastroenterology 106 (1994):  820-1|Etches RC "Respiratory depression associated with patient-controlled analgesia - a review of eight cases." Can J Anaesth 41 (1994):  125-32|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Sandler AN, Baxter AD, Katz J, Samson B, Friedlander M, Norman P, Koren G, Roger S, Hull K, Klein J "A double-blind, placebo-controlled trial of transdermal fentanyl after abdominal hysterectomy: analgesic, respiratory, and pharmacokinetic effects." Anesthesiology 81 (1994):  1169-80|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Hudson RJ "Apnoea and unconsciousness after apparent recovery from alfentanil- supplemented anaesthesia." Can J Anaesth 37 (1990):  255-7|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|Morley AD "Profound respiratory depression with morphine patient-controlled analgesia in an elderly patient." Anaesth Intensive Care 24 (1996):  287|Amin HM, Sopchak AM, Esposito BF, Henson LG, Batenhorst RL, Fox AW, Camporesi EM "Naloxone-induced and spontaneous reversal of depressed ventilatory responses to hypoxia during and after continuous infusion of remifentanil or alfentanil." J Pharmacol Exp Ther 274 (1995):  34-9|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51443, 17982, 'Fentanyl', 'Respiratory Insufficiency', 'Opiate agonists may produce significant central nervous system and respiratory depression of varying duration, particularly when given in high dosages and/or by rapid intravenous administration.  Apnea may result from decreased respiratory drive as well as increased airway resistance, and rigidity of respiratory muscles may occur during rapid IV administration or when these agents are used in the induction of anesthesia.  At therapeutic analgesic dosages, the respiratory effects are usually not clinically important except in patients with preexisting pulmonary impairment.  Therapy with opiate agonists should be avoided or administered with extreme caution and initiated at reduced dosages in patients with severe CNS depression; sleep apnea; hypoxia, anoxia, or hypercapnia; upper airway obstruction; chronic pulmonary insufficiency; a limited ventilatory reserve; or other respiratory disorders.  In the presence of excessive respiratory secretions, the use of opiate agonists may also be problematic because they decrease ciliary activity and reduce the cough reflex.  Caution is also advised in patients who may be at increased risk for respiratory depression, such as comatose patients or those with head injury, intracranial lesions, or intracranial hypertension.  Clinical monitoring of pulmonary function is recommended, and equipment for resuscitation should be immediately available if parenteral or neuraxial routes are used.  Naloxone may be administered to reverse clinically significant respiratory depression, which may be prolonged depending on the opioid agent, cumulative dose, and route of administration.', '3', 'Redpath JB, Pleuvry BJ "Double-blind comparison of the respiratory and sedative effects of codeine phosphate and (+/-)-glaucine phosphate in human volunteers." Br J Clin Pharmacol 14 (1982):  555-8|Rigg JR, Ilsley AH, Vedig AE "Relationship of ventilatory depression to steady-state blood pethidine concentrations." Br J Anaesth 53 (1981):  613-9|Samuels SI, Rabinov W "Difficulty reversing drug-induced coma in a patient with sleep apnea." Anesth Analg 65 (1986):  1222-4|Elloway R, Sherman S, Maas L, et al. "Meperidine-induced bronchospasm." Gastrointest Endosc 38 (1992):  93|Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|Bigler D, Eriksen J, Christensen CB "Prolonged respiratory depression caused by slow release morphine." Lancet 06/30/84 (1984):  1477|Covington EC, Gonsalves-Ebrahim L, Currie KO, et al. "Severe respiratory depression from patient-controlled analgesia in renal failure." Psychosomatics 30 (1989):  226-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sackner MA "Effects of hydrocodone bitartrate on breathing pattern of patients with chronic obstructive pulmonary disease and restrictive lung disease." Mt Sinai J Med 51 (1984):  222-6|Comstock MK, Carter JG, Moyers JR, Stevens WC "Rigidity and hypercarbia associated with high dose fentanyl induction of anesthesia." Anesth Analg 60 (1981):  362-3|Eisenach JC "Respiratory depression following intrathecal opioids." Anesthesiology 75 (1991):  712|Palmer CM "Early respiratory depression following intrathecal fentanyl-morphine combination." Anesthesiology 74 (1991):  1153-5|Brockway MS, Noble DW, Sharwood-Smith GH, McClure JH "Profound respiratory depression after extradural fentanyl." Br J Anaesth 64 (1990):  243-5|Harper MH, Hickey RF, Cromwell TH, Linwood S "The magnitude and duration of respiratory depression produced by fentanyl and fentanyl plus droperidol in man." J Pharmacol Exp Ther 199 (1976):  464-8|Varrassi G, Celleno D, Capogna G, et al. "Ventilatory effects of subarachnoid fentanyl in the elderly." Anaesthesia 47 (1992):  558-62|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Ogawa K, Iranami H, Yoshiyama T, Maeda H, Hatano Y "Severe respiratory depression after epidural morphine in a patient with myotonic dystrophy." Can J Anaesth 40 (1993):  968-70|Noble DW, Morrison LM, Brockway MS, Mcclure JH "Respiratory depression after extradural fentanyl." Br J Anaesth 72 (1994):  251|Houghton IT, Aun CST, Wong YC, Chan K, Lau JTF, Oh TE "The respiratory depressant effect of morphine - a comparative study in three ethnic groups." Anaesthesia 49 (1994):  197-201|Jackson FW "Fentanyl and the wooden chest." Gastroenterology 106 (1994):  820-1|Etches RC "Respiratory depression associated with patient-controlled analgesia - a review of eight cases." Can J Anaesth 41 (1994):  125-32|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Sandler AN, Baxter AD, Katz J, Samson B, Friedlander M, Norman P, Koren G, Roger S, Hull K, Klein J "A double-blind, placebo-controlled trial of transdermal fentanyl after abdominal hysterectomy: analgesic, respiratory, and pharmacokinetic effects." Anesthesiology 81 (1994):  1169-80|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Hudson RJ "Apnoea and unconsciousness after apparent recovery from alfentanil- supplemented anaesthesia." Can J Anaesth 37 (1990):  255-7|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|Morley AD "Profound respiratory depression with morphine patient-controlled analgesia in an elderly patient." Anaesth Intensive Care 24 (1996):  287|Amin HM, Sopchak AM, Esposito BF, Henson LG, Batenhorst RL, Fox AW, Camporesi EM "Naloxone-induced and spontaneous reversal of depressed ventilatory responses to hypoxia during and after continuous infusion of remifentanil or alfentanil." J Pharmacol Exp Ther 274 (1995):  34-9|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51444, 17983, 'Fentanyl', 'Respiratory Insufficiency', 'Opiate agonists may produce significant central nervous system and respiratory depression of varying duration, particularly when given in high dosages and/or by rapid intravenous administration.  Apnea may result from decreased respiratory drive as well as increased airway resistance, and rigidity of respiratory muscles may occur during rapid IV administration or when these agents are used in the induction of anesthesia.  At therapeutic analgesic dosages, the respiratory effects are usually not clinically important except in patients with preexisting pulmonary impairment.  Therapy with opiate agonists should be avoided or administered with extreme caution and initiated at reduced dosages in patients with severe CNS depression; sleep apnea; hypoxia, anoxia, or hypercapnia; upper airway obstruction; chronic pulmonary insufficiency; a limited ventilatory reserve; or other respiratory disorders.  In the presence of excessive respiratory secretions, the use of opiate agonists may also be problematic because they decrease ciliary activity and reduce the cough reflex.  Caution is also advised in patients who may be at increased risk for respiratory depression, such as comatose patients or those with head injury, intracranial lesions, or intracranial hypertension.  Clinical monitoring of pulmonary function is recommended, and equipment for resuscitation should be immediately available if parenteral or neuraxial routes are used.  Naloxone may be administered to reverse clinically significant respiratory depression, which may be prolonged depending on the opioid agent, cumulative dose, and route of administration.', '3', 'Redpath JB, Pleuvry BJ "Double-blind comparison of the respiratory and sedative effects of codeine phosphate and (+/-)-glaucine phosphate in human volunteers." Br J Clin Pharmacol 14 (1982):  555-8|Rigg JR, Ilsley AH, Vedig AE "Relationship of ventilatory depression to steady-state blood pethidine concentrations." Br J Anaesth 53 (1981):  613-9|Samuels SI, Rabinov W "Difficulty reversing drug-induced coma in a patient with sleep apnea." Anesth Analg 65 (1986):  1222-4|Elloway R, Sherman S, Maas L, et al. "Meperidine-induced bronchospasm." Gastrointest Endosc 38 (1992):  93|Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|Bigler D, Eriksen J, Christensen CB "Prolonged respiratory depression caused by slow release morphine." Lancet 06/30/84 (1984):  1477|Covington EC, Gonsalves-Ebrahim L, Currie KO, et al. "Severe respiratory depression from patient-controlled analgesia in renal failure." Psychosomatics 30 (1989):  226-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sackner MA "Effects of hydrocodone bitartrate on breathing pattern of patients with chronic obstructive pulmonary disease and restrictive lung disease." Mt Sinai J Med 51 (1984):  222-6|Comstock MK, Carter JG, Moyers JR, Stevens WC "Rigidity and hypercarbia associated with high dose fentanyl induction of anesthesia." Anesth Analg 60 (1981):  362-3|Eisenach JC "Respiratory depression following intrathecal opioids." Anesthesiology 75 (1991):  712|Palmer CM "Early respiratory depression following intrathecal fentanyl-morphine combination." Anesthesiology 74 (1991):  1153-5|Brockway MS, Noble DW, Sharwood-Smith GH, McClure JH "Profound respiratory depression after extradural fentanyl." Br J Anaesth 64 (1990):  243-5|Harper MH, Hickey RF, Cromwell TH, Linwood S "The magnitude and duration of respiratory depression produced by fentanyl and fentanyl plus droperidol in man." J Pharmacol Exp Ther 199 (1976):  464-8|Varrassi G, Celleno D, Capogna G, et al. "Ventilatory effects of subarachnoid fentanyl in the elderly." Anaesthesia 47 (1992):  558-62|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Ogawa K, Iranami H, Yoshiyama T, Maeda H, Hatano Y "Severe respiratory depression after epidural morphine in a patient with myotonic dystrophy." Can J Anaesth 40 (1993):  968-70|Noble DW, Morrison LM, Brockway MS, Mcclure JH "Respiratory depression after extradural fentanyl." Br J Anaesth 72 (1994):  251|Houghton IT, Aun CST, Wong YC, Chan K, Lau JTF, Oh TE "The respiratory depressant effect of morphine - a comparative study in three ethnic groups." Anaesthesia 49 (1994):  197-201|Jackson FW "Fentanyl and the wooden chest." Gastroenterology 106 (1994):  820-1|Etches RC "Respiratory depression associated with patient-controlled analgesia - a review of eight cases." Can J Anaesth 41 (1994):  125-32|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Sandler AN, Baxter AD, Katz J, Samson B, Friedlander M, Norman P, Koren G, Roger S, Hull K, Klein J "A double-blind, placebo-controlled trial of transdermal fentanyl after abdominal hysterectomy: analgesic, respiratory, and pharmacokinetic effects." Anesthesiology 81 (1994):  1169-80|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Hudson RJ "Apnoea and unconsciousness after apparent recovery from alfentanil- supplemented anaesthesia." Can J Anaesth 37 (1990):  255-7|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|Morley AD "Profound respiratory depression with morphine patient-controlled analgesia in an elderly patient." Anaesth Intensive Care 24 (1996):  287|Amin HM, Sopchak AM, Esposito BF, Henson LG, Batenhorst RL, Fox AW, Camporesi EM "Naloxone-induced and spontaneous reversal of depressed ventilatory responses to hypoxia during and after continuous infusion of remifentanil or alfentanil." J Pharmacol Exp Ther 274 (1995):  34-9|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51445, 17984, 'Fentanyl', 'Respiratory Insufficiency', 'Opiate agonists may produce significant central nervous system and respiratory depression of varying duration, particularly when given in high dosages and/or by rapid intravenous administration.  Apnea may result from decreased respiratory drive as well as increased airway resistance, and rigidity of respiratory muscles may occur during rapid IV administration or when these agents are used in the induction of anesthesia.  At therapeutic analgesic dosages, the respiratory effects are usually not clinically important except in patients with preexisting pulmonary impairment.  Therapy with opiate agonists should be avoided or administered with extreme caution and initiated at reduced dosages in patients with severe CNS depression; sleep apnea; hypoxia, anoxia, or hypercapnia; upper airway obstruction; chronic pulmonary insufficiency; a limited ventilatory reserve; or other respiratory disorders.  In the presence of excessive respiratory secretions, the use of opiate agonists may also be problematic because they decrease ciliary activity and reduce the cough reflex.  Caution is also advised in patients who may be at increased risk for respiratory depression, such as comatose patients or those with head injury, intracranial lesions, or intracranial hypertension.  Clinical monitoring of pulmonary function is recommended, and equipment for resuscitation should be immediately available if parenteral or neuraxial routes are used.  Naloxone may be administered to reverse clinically significant respiratory depression, which may be prolonged depending on the opioid agent, cumulative dose, and route of administration.', '3', 'Redpath JB, Pleuvry BJ "Double-blind comparison of the respiratory and sedative effects of codeine phosphate and (+/-)-glaucine phosphate in human volunteers." Br J Clin Pharmacol 14 (1982):  555-8|Rigg JR, Ilsley AH, Vedig AE "Relationship of ventilatory depression to steady-state blood pethidine concentrations." Br J Anaesth 53 (1981):  613-9|Samuels SI, Rabinov W "Difficulty reversing drug-induced coma in a patient with sleep apnea." Anesth Analg 65 (1986):  1222-4|Elloway R, Sherman S, Maas L, et al. "Meperidine-induced bronchospasm." Gastrointest Endosc 38 (1992):  93|Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|Bigler D, Eriksen J, Christensen CB "Prolonged respiratory depression caused by slow release morphine." Lancet 06/30/84 (1984):  1477|Covington EC, Gonsalves-Ebrahim L, Currie KO, et al. "Severe respiratory depression from patient-controlled analgesia in renal failure." Psychosomatics 30 (1989):  226-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sackner MA "Effects of hydrocodone bitartrate on breathing pattern of patients with chronic obstructive pulmonary disease and restrictive lung disease." Mt Sinai J Med 51 (1984):  222-6|Comstock MK, Carter JG, Moyers JR, Stevens WC "Rigidity and hypercarbia associated with high dose fentanyl induction of anesthesia." Anesth Analg 60 (1981):  362-3|Eisenach JC "Respiratory depression following intrathecal opioids." Anesthesiology 75 (1991):  712|Palmer CM "Early respiratory depression following intrathecal fentanyl-morphine combination." Anesthesiology 74 (1991):  1153-5|Brockway MS, Noble DW, Sharwood-Smith GH, McClure JH "Profound respiratory depression after extradural fentanyl." Br J Anaesth 64 (1990):  243-5|Harper MH, Hickey RF, Cromwell TH, Linwood S "The magnitude and duration of respiratory depression produced by fentanyl and fentanyl plus droperidol in man." J Pharmacol Exp Ther 199 (1976):  464-8|Varrassi G, Celleno D, Capogna G, et al. "Ventilatory effects of subarachnoid fentanyl in the elderly." Anaesthesia 47 (1992):  558-62|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Ogawa K, Iranami H, Yoshiyama T, Maeda H, Hatano Y "Severe respiratory depression after epidural morphine in a patient with myotonic dystrophy." Can J Anaesth 40 (1993):  968-70|Noble DW, Morrison LM, Brockway MS, Mcclure JH "Respiratory depression after extradural fentanyl." Br J Anaesth 72 (1994):  251|Houghton IT, Aun CST, Wong YC, Chan K, Lau JTF, Oh TE "The respiratory depressant effect of morphine - a comparative study in three ethnic groups." Anaesthesia 49 (1994):  197-201|Jackson FW "Fentanyl and the wooden chest." Gastroenterology 106 (1994):  820-1|Etches RC "Respiratory depression associated with patient-controlled analgesia - a review of eight cases." Can J Anaesth 41 (1994):  125-32|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Sandler AN, Baxter AD, Katz J, Samson B, Friedlander M, Norman P, Koren G, Roger S, Hull K, Klein J "A double-blind, placebo-controlled trial of transdermal fentanyl after abdominal hysterectomy: analgesic, respiratory, and pharmacokinetic effects." Anesthesiology 81 (1994):  1169-80|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Hudson RJ "Apnoea and unconsciousness after apparent recovery from alfentanil- supplemented anaesthesia." Can J Anaesth 37 (1990):  255-7|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|Morley AD "Profound respiratory depression with morphine patient-controlled analgesia in an elderly patient." Anaesth Intensive Care 24 (1996):  287|Amin HM, Sopchak AM, Esposito BF, Henson LG, Batenhorst RL, Fox AW, Camporesi EM "Naloxone-induced and spontaneous reversal of depressed ventilatory responses to hypoxia during and after continuous infusion of remifentanil or alfentanil." J Pharmacol Exp Ther 274 (1995):  34-9|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51446, 17985, 'Fentanyl', 'Respiratory Insufficiency', 'Opiate agonists may produce significant central nervous system and respiratory depression of varying duration, particularly when given in high dosages and/or by rapid intravenous administration.  Apnea may result from decreased respiratory drive as well as increased airway resistance, and rigidity of respiratory muscles may occur during rapid IV administration or when these agents are used in the induction of anesthesia.  At therapeutic analgesic dosages, the respiratory effects are usually not clinically important except in patients with preexisting pulmonary impairment.  Therapy with opiate agonists should be avoided or administered with extreme caution and initiated at reduced dosages in patients with severe CNS depression; sleep apnea; hypoxia, anoxia, or hypercapnia; upper airway obstruction; chronic pulmonary insufficiency; a limited ventilatory reserve; or other respiratory disorders.  In the presence of excessive respiratory secretions, the use of opiate agonists may also be problematic because they decrease ciliary activity and reduce the cough reflex.  Caution is also advised in patients who may be at increased risk for respiratory depression, such as comatose patients or those with head injury, intracranial lesions, or intracranial hypertension.  Clinical monitoring of pulmonary function is recommended, and equipment for resuscitation should be immediately available if parenteral or neuraxial routes are used.  Naloxone may be administered to reverse clinically significant respiratory depression, which may be prolonged depending on the opioid agent, cumulative dose, and route of administration.', '3', 'Redpath JB, Pleuvry BJ "Double-blind comparison of the respiratory and sedative effects of codeine phosphate and (+/-)-glaucine phosphate in human volunteers." Br J Clin Pharmacol 14 (1982):  555-8|Rigg JR, Ilsley AH, Vedig AE "Relationship of ventilatory depression to steady-state blood pethidine concentrations." Br J Anaesth 53 (1981):  613-9|Samuels SI, Rabinov W "Difficulty reversing drug-induced coma in a patient with sleep apnea." Anesth Analg 65 (1986):  1222-4|Elloway R, Sherman S, Maas L, et al. "Meperidine-induced bronchospasm." Gastrointest Endosc 38 (1992):  93|Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|Bigler D, Eriksen J, Christensen CB "Prolonged respiratory depression caused by slow release morphine." Lancet 06/30/84 (1984):  1477|Covington EC, Gonsalves-Ebrahim L, Currie KO, et al. "Severe respiratory depression from patient-controlled analgesia in renal failure." Psychosomatics 30 (1989):  226-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sackner MA "Effects of hydrocodone bitartrate on breathing pattern of patients with chronic obstructive pulmonary disease and restrictive lung disease." Mt Sinai J Med 51 (1984):  222-6|Comstock MK, Carter JG, Moyers JR, Stevens WC "Rigidity and hypercarbia associated with high dose fentanyl induction of anesthesia." Anesth Analg 60 (1981):  362-3|Eisenach JC "Respiratory depression following intrathecal opioids." Anesthesiology 75 (1991):  712|Palmer CM "Early respiratory depression following intrathecal fentanyl-morphine combination." Anesthesiology 74 (1991):  1153-5|Brockway MS, Noble DW, Sharwood-Smith GH, McClure JH "Profound respiratory depression after extradural fentanyl." Br J Anaesth 64 (1990):  243-5|Harper MH, Hickey RF, Cromwell TH, Linwood S "The magnitude and duration of respiratory depression produced by fentanyl and fentanyl plus droperidol in man." J Pharmacol Exp Ther 199 (1976):  464-8|Varrassi G, Celleno D, Capogna G, et al. "Ventilatory effects of subarachnoid fentanyl in the elderly." Anaesthesia 47 (1992):  558-62|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Ogawa K, Iranami H, Yoshiyama T, Maeda H, Hatano Y "Severe respiratory depression after epidural morphine in a patient with myotonic dystrophy." Can J Anaesth 40 (1993):  968-70|Noble DW, Morrison LM, Brockway MS, Mcclure JH "Respiratory depression after extradural fentanyl." Br J Anaesth 72 (1994):  251|Houghton IT, Aun CST, Wong YC, Chan K, Lau JTF, Oh TE "The respiratory depressant effect of morphine - a comparative study in three ethnic groups." Anaesthesia 49 (1994):  197-201|Jackson FW "Fentanyl and the wooden chest." Gastroenterology 106 (1994):  820-1|Etches RC "Respiratory depression associated with patient-controlled analgesia - a review of eight cases." Can J Anaesth 41 (1994):  125-32|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Sandler AN, Baxter AD, Katz J, Samson B, Friedlander M, Norman P, Koren G, Roger S, Hull K, Klein J "A double-blind, placebo-controlled trial of transdermal fentanyl after abdominal hysterectomy: analgesic, respiratory, and pharmacokinetic effects." Anesthesiology 81 (1994):  1169-80|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Hudson RJ "Apnoea and unconsciousness after apparent recovery from alfentanil- supplemented anaesthesia." Can J Anaesth 37 (1990):  255-7|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|Morley AD "Profound respiratory depression with morphine patient-controlled analgesia in an elderly patient." Anaesth Intensive Care 24 (1996):  287|Amin HM, Sopchak AM, Esposito BF, Henson LG, Batenhorst RL, Fox AW, Camporesi EM "Naloxone-induced and spontaneous reversal of depressed ventilatory responses to hypoxia during and after continuous infusion of remifentanil or alfentanil." J Pharmacol Exp Ther 274 (1995):  34-9|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51447, 18952, 'Fentanyl', 'Respiratory Insufficiency', 'Opiate agonists may produce significant central nervous system and respiratory depression of varying duration, particularly when given in high dosages and/or by rapid intravenous administration.  Apnea may result from decreased respiratory drive as well as increased airway resistance, and rigidity of respiratory muscles may occur during rapid IV administration or when these agents are used in the induction of anesthesia.  At therapeutic analgesic dosages, the respiratory effects are usually not clinically important except in patients with preexisting pulmonary impairment.  Therapy with opiate agonists should be avoided or administered with extreme caution and initiated at reduced dosages in patients with severe CNS depression; sleep apnea; hypoxia, anoxia, or hypercapnia; upper airway obstruction; chronic pulmonary insufficiency; a limited ventilatory reserve; or other respiratory disorders.  In the presence of excessive respiratory secretions, the use of opiate agonists may also be problematic because they decrease ciliary activity and reduce the cough reflex.  Caution is also advised in patients who may be at increased risk for respiratory depression, such as comatose patients or those with head injury, intracranial lesions, or intracranial hypertension.  Clinical monitoring of pulmonary function is recommended, and equipment for resuscitation should be immediately available if parenteral or neuraxial routes are used.  Naloxone may be administered to reverse clinically significant respiratory depression, which may be prolonged depending on the opioid agent, cumulative dose, and route of administration.', '3', 'Redpath JB, Pleuvry BJ "Double-blind comparison of the respiratory and sedative effects of codeine phosphate and (+/-)-glaucine phosphate in human volunteers." Br J Clin Pharmacol 14 (1982):  555-8|Rigg JR, Ilsley AH, Vedig AE "Relationship of ventilatory depression to steady-state blood pethidine concentrations." Br J Anaesth 53 (1981):  613-9|Samuels SI, Rabinov W "Difficulty reversing drug-induced coma in a patient with sleep apnea." Anesth Analg 65 (1986):  1222-4|Elloway R, Sherman S, Maas L, et al. "Meperidine-induced bronchospasm." Gastrointest Endosc 38 (1992):  93|Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|Bigler D, Eriksen J, Christensen CB "Prolonged respiratory depression caused by slow release morphine." Lancet 06/30/84 (1984):  1477|Covington EC, Gonsalves-Ebrahim L, Currie KO, et al. "Severe respiratory depression from patient-controlled analgesia in renal failure." Psychosomatics 30 (1989):  226-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sackner MA "Effects of hydrocodone bitartrate on breathing pattern of patients with chronic obstructive pulmonary disease and restrictive lung disease." Mt Sinai J Med 51 (1984):  222-6|Comstock MK, Carter JG, Moyers JR, Stevens WC "Rigidity and hypercarbia associated with high dose fentanyl induction of anesthesia." Anesth Analg 60 (1981):  362-3|Eisenach JC "Respiratory depression following intrathecal opioids." Anesthesiology 75 (1991):  712|Palmer CM "Early respiratory depression following intrathecal fentanyl-morphine combination." Anesthesiology 74 (1991):  1153-5|Brockway MS, Noble DW, Sharwood-Smith GH, McClure JH "Profound respiratory depression after extradural fentanyl." Br J Anaesth 64 (1990):  243-5|Harper MH, Hickey RF, Cromwell TH, Linwood S "The magnitude and duration of respiratory depression produced by fentanyl and fentanyl plus droperidol in man." J Pharmacol Exp Ther 199 (1976):  464-8|Varrassi G, Celleno D, Capogna G, et al. "Ventilatory effects of subarachnoid fentanyl in the elderly." Anaesthesia 47 (1992):  558-62|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Ogawa K, Iranami H, Yoshiyama T, Maeda H, Hatano Y "Severe respiratory depression after epidural morphine in a patient with myotonic dystrophy." Can J Anaesth 40 (1993):  968-70|Noble DW, Morrison LM, Brockway MS, Mcclure JH "Respiratory depression after extradural fentanyl." Br J Anaesth 72 (1994):  251|Houghton IT, Aun CST, Wong YC, Chan K, Lau JTF, Oh TE "The respiratory depressant effect of morphine - a comparative study in three ethnic groups." Anaesthesia 49 (1994):  197-201|Jackson FW "Fentanyl and the wooden chest." Gastroenterology 106 (1994):  820-1|Etches RC "Respiratory depression associated with patient-controlled analgesia - a review of eight cases." Can J Anaesth 41 (1994):  125-32|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Sandler AN, Baxter AD, Katz J, Samson B, Friedlander M, Norman P, Koren G, Roger S, Hull K, Klein J "A double-blind, placebo-controlled trial of transdermal fentanyl after abdominal hysterectomy: analgesic, respiratory, and pharmacokinetic effects." Anesthesiology 81 (1994):  1169-80|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Hudson RJ "Apnoea and unconsciousness after apparent recovery from alfentanil- supplemented anaesthesia." Can J Anaesth 37 (1990):  255-7|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|Morley AD "Profound respiratory depression with morphine patient-controlled analgesia in an elderly patient." Anaesth Intensive Care 24 (1996):  287|Amin HM, Sopchak AM, Esposito BF, Henson LG, Batenhorst RL, Fox AW, Camporesi EM "Naloxone-induced and spontaneous reversal of depressed ventilatory responses to hypoxia during and after continuous infusion of remifentanil or alfentanil." J Pharmacol Exp Ther 274 (1995):  34-9|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51448, 18953, 'Fentanyl', 'Respiratory Insufficiency', 'Opiate agonists may produce significant central nervous system and respiratory depression of varying duration, particularly when given in high dosages and/or by rapid intravenous administration.  Apnea may result from decreased respiratory drive as well as increased airway resistance, and rigidity of respiratory muscles may occur during rapid IV administration or when these agents are used in the induction of anesthesia.  At therapeutic analgesic dosages, the respiratory effects are usually not clinically important except in patients with preexisting pulmonary impairment.  Therapy with opiate agonists should be avoided or administered with extreme caution and initiated at reduced dosages in patients with severe CNS depression; sleep apnea; hypoxia, anoxia, or hypercapnia; upper airway obstruction; chronic pulmonary insufficiency; a limited ventilatory reserve; or other respiratory disorders.  In the presence of excessive respiratory secretions, the use of opiate agonists may also be problematic because they decrease ciliary activity and reduce the cough reflex.  Caution is also advised in patients who may be at increased risk for respiratory depression, such as comatose patients or those with head injury, intracranial lesions, or intracranial hypertension.  Clinical monitoring of pulmonary function is recommended, and equipment for resuscitation should be immediately available if parenteral or neuraxial routes are used.  Naloxone may be administered to reverse clinically significant respiratory depression, which may be prolonged depending on the opioid agent, cumulative dose, and route of administration.', '3', 'Redpath JB, Pleuvry BJ "Double-blind comparison of the respiratory and sedative effects of codeine phosphate and (+/-)-glaucine phosphate in human volunteers." Br J Clin Pharmacol 14 (1982):  555-8|Rigg JR, Ilsley AH, Vedig AE "Relationship of ventilatory depression to steady-state blood pethidine concentrations." Br J Anaesth 53 (1981):  613-9|Samuels SI, Rabinov W "Difficulty reversing drug-induced coma in a patient with sleep apnea." Anesth Analg 65 (1986):  1222-4|Elloway R, Sherman S, Maas L, et al. "Meperidine-induced bronchospasm." Gastrointest Endosc 38 (1992):  93|Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|Bigler D, Eriksen J, Christensen CB "Prolonged respiratory depression caused by slow release morphine." Lancet 06/30/84 (1984):  1477|Covington EC, Gonsalves-Ebrahim L, Currie KO, et al. "Severe respiratory depression from patient-controlled analgesia in renal failure." Psychosomatics 30 (1989):  226-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sackner MA "Effects of hydrocodone bitartrate on breathing pattern of patients with chronic obstructive pulmonary disease and restrictive lung disease." Mt Sinai J Med 51 (1984):  222-6|Comstock MK, Carter JG, Moyers JR, Stevens WC "Rigidity and hypercarbia associated with high dose fentanyl induction of anesthesia." Anesth Analg 60 (1981):  362-3|Eisenach JC "Respiratory depression following intrathecal opioids." Anesthesiology 75 (1991):  712|Palmer CM "Early respiratory depression following intrathecal fentanyl-morphine combination." Anesthesiology 74 (1991):  1153-5|Brockway MS, Noble DW, Sharwood-Smith GH, McClure JH "Profound respiratory depression after extradural fentanyl." Br J Anaesth 64 (1990):  243-5|Harper MH, Hickey RF, Cromwell TH, Linwood S "The magnitude and duration of respiratory depression produced by fentanyl and fentanyl plus droperidol in man." J Pharmacol Exp Ther 199 (1976):  464-8|Varrassi G, Celleno D, Capogna G, et al. "Ventilatory effects of subarachnoid fentanyl in the elderly." Anaesthesia 47 (1992):  558-62|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Ogawa K, Iranami H, Yoshiyama T, Maeda H, Hatano Y "Severe respiratory depression after epidural morphine in a patient with myotonic dystrophy." Can J Anaesth 40 (1993):  968-70|Noble DW, Morrison LM, Brockway MS, Mcclure JH "Respiratory depression after extradural fentanyl." Br J Anaesth 72 (1994):  251|Houghton IT, Aun CST, Wong YC, Chan K, Lau JTF, Oh TE "The respiratory depressant effect of morphine - a comparative study in three ethnic groups." Anaesthesia 49 (1994):  197-201|Jackson FW "Fentanyl and the wooden chest." Gastroenterology 106 (1994):  820-1|Etches RC "Respiratory depression associated with patient-controlled analgesia - a review of eight cases." Can J Anaesth 41 (1994):  125-32|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Sandler AN, Baxter AD, Katz J, Samson B, Friedlander M, Norman P, Koren G, Roger S, Hull K, Klein J "A double-blind, placebo-controlled trial of transdermal fentanyl after abdominal hysterectomy: analgesic, respiratory, and pharmacokinetic effects." Anesthesiology 81 (1994):  1169-80|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Hudson RJ "Apnoea and unconsciousness after apparent recovery from alfentanil- supplemented anaesthesia." Can J Anaesth 37 (1990):  255-7|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|Morley AD "Profound respiratory depression with morphine patient-controlled analgesia in an elderly patient." Anaesth Intensive Care 24 (1996):  287|Amin HM, Sopchak AM, Esposito BF, Henson LG, Batenhorst RL, Fox AW, Camporesi EM "Naloxone-induced and spontaneous reversal of depressed ventilatory responses to hypoxia during and after continuous infusion of remifentanil or alfentanil." J Pharmacol Exp Ther 274 (1995):  34-9|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51449, 18955, 'Fentanyl', 'Respiratory Insufficiency', 'Opiate agonists may produce significant central nervous system and respiratory depression of varying duration, particularly when given in high dosages and/or by rapid intravenous administration.  Apnea may result from decreased respiratory drive as well as increased airway resistance, and rigidity of respiratory muscles may occur during rapid IV administration or when these agents are used in the induction of anesthesia.  At therapeutic analgesic dosages, the respiratory effects are usually not clinically important except in patients with preexisting pulmonary impairment.  Therapy with opiate agonists should be avoided or administered with extreme caution and initiated at reduced dosages in patients with severe CNS depression; sleep apnea; hypoxia, anoxia, or hypercapnia; upper airway obstruction; chronic pulmonary insufficiency; a limited ventilatory reserve; or other respiratory disorders.  In the presence of excessive respiratory secretions, the use of opiate agonists may also be problematic because they decrease ciliary activity and reduce the cough reflex.  Caution is also advised in patients who may be at increased risk for respiratory depression, such as comatose patients or those with head injury, intracranial lesions, or intracranial hypertension.  Clinical monitoring of pulmonary function is recommended, and equipment for resuscitation should be immediately available if parenteral or neuraxial routes are used.  Naloxone may be administered to reverse clinically significant respiratory depression, which may be prolonged depending on the opioid agent, cumulative dose, and route of administration.', '3', 'Redpath JB, Pleuvry BJ "Double-blind comparison of the respiratory and sedative effects of codeine phosphate and (+/-)-glaucine phosphate in human volunteers." Br J Clin Pharmacol 14 (1982):  555-8|Rigg JR, Ilsley AH, Vedig AE "Relationship of ventilatory depression to steady-state blood pethidine concentrations." Br J Anaesth 53 (1981):  613-9|Samuels SI, Rabinov W "Difficulty reversing drug-induced coma in a patient with sleep apnea." Anesth Analg 65 (1986):  1222-4|Elloway R, Sherman S, Maas L, et al. "Meperidine-induced bronchospasm." Gastrointest Endosc 38 (1992):  93|Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|Bigler D, Eriksen J, Christensen CB "Prolonged respiratory depression caused by slow release morphine." Lancet 06/30/84 (1984):  1477|Covington EC, Gonsalves-Ebrahim L, Currie KO, et al. "Severe respiratory depression from patient-controlled analgesia in renal failure." Psychosomatics 30 (1989):  226-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sackner MA "Effects of hydrocodone bitartrate on breathing pattern of patients with chronic obstructive pulmonary disease and restrictive lung disease." Mt Sinai J Med 51 (1984):  222-6|Comstock MK, Carter JG, Moyers JR, Stevens WC "Rigidity and hypercarbia associated with high dose fentanyl induction of anesthesia." Anesth Analg 60 (1981):  362-3|Eisenach JC "Respiratory depression following intrathecal opioids." Anesthesiology 75 (1991):  712|Palmer CM "Early respiratory depression following intrathecal fentanyl-morphine combination." Anesthesiology 74 (1991):  1153-5|Brockway MS, Noble DW, Sharwood-Smith GH, McClure JH "Profound respiratory depression after extradural fentanyl." Br J Anaesth 64 (1990):  243-5|Harper MH, Hickey RF, Cromwell TH, Linwood S "The magnitude and duration of respiratory depression produced by fentanyl and fentanyl plus droperidol in man." J Pharmacol Exp Ther 199 (1976):  464-8|Varrassi G, Celleno D, Capogna G, et al. "Ventilatory effects of subarachnoid fentanyl in the elderly." Anaesthesia 47 (1992):  558-62|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Ogawa K, Iranami H, Yoshiyama T, Maeda H, Hatano Y "Severe respiratory depression after epidural morphine in a patient with myotonic dystrophy." Can J Anaesth 40 (1993):  968-70|Noble DW, Morrison LM, Brockway MS, Mcclure JH "Respiratory depression after extradural fentanyl." Br J Anaesth 72 (1994):  251|Houghton IT, Aun CST, Wong YC, Chan K, Lau JTF, Oh TE "The respiratory depressant effect of morphine - a comparative study in three ethnic groups." Anaesthesia 49 (1994):  197-201|Jackson FW "Fentanyl and the wooden chest." Gastroenterology 106 (1994):  820-1|Etches RC "Respiratory depression associated with patient-controlled analgesia - a review of eight cases." Can J Anaesth 41 (1994):  125-32|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Sandler AN, Baxter AD, Katz J, Samson B, Friedlander M, Norman P, Koren G, Roger S, Hull K, Klein J "A double-blind, placebo-controlled trial of transdermal fentanyl after abdominal hysterectomy: analgesic, respiratory, and pharmacokinetic effects." Anesthesiology 81 (1994):  1169-80|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Hudson RJ "Apnoea and unconsciousness after apparent recovery from alfentanil- supplemented anaesthesia." Can J Anaesth 37 (1990):  255-7|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|Morley AD "Profound respiratory depression with morphine patient-controlled analgesia in an elderly patient." Anaesth Intensive Care 24 (1996):  287|Amin HM, Sopchak AM, Esposito BF, Henson LG, Batenhorst RL, Fox AW, Camporesi EM "Naloxone-induced and spontaneous reversal of depressed ventilatory responses to hypoxia during and after continuous infusion of remifentanil or alfentanil." J Pharmacol Exp Ther 274 (1995):  34-9|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51450, 30532, 'Fentanyl', 'Respiratory Insufficiency', 'Opiate agonists may produce significant central nervous system and respiratory depression of varying duration, particularly when given in high dosages and/or by rapid intravenous administration.  Apnea may result from decreased respiratory drive as well as increased airway resistance, and rigidity of respiratory muscles may occur during rapid IV administration or when these agents are used in the induction of anesthesia.  At therapeutic analgesic dosages, the respiratory effects are usually not clinically important except in patients with preexisting pulmonary impairment.  Therapy with opiate agonists should be avoided or administered with extreme caution and initiated at reduced dosages in patients with severe CNS depression; sleep apnea; hypoxia, anoxia, or hypercapnia; upper airway obstruction; chronic pulmonary insufficiency; a limited ventilatory reserve; or other respiratory disorders.  In the presence of excessive respiratory secretions, the use of opiate agonists may also be problematic because they decrease ciliary activity and reduce the cough reflex.  Caution is also advised in patients who may be at increased risk for respiratory depression, such as comatose patients or those with head injury, intracranial lesions, or intracranial hypertension.  Clinical monitoring of pulmonary function is recommended, and equipment for resuscitation should be immediately available if parenteral or neuraxial routes are used.  Naloxone may be administered to reverse clinically significant respiratory depression, which may be prolonged depending on the opioid agent, cumulative dose, and route of administration.', '3', 'Redpath JB, Pleuvry BJ "Double-blind comparison of the respiratory and sedative effects of codeine phosphate and (+/-)-glaucine phosphate in human volunteers." Br J Clin Pharmacol 14 (1982):  555-8|Rigg JR, Ilsley AH, Vedig AE "Relationship of ventilatory depression to steady-state blood pethidine concentrations." Br J Anaesth 53 (1981):  613-9|Samuels SI, Rabinov W "Difficulty reversing drug-induced coma in a patient with sleep apnea." Anesth Analg 65 (1986):  1222-4|Elloway R, Sherman S, Maas L, et al. "Meperidine-induced bronchospasm." Gastrointest Endosc 38 (1992):  93|Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|Bigler D, Eriksen J, Christensen CB "Prolonged respiratory depression caused by slow release morphine." Lancet 06/30/84 (1984):  1477|Covington EC, Gonsalves-Ebrahim L, Currie KO, et al. "Severe respiratory depression from patient-controlled analgesia in renal failure." Psychosomatics 30 (1989):  226-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sackner MA "Effects of hydrocodone bitartrate on breathing pattern of patients with chronic obstructive pulmonary disease and restrictive lung disease." Mt Sinai J Med 51 (1984):  222-6|Comstock MK, Carter JG, Moyers JR, Stevens WC "Rigidity and hypercarbia associated with high dose fentanyl induction of anesthesia." Anesth Analg 60 (1981):  362-3|Eisenach JC "Respiratory depression following intrathecal opioids." Anesthesiology 75 (1991):  712|Palmer CM "Early respiratory depression following intrathecal fentanyl-morphine combination." Anesthesiology 74 (1991):  1153-5|Brockway MS, Noble DW, Sharwood-Smith GH, McClure JH "Profound respiratory depression after extradural fentanyl." Br J Anaesth 64 (1990):  243-5|Harper MH, Hickey RF, Cromwell TH, Linwood S "The magnitude and duration of respiratory depression produced by fentanyl and fentanyl plus droperidol in man." J Pharmacol Exp Ther 199 (1976):  464-8|Varrassi G, Celleno D, Capogna G, et al. "Ventilatory effects of subarachnoid fentanyl in the elderly." Anaesthesia 47 (1992):  558-62|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Ogawa K, Iranami H, Yoshiyama T, Maeda H, Hatano Y "Severe respiratory depression after epidural morphine in a patient with myotonic dystrophy." Can J Anaesth 40 (1993):  968-70|Noble DW, Morrison LM, Brockway MS, Mcclure JH "Respiratory depression after extradural fentanyl." Br J Anaesth 72 (1994):  251|Houghton IT, Aun CST, Wong YC, Chan K, Lau JTF, Oh TE "The respiratory depressant effect of morphine - a comparative study in three ethnic groups." Anaesthesia 49 (1994):  197-201|Jackson FW "Fentanyl and the wooden chest." Gastroenterology 106 (1994):  820-1|Etches RC "Respiratory depression associated with patient-controlled analgesia - a review of eight cases." Can J Anaesth 41 (1994):  125-32|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Sandler AN, Baxter AD, Katz J, Samson B, Friedlander M, Norman P, Koren G, Roger S, Hull K, Klein J "A double-blind, placebo-controlled trial of transdermal fentanyl after abdominal hysterectomy: analgesic, respiratory, and pharmacokinetic effects." Anesthesiology 81 (1994):  1169-80|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Hudson RJ "Apnoea and unconsciousness after apparent recovery from alfentanil- supplemented anaesthesia." Can J Anaesth 37 (1990):  255-7|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|Morley AD "Profound respiratory depression with morphine patient-controlled analgesia in an elderly patient." Anaesth Intensive Care 24 (1996):  287|Amin HM, Sopchak AM, Esposito BF, Henson LG, Batenhorst RL, Fox AW, Camporesi EM "Naloxone-induced and spontaneous reversal of depressed ventilatory responses to hypoxia during and after continuous infusion of remifentanil or alfentanil." J Pharmacol Exp Ther 274 (1995):  34-9|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51451, 4802, 'Fentanyl', 'Fever', 'The release of fentanyl from the transdermal system may be temperature-dependent.  According to the manufacturer, a body temperature of 40 C (102 F) may theoretically increase serum fentanyl concentrations by approximately one-third due to increased drug release and skin permeability.  Therapy with fentanyl transdermal systems should be administered cautiously and possibly at reduced dosages in patients with a high fever.', '2', '"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51452, 13291, 'Fentanyl', 'Fever', 'The release of fentanyl from the transdermal system may be temperature-dependent.  According to the manufacturer, a body temperature of 40 C (102 F) may theoretically increase serum fentanyl concentrations by approximately one-third due to increased drug release and skin permeability.  Therapy with fentanyl transdermal systems should be administered cautiously and possibly at reduced dosages in patients with a high fever.', '2', '"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51453, 13292, 'Fentanyl', 'Fever', 'The release of fentanyl from the transdermal system may be temperature-dependent.  According to the manufacturer, a body temperature of 40 C (102 F) may theoretically increase serum fentanyl concentrations by approximately one-third due to increased drug release and skin permeability.  Therapy with fentanyl transdermal systems should be administered cautiously and possibly at reduced dosages in patients with a high fever.', '2', '"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51454, 17981, 'Fentanyl', 'Fever', 'The release of fentanyl from the transdermal system may be temperature-dependent.  According to the manufacturer, a body temperature of 40 C (102 F) may theoretically increase serum fentanyl concentrations by approximately one-third due to increased drug release and skin permeability.  Therapy with fentanyl transdermal systems should be administered cautiously and possibly at reduced dosages in patients with a high fever.', '2', '"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51455, 17982, 'Fentanyl', 'Fever', 'The release of fentanyl from the transdermal system may be temperature-dependent.  According to the manufacturer, a body temperature of 40 C (102 F) may theoretically increase serum fentanyl concentrations by approximately one-third due to increased drug release and skin permeability.  Therapy with fentanyl transdermal systems should be administered cautiously and possibly at reduced dosages in patients with a high fever.', '2', '"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51456, 17983, 'Fentanyl', 'Fever', 'The release of fentanyl from the transdermal system may be temperature-dependent.  According to the manufacturer, a body temperature of 40 C (102 F) may theoretically increase serum fentanyl concentrations by approximately one-third due to increased drug release and skin permeability.  Therapy with fentanyl transdermal systems should be administered cautiously and possibly at reduced dosages in patients with a high fever.', '2', '"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51457, 17984, 'Fentanyl', 'Fever', 'The release of fentanyl from the transdermal system may be temperature-dependent.  According to the manufacturer, a body temperature of 40 C (102 F) may theoretically increase serum fentanyl concentrations by approximately one-third due to increased drug release and skin permeability.  Therapy with fentanyl transdermal systems should be administered cautiously and possibly at reduced dosages in patients with a high fever.', '2', '"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51458, 17985, 'Fentanyl', 'Fever', 'The release of fentanyl from the transdermal system may be temperature-dependent.  According to the manufacturer, a body temperature of 40 C (102 F) may theoretically increase serum fentanyl concentrations by approximately one-third due to increased drug release and skin permeability.  Therapy with fentanyl transdermal systems should be administered cautiously and possibly at reduced dosages in patients with a high fever.', '2', '"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51459, 18952, 'Fentanyl', 'Fever', 'The release of fentanyl from the transdermal system may be temperature-dependent.  According to the manufacturer, a body temperature of 40 C (102 F) may theoretically increase serum fentanyl concentrations by approximately one-third due to increased drug release and skin permeability.  Therapy with fentanyl transdermal systems should be administered cautiously and possibly at reduced dosages in patients with a high fever.', '2', '"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51460, 18953, 'Fentanyl', 'Fever', 'The release of fentanyl from the transdermal system may be temperature-dependent.  According to the manufacturer, a body temperature of 40 C (102 F) may theoretically increase serum fentanyl concentrations by approximately one-third due to increased drug release and skin permeability.  Therapy with fentanyl transdermal systems should be administered cautiously and possibly at reduced dosages in patients with a high fever.', '2', '"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51461, 18955, 'Fentanyl', 'Fever', 'The release of fentanyl from the transdermal system may be temperature-dependent.  According to the manufacturer, a body temperature of 40 C (102 F) may theoretically increase serum fentanyl concentrations by approximately one-third due to increased drug release and skin permeability.  Therapy with fentanyl transdermal systems should be administered cautiously and possibly at reduced dosages in patients with a high fever.', '2', '"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51462, 30532, 'Fentanyl', 'Fever', 'The release of fentanyl from the transdermal system may be temperature-dependent.  According to the manufacturer, a body temperature of 40 C (102 F) may theoretically increase serum fentanyl concentrations by approximately one-third due to increased drug release and skin permeability.  Therapy with fentanyl transdermal systems should be administered cautiously and possibly at reduced dosages in patients with a high fever.', '2', '"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51463, 4802, 'Fentanyl', 'Adrenal Insufficiency', 'Patients with Addison''s disease may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  Conversely, these agents may cause or potentiate adrenal insufficiency.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with adrenocortical insufficiency.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Olinvyk (oliceridine)." Trevena Inc  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51464, 13291, 'Fentanyl', 'Adrenal Insufficiency', 'Patients with Addison''s disease may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  Conversely, these agents may cause or potentiate adrenal insufficiency.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with adrenocortical insufficiency.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Olinvyk (oliceridine)." Trevena Inc  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51465, 13292, 'Fentanyl', 'Adrenal Insufficiency', 'Patients with Addison''s disease may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  Conversely, these agents may cause or potentiate adrenal insufficiency.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with adrenocortical insufficiency.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Olinvyk (oliceridine)." Trevena Inc  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51466, 17981, 'Fentanyl', 'Adrenal Insufficiency', 'Patients with Addison''s disease may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  Conversely, these agents may cause or potentiate adrenal insufficiency.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with adrenocortical insufficiency.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Olinvyk (oliceridine)." Trevena Inc  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51467, 17982, 'Fentanyl', 'Adrenal Insufficiency', 'Patients with Addison''s disease may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  Conversely, these agents may cause or potentiate adrenal insufficiency.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with adrenocortical insufficiency.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Olinvyk (oliceridine)." Trevena Inc  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51468, 17983, 'Fentanyl', 'Adrenal Insufficiency', 'Patients with Addison''s disease may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  Conversely, these agents may cause or potentiate adrenal insufficiency.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with adrenocortical insufficiency.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Olinvyk (oliceridine)." Trevena Inc  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51469, 17984, 'Fentanyl', 'Adrenal Insufficiency', 'Patients with Addison''s disease may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  Conversely, these agents may cause or potentiate adrenal insufficiency.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with adrenocortical insufficiency.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Olinvyk (oliceridine)." Trevena Inc  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51470, 17985, 'Fentanyl', 'Adrenal Insufficiency', 'Patients with Addison''s disease may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  Conversely, these agents may cause or potentiate adrenal insufficiency.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with adrenocortical insufficiency.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Olinvyk (oliceridine)." Trevena Inc  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51471, 18952, 'Fentanyl', 'Adrenal Insufficiency', 'Patients with Addison''s disease may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  Conversely, these agents may cause or potentiate adrenal insufficiency.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with adrenocortical insufficiency.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Olinvyk (oliceridine)." Trevena Inc  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51472, 18953, 'Fentanyl', 'Adrenal Insufficiency', 'Patients with Addison''s disease may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  Conversely, these agents may cause or potentiate adrenal insufficiency.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with adrenocortical insufficiency.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Olinvyk (oliceridine)." Trevena Inc  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51473, 18955, 'Fentanyl', 'Adrenal Insufficiency', 'Patients with Addison''s disease may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  Conversely, these agents may cause or potentiate adrenal insufficiency.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with adrenocortical insufficiency.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Olinvyk (oliceridine)." Trevena Inc  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51474, 30532, 'Fentanyl', 'Adrenal Insufficiency', 'Patients with Addison''s disease may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  Conversely, these agents may cause or potentiate adrenal insufficiency.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with adrenocortical insufficiency.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Olinvyk (oliceridine)." Trevena Inc  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51475, 4802, 'Fentanyl', 'Gallbladder Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the biliary tract, which can lead to spasm and elevated biliary tract pressure, especially in the sphincter of Oddi.  Biliary effects appear to be the most pronounced with morphine, although they do not always occur with therapeutic doses.  Therapy with opioids should be administered cautiously in patients with biliary or gallbladder disease.', '2', 'Jones RM, Fiddian-Green R, Knight PR "Narcotic-induced choledochoduodenal sphincter spasm reversed by glucagon." Anesth Analg 59 (1980):  946-7|Hey VM, Ostick DG, Mazumder JK, Lord WD "Pethidine, metoclopramide and the gastro-oesophageal sphincter." Anaesthesia 36 (1981):  173-6|Lang DW, Pilon RN "Naloxone reversal of morphine-induced biliary colic." Anesth Analg 59 (1980):  619-20|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|McCammon RL, Viegas OJ, Stoelting RK, Dryden GE "Naloxone reversal of choledochoduodenal sphincter spasm associated with narcotic administration." Anesthesiology 48 (1978):  437|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Zsigmond EK, Vieira ZEG, Duarte B, Renigers SA, Hirota K "Double-blind placebo-controlled ultrasonographic confirmation of constriction of the common bile duct by morphine." Int J Clin Pharmacol Ther Toxicol 31 (1993):  506-9|Ford MJ, Kellett RJ, Busuttil A, Finlayson ND "Dextropropoxyphene and jaundice." Br Med J 2 (1977):  674|Daikos GK, Kosmidis JC "Propoxyphene jaundice." JAMA 232 (1975):  835|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51476, 13291, 'Fentanyl', 'Gallbladder Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the biliary tract, which can lead to spasm and elevated biliary tract pressure, especially in the sphincter of Oddi.  Biliary effects appear to be the most pronounced with morphine, although they do not always occur with therapeutic doses.  Therapy with opioids should be administered cautiously in patients with biliary or gallbladder disease.', '2', 'Jones RM, Fiddian-Green R, Knight PR "Narcotic-induced choledochoduodenal sphincter spasm reversed by glucagon." Anesth Analg 59 (1980):  946-7|Hey VM, Ostick DG, Mazumder JK, Lord WD "Pethidine, metoclopramide and the gastro-oesophageal sphincter." Anaesthesia 36 (1981):  173-6|Lang DW, Pilon RN "Naloxone reversal of morphine-induced biliary colic." Anesth Analg 59 (1980):  619-20|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|McCammon RL, Viegas OJ, Stoelting RK, Dryden GE "Naloxone reversal of choledochoduodenal sphincter spasm associated with narcotic administration." Anesthesiology 48 (1978):  437|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Zsigmond EK, Vieira ZEG, Duarte B, Renigers SA, Hirota K "Double-blind placebo-controlled ultrasonographic confirmation of constriction of the common bile duct by morphine." Int J Clin Pharmacol Ther Toxicol 31 (1993):  506-9|Ford MJ, Kellett RJ, Busuttil A, Finlayson ND "Dextropropoxyphene and jaundice." Br Med J 2 (1977):  674|Daikos GK, Kosmidis JC "Propoxyphene jaundice." JAMA 232 (1975):  835|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51477, 13292, 'Fentanyl', 'Gallbladder Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the biliary tract, which can lead to spasm and elevated biliary tract pressure, especially in the sphincter of Oddi.  Biliary effects appear to be the most pronounced with morphine, although they do not always occur with therapeutic doses.  Therapy with opioids should be administered cautiously in patients with biliary or gallbladder disease.', '2', 'Jones RM, Fiddian-Green R, Knight PR "Narcotic-induced choledochoduodenal sphincter spasm reversed by glucagon." Anesth Analg 59 (1980):  946-7|Hey VM, Ostick DG, Mazumder JK, Lord WD "Pethidine, metoclopramide and the gastro-oesophageal sphincter." Anaesthesia 36 (1981):  173-6|Lang DW, Pilon RN "Naloxone reversal of morphine-induced biliary colic." Anesth Analg 59 (1980):  619-20|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|McCammon RL, Viegas OJ, Stoelting RK, Dryden GE "Naloxone reversal of choledochoduodenal sphincter spasm associated with narcotic administration." Anesthesiology 48 (1978):  437|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Zsigmond EK, Vieira ZEG, Duarte B, Renigers SA, Hirota K "Double-blind placebo-controlled ultrasonographic confirmation of constriction of the common bile duct by morphine." Int J Clin Pharmacol Ther Toxicol 31 (1993):  506-9|Ford MJ, Kellett RJ, Busuttil A, Finlayson ND "Dextropropoxyphene and jaundice." Br Med J 2 (1977):  674|Daikos GK, Kosmidis JC "Propoxyphene jaundice." JAMA 232 (1975):  835|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51478, 17981, 'Fentanyl', 'Gallbladder Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the biliary tract, which can lead to spasm and elevated biliary tract pressure, especially in the sphincter of Oddi.  Biliary effects appear to be the most pronounced with morphine, although they do not always occur with therapeutic doses.  Therapy with opioids should be administered cautiously in patients with biliary or gallbladder disease.', '2', 'Jones RM, Fiddian-Green R, Knight PR "Narcotic-induced choledochoduodenal sphincter spasm reversed by glucagon." Anesth Analg 59 (1980):  946-7|Hey VM, Ostick DG, Mazumder JK, Lord WD "Pethidine, metoclopramide and the gastro-oesophageal sphincter." Anaesthesia 36 (1981):  173-6|Lang DW, Pilon RN "Naloxone reversal of morphine-induced biliary colic." Anesth Analg 59 (1980):  619-20|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|McCammon RL, Viegas OJ, Stoelting RK, Dryden GE "Naloxone reversal of choledochoduodenal sphincter spasm associated with narcotic administration." Anesthesiology 48 (1978):  437|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Zsigmond EK, Vieira ZEG, Duarte B, Renigers SA, Hirota K "Double-blind placebo-controlled ultrasonographic confirmation of constriction of the common bile duct by morphine." Int J Clin Pharmacol Ther Toxicol 31 (1993):  506-9|Ford MJ, Kellett RJ, Busuttil A, Finlayson ND "Dextropropoxyphene and jaundice." Br Med J 2 (1977):  674|Daikos GK, Kosmidis JC "Propoxyphene jaundice." JAMA 232 (1975):  835|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51479, 17982, 'Fentanyl', 'Gallbladder Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the biliary tract, which can lead to spasm and elevated biliary tract pressure, especially in the sphincter of Oddi.  Biliary effects appear to be the most pronounced with morphine, although they do not always occur with therapeutic doses.  Therapy with opioids should be administered cautiously in patients with biliary or gallbladder disease.', '2', 'Jones RM, Fiddian-Green R, Knight PR "Narcotic-induced choledochoduodenal sphincter spasm reversed by glucagon." Anesth Analg 59 (1980):  946-7|Hey VM, Ostick DG, Mazumder JK, Lord WD "Pethidine, metoclopramide and the gastro-oesophageal sphincter." Anaesthesia 36 (1981):  173-6|Lang DW, Pilon RN "Naloxone reversal of morphine-induced biliary colic." Anesth Analg 59 (1980):  619-20|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|McCammon RL, Viegas OJ, Stoelting RK, Dryden GE "Naloxone reversal of choledochoduodenal sphincter spasm associated with narcotic administration." Anesthesiology 48 (1978):  437|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Zsigmond EK, Vieira ZEG, Duarte B, Renigers SA, Hirota K "Double-blind placebo-controlled ultrasonographic confirmation of constriction of the common bile duct by morphine." Int J Clin Pharmacol Ther Toxicol 31 (1993):  506-9|Ford MJ, Kellett RJ, Busuttil A, Finlayson ND "Dextropropoxyphene and jaundice." Br Med J 2 (1977):  674|Daikos GK, Kosmidis JC "Propoxyphene jaundice." JAMA 232 (1975):  835|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51480, 17983, 'Fentanyl', 'Gallbladder Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the biliary tract, which can lead to spasm and elevated biliary tract pressure, especially in the sphincter of Oddi.  Biliary effects appear to be the most pronounced with morphine, although they do not always occur with therapeutic doses.  Therapy with opioids should be administered cautiously in patients with biliary or gallbladder disease.', '2', 'Jones RM, Fiddian-Green R, Knight PR "Narcotic-induced choledochoduodenal sphincter spasm reversed by glucagon." Anesth Analg 59 (1980):  946-7|Hey VM, Ostick DG, Mazumder JK, Lord WD "Pethidine, metoclopramide and the gastro-oesophageal sphincter." Anaesthesia 36 (1981):  173-6|Lang DW, Pilon RN "Naloxone reversal of morphine-induced biliary colic." Anesth Analg 59 (1980):  619-20|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|McCammon RL, Viegas OJ, Stoelting RK, Dryden GE "Naloxone reversal of choledochoduodenal sphincter spasm associated with narcotic administration." Anesthesiology 48 (1978):  437|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Zsigmond EK, Vieira ZEG, Duarte B, Renigers SA, Hirota K "Double-blind placebo-controlled ultrasonographic confirmation of constriction of the common bile duct by morphine." Int J Clin Pharmacol Ther Toxicol 31 (1993):  506-9|Ford MJ, Kellett RJ, Busuttil A, Finlayson ND "Dextropropoxyphene and jaundice." Br Med J 2 (1977):  674|Daikos GK, Kosmidis JC "Propoxyphene jaundice." JAMA 232 (1975):  835|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51481, 17984, 'Fentanyl', 'Gallbladder Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the biliary tract, which can lead to spasm and elevated biliary tract pressure, especially in the sphincter of Oddi.  Biliary effects appear to be the most pronounced with morphine, although they do not always occur with therapeutic doses.  Therapy with opioids should be administered cautiously in patients with biliary or gallbladder disease.', '2', 'Jones RM, Fiddian-Green R, Knight PR "Narcotic-induced choledochoduodenal sphincter spasm reversed by glucagon." Anesth Analg 59 (1980):  946-7|Hey VM, Ostick DG, Mazumder JK, Lord WD "Pethidine, metoclopramide and the gastro-oesophageal sphincter." Anaesthesia 36 (1981):  173-6|Lang DW, Pilon RN "Naloxone reversal of morphine-induced biliary colic." Anesth Analg 59 (1980):  619-20|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|McCammon RL, Viegas OJ, Stoelting RK, Dryden GE "Naloxone reversal of choledochoduodenal sphincter spasm associated with narcotic administration." Anesthesiology 48 (1978):  437|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Zsigmond EK, Vieira ZEG, Duarte B, Renigers SA, Hirota K "Double-blind placebo-controlled ultrasonographic confirmation of constriction of the common bile duct by morphine." Int J Clin Pharmacol Ther Toxicol 31 (1993):  506-9|Ford MJ, Kellett RJ, Busuttil A, Finlayson ND "Dextropropoxyphene and jaundice." Br Med J 2 (1977):  674|Daikos GK, Kosmidis JC "Propoxyphene jaundice." JAMA 232 (1975):  835|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51482, 17985, 'Fentanyl', 'Gallbladder Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the biliary tract, which can lead to spasm and elevated biliary tract pressure, especially in the sphincter of Oddi.  Biliary effects appear to be the most pronounced with morphine, although they do not always occur with therapeutic doses.  Therapy with opioids should be administered cautiously in patients with biliary or gallbladder disease.', '2', 'Jones RM, Fiddian-Green R, Knight PR "Narcotic-induced choledochoduodenal sphincter spasm reversed by glucagon." Anesth Analg 59 (1980):  946-7|Hey VM, Ostick DG, Mazumder JK, Lord WD "Pethidine, metoclopramide and the gastro-oesophageal sphincter." Anaesthesia 36 (1981):  173-6|Lang DW, Pilon RN "Naloxone reversal of morphine-induced biliary colic." Anesth Analg 59 (1980):  619-20|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|McCammon RL, Viegas OJ, Stoelting RK, Dryden GE "Naloxone reversal of choledochoduodenal sphincter spasm associated with narcotic administration." Anesthesiology 48 (1978):  437|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Zsigmond EK, Vieira ZEG, Duarte B, Renigers SA, Hirota K "Double-blind placebo-controlled ultrasonographic confirmation of constriction of the common bile duct by morphine." Int J Clin Pharmacol Ther Toxicol 31 (1993):  506-9|Ford MJ, Kellett RJ, Busuttil A, Finlayson ND "Dextropropoxyphene and jaundice." Br Med J 2 (1977):  674|Daikos GK, Kosmidis JC "Propoxyphene jaundice." JAMA 232 (1975):  835|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51483, 18952, 'Fentanyl', 'Gallbladder Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the biliary tract, which can lead to spasm and elevated biliary tract pressure, especially in the sphincter of Oddi.  Biliary effects appear to be the most pronounced with morphine, although they do not always occur with therapeutic doses.  Therapy with opioids should be administered cautiously in patients with biliary or gallbladder disease.', '2', 'Jones RM, Fiddian-Green R, Knight PR "Narcotic-induced choledochoduodenal sphincter spasm reversed by glucagon." Anesth Analg 59 (1980):  946-7|Hey VM, Ostick DG, Mazumder JK, Lord WD "Pethidine, metoclopramide and the gastro-oesophageal sphincter." Anaesthesia 36 (1981):  173-6|Lang DW, Pilon RN "Naloxone reversal of morphine-induced biliary colic." Anesth Analg 59 (1980):  619-20|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|McCammon RL, Viegas OJ, Stoelting RK, Dryden GE "Naloxone reversal of choledochoduodenal sphincter spasm associated with narcotic administration." Anesthesiology 48 (1978):  437|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Zsigmond EK, Vieira ZEG, Duarte B, Renigers SA, Hirota K "Double-blind placebo-controlled ultrasonographic confirmation of constriction of the common bile duct by morphine." Int J Clin Pharmacol Ther Toxicol 31 (1993):  506-9|Ford MJ, Kellett RJ, Busuttil A, Finlayson ND "Dextropropoxyphene and jaundice." Br Med J 2 (1977):  674|Daikos GK, Kosmidis JC "Propoxyphene jaundice." JAMA 232 (1975):  835|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51484, 18953, 'Fentanyl', 'Gallbladder Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the biliary tract, which can lead to spasm and elevated biliary tract pressure, especially in the sphincter of Oddi.  Biliary effects appear to be the most pronounced with morphine, although they do not always occur with therapeutic doses.  Therapy with opioids should be administered cautiously in patients with biliary or gallbladder disease.', '2', 'Jones RM, Fiddian-Green R, Knight PR "Narcotic-induced choledochoduodenal sphincter spasm reversed by glucagon." Anesth Analg 59 (1980):  946-7|Hey VM, Ostick DG, Mazumder JK, Lord WD "Pethidine, metoclopramide and the gastro-oesophageal sphincter." Anaesthesia 36 (1981):  173-6|Lang DW, Pilon RN "Naloxone reversal of morphine-induced biliary colic." Anesth Analg 59 (1980):  619-20|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|McCammon RL, Viegas OJ, Stoelting RK, Dryden GE "Naloxone reversal of choledochoduodenal sphincter spasm associated with narcotic administration." Anesthesiology 48 (1978):  437|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Zsigmond EK, Vieira ZEG, Duarte B, Renigers SA, Hirota K "Double-blind placebo-controlled ultrasonographic confirmation of constriction of the common bile duct by morphine." Int J Clin Pharmacol Ther Toxicol 31 (1993):  506-9|Ford MJ, Kellett RJ, Busuttil A, Finlayson ND "Dextropropoxyphene and jaundice." Br Med J 2 (1977):  674|Daikos GK, Kosmidis JC "Propoxyphene jaundice." JAMA 232 (1975):  835|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51485, 18955, 'Fentanyl', 'Gallbladder Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the biliary tract, which can lead to spasm and elevated biliary tract pressure, especially in the sphincter of Oddi.  Biliary effects appear to be the most pronounced with morphine, although they do not always occur with therapeutic doses.  Therapy with opioids should be administered cautiously in patients with biliary or gallbladder disease.', '2', 'Jones RM, Fiddian-Green R, Knight PR "Narcotic-induced choledochoduodenal sphincter spasm reversed by glucagon." Anesth Analg 59 (1980):  946-7|Hey VM, Ostick DG, Mazumder JK, Lord WD "Pethidine, metoclopramide and the gastro-oesophageal sphincter." Anaesthesia 36 (1981):  173-6|Lang DW, Pilon RN "Naloxone reversal of morphine-induced biliary colic." Anesth Analg 59 (1980):  619-20|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|McCammon RL, Viegas OJ, Stoelting RK, Dryden GE "Naloxone reversal of choledochoduodenal sphincter spasm associated with narcotic administration." Anesthesiology 48 (1978):  437|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Zsigmond EK, Vieira ZEG, Duarte B, Renigers SA, Hirota K "Double-blind placebo-controlled ultrasonographic confirmation of constriction of the common bile duct by morphine." Int J Clin Pharmacol Ther Toxicol 31 (1993):  506-9|Ford MJ, Kellett RJ, Busuttil A, Finlayson ND "Dextropropoxyphene and jaundice." Br Med J 2 (1977):  674|Daikos GK, Kosmidis JC "Propoxyphene jaundice." JAMA 232 (1975):  835|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51486, 30532, 'Fentanyl', 'Gallbladder Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the biliary tract, which can lead to spasm and elevated biliary tract pressure, especially in the sphincter of Oddi.  Biliary effects appear to be the most pronounced with morphine, although they do not always occur with therapeutic doses.  Therapy with opioids should be administered cautiously in patients with biliary or gallbladder disease.', '2', 'Jones RM, Fiddian-Green R, Knight PR "Narcotic-induced choledochoduodenal sphincter spasm reversed by glucagon." Anesth Analg 59 (1980):  946-7|Hey VM, Ostick DG, Mazumder JK, Lord WD "Pethidine, metoclopramide and the gastro-oesophageal sphincter." Anaesthesia 36 (1981):  173-6|Lang DW, Pilon RN "Naloxone reversal of morphine-induced biliary colic." Anesth Analg 59 (1980):  619-20|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|McCammon RL, Viegas OJ, Stoelting RK, Dryden GE "Naloxone reversal of choledochoduodenal sphincter spasm associated with narcotic administration." Anesthesiology 48 (1978):  437|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Zsigmond EK, Vieira ZEG, Duarte B, Renigers SA, Hirota K "Double-blind placebo-controlled ultrasonographic confirmation of constriction of the common bile duct by morphine." Int J Clin Pharmacol Ther Toxicol 31 (1993):  506-9|Ford MJ, Kellett RJ, Busuttil A, Finlayson ND "Dextropropoxyphene and jaundice." Br Med J 2 (1977):  674|Daikos GK, Kosmidis JC "Propoxyphene jaundice." JAMA 232 (1975):  835|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51487, 4802, 'Fentanyl', 'Hypothyroidism', 'Patients with hypothyroidism may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  These agents may also exacerbate the effects of hypothyroidism such as lethargy, impaired mentation, depression, and constipation.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with uncontrolled hypothyroidism or myxedema.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51488, 13291, 'Fentanyl', 'Hypothyroidism', 'Patients with hypothyroidism may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  These agents may also exacerbate the effects of hypothyroidism such as lethargy, impaired mentation, depression, and constipation.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with uncontrolled hypothyroidism or myxedema.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51489, 13292, 'Fentanyl', 'Hypothyroidism', 'Patients with hypothyroidism may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  These agents may also exacerbate the effects of hypothyroidism such as lethargy, impaired mentation, depression, and constipation.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with uncontrolled hypothyroidism or myxedema.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51490, 17981, 'Fentanyl', 'Hypothyroidism', 'Patients with hypothyroidism may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  These agents may also exacerbate the effects of hypothyroidism such as lethargy, impaired mentation, depression, and constipation.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with uncontrolled hypothyroidism or myxedema.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51491, 17982, 'Fentanyl', 'Hypothyroidism', 'Patients with hypothyroidism may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  These agents may also exacerbate the effects of hypothyroidism such as lethargy, impaired mentation, depression, and constipation.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with uncontrolled hypothyroidism or myxedema.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51492, 17983, 'Fentanyl', 'Hypothyroidism', 'Patients with hypothyroidism may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  These agents may also exacerbate the effects of hypothyroidism such as lethargy, impaired mentation, depression, and constipation.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with uncontrolled hypothyroidism or myxedema.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51493, 17984, 'Fentanyl', 'Hypothyroidism', 'Patients with hypothyroidism may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  These agents may also exacerbate the effects of hypothyroidism such as lethargy, impaired mentation, depression, and constipation.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with uncontrolled hypothyroidism or myxedema.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51494, 17985, 'Fentanyl', 'Hypothyroidism', 'Patients with hypothyroidism may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  These agents may also exacerbate the effects of hypothyroidism such as lethargy, impaired mentation, depression, and constipation.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with uncontrolled hypothyroidism or myxedema.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51495, 18952, 'Fentanyl', 'Hypothyroidism', 'Patients with hypothyroidism may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  These agents may also exacerbate the effects of hypothyroidism such as lethargy, impaired mentation, depression, and constipation.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with uncontrolled hypothyroidism or myxedema.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51496, 18953, 'Fentanyl', 'Hypothyroidism', 'Patients with hypothyroidism may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  These agents may also exacerbate the effects of hypothyroidism such as lethargy, impaired mentation, depression, and constipation.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with uncontrolled hypothyroidism or myxedema.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51497, 18955, 'Fentanyl', 'Hypothyroidism', 'Patients with hypothyroidism may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  These agents may also exacerbate the effects of hypothyroidism such as lethargy, impaired mentation, depression, and constipation.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with uncontrolled hypothyroidism or myxedema.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51498, 30532, 'Fentanyl', 'Hypothyroidism', 'Patients with hypothyroidism may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  These agents may also exacerbate the effects of hypothyroidism such as lethargy, impaired mentation, depression, and constipation.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with uncontrolled hypothyroidism or myxedema.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51499, 4802, 'Fentanyl', 'Kidney Diseases', 'Although narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and their metabolites (some of which are pharmacologically active), resulting in drug accumulation and increased risk of toxicity.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with significantly impaired renal function.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'Findlay JW, Butz RF, Welch RM "Codeine kinetics as determined by radioimmunoassay." Clin Pharmacol Ther 22 (1977):  439-46|Barnes JN, Williams AJ, Tomson MJ, et al. "Dihydrocodeine in renal failure: further evidence for an important role of the kidney in the handling of opioid drugs." Br Med J (Clin Res Ed) 290 (1985):  740-2|Matske GR, Chan GL, Abraham PA "Codeine dosage in renal failure." Clin Pharm 5 (1986):  15-6|Guy DR, Awni WM, Findlay JW, et al. "Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease." Clin Pharmacol Ther 43 (1988):  63-71|Charuvastra VC, Ouren J "Renal failure and treatment of a methadone maintenance patient." Med J Aust 09/24/77 (1977):  433-4|Verbeeck RK, Branch RA, Wilkinson GR "Drug metabolites in renal failure: pharmacokinetic and clinical implications." Clin Pharmacokinet 6 (1981):  329-45|Drayer DE "Active drug metabolites and renal failure." Am J Med 62 (1977):  486-9|Drayer DE "Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure." Clin Pharmacokinet 1 (1976):  426-43|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Wolff J, Bigler D, Christensen CB, et al. "Influence of renal function on the elimination of morphine and morphine glucoronides." Eur J Clin Pharmacol 34 (1988):  353-7|Covington EC, Gonsalves-Ebrahim L, Currie KO, et al. "Severe respiratory depression from patient-controlled analgesia in renal failure." Psychosomatics 30 (1989):  226-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Bechtel WD, Sinterhauf K "Plasma level and renal excretion of [3H] codeine phosphate in man and in the dog." Arzneimittelforschung 28 (1978):  308-11|Wolfert AI, Sica DA "Narcotic usage in renal failure." Int J Artif Organs 11 (1988):  411-5|Inturrisi CE "Disposition of narcotics in patients with renal disease." Am J Med 62 (1977):  528-9|Chan K, Jennings F, Orme ML "Pharmacokinetics of low-dose intravenous pethidine in patients with renal dysfunction." J Clin Pharmacol 27 (1987):  516-22|Chauvin M, Sandouk P, Scherrmann JM, Farinotti R, Strumza P, Duvaldestin P "Morphine pharmacokinetics in renal failure." Anesthesiology 66 (1987):  327-31|Aitkenhead AR, Vater M, Achola K, Cooper CM, Smith G "Pharmacokinetics of single-dose i.v. morphine in normal volunteers and patients with end-stage renal failure." Br J Anaesth 56 (1984):  813-9|Sawe J, Odar-Cederlof I "Kinetics of morphine in patients with renal failure." Eur J Clin Pharmacol 32 (1987):  377-82|Baselt RC, Casarett LJ "Urinary excretion of methadone in man." Clin Pharmacol Ther 13 (1972):  64-70|Kreek MJ, Schecter AJ, Gutjahr CL, et al. "Methadone use in patients with chronic renal failure." Drug Alcohol Depend 5 (1980):  197-205|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hanna MH, D''Costa F, Peat SJ, Fung C, Venkat N, Zilkha TR, Davies S "Morphine-6-glucuronide disposition in renal impairment." Br J Anaesth 70 (1993):  511-4|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Gibson TP, Giacomini KM, Briggs WA, Whitman W, Levy G "Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient." Clin Pharmacol Ther 27 (1980):  665-70|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Giacomini KM, Gibson TP, Levy G "Plasma protein binding of d-propoxyphene in normal subjects and anephric patients." J Clin Pharmacol 18 (1978):  106-9|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Dhonneur G, Gilton A, Sandouk P, Scherrmann JM, Duvaldestin P "Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine - the influence of renal failure." Anesthesiology 81 (1994):  87-93|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51500, 13291, 'Fentanyl', 'Kidney Diseases', 'Although narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and their metabolites (some of which are pharmacologically active), resulting in drug accumulation and increased risk of toxicity.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with significantly impaired renal function.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'Findlay JW, Butz RF, Welch RM "Codeine kinetics as determined by radioimmunoassay." Clin Pharmacol Ther 22 (1977):  439-46|Barnes JN, Williams AJ, Tomson MJ, et al. "Dihydrocodeine in renal failure: further evidence for an important role of the kidney in the handling of opioid drugs." Br Med J (Clin Res Ed) 290 (1985):  740-2|Matske GR, Chan GL, Abraham PA "Codeine dosage in renal failure." Clin Pharm 5 (1986):  15-6|Guy DR, Awni WM, Findlay JW, et al. "Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease." Clin Pharmacol Ther 43 (1988):  63-71|Charuvastra VC, Ouren J "Renal failure and treatment of a methadone maintenance patient." Med J Aust 09/24/77 (1977):  433-4|Verbeeck RK, Branch RA, Wilkinson GR "Drug metabolites in renal failure: pharmacokinetic and clinical implications." Clin Pharmacokinet 6 (1981):  329-45|Drayer DE "Active drug metabolites and renal failure." Am J Med 62 (1977):  486-9|Drayer DE "Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure." Clin Pharmacokinet 1 (1976):  426-43|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Wolff J, Bigler D, Christensen CB, et al. "Influence of renal function on the elimination of morphine and morphine glucoronides." Eur J Clin Pharmacol 34 (1988):  353-7|Covington EC, Gonsalves-Ebrahim L, Currie KO, et al. "Severe respiratory depression from patient-controlled analgesia in renal failure." Psychosomatics 30 (1989):  226-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Bechtel WD, Sinterhauf K "Plasma level and renal excretion of [3H] codeine phosphate in man and in the dog." Arzneimittelforschung 28 (1978):  308-11|Wolfert AI, Sica DA "Narcotic usage in renal failure." Int J Artif Organs 11 (1988):  411-5|Inturrisi CE "Disposition of narcotics in patients with renal disease." Am J Med 62 (1977):  528-9|Chan K, Jennings F, Orme ML "Pharmacokinetics of low-dose intravenous pethidine in patients with renal dysfunction." J Clin Pharmacol 27 (1987):  516-22|Chauvin M, Sandouk P, Scherrmann JM, Farinotti R, Strumza P, Duvaldestin P "Morphine pharmacokinetics in renal failure." Anesthesiology 66 (1987):  327-31|Aitkenhead AR, Vater M, Achola K, Cooper CM, Smith G "Pharmacokinetics of single-dose i.v. morphine in normal volunteers and patients with end-stage renal failure." Br J Anaesth 56 (1984):  813-9|Sawe J, Odar-Cederlof I "Kinetics of morphine in patients with renal failure." Eur J Clin Pharmacol 32 (1987):  377-82|Baselt RC, Casarett LJ "Urinary excretion of methadone in man." Clin Pharmacol Ther 13 (1972):  64-70|Kreek MJ, Schecter AJ, Gutjahr CL, et al. "Methadone use in patients with chronic renal failure." Drug Alcohol Depend 5 (1980):  197-205|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hanna MH, D''Costa F, Peat SJ, Fung C, Venkat N, Zilkha TR, Davies S "Morphine-6-glucuronide disposition in renal impairment." Br J Anaesth 70 (1993):  511-4|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Gibson TP, Giacomini KM, Briggs WA, Whitman W, Levy G "Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient." Clin Pharmacol Ther 27 (1980):  665-70|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Giacomini KM, Gibson TP, Levy G "Plasma protein binding of d-propoxyphene in normal subjects and anephric patients." J Clin Pharmacol 18 (1978):  106-9|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Dhonneur G, Gilton A, Sandouk P, Scherrmann JM, Duvaldestin P "Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine - the influence of renal failure." Anesthesiology 81 (1994):  87-93|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51501, 13292, 'Fentanyl', 'Kidney Diseases', 'Although narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and their metabolites (some of which are pharmacologically active), resulting in drug accumulation and increased risk of toxicity.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with significantly impaired renal function.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'Findlay JW, Butz RF, Welch RM "Codeine kinetics as determined by radioimmunoassay." Clin Pharmacol Ther 22 (1977):  439-46|Barnes JN, Williams AJ, Tomson MJ, et al. "Dihydrocodeine in renal failure: further evidence for an important role of the kidney in the handling of opioid drugs." Br Med J (Clin Res Ed) 290 (1985):  740-2|Matske GR, Chan GL, Abraham PA "Codeine dosage in renal failure." Clin Pharm 5 (1986):  15-6|Guy DR, Awni WM, Findlay JW, et al. "Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease." Clin Pharmacol Ther 43 (1988):  63-71|Charuvastra VC, Ouren J "Renal failure and treatment of a methadone maintenance patient." Med J Aust 09/24/77 (1977):  433-4|Verbeeck RK, Branch RA, Wilkinson GR "Drug metabolites in renal failure: pharmacokinetic and clinical implications." Clin Pharmacokinet 6 (1981):  329-45|Drayer DE "Active drug metabolites and renal failure." Am J Med 62 (1977):  486-9|Drayer DE "Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure." Clin Pharmacokinet 1 (1976):  426-43|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Wolff J, Bigler D, Christensen CB, et al. "Influence of renal function on the elimination of morphine and morphine glucoronides." Eur J Clin Pharmacol 34 (1988):  353-7|Covington EC, Gonsalves-Ebrahim L, Currie KO, et al. "Severe respiratory depression from patient-controlled analgesia in renal failure." Psychosomatics 30 (1989):  226-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Bechtel WD, Sinterhauf K "Plasma level and renal excretion of [3H] codeine phosphate in man and in the dog." Arzneimittelforschung 28 (1978):  308-11|Wolfert AI, Sica DA "Narcotic usage in renal failure." Int J Artif Organs 11 (1988):  411-5|Inturrisi CE "Disposition of narcotics in patients with renal disease." Am J Med 62 (1977):  528-9|Chan K, Jennings F, Orme ML "Pharmacokinetics of low-dose intravenous pethidine in patients with renal dysfunction." J Clin Pharmacol 27 (1987):  516-22|Chauvin M, Sandouk P, Scherrmann JM, Farinotti R, Strumza P, Duvaldestin P "Morphine pharmacokinetics in renal failure." Anesthesiology 66 (1987):  327-31|Aitkenhead AR, Vater M, Achola K, Cooper CM, Smith G "Pharmacokinetics of single-dose i.v. morphine in normal volunteers and patients with end-stage renal failure." Br J Anaesth 56 (1984):  813-9|Sawe J, Odar-Cederlof I "Kinetics of morphine in patients with renal failure." Eur J Clin Pharmacol 32 (1987):  377-82|Baselt RC, Casarett LJ "Urinary excretion of methadone in man." Clin Pharmacol Ther 13 (1972):  64-70|Kreek MJ, Schecter AJ, Gutjahr CL, et al. "Methadone use in patients with chronic renal failure." Drug Alcohol Depend 5 (1980):  197-205|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hanna MH, D''Costa F, Peat SJ, Fung C, Venkat N, Zilkha TR, Davies S "Morphine-6-glucuronide disposition in renal impairment." Br J Anaesth 70 (1993):  511-4|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Gibson TP, Giacomini KM, Briggs WA, Whitman W, Levy G "Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient." Clin Pharmacol Ther 27 (1980):  665-70|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Giacomini KM, Gibson TP, Levy G "Plasma protein binding of d-propoxyphene in normal subjects and anephric patients." J Clin Pharmacol 18 (1978):  106-9|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Dhonneur G, Gilton A, Sandouk P, Scherrmann JM, Duvaldestin P "Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine - the influence of renal failure." Anesthesiology 81 (1994):  87-93|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51502, 17981, 'Fentanyl', 'Kidney Diseases', 'Although narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and their metabolites (some of which are pharmacologically active), resulting in drug accumulation and increased risk of toxicity.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with significantly impaired renal function.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'Findlay JW, Butz RF, Welch RM "Codeine kinetics as determined by radioimmunoassay." Clin Pharmacol Ther 22 (1977):  439-46|Barnes JN, Williams AJ, Tomson MJ, et al. "Dihydrocodeine in renal failure: further evidence for an important role of the kidney in the handling of opioid drugs." Br Med J (Clin Res Ed) 290 (1985):  740-2|Matske GR, Chan GL, Abraham PA "Codeine dosage in renal failure." Clin Pharm 5 (1986):  15-6|Guy DR, Awni WM, Findlay JW, et al. "Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease." Clin Pharmacol Ther 43 (1988):  63-71|Charuvastra VC, Ouren J "Renal failure and treatment of a methadone maintenance patient." Med J Aust 09/24/77 (1977):  433-4|Verbeeck RK, Branch RA, Wilkinson GR "Drug metabolites in renal failure: pharmacokinetic and clinical implications." Clin Pharmacokinet 6 (1981):  329-45|Drayer DE "Active drug metabolites and renal failure." Am J Med 62 (1977):  486-9|Drayer DE "Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure." Clin Pharmacokinet 1 (1976):  426-43|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Wolff J, Bigler D, Christensen CB, et al. "Influence of renal function on the elimination of morphine and morphine glucoronides." Eur J Clin Pharmacol 34 (1988):  353-7|Covington EC, Gonsalves-Ebrahim L, Currie KO, et al. "Severe respiratory depression from patient-controlled analgesia in renal failure." Psychosomatics 30 (1989):  226-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Bechtel WD, Sinterhauf K "Plasma level and renal excretion of [3H] codeine phosphate in man and in the dog." Arzneimittelforschung 28 (1978):  308-11|Wolfert AI, Sica DA "Narcotic usage in renal failure." Int J Artif Organs 11 (1988):  411-5|Inturrisi CE "Disposition of narcotics in patients with renal disease." Am J Med 62 (1977):  528-9|Chan K, Jennings F, Orme ML "Pharmacokinetics of low-dose intravenous pethidine in patients with renal dysfunction." J Clin Pharmacol 27 (1987):  516-22|Chauvin M, Sandouk P, Scherrmann JM, Farinotti R, Strumza P, Duvaldestin P "Morphine pharmacokinetics in renal failure." Anesthesiology 66 (1987):  327-31|Aitkenhead AR, Vater M, Achola K, Cooper CM, Smith G "Pharmacokinetics of single-dose i.v. morphine in normal volunteers and patients with end-stage renal failure." Br J Anaesth 56 (1984):  813-9|Sawe J, Odar-Cederlof I "Kinetics of morphine in patients with renal failure." Eur J Clin Pharmacol 32 (1987):  377-82|Baselt RC, Casarett LJ "Urinary excretion of methadone in man." Clin Pharmacol Ther 13 (1972):  64-70|Kreek MJ, Schecter AJ, Gutjahr CL, et al. "Methadone use in patients with chronic renal failure." Drug Alcohol Depend 5 (1980):  197-205|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hanna MH, D''Costa F, Peat SJ, Fung C, Venkat N, Zilkha TR, Davies S "Morphine-6-glucuronide disposition in renal impairment." Br J Anaesth 70 (1993):  511-4|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Gibson TP, Giacomini KM, Briggs WA, Whitman W, Levy G "Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient." Clin Pharmacol Ther 27 (1980):  665-70|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Giacomini KM, Gibson TP, Levy G "Plasma protein binding of d-propoxyphene in normal subjects and anephric patients." J Clin Pharmacol 18 (1978):  106-9|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Dhonneur G, Gilton A, Sandouk P, Scherrmann JM, Duvaldestin P "Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine - the influence of renal failure." Anesthesiology 81 (1994):  87-93|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51503, 17982, 'Fentanyl', 'Kidney Diseases', 'Although narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and their metabolites (some of which are pharmacologically active), resulting in drug accumulation and increased risk of toxicity.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with significantly impaired renal function.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'Findlay JW, Butz RF, Welch RM "Codeine kinetics as determined by radioimmunoassay." Clin Pharmacol Ther 22 (1977):  439-46|Barnes JN, Williams AJ, Tomson MJ, et al. "Dihydrocodeine in renal failure: further evidence for an important role of the kidney in the handling of opioid drugs." Br Med J (Clin Res Ed) 290 (1985):  740-2|Matske GR, Chan GL, Abraham PA "Codeine dosage in renal failure." Clin Pharm 5 (1986):  15-6|Guy DR, Awni WM, Findlay JW, et al. "Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease." Clin Pharmacol Ther 43 (1988):  63-71|Charuvastra VC, Ouren J "Renal failure and treatment of a methadone maintenance patient." Med J Aust 09/24/77 (1977):  433-4|Verbeeck RK, Branch RA, Wilkinson GR "Drug metabolites in renal failure: pharmacokinetic and clinical implications." Clin Pharmacokinet 6 (1981):  329-45|Drayer DE "Active drug metabolites and renal failure." Am J Med 62 (1977):  486-9|Drayer DE "Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure." Clin Pharmacokinet 1 (1976):  426-43|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Wolff J, Bigler D, Christensen CB, et al. "Influence of renal function on the elimination of morphine and morphine glucoronides." Eur J Clin Pharmacol 34 (1988):  353-7|Covington EC, Gonsalves-Ebrahim L, Currie KO, et al. "Severe respiratory depression from patient-controlled analgesia in renal failure." Psychosomatics 30 (1989):  226-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Bechtel WD, Sinterhauf K "Plasma level and renal excretion of [3H] codeine phosphate in man and in the dog." Arzneimittelforschung 28 (1978):  308-11|Wolfert AI, Sica DA "Narcotic usage in renal failure." Int J Artif Organs 11 (1988):  411-5|Inturrisi CE "Disposition of narcotics in patients with renal disease." Am J Med 62 (1977):  528-9|Chan K, Jennings F, Orme ML "Pharmacokinetics of low-dose intravenous pethidine in patients with renal dysfunction." J Clin Pharmacol 27 (1987):  516-22|Chauvin M, Sandouk P, Scherrmann JM, Farinotti R, Strumza P, Duvaldestin P "Morphine pharmacokinetics in renal failure." Anesthesiology 66 (1987):  327-31|Aitkenhead AR, Vater M, Achola K, Cooper CM, Smith G "Pharmacokinetics of single-dose i.v. morphine in normal volunteers and patients with end-stage renal failure." Br J Anaesth 56 (1984):  813-9|Sawe J, Odar-Cederlof I "Kinetics of morphine in patients with renal failure." Eur J Clin Pharmacol 32 (1987):  377-82|Baselt RC, Casarett LJ "Urinary excretion of methadone in man." Clin Pharmacol Ther 13 (1972):  64-70|Kreek MJ, Schecter AJ, Gutjahr CL, et al. "Methadone use in patients with chronic renal failure." Drug Alcohol Depend 5 (1980):  197-205|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hanna MH, D''Costa F, Peat SJ, Fung C, Venkat N, Zilkha TR, Davies S "Morphine-6-glucuronide disposition in renal impairment." Br J Anaesth 70 (1993):  511-4|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Gibson TP, Giacomini KM, Briggs WA, Whitman W, Levy G "Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient." Clin Pharmacol Ther 27 (1980):  665-70|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Giacomini KM, Gibson TP, Levy G "Plasma protein binding of d-propoxyphene in normal subjects and anephric patients." J Clin Pharmacol 18 (1978):  106-9|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Dhonneur G, Gilton A, Sandouk P, Scherrmann JM, Duvaldestin P "Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine - the influence of renal failure." Anesthesiology 81 (1994):  87-93|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51504, 17983, 'Fentanyl', 'Kidney Diseases', 'Although narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and their metabolites (some of which are pharmacologically active), resulting in drug accumulation and increased risk of toxicity.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with significantly impaired renal function.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'Findlay JW, Butz RF, Welch RM "Codeine kinetics as determined by radioimmunoassay." Clin Pharmacol Ther 22 (1977):  439-46|Barnes JN, Williams AJ, Tomson MJ, et al. "Dihydrocodeine in renal failure: further evidence for an important role of the kidney in the handling of opioid drugs." Br Med J (Clin Res Ed) 290 (1985):  740-2|Matske GR, Chan GL, Abraham PA "Codeine dosage in renal failure." Clin Pharm 5 (1986):  15-6|Guy DR, Awni WM, Findlay JW, et al. "Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease." Clin Pharmacol Ther 43 (1988):  63-71|Charuvastra VC, Ouren J "Renal failure and treatment of a methadone maintenance patient." Med J Aust 09/24/77 (1977):  433-4|Verbeeck RK, Branch RA, Wilkinson GR "Drug metabolites in renal failure: pharmacokinetic and clinical implications." Clin Pharmacokinet 6 (1981):  329-45|Drayer DE "Active drug metabolites and renal failure." Am J Med 62 (1977):  486-9|Drayer DE "Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure." Clin Pharmacokinet 1 (1976):  426-43|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Wolff J, Bigler D, Christensen CB, et al. "Influence of renal function on the elimination of morphine and morphine glucoronides." Eur J Clin Pharmacol 34 (1988):  353-7|Covington EC, Gonsalves-Ebrahim L, Currie KO, et al. "Severe respiratory depression from patient-controlled analgesia in renal failure." Psychosomatics 30 (1989):  226-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Bechtel WD, Sinterhauf K "Plasma level and renal excretion of [3H] codeine phosphate in man and in the dog." Arzneimittelforschung 28 (1978):  308-11|Wolfert AI, Sica DA "Narcotic usage in renal failure." Int J Artif Organs 11 (1988):  411-5|Inturrisi CE "Disposition of narcotics in patients with renal disease." Am J Med 62 (1977):  528-9|Chan K, Jennings F, Orme ML "Pharmacokinetics of low-dose intravenous pethidine in patients with renal dysfunction." J Clin Pharmacol 27 (1987):  516-22|Chauvin M, Sandouk P, Scherrmann JM, Farinotti R, Strumza P, Duvaldestin P "Morphine pharmacokinetics in renal failure." Anesthesiology 66 (1987):  327-31|Aitkenhead AR, Vater M, Achola K, Cooper CM, Smith G "Pharmacokinetics of single-dose i.v. morphine in normal volunteers and patients with end-stage renal failure." Br J Anaesth 56 (1984):  813-9|Sawe J, Odar-Cederlof I "Kinetics of morphine in patients with renal failure." Eur J Clin Pharmacol 32 (1987):  377-82|Baselt RC, Casarett LJ "Urinary excretion of methadone in man." Clin Pharmacol Ther 13 (1972):  64-70|Kreek MJ, Schecter AJ, Gutjahr CL, et al. "Methadone use in patients with chronic renal failure." Drug Alcohol Depend 5 (1980):  197-205|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hanna MH, D''Costa F, Peat SJ, Fung C, Venkat N, Zilkha TR, Davies S "Morphine-6-glucuronide disposition in renal impairment." Br J Anaesth 70 (1993):  511-4|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Gibson TP, Giacomini KM, Briggs WA, Whitman W, Levy G "Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient." Clin Pharmacol Ther 27 (1980):  665-70|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Giacomini KM, Gibson TP, Levy G "Plasma protein binding of d-propoxyphene in normal subjects and anephric patients." J Clin Pharmacol 18 (1978):  106-9|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Dhonneur G, Gilton A, Sandouk P, Scherrmann JM, Duvaldestin P "Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine - the influence of renal failure." Anesthesiology 81 (1994):  87-93|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51505, 17984, 'Fentanyl', 'Kidney Diseases', 'Although narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and their metabolites (some of which are pharmacologically active), resulting in drug accumulation and increased risk of toxicity.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with significantly impaired renal function.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'Findlay JW, Butz RF, Welch RM "Codeine kinetics as determined by radioimmunoassay." Clin Pharmacol Ther 22 (1977):  439-46|Barnes JN, Williams AJ, Tomson MJ, et al. "Dihydrocodeine in renal failure: further evidence for an important role of the kidney in the handling of opioid drugs." Br Med J (Clin Res Ed) 290 (1985):  740-2|Matske GR, Chan GL, Abraham PA "Codeine dosage in renal failure." Clin Pharm 5 (1986):  15-6|Guy DR, Awni WM, Findlay JW, et al. "Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease." Clin Pharmacol Ther 43 (1988):  63-71|Charuvastra VC, Ouren J "Renal failure and treatment of a methadone maintenance patient." Med J Aust 09/24/77 (1977):  433-4|Verbeeck RK, Branch RA, Wilkinson GR "Drug metabolites in renal failure: pharmacokinetic and clinical implications." Clin Pharmacokinet 6 (1981):  329-45|Drayer DE "Active drug metabolites and renal failure." Am J Med 62 (1977):  486-9|Drayer DE "Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure." Clin Pharmacokinet 1 (1976):  426-43|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Wolff J, Bigler D, Christensen CB, et al. "Influence of renal function on the elimination of morphine and morphine glucoronides." Eur J Clin Pharmacol 34 (1988):  353-7|Covington EC, Gonsalves-Ebrahim L, Currie KO, et al. "Severe respiratory depression from patient-controlled analgesia in renal failure." Psychosomatics 30 (1989):  226-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Bechtel WD, Sinterhauf K "Plasma level and renal excretion of [3H] codeine phosphate in man and in the dog." Arzneimittelforschung 28 (1978):  308-11|Wolfert AI, Sica DA "Narcotic usage in renal failure." Int J Artif Organs 11 (1988):  411-5|Inturrisi CE "Disposition of narcotics in patients with renal disease." Am J Med 62 (1977):  528-9|Chan K, Jennings F, Orme ML "Pharmacokinetics of low-dose intravenous pethidine in patients with renal dysfunction." J Clin Pharmacol 27 (1987):  516-22|Chauvin M, Sandouk P, Scherrmann JM, Farinotti R, Strumza P, Duvaldestin P "Morphine pharmacokinetics in renal failure." Anesthesiology 66 (1987):  327-31|Aitkenhead AR, Vater M, Achola K, Cooper CM, Smith G "Pharmacokinetics of single-dose i.v. morphine in normal volunteers and patients with end-stage renal failure." Br J Anaesth 56 (1984):  813-9|Sawe J, Odar-Cederlof I "Kinetics of morphine in patients with renal failure." Eur J Clin Pharmacol 32 (1987):  377-82|Baselt RC, Casarett LJ "Urinary excretion of methadone in man." Clin Pharmacol Ther 13 (1972):  64-70|Kreek MJ, Schecter AJ, Gutjahr CL, et al. "Methadone use in patients with chronic renal failure." Drug Alcohol Depend 5 (1980):  197-205|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hanna MH, D''Costa F, Peat SJ, Fung C, Venkat N, Zilkha TR, Davies S "Morphine-6-glucuronide disposition in renal impairment." Br J Anaesth 70 (1993):  511-4|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Gibson TP, Giacomini KM, Briggs WA, Whitman W, Levy G "Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient." Clin Pharmacol Ther 27 (1980):  665-70|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Giacomini KM, Gibson TP, Levy G "Plasma protein binding of d-propoxyphene in normal subjects and anephric patients." J Clin Pharmacol 18 (1978):  106-9|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Dhonneur G, Gilton A, Sandouk P, Scherrmann JM, Duvaldestin P "Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine - the influence of renal failure." Anesthesiology 81 (1994):  87-93|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51506, 17985, 'Fentanyl', 'Kidney Diseases', 'Although narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and their metabolites (some of which are pharmacologically active), resulting in drug accumulation and increased risk of toxicity.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with significantly impaired renal function.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'Findlay JW, Butz RF, Welch RM "Codeine kinetics as determined by radioimmunoassay." Clin Pharmacol Ther 22 (1977):  439-46|Barnes JN, Williams AJ, Tomson MJ, et al. "Dihydrocodeine in renal failure: further evidence for an important role of the kidney in the handling of opioid drugs." Br Med J (Clin Res Ed) 290 (1985):  740-2|Matske GR, Chan GL, Abraham PA "Codeine dosage in renal failure." Clin Pharm 5 (1986):  15-6|Guy DR, Awni WM, Findlay JW, et al. "Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease." Clin Pharmacol Ther 43 (1988):  63-71|Charuvastra VC, Ouren J "Renal failure and treatment of a methadone maintenance patient." Med J Aust 09/24/77 (1977):  433-4|Verbeeck RK, Branch RA, Wilkinson GR "Drug metabolites in renal failure: pharmacokinetic and clinical implications." Clin Pharmacokinet 6 (1981):  329-45|Drayer DE "Active drug metabolites and renal failure." Am J Med 62 (1977):  486-9|Drayer DE "Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure." Clin Pharmacokinet 1 (1976):  426-43|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Wolff J, Bigler D, Christensen CB, et al. "Influence of renal function on the elimination of morphine and morphine glucoronides." Eur J Clin Pharmacol 34 (1988):  353-7|Covington EC, Gonsalves-Ebrahim L, Currie KO, et al. "Severe respiratory depression from patient-controlled analgesia in renal failure." Psychosomatics 30 (1989):  226-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Bechtel WD, Sinterhauf K "Plasma level and renal excretion of [3H] codeine phosphate in man and in the dog." Arzneimittelforschung 28 (1978):  308-11|Wolfert AI, Sica DA "Narcotic usage in renal failure." Int J Artif Organs 11 (1988):  411-5|Inturrisi CE "Disposition of narcotics in patients with renal disease." Am J Med 62 (1977):  528-9|Chan K, Jennings F, Orme ML "Pharmacokinetics of low-dose intravenous pethidine in patients with renal dysfunction." J Clin Pharmacol 27 (1987):  516-22|Chauvin M, Sandouk P, Scherrmann JM, Farinotti R, Strumza P, Duvaldestin P "Morphine pharmacokinetics in renal failure." Anesthesiology 66 (1987):  327-31|Aitkenhead AR, Vater M, Achola K, Cooper CM, Smith G "Pharmacokinetics of single-dose i.v. morphine in normal volunteers and patients with end-stage renal failure." Br J Anaesth 56 (1984):  813-9|Sawe J, Odar-Cederlof I "Kinetics of morphine in patients with renal failure." Eur J Clin Pharmacol 32 (1987):  377-82|Baselt RC, Casarett LJ "Urinary excretion of methadone in man." Clin Pharmacol Ther 13 (1972):  64-70|Kreek MJ, Schecter AJ, Gutjahr CL, et al. "Methadone use in patients with chronic renal failure." Drug Alcohol Depend 5 (1980):  197-205|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hanna MH, D''Costa F, Peat SJ, Fung C, Venkat N, Zilkha TR, Davies S "Morphine-6-glucuronide disposition in renal impairment." Br J Anaesth 70 (1993):  511-4|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Gibson TP, Giacomini KM, Briggs WA, Whitman W, Levy G "Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient." Clin Pharmacol Ther 27 (1980):  665-70|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Giacomini KM, Gibson TP, Levy G "Plasma protein binding of d-propoxyphene in normal subjects and anephric patients." J Clin Pharmacol 18 (1978):  106-9|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Dhonneur G, Gilton A, Sandouk P, Scherrmann JM, Duvaldestin P "Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine - the influence of renal failure." Anesthesiology 81 (1994):  87-93|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51507, 18952, 'Fentanyl', 'Kidney Diseases', 'Although narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and their metabolites (some of which are pharmacologically active), resulting in drug accumulation and increased risk of toxicity.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with significantly impaired renal function.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'Findlay JW, Butz RF, Welch RM "Codeine kinetics as determined by radioimmunoassay." Clin Pharmacol Ther 22 (1977):  439-46|Barnes JN, Williams AJ, Tomson MJ, et al. "Dihydrocodeine in renal failure: further evidence for an important role of the kidney in the handling of opioid drugs." Br Med J (Clin Res Ed) 290 (1985):  740-2|Matske GR, Chan GL, Abraham PA "Codeine dosage in renal failure." Clin Pharm 5 (1986):  15-6|Guy DR, Awni WM, Findlay JW, et al. "Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease." Clin Pharmacol Ther 43 (1988):  63-71|Charuvastra VC, Ouren J "Renal failure and treatment of a methadone maintenance patient." Med J Aust 09/24/77 (1977):  433-4|Verbeeck RK, Branch RA, Wilkinson GR "Drug metabolites in renal failure: pharmacokinetic and clinical implications." Clin Pharmacokinet 6 (1981):  329-45|Drayer DE "Active drug metabolites and renal failure." Am J Med 62 (1977):  486-9|Drayer DE "Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure." Clin Pharmacokinet 1 (1976):  426-43|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Wolff J, Bigler D, Christensen CB, et al. "Influence of renal function on the elimination of morphine and morphine glucoronides." Eur J Clin Pharmacol 34 (1988):  353-7|Covington EC, Gonsalves-Ebrahim L, Currie KO, et al. "Severe respiratory depression from patient-controlled analgesia in renal failure." Psychosomatics 30 (1989):  226-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Bechtel WD, Sinterhauf K "Plasma level and renal excretion of [3H] codeine phosphate in man and in the dog." Arzneimittelforschung 28 (1978):  308-11|Wolfert AI, Sica DA "Narcotic usage in renal failure." Int J Artif Organs 11 (1988):  411-5|Inturrisi CE "Disposition of narcotics in patients with renal disease." Am J Med 62 (1977):  528-9|Chan K, Jennings F, Orme ML "Pharmacokinetics of low-dose intravenous pethidine in patients with renal dysfunction." J Clin Pharmacol 27 (1987):  516-22|Chauvin M, Sandouk P, Scherrmann JM, Farinotti R, Strumza P, Duvaldestin P "Morphine pharmacokinetics in renal failure." Anesthesiology 66 (1987):  327-31|Aitkenhead AR, Vater M, Achola K, Cooper CM, Smith G "Pharmacokinetics of single-dose i.v. morphine in normal volunteers and patients with end-stage renal failure." Br J Anaesth 56 (1984):  813-9|Sawe J, Odar-Cederlof I "Kinetics of morphine in patients with renal failure." Eur J Clin Pharmacol 32 (1987):  377-82|Baselt RC, Casarett LJ "Urinary excretion of methadone in man." Clin Pharmacol Ther 13 (1972):  64-70|Kreek MJ, Schecter AJ, Gutjahr CL, et al. "Methadone use in patients with chronic renal failure." Drug Alcohol Depend 5 (1980):  197-205|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hanna MH, D''Costa F, Peat SJ, Fung C, Venkat N, Zilkha TR, Davies S "Morphine-6-glucuronide disposition in renal impairment." Br J Anaesth 70 (1993):  511-4|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Gibson TP, Giacomini KM, Briggs WA, Whitman W, Levy G "Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient." Clin Pharmacol Ther 27 (1980):  665-70|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Giacomini KM, Gibson TP, Levy G "Plasma protein binding of d-propoxyphene in normal subjects and anephric patients." J Clin Pharmacol 18 (1978):  106-9|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Dhonneur G, Gilton A, Sandouk P, Scherrmann JM, Duvaldestin P "Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine - the influence of renal failure." Anesthesiology 81 (1994):  87-93|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51508, 18953, 'Fentanyl', 'Kidney Diseases', 'Although narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and their metabolites (some of which are pharmacologically active), resulting in drug accumulation and increased risk of toxicity.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with significantly impaired renal function.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'Findlay JW, Butz RF, Welch RM "Codeine kinetics as determined by radioimmunoassay." Clin Pharmacol Ther 22 (1977):  439-46|Barnes JN, Williams AJ, Tomson MJ, et al. "Dihydrocodeine in renal failure: further evidence for an important role of the kidney in the handling of opioid drugs." Br Med J (Clin Res Ed) 290 (1985):  740-2|Matske GR, Chan GL, Abraham PA "Codeine dosage in renal failure." Clin Pharm 5 (1986):  15-6|Guy DR, Awni WM, Findlay JW, et al. "Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease." Clin Pharmacol Ther 43 (1988):  63-71|Charuvastra VC, Ouren J "Renal failure and treatment of a methadone maintenance patient." Med J Aust 09/24/77 (1977):  433-4|Verbeeck RK, Branch RA, Wilkinson GR "Drug metabolites in renal failure: pharmacokinetic and clinical implications." Clin Pharmacokinet 6 (1981):  329-45|Drayer DE "Active drug metabolites and renal failure." Am J Med 62 (1977):  486-9|Drayer DE "Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure." Clin Pharmacokinet 1 (1976):  426-43|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Wolff J, Bigler D, Christensen CB, et al. "Influence of renal function on the elimination of morphine and morphine glucoronides." Eur J Clin Pharmacol 34 (1988):  353-7|Covington EC, Gonsalves-Ebrahim L, Currie KO, et al. "Severe respiratory depression from patient-controlled analgesia in renal failure." Psychosomatics 30 (1989):  226-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Bechtel WD, Sinterhauf K "Plasma level and renal excretion of [3H] codeine phosphate in man and in the dog." Arzneimittelforschung 28 (1978):  308-11|Wolfert AI, Sica DA "Narcotic usage in renal failure." Int J Artif Organs 11 (1988):  411-5|Inturrisi CE "Disposition of narcotics in patients with renal disease." Am J Med 62 (1977):  528-9|Chan K, Jennings F, Orme ML "Pharmacokinetics of low-dose intravenous pethidine in patients with renal dysfunction." J Clin Pharmacol 27 (1987):  516-22|Chauvin M, Sandouk P, Scherrmann JM, Farinotti R, Strumza P, Duvaldestin P "Morphine pharmacokinetics in renal failure." Anesthesiology 66 (1987):  327-31|Aitkenhead AR, Vater M, Achola K, Cooper CM, Smith G "Pharmacokinetics of single-dose i.v. morphine in normal volunteers and patients with end-stage renal failure." Br J Anaesth 56 (1984):  813-9|Sawe J, Odar-Cederlof I "Kinetics of morphine in patients with renal failure." Eur J Clin Pharmacol 32 (1987):  377-82|Baselt RC, Casarett LJ "Urinary excretion of methadone in man." Clin Pharmacol Ther 13 (1972):  64-70|Kreek MJ, Schecter AJ, Gutjahr CL, et al. "Methadone use in patients with chronic renal failure." Drug Alcohol Depend 5 (1980):  197-205|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hanna MH, D''Costa F, Peat SJ, Fung C, Venkat N, Zilkha TR, Davies S "Morphine-6-glucuronide disposition in renal impairment." Br J Anaesth 70 (1993):  511-4|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Gibson TP, Giacomini KM, Briggs WA, Whitman W, Levy G "Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient." Clin Pharmacol Ther 27 (1980):  665-70|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Giacomini KM, Gibson TP, Levy G "Plasma protein binding of d-propoxyphene in normal subjects and anephric patients." J Clin Pharmacol 18 (1978):  106-9|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Dhonneur G, Gilton A, Sandouk P, Scherrmann JM, Duvaldestin P "Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine - the influence of renal failure." Anesthesiology 81 (1994):  87-93|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51509, 18955, 'Fentanyl', 'Kidney Diseases', 'Although narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and their metabolites (some of which are pharmacologically active), resulting in drug accumulation and increased risk of toxicity.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with significantly impaired renal function.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'Findlay JW, Butz RF, Welch RM "Codeine kinetics as determined by radioimmunoassay." Clin Pharmacol Ther 22 (1977):  439-46|Barnes JN, Williams AJ, Tomson MJ, et al. "Dihydrocodeine in renal failure: further evidence for an important role of the kidney in the handling of opioid drugs." Br Med J (Clin Res Ed) 290 (1985):  740-2|Matske GR, Chan GL, Abraham PA "Codeine dosage in renal failure." Clin Pharm 5 (1986):  15-6|Guy DR, Awni WM, Findlay JW, et al. "Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease." Clin Pharmacol Ther 43 (1988):  63-71|Charuvastra VC, Ouren J "Renal failure and treatment of a methadone maintenance patient." Med J Aust 09/24/77 (1977):  433-4|Verbeeck RK, Branch RA, Wilkinson GR "Drug metabolites in renal failure: pharmacokinetic and clinical implications." Clin Pharmacokinet 6 (1981):  329-45|Drayer DE "Active drug metabolites and renal failure." Am J Med 62 (1977):  486-9|Drayer DE "Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure." Clin Pharmacokinet 1 (1976):  426-43|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Wolff J, Bigler D, Christensen CB, et al. "Influence of renal function on the elimination of morphine and morphine glucoronides." Eur J Clin Pharmacol 34 (1988):  353-7|Covington EC, Gonsalves-Ebrahim L, Currie KO, et al. "Severe respiratory depression from patient-controlled analgesia in renal failure." Psychosomatics 30 (1989):  226-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Bechtel WD, Sinterhauf K "Plasma level and renal excretion of [3H] codeine phosphate in man and in the dog." Arzneimittelforschung 28 (1978):  308-11|Wolfert AI, Sica DA "Narcotic usage in renal failure." Int J Artif Organs 11 (1988):  411-5|Inturrisi CE "Disposition of narcotics in patients with renal disease." Am J Med 62 (1977):  528-9|Chan K, Jennings F, Orme ML "Pharmacokinetics of low-dose intravenous pethidine in patients with renal dysfunction." J Clin Pharmacol 27 (1987):  516-22|Chauvin M, Sandouk P, Scherrmann JM, Farinotti R, Strumza P, Duvaldestin P "Morphine pharmacokinetics in renal failure." Anesthesiology 66 (1987):  327-31|Aitkenhead AR, Vater M, Achola K, Cooper CM, Smith G "Pharmacokinetics of single-dose i.v. morphine in normal volunteers and patients with end-stage renal failure." Br J Anaesth 56 (1984):  813-9|Sawe J, Odar-Cederlof I "Kinetics of morphine in patients with renal failure." Eur J Clin Pharmacol 32 (1987):  377-82|Baselt RC, Casarett LJ "Urinary excretion of methadone in man." Clin Pharmacol Ther 13 (1972):  64-70|Kreek MJ, Schecter AJ, Gutjahr CL, et al. "Methadone use in patients with chronic renal failure." Drug Alcohol Depend 5 (1980):  197-205|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hanna MH, D''Costa F, Peat SJ, Fung C, Venkat N, Zilkha TR, Davies S "Morphine-6-glucuronide disposition in renal impairment." Br J Anaesth 70 (1993):  511-4|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Gibson TP, Giacomini KM, Briggs WA, Whitman W, Levy G "Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient." Clin Pharmacol Ther 27 (1980):  665-70|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Giacomini KM, Gibson TP, Levy G "Plasma protein binding of d-propoxyphene in normal subjects and anephric patients." J Clin Pharmacol 18 (1978):  106-9|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Dhonneur G, Gilton A, Sandouk P, Scherrmann JM, Duvaldestin P "Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine - the influence of renal failure." Anesthesiology 81 (1994):  87-93|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51510, 30532, 'Fentanyl', 'Kidney Diseases', 'Although narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and their metabolites (some of which are pharmacologically active), resulting in drug accumulation and increased risk of toxicity.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with significantly impaired renal function.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'Findlay JW, Butz RF, Welch RM "Codeine kinetics as determined by radioimmunoassay." Clin Pharmacol Ther 22 (1977):  439-46|Barnes JN, Williams AJ, Tomson MJ, et al. "Dihydrocodeine in renal failure: further evidence for an important role of the kidney in the handling of opioid drugs." Br Med J (Clin Res Ed) 290 (1985):  740-2|Matske GR, Chan GL, Abraham PA "Codeine dosage in renal failure." Clin Pharm 5 (1986):  15-6|Guy DR, Awni WM, Findlay JW, et al. "Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease." Clin Pharmacol Ther 43 (1988):  63-71|Charuvastra VC, Ouren J "Renal failure and treatment of a methadone maintenance patient." Med J Aust 09/24/77 (1977):  433-4|Verbeeck RK, Branch RA, Wilkinson GR "Drug metabolites in renal failure: pharmacokinetic and clinical implications." Clin Pharmacokinet 6 (1981):  329-45|Drayer DE "Active drug metabolites and renal failure." Am J Med 62 (1977):  486-9|Drayer DE "Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure." Clin Pharmacokinet 1 (1976):  426-43|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Wolff J, Bigler D, Christensen CB, et al. "Influence of renal function on the elimination of morphine and morphine glucoronides." Eur J Clin Pharmacol 34 (1988):  353-7|Covington EC, Gonsalves-Ebrahim L, Currie KO, et al. "Severe respiratory depression from patient-controlled analgesia in renal failure." Psychosomatics 30 (1989):  226-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Bechtel WD, Sinterhauf K "Plasma level and renal excretion of [3H] codeine phosphate in man and in the dog." Arzneimittelforschung 28 (1978):  308-11|Wolfert AI, Sica DA "Narcotic usage in renal failure." Int J Artif Organs 11 (1988):  411-5|Inturrisi CE "Disposition of narcotics in patients with renal disease." Am J Med 62 (1977):  528-9|Chan K, Jennings F, Orme ML "Pharmacokinetics of low-dose intravenous pethidine in patients with renal dysfunction." J Clin Pharmacol 27 (1987):  516-22|Chauvin M, Sandouk P, Scherrmann JM, Farinotti R, Strumza P, Duvaldestin P "Morphine pharmacokinetics in renal failure." Anesthesiology 66 (1987):  327-31|Aitkenhead AR, Vater M, Achola K, Cooper CM, Smith G "Pharmacokinetics of single-dose i.v. morphine in normal volunteers and patients with end-stage renal failure." Br J Anaesth 56 (1984):  813-9|Sawe J, Odar-Cederlof I "Kinetics of morphine in patients with renal failure." Eur J Clin Pharmacol 32 (1987):  377-82|Baselt RC, Casarett LJ "Urinary excretion of methadone in man." Clin Pharmacol Ther 13 (1972):  64-70|Kreek MJ, Schecter AJ, Gutjahr CL, et al. "Methadone use in patients with chronic renal failure." Drug Alcohol Depend 5 (1980):  197-205|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hanna MH, D''Costa F, Peat SJ, Fung C, Venkat N, Zilkha TR, Davies S "Morphine-6-glucuronide disposition in renal impairment." Br J Anaesth 70 (1993):  511-4|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Gibson TP, Giacomini KM, Briggs WA, Whitman W, Levy G "Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient." Clin Pharmacol Ther 27 (1980):  665-70|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Giacomini KM, Gibson TP, Levy G "Plasma protein binding of d-propoxyphene in normal subjects and anephric patients." J Clin Pharmacol 18 (1978):  106-9|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Dhonneur G, Gilton A, Sandouk P, Scherrmann JM, Duvaldestin P "Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine - the influence of renal failure." Anesthesiology 81 (1994):  87-93|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51511, 4802, 'Fentanyl', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', 'Kaiko RF, Foley KM, Grabinski PY, et al. "Central nervous system excitatory effects of meperidine in cancer patients." Ann Neurol 13 (1983):  180-5|Goetting MG, Thirman MJ "Neurotoxicity of meperidine." Ann Emerg Med 14 (1985):  1007-9|Mauro VF, Bonfiglio MF, Spunt AL "Meperidine-induced seizure in a patient without renal dysfunction or sickle cell anemia." Clin Pharm 5 (1986):  837-9|Reutens DC, Stewart-Wynne EG "Norpethidine induced myoclonus in a patient with renal failure." J Neurol Neurosurg Psychiatry 52 (1989):  1450-1|Armstrong PJ, Bersten A "Normeperidine toxicity." Anesth Analg 65 (1986):  536-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Babul N, Darke AC "Putative role of hydromorphone metabolites in myoclonus." Pain 51 (1992):  260-1|Hagmeyer KO, Mauro LS, Mauro VF "Meperidine-related seizures associated with patient-controlled analgesia pumps." Ann Pharmacother 27 (1993):  29-32|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG "Fentanyl and convulsions." Anesth Analg 62 (1983):  858-9|Rao TL, Mummaneni N, El-Etr AA "Convulsions: an unusual response to intravenous fentanyl administration." Anesth Analg 61 (1982):  1020-1|Goroszeniuk T, Albin M, Jones RM "Generalized grand mal seizure after recovery from uncomplicated fentanyl-etomidate anesthesia." Anesth Analg 65 (1986):  979-81|Hoien AO "Another case of grand mal seizure after fentanyl administration." Anesthesiology 60 (1984):  387-8|Safwat AM, Daniel D "Grand mal seizure after fentanyl administration." Anesthesiology 59 (1983):  78|Smith NT, Benthuysen JL, Bickford RG, Sanford TJ, Blasco T, Duke PC, Head N, Dec-Silver H "Seizures during opioid anesthetic induction--are they opioid-induced rigidity?" Anesthesiology 71 (1989):  852-62|Benthuysen JL, Stanley TH "Concerning the possible nature of reported fentanyl seizures." Anesthesiology 62 (1985):  205|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Stone PA, Macintyre PE, Jarvis DA "Norpethidine toxicity and patient controlled analgesia." Br J Anaesth 71 (1993):  738-40|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Strong WE, Matson M "Probable seizure after alfentanil." Anesth Analg 68 (1989):  692-3|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51512, 13291, 'Fentanyl', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', 'Kaiko RF, Foley KM, Grabinski PY, et al. "Central nervous system excitatory effects of meperidine in cancer patients." Ann Neurol 13 (1983):  180-5|Goetting MG, Thirman MJ "Neurotoxicity of meperidine." Ann Emerg Med 14 (1985):  1007-9|Mauro VF, Bonfiglio MF, Spunt AL "Meperidine-induced seizure in a patient without renal dysfunction or sickle cell anemia." Clin Pharm 5 (1986):  837-9|Reutens DC, Stewart-Wynne EG "Norpethidine induced myoclonus in a patient with renal failure." J Neurol Neurosurg Psychiatry 52 (1989):  1450-1|Armstrong PJ, Bersten A "Normeperidine toxicity." Anesth Analg 65 (1986):  536-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Babul N, Darke AC "Putative role of hydromorphone metabolites in myoclonus." Pain 51 (1992):  260-1|Hagmeyer KO, Mauro LS, Mauro VF "Meperidine-related seizures associated with patient-controlled analgesia pumps." Ann Pharmacother 27 (1993):  29-32|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG "Fentanyl and convulsions." Anesth Analg 62 (1983):  858-9|Rao TL, Mummaneni N, El-Etr AA "Convulsions: an unusual response to intravenous fentanyl administration." Anesth Analg 61 (1982):  1020-1|Goroszeniuk T, Albin M, Jones RM "Generalized grand mal seizure after recovery from uncomplicated fentanyl-etomidate anesthesia." Anesth Analg 65 (1986):  979-81|Hoien AO "Another case of grand mal seizure after fentanyl administration." Anesthesiology 60 (1984):  387-8|Safwat AM, Daniel D "Grand mal seizure after fentanyl administration." Anesthesiology 59 (1983):  78|Smith NT, Benthuysen JL, Bickford RG, Sanford TJ, Blasco T, Duke PC, Head N, Dec-Silver H "Seizures during opioid anesthetic induction--are they opioid-induced rigidity?" Anesthesiology 71 (1989):  852-62|Benthuysen JL, Stanley TH "Concerning the possible nature of reported fentanyl seizures." Anesthesiology 62 (1985):  205|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Stone PA, Macintyre PE, Jarvis DA "Norpethidine toxicity and patient controlled analgesia." Br J Anaesth 71 (1993):  738-40|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Strong WE, Matson M "Probable seizure after alfentanil." Anesth Analg 68 (1989):  692-3|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51513, 13292, 'Fentanyl', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', 'Kaiko RF, Foley KM, Grabinski PY, et al. "Central nervous system excitatory effects of meperidine in cancer patients." Ann Neurol 13 (1983):  180-5|Goetting MG, Thirman MJ "Neurotoxicity of meperidine." Ann Emerg Med 14 (1985):  1007-9|Mauro VF, Bonfiglio MF, Spunt AL "Meperidine-induced seizure in a patient without renal dysfunction or sickle cell anemia." Clin Pharm 5 (1986):  837-9|Reutens DC, Stewart-Wynne EG "Norpethidine induced myoclonus in a patient with renal failure." J Neurol Neurosurg Psychiatry 52 (1989):  1450-1|Armstrong PJ, Bersten A "Normeperidine toxicity." Anesth Analg 65 (1986):  536-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Babul N, Darke AC "Putative role of hydromorphone metabolites in myoclonus." Pain 51 (1992):  260-1|Hagmeyer KO, Mauro LS, Mauro VF "Meperidine-related seizures associated with patient-controlled analgesia pumps." Ann Pharmacother 27 (1993):  29-32|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG "Fentanyl and convulsions." Anesth Analg 62 (1983):  858-9|Rao TL, Mummaneni N, El-Etr AA "Convulsions: an unusual response to intravenous fentanyl administration." Anesth Analg 61 (1982):  1020-1|Goroszeniuk T, Albin M, Jones RM "Generalized grand mal seizure after recovery from uncomplicated fentanyl-etomidate anesthesia." Anesth Analg 65 (1986):  979-81|Hoien AO "Another case of grand mal seizure after fentanyl administration." Anesthesiology 60 (1984):  387-8|Safwat AM, Daniel D "Grand mal seizure after fentanyl administration." Anesthesiology 59 (1983):  78|Smith NT, Benthuysen JL, Bickford RG, Sanford TJ, Blasco T, Duke PC, Head N, Dec-Silver H "Seizures during opioid anesthetic induction--are they opioid-induced rigidity?" Anesthesiology 71 (1989):  852-62|Benthuysen JL, Stanley TH "Concerning the possible nature of reported fentanyl seizures." Anesthesiology 62 (1985):  205|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Stone PA, Macintyre PE, Jarvis DA "Norpethidine toxicity and patient controlled analgesia." Br J Anaesth 71 (1993):  738-40|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Strong WE, Matson M "Probable seizure after alfentanil." Anesth Analg 68 (1989):  692-3|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51514, 17981, 'Fentanyl', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', 'Kaiko RF, Foley KM, Grabinski PY, et al. "Central nervous system excitatory effects of meperidine in cancer patients." Ann Neurol 13 (1983):  180-5|Goetting MG, Thirman MJ "Neurotoxicity of meperidine." Ann Emerg Med 14 (1985):  1007-9|Mauro VF, Bonfiglio MF, Spunt AL "Meperidine-induced seizure in a patient without renal dysfunction or sickle cell anemia." Clin Pharm 5 (1986):  837-9|Reutens DC, Stewart-Wynne EG "Norpethidine induced myoclonus in a patient with renal failure." J Neurol Neurosurg Psychiatry 52 (1989):  1450-1|Armstrong PJ, Bersten A "Normeperidine toxicity." Anesth Analg 65 (1986):  536-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Babul N, Darke AC "Putative role of hydromorphone metabolites in myoclonus." Pain 51 (1992):  260-1|Hagmeyer KO, Mauro LS, Mauro VF "Meperidine-related seizures associated with patient-controlled analgesia pumps." Ann Pharmacother 27 (1993):  29-32|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG "Fentanyl and convulsions." Anesth Analg 62 (1983):  858-9|Rao TL, Mummaneni N, El-Etr AA "Convulsions: an unusual response to intravenous fentanyl administration." Anesth Analg 61 (1982):  1020-1|Goroszeniuk T, Albin M, Jones RM "Generalized grand mal seizure after recovery from uncomplicated fentanyl-etomidate anesthesia." Anesth Analg 65 (1986):  979-81|Hoien AO "Another case of grand mal seizure after fentanyl administration." Anesthesiology 60 (1984):  387-8|Safwat AM, Daniel D "Grand mal seizure after fentanyl administration." Anesthesiology 59 (1983):  78|Smith NT, Benthuysen JL, Bickford RG, Sanford TJ, Blasco T, Duke PC, Head N, Dec-Silver H "Seizures during opioid anesthetic induction--are they opioid-induced rigidity?" Anesthesiology 71 (1989):  852-62|Benthuysen JL, Stanley TH "Concerning the possible nature of reported fentanyl seizures." Anesthesiology 62 (1985):  205|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Stone PA, Macintyre PE, Jarvis DA "Norpethidine toxicity and patient controlled analgesia." Br J Anaesth 71 (1993):  738-40|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Strong WE, Matson M "Probable seizure after alfentanil." Anesth Analg 68 (1989):  692-3|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51515, 17982, 'Fentanyl', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', 'Kaiko RF, Foley KM, Grabinski PY, et al. "Central nervous system excitatory effects of meperidine in cancer patients." Ann Neurol 13 (1983):  180-5|Goetting MG, Thirman MJ "Neurotoxicity of meperidine." Ann Emerg Med 14 (1985):  1007-9|Mauro VF, Bonfiglio MF, Spunt AL "Meperidine-induced seizure in a patient without renal dysfunction or sickle cell anemia." Clin Pharm 5 (1986):  837-9|Reutens DC, Stewart-Wynne EG "Norpethidine induced myoclonus in a patient with renal failure." J Neurol Neurosurg Psychiatry 52 (1989):  1450-1|Armstrong PJ, Bersten A "Normeperidine toxicity." Anesth Analg 65 (1986):  536-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Babul N, Darke AC "Putative role of hydromorphone metabolites in myoclonus." Pain 51 (1992):  260-1|Hagmeyer KO, Mauro LS, Mauro VF "Meperidine-related seizures associated with patient-controlled analgesia pumps." Ann Pharmacother 27 (1993):  29-32|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG "Fentanyl and convulsions." Anesth Analg 62 (1983):  858-9|Rao TL, Mummaneni N, El-Etr AA "Convulsions: an unusual response to intravenous fentanyl administration." Anesth Analg 61 (1982):  1020-1|Goroszeniuk T, Albin M, Jones RM "Generalized grand mal seizure after recovery from uncomplicated fentanyl-etomidate anesthesia." Anesth Analg 65 (1986):  979-81|Hoien AO "Another case of grand mal seizure after fentanyl administration." Anesthesiology 60 (1984):  387-8|Safwat AM, Daniel D "Grand mal seizure after fentanyl administration." Anesthesiology 59 (1983):  78|Smith NT, Benthuysen JL, Bickford RG, Sanford TJ, Blasco T, Duke PC, Head N, Dec-Silver H "Seizures during opioid anesthetic induction--are they opioid-induced rigidity?" Anesthesiology 71 (1989):  852-62|Benthuysen JL, Stanley TH "Concerning the possible nature of reported fentanyl seizures." Anesthesiology 62 (1985):  205|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Stone PA, Macintyre PE, Jarvis DA "Norpethidine toxicity and patient controlled analgesia." Br J Anaesth 71 (1993):  738-40|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Strong WE, Matson M "Probable seizure after alfentanil." Anesth Analg 68 (1989):  692-3|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51516, 17983, 'Fentanyl', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', 'Kaiko RF, Foley KM, Grabinski PY, et al. "Central nervous system excitatory effects of meperidine in cancer patients." Ann Neurol 13 (1983):  180-5|Goetting MG, Thirman MJ "Neurotoxicity of meperidine." Ann Emerg Med 14 (1985):  1007-9|Mauro VF, Bonfiglio MF, Spunt AL "Meperidine-induced seizure in a patient without renal dysfunction or sickle cell anemia." Clin Pharm 5 (1986):  837-9|Reutens DC, Stewart-Wynne EG "Norpethidine induced myoclonus in a patient with renal failure." J Neurol Neurosurg Psychiatry 52 (1989):  1450-1|Armstrong PJ, Bersten A "Normeperidine toxicity." Anesth Analg 65 (1986):  536-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Babul N, Darke AC "Putative role of hydromorphone metabolites in myoclonus." Pain 51 (1992):  260-1|Hagmeyer KO, Mauro LS, Mauro VF "Meperidine-related seizures associated with patient-controlled analgesia pumps." Ann Pharmacother 27 (1993):  29-32|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG "Fentanyl and convulsions." Anesth Analg 62 (1983):  858-9|Rao TL, Mummaneni N, El-Etr AA "Convulsions: an unusual response to intravenous fentanyl administration." Anesth Analg 61 (1982):  1020-1|Goroszeniuk T, Albin M, Jones RM "Generalized grand mal seizure after recovery from uncomplicated fentanyl-etomidate anesthesia." Anesth Analg 65 (1986):  979-81|Hoien AO "Another case of grand mal seizure after fentanyl administration." Anesthesiology 60 (1984):  387-8|Safwat AM, Daniel D "Grand mal seizure after fentanyl administration." Anesthesiology 59 (1983):  78|Smith NT, Benthuysen JL, Bickford RG, Sanford TJ, Blasco T, Duke PC, Head N, Dec-Silver H "Seizures during opioid anesthetic induction--are they opioid-induced rigidity?" Anesthesiology 71 (1989):  852-62|Benthuysen JL, Stanley TH "Concerning the possible nature of reported fentanyl seizures." Anesthesiology 62 (1985):  205|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Stone PA, Macintyre PE, Jarvis DA "Norpethidine toxicity and patient controlled analgesia." Br J Anaesth 71 (1993):  738-40|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Strong WE, Matson M "Probable seizure after alfentanil." Anesth Analg 68 (1989):  692-3|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51517, 17984, 'Fentanyl', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', 'Kaiko RF, Foley KM, Grabinski PY, et al. "Central nervous system excitatory effects of meperidine in cancer patients." Ann Neurol 13 (1983):  180-5|Goetting MG, Thirman MJ "Neurotoxicity of meperidine." Ann Emerg Med 14 (1985):  1007-9|Mauro VF, Bonfiglio MF, Spunt AL "Meperidine-induced seizure in a patient without renal dysfunction or sickle cell anemia." Clin Pharm 5 (1986):  837-9|Reutens DC, Stewart-Wynne EG "Norpethidine induced myoclonus in a patient with renal failure." J Neurol Neurosurg Psychiatry 52 (1989):  1450-1|Armstrong PJ, Bersten A "Normeperidine toxicity." Anesth Analg 65 (1986):  536-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Babul N, Darke AC "Putative role of hydromorphone metabolites in myoclonus." Pain 51 (1992):  260-1|Hagmeyer KO, Mauro LS, Mauro VF "Meperidine-related seizures associated with patient-controlled analgesia pumps." Ann Pharmacother 27 (1993):  29-32|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG "Fentanyl and convulsions." Anesth Analg 62 (1983):  858-9|Rao TL, Mummaneni N, El-Etr AA "Convulsions: an unusual response to intravenous fentanyl administration." Anesth Analg 61 (1982):  1020-1|Goroszeniuk T, Albin M, Jones RM "Generalized grand mal seizure after recovery from uncomplicated fentanyl-etomidate anesthesia." Anesth Analg 65 (1986):  979-81|Hoien AO "Another case of grand mal seizure after fentanyl administration." Anesthesiology 60 (1984):  387-8|Safwat AM, Daniel D "Grand mal seizure after fentanyl administration." Anesthesiology 59 (1983):  78|Smith NT, Benthuysen JL, Bickford RG, Sanford TJ, Blasco T, Duke PC, Head N, Dec-Silver H "Seizures during opioid anesthetic induction--are they opioid-induced rigidity?" Anesthesiology 71 (1989):  852-62|Benthuysen JL, Stanley TH "Concerning the possible nature of reported fentanyl seizures." Anesthesiology 62 (1985):  205|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Stone PA, Macintyre PE, Jarvis DA "Norpethidine toxicity and patient controlled analgesia." Br J Anaesth 71 (1993):  738-40|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Strong WE, Matson M "Probable seizure after alfentanil." Anesth Analg 68 (1989):  692-3|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51518, 17985, 'Fentanyl', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', 'Kaiko RF, Foley KM, Grabinski PY, et al. "Central nervous system excitatory effects of meperidine in cancer patients." Ann Neurol 13 (1983):  180-5|Goetting MG, Thirman MJ "Neurotoxicity of meperidine." Ann Emerg Med 14 (1985):  1007-9|Mauro VF, Bonfiglio MF, Spunt AL "Meperidine-induced seizure in a patient without renal dysfunction or sickle cell anemia." Clin Pharm 5 (1986):  837-9|Reutens DC, Stewart-Wynne EG "Norpethidine induced myoclonus in a patient with renal failure." J Neurol Neurosurg Psychiatry 52 (1989):  1450-1|Armstrong PJ, Bersten A "Normeperidine toxicity." Anesth Analg 65 (1986):  536-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Babul N, Darke AC "Putative role of hydromorphone metabolites in myoclonus." Pain 51 (1992):  260-1|Hagmeyer KO, Mauro LS, Mauro VF "Meperidine-related seizures associated with patient-controlled analgesia pumps." Ann Pharmacother 27 (1993):  29-32|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG "Fentanyl and convulsions." Anesth Analg 62 (1983):  858-9|Rao TL, Mummaneni N, El-Etr AA "Convulsions: an unusual response to intravenous fentanyl administration." Anesth Analg 61 (1982):  1020-1|Goroszeniuk T, Albin M, Jones RM "Generalized grand mal seizure after recovery from uncomplicated fentanyl-etomidate anesthesia." Anesth Analg 65 (1986):  979-81|Hoien AO "Another case of grand mal seizure after fentanyl administration." Anesthesiology 60 (1984):  387-8|Safwat AM, Daniel D "Grand mal seizure after fentanyl administration." Anesthesiology 59 (1983):  78|Smith NT, Benthuysen JL, Bickford RG, Sanford TJ, Blasco T, Duke PC, Head N, Dec-Silver H "Seizures during opioid anesthetic induction--are they opioid-induced rigidity?" Anesthesiology 71 (1989):  852-62|Benthuysen JL, Stanley TH "Concerning the possible nature of reported fentanyl seizures." Anesthesiology 62 (1985):  205|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Stone PA, Macintyre PE, Jarvis DA "Norpethidine toxicity and patient controlled analgesia." Br J Anaesth 71 (1993):  738-40|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Strong WE, Matson M "Probable seizure after alfentanil." Anesth Analg 68 (1989):  692-3|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51519, 18952, 'Fentanyl', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', 'Kaiko RF, Foley KM, Grabinski PY, et al. "Central nervous system excitatory effects of meperidine in cancer patients." Ann Neurol 13 (1983):  180-5|Goetting MG, Thirman MJ "Neurotoxicity of meperidine." Ann Emerg Med 14 (1985):  1007-9|Mauro VF, Bonfiglio MF, Spunt AL "Meperidine-induced seizure in a patient without renal dysfunction or sickle cell anemia." Clin Pharm 5 (1986):  837-9|Reutens DC, Stewart-Wynne EG "Norpethidine induced myoclonus in a patient with renal failure." J Neurol Neurosurg Psychiatry 52 (1989):  1450-1|Armstrong PJ, Bersten A "Normeperidine toxicity." Anesth Analg 65 (1986):  536-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Babul N, Darke AC "Putative role of hydromorphone metabolites in myoclonus." Pain 51 (1992):  260-1|Hagmeyer KO, Mauro LS, Mauro VF "Meperidine-related seizures associated with patient-controlled analgesia pumps." Ann Pharmacother 27 (1993):  29-32|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG "Fentanyl and convulsions." Anesth Analg 62 (1983):  858-9|Rao TL, Mummaneni N, El-Etr AA "Convulsions: an unusual response to intravenous fentanyl administration." Anesth Analg 61 (1982):  1020-1|Goroszeniuk T, Albin M, Jones RM "Generalized grand mal seizure after recovery from uncomplicated fentanyl-etomidate anesthesia." Anesth Analg 65 (1986):  979-81|Hoien AO "Another case of grand mal seizure after fentanyl administration." Anesthesiology 60 (1984):  387-8|Safwat AM, Daniel D "Grand mal seizure after fentanyl administration." Anesthesiology 59 (1983):  78|Smith NT, Benthuysen JL, Bickford RG, Sanford TJ, Blasco T, Duke PC, Head N, Dec-Silver H "Seizures during opioid anesthetic induction--are they opioid-induced rigidity?" Anesthesiology 71 (1989):  852-62|Benthuysen JL, Stanley TH "Concerning the possible nature of reported fentanyl seizures." Anesthesiology 62 (1985):  205|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Stone PA, Macintyre PE, Jarvis DA "Norpethidine toxicity and patient controlled analgesia." Br J Anaesth 71 (1993):  738-40|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Strong WE, Matson M "Probable seizure after alfentanil." Anesth Analg 68 (1989):  692-3|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51520, 18953, 'Fentanyl', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', 'Kaiko RF, Foley KM, Grabinski PY, et al. "Central nervous system excitatory effects of meperidine in cancer patients." Ann Neurol 13 (1983):  180-5|Goetting MG, Thirman MJ "Neurotoxicity of meperidine." Ann Emerg Med 14 (1985):  1007-9|Mauro VF, Bonfiglio MF, Spunt AL "Meperidine-induced seizure in a patient without renal dysfunction or sickle cell anemia." Clin Pharm 5 (1986):  837-9|Reutens DC, Stewart-Wynne EG "Norpethidine induced myoclonus in a patient with renal failure." J Neurol Neurosurg Psychiatry 52 (1989):  1450-1|Armstrong PJ, Bersten A "Normeperidine toxicity." Anesth Analg 65 (1986):  536-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Babul N, Darke AC "Putative role of hydromorphone metabolites in myoclonus." Pain 51 (1992):  260-1|Hagmeyer KO, Mauro LS, Mauro VF "Meperidine-related seizures associated with patient-controlled analgesia pumps." Ann Pharmacother 27 (1993):  29-32|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG "Fentanyl and convulsions." Anesth Analg 62 (1983):  858-9|Rao TL, Mummaneni N, El-Etr AA "Convulsions: an unusual response to intravenous fentanyl administration." Anesth Analg 61 (1982):  1020-1|Goroszeniuk T, Albin M, Jones RM "Generalized grand mal seizure after recovery from uncomplicated fentanyl-etomidate anesthesia." Anesth Analg 65 (1986):  979-81|Hoien AO "Another case of grand mal seizure after fentanyl administration." Anesthesiology 60 (1984):  387-8|Safwat AM, Daniel D "Grand mal seizure after fentanyl administration." Anesthesiology 59 (1983):  78|Smith NT, Benthuysen JL, Bickford RG, Sanford TJ, Blasco T, Duke PC, Head N, Dec-Silver H "Seizures during opioid anesthetic induction--are they opioid-induced rigidity?" Anesthesiology 71 (1989):  852-62|Benthuysen JL, Stanley TH "Concerning the possible nature of reported fentanyl seizures." Anesthesiology 62 (1985):  205|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Stone PA, Macintyre PE, Jarvis DA "Norpethidine toxicity and patient controlled analgesia." Br J Anaesth 71 (1993):  738-40|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Strong WE, Matson M "Probable seizure after alfentanil." Anesth Analg 68 (1989):  692-3|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51521, 18955, 'Fentanyl', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', 'Kaiko RF, Foley KM, Grabinski PY, et al. "Central nervous system excitatory effects of meperidine in cancer patients." Ann Neurol 13 (1983):  180-5|Goetting MG, Thirman MJ "Neurotoxicity of meperidine." Ann Emerg Med 14 (1985):  1007-9|Mauro VF, Bonfiglio MF, Spunt AL "Meperidine-induced seizure in a patient without renal dysfunction or sickle cell anemia." Clin Pharm 5 (1986):  837-9|Reutens DC, Stewart-Wynne EG "Norpethidine induced myoclonus in a patient with renal failure." J Neurol Neurosurg Psychiatry 52 (1989):  1450-1|Armstrong PJ, Bersten A "Normeperidine toxicity." Anesth Analg 65 (1986):  536-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Babul N, Darke AC "Putative role of hydromorphone metabolites in myoclonus." Pain 51 (1992):  260-1|Hagmeyer KO, Mauro LS, Mauro VF "Meperidine-related seizures associated with patient-controlled analgesia pumps." Ann Pharmacother 27 (1993):  29-32|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG "Fentanyl and convulsions." Anesth Analg 62 (1983):  858-9|Rao TL, Mummaneni N, El-Etr AA "Convulsions: an unusual response to intravenous fentanyl administration." Anesth Analg 61 (1982):  1020-1|Goroszeniuk T, Albin M, Jones RM "Generalized grand mal seizure after recovery from uncomplicated fentanyl-etomidate anesthesia." Anesth Analg 65 (1986):  979-81|Hoien AO "Another case of grand mal seizure after fentanyl administration." Anesthesiology 60 (1984):  387-8|Safwat AM, Daniel D "Grand mal seizure after fentanyl administration." Anesthesiology 59 (1983):  78|Smith NT, Benthuysen JL, Bickford RG, Sanford TJ, Blasco T, Duke PC, Head N, Dec-Silver H "Seizures during opioid anesthetic induction--are they opioid-induced rigidity?" Anesthesiology 71 (1989):  852-62|Benthuysen JL, Stanley TH "Concerning the possible nature of reported fentanyl seizures." Anesthesiology 62 (1985):  205|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Stone PA, Macintyre PE, Jarvis DA "Norpethidine toxicity and patient controlled analgesia." Br J Anaesth 71 (1993):  738-40|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Strong WE, Matson M "Probable seizure after alfentanil." Anesth Analg 68 (1989):  692-3|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51522, 30532, 'Fentanyl', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', 'Kaiko RF, Foley KM, Grabinski PY, et al. "Central nervous system excitatory effects of meperidine in cancer patients." Ann Neurol 13 (1983):  180-5|Goetting MG, Thirman MJ "Neurotoxicity of meperidine." Ann Emerg Med 14 (1985):  1007-9|Mauro VF, Bonfiglio MF, Spunt AL "Meperidine-induced seizure in a patient without renal dysfunction or sickle cell anemia." Clin Pharm 5 (1986):  837-9|Reutens DC, Stewart-Wynne EG "Norpethidine induced myoclonus in a patient with renal failure." J Neurol Neurosurg Psychiatry 52 (1989):  1450-1|Armstrong PJ, Bersten A "Normeperidine toxicity." Anesth Analg 65 (1986):  536-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Babul N, Darke AC "Putative role of hydromorphone metabolites in myoclonus." Pain 51 (1992):  260-1|Hagmeyer KO, Mauro LS, Mauro VF "Meperidine-related seizures associated with patient-controlled analgesia pumps." Ann Pharmacother 27 (1993):  29-32|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG "Fentanyl and convulsions." Anesth Analg 62 (1983):  858-9|Rao TL, Mummaneni N, El-Etr AA "Convulsions: an unusual response to intravenous fentanyl administration." Anesth Analg 61 (1982):  1020-1|Goroszeniuk T, Albin M, Jones RM "Generalized grand mal seizure after recovery from uncomplicated fentanyl-etomidate anesthesia." Anesth Analg 65 (1986):  979-81|Hoien AO "Another case of grand mal seizure after fentanyl administration." Anesthesiology 60 (1984):  387-8|Safwat AM, Daniel D "Grand mal seizure after fentanyl administration." Anesthesiology 59 (1983):  78|Smith NT, Benthuysen JL, Bickford RG, Sanford TJ, Blasco T, Duke PC, Head N, Dec-Silver H "Seizures during opioid anesthetic induction--are they opioid-induced rigidity?" Anesthesiology 71 (1989):  852-62|Benthuysen JL, Stanley TH "Concerning the possible nature of reported fentanyl seizures." Anesthesiology 62 (1985):  205|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Stone PA, Macintyre PE, Jarvis DA "Norpethidine toxicity and patient controlled analgesia." Br J Anaesth 71 (1993):  738-40|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Strong WE, Matson M "Probable seizure after alfentanil." Anesth Analg 68 (1989):  692-3|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51523, 4802, 'Fentanyl', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Petersen TK, Husted SE, Rybro L, et al. "Urinary retention during I.M. and extradural morphine analgesia." Br J Anaesth 54 (1982):  1175-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|Petros JG, Mallen JK, Howe K, Rimm EB, Robillard RJ "Patient-controlled analgesia and postoperative urinary retention after open appendectomy." Surg Gynecol Obstet 177 (1993):  172-5|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51524, 13291, 'Fentanyl', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Petersen TK, Husted SE, Rybro L, et al. "Urinary retention during I.M. and extradural morphine analgesia." Br J Anaesth 54 (1982):  1175-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|Petros JG, Mallen JK, Howe K, Rimm EB, Robillard RJ "Patient-controlled analgesia and postoperative urinary retention after open appendectomy." Surg Gynecol Obstet 177 (1993):  172-5|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51525, 13292, 'Fentanyl', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Petersen TK, Husted SE, Rybro L, et al. "Urinary retention during I.M. and extradural morphine analgesia." Br J Anaesth 54 (1982):  1175-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|Petros JG, Mallen JK, Howe K, Rimm EB, Robillard RJ "Patient-controlled analgesia and postoperative urinary retention after open appendectomy." Surg Gynecol Obstet 177 (1993):  172-5|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51526, 17981, 'Fentanyl', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Petersen TK, Husted SE, Rybro L, et al. "Urinary retention during I.M. and extradural morphine analgesia." Br J Anaesth 54 (1982):  1175-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|Petros JG, Mallen JK, Howe K, Rimm EB, Robillard RJ "Patient-controlled analgesia and postoperative urinary retention after open appendectomy." Surg Gynecol Obstet 177 (1993):  172-5|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51527, 17982, 'Fentanyl', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Petersen TK, Husted SE, Rybro L, et al. "Urinary retention during I.M. and extradural morphine analgesia." Br J Anaesth 54 (1982):  1175-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|Petros JG, Mallen JK, Howe K, Rimm EB, Robillard RJ "Patient-controlled analgesia and postoperative urinary retention after open appendectomy." Surg Gynecol Obstet 177 (1993):  172-5|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51528, 17983, 'Fentanyl', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Petersen TK, Husted SE, Rybro L, et al. "Urinary retention during I.M. and extradural morphine analgesia." Br J Anaesth 54 (1982):  1175-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|Petros JG, Mallen JK, Howe K, Rimm EB, Robillard RJ "Patient-controlled analgesia and postoperative urinary retention after open appendectomy." Surg Gynecol Obstet 177 (1993):  172-5|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51529, 17984, 'Fentanyl', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Petersen TK, Husted SE, Rybro L, et al. "Urinary retention during I.M. and extradural morphine analgesia." Br J Anaesth 54 (1982):  1175-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|Petros JG, Mallen JK, Howe K, Rimm EB, Robillard RJ "Patient-controlled analgesia and postoperative urinary retention after open appendectomy." Surg Gynecol Obstet 177 (1993):  172-5|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51530, 17985, 'Fentanyl', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Petersen TK, Husted SE, Rybro L, et al. "Urinary retention during I.M. and extradural morphine analgesia." Br J Anaesth 54 (1982):  1175-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|Petros JG, Mallen JK, Howe K, Rimm EB, Robillard RJ "Patient-controlled analgesia and postoperative urinary retention after open appendectomy." Surg Gynecol Obstet 177 (1993):  172-5|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51531, 18952, 'Fentanyl', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Petersen TK, Husted SE, Rybro L, et al. "Urinary retention during I.M. and extradural morphine analgesia." Br J Anaesth 54 (1982):  1175-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|Petros JG, Mallen JK, Howe K, Rimm EB, Robillard RJ "Patient-controlled analgesia and postoperative urinary retention after open appendectomy." Surg Gynecol Obstet 177 (1993):  172-5|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51532, 18953, 'Fentanyl', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Petersen TK, Husted SE, Rybro L, et al. "Urinary retention during I.M. and extradural morphine analgesia." Br J Anaesth 54 (1982):  1175-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|Petros JG, Mallen JK, Howe K, Rimm EB, Robillard RJ "Patient-controlled analgesia and postoperative urinary retention after open appendectomy." Surg Gynecol Obstet 177 (1993):  172-5|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51533, 18955, 'Fentanyl', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Petersen TK, Husted SE, Rybro L, et al. "Urinary retention during I.M. and extradural morphine analgesia." Br J Anaesth 54 (1982):  1175-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|Petros JG, Mallen JK, Howe K, Rimm EB, Robillard RJ "Patient-controlled analgesia and postoperative urinary retention after open appendectomy." Surg Gynecol Obstet 177 (1993):  172-5|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51534, 30532, 'Fentanyl', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Petersen TK, Husted SE, Rybro L, et al. "Urinary retention during I.M. and extradural morphine analgesia." Br J Anaesth 54 (1982):  1175-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|Petros JG, Mallen JK, Howe K, Rimm EB, Robillard RJ "Patient-controlled analgesia and postoperative urinary retention after open appendectomy." Surg Gynecol Obstet 177 (1993):  172-5|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51535, 4802, 'Fentanyl', 'Arrhythmias, Cardiac', 'Opiate agonists have cholinergic activity.  Large doses and/or rapid intravenous administration may produce bradycardia and arrhythmia via stimulation of medullary vagal nuclei.  Unlike other agents in the class, meperidine also has anticholinergic activity and may cause either bradycardia or tachycardia.  Therapy with opiate agonists should be administered cautiously in patients with a history of arrhythmias.  Clinical monitoring of cardiovascular status is recommended during therapy.  Bradycardia and other cholinergic effects produced by these agents may be controlled with atropine.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hilgenberg JC, Johantgen WC "Bradycardia after intravenous fentanyl during subarachnoid anesthesia." Anesth Analg 59 (1980):  162-3|Blair JR, Pruett JK, Crumrine RS, Balser JJ "Prolongation of QT interval in association with the administration of large doses of opiates." Anesthesiology 67 (1987):  442-3|Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982):  308-15|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Heaney RM "Left bundle branch block associated with propoxyphene hydrochloride poisoning." Ann Emerg Med 12 (1983):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51536, 13291, 'Fentanyl', 'Arrhythmias, Cardiac', 'Opiate agonists have cholinergic activity.  Large doses and/or rapid intravenous administration may produce bradycardia and arrhythmia via stimulation of medullary vagal nuclei.  Unlike other agents in the class, meperidine also has anticholinergic activity and may cause either bradycardia or tachycardia.  Therapy with opiate agonists should be administered cautiously in patients with a history of arrhythmias.  Clinical monitoring of cardiovascular status is recommended during therapy.  Bradycardia and other cholinergic effects produced by these agents may be controlled with atropine.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hilgenberg JC, Johantgen WC "Bradycardia after intravenous fentanyl during subarachnoid anesthesia." Anesth Analg 59 (1980):  162-3|Blair JR, Pruett JK, Crumrine RS, Balser JJ "Prolongation of QT interval in association with the administration of large doses of opiates." Anesthesiology 67 (1987):  442-3|Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982):  308-15|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Heaney RM "Left bundle branch block associated with propoxyphene hydrochloride poisoning." Ann Emerg Med 12 (1983):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51537, 13292, 'Fentanyl', 'Arrhythmias, Cardiac', 'Opiate agonists have cholinergic activity.  Large doses and/or rapid intravenous administration may produce bradycardia and arrhythmia via stimulation of medullary vagal nuclei.  Unlike other agents in the class, meperidine also has anticholinergic activity and may cause either bradycardia or tachycardia.  Therapy with opiate agonists should be administered cautiously in patients with a history of arrhythmias.  Clinical monitoring of cardiovascular status is recommended during therapy.  Bradycardia and other cholinergic effects produced by these agents may be controlled with atropine.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hilgenberg JC, Johantgen WC "Bradycardia after intravenous fentanyl during subarachnoid anesthesia." Anesth Analg 59 (1980):  162-3|Blair JR, Pruett JK, Crumrine RS, Balser JJ "Prolongation of QT interval in association with the administration of large doses of opiates." Anesthesiology 67 (1987):  442-3|Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982):  308-15|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Heaney RM "Left bundle branch block associated with propoxyphene hydrochloride poisoning." Ann Emerg Med 12 (1983):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51538, 17981, 'Fentanyl', 'Arrhythmias, Cardiac', 'Opiate agonists have cholinergic activity.  Large doses and/or rapid intravenous administration may produce bradycardia and arrhythmia via stimulation of medullary vagal nuclei.  Unlike other agents in the class, meperidine also has anticholinergic activity and may cause either bradycardia or tachycardia.  Therapy with opiate agonists should be administered cautiously in patients with a history of arrhythmias.  Clinical monitoring of cardiovascular status is recommended during therapy.  Bradycardia and other cholinergic effects produced by these agents may be controlled with atropine.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hilgenberg JC, Johantgen WC "Bradycardia after intravenous fentanyl during subarachnoid anesthesia." Anesth Analg 59 (1980):  162-3|Blair JR, Pruett JK, Crumrine RS, Balser JJ "Prolongation of QT interval in association with the administration of large doses of opiates." Anesthesiology 67 (1987):  442-3|Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982):  308-15|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Heaney RM "Left bundle branch block associated with propoxyphene hydrochloride poisoning." Ann Emerg Med 12 (1983):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51539, 17982, 'Fentanyl', 'Arrhythmias, Cardiac', 'Opiate agonists have cholinergic activity.  Large doses and/or rapid intravenous administration may produce bradycardia and arrhythmia via stimulation of medullary vagal nuclei.  Unlike other agents in the class, meperidine also has anticholinergic activity and may cause either bradycardia or tachycardia.  Therapy with opiate agonists should be administered cautiously in patients with a history of arrhythmias.  Clinical monitoring of cardiovascular status is recommended during therapy.  Bradycardia and other cholinergic effects produced by these agents may be controlled with atropine.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hilgenberg JC, Johantgen WC "Bradycardia after intravenous fentanyl during subarachnoid anesthesia." Anesth Analg 59 (1980):  162-3|Blair JR, Pruett JK, Crumrine RS, Balser JJ "Prolongation of QT interval in association with the administration of large doses of opiates." Anesthesiology 67 (1987):  442-3|Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982):  308-15|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Heaney RM "Left bundle branch block associated with propoxyphene hydrochloride poisoning." Ann Emerg Med 12 (1983):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51540, 17983, 'Fentanyl', 'Arrhythmias, Cardiac', 'Opiate agonists have cholinergic activity.  Large doses and/or rapid intravenous administration may produce bradycardia and arrhythmia via stimulation of medullary vagal nuclei.  Unlike other agents in the class, meperidine also has anticholinergic activity and may cause either bradycardia or tachycardia.  Therapy with opiate agonists should be administered cautiously in patients with a history of arrhythmias.  Clinical monitoring of cardiovascular status is recommended during therapy.  Bradycardia and other cholinergic effects produced by these agents may be controlled with atropine.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hilgenberg JC, Johantgen WC "Bradycardia after intravenous fentanyl during subarachnoid anesthesia." Anesth Analg 59 (1980):  162-3|Blair JR, Pruett JK, Crumrine RS, Balser JJ "Prolongation of QT interval in association with the administration of large doses of opiates." Anesthesiology 67 (1987):  442-3|Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982):  308-15|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Heaney RM "Left bundle branch block associated with propoxyphene hydrochloride poisoning." Ann Emerg Med 12 (1983):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51541, 17984, 'Fentanyl', 'Arrhythmias, Cardiac', 'Opiate agonists have cholinergic activity.  Large doses and/or rapid intravenous administration may produce bradycardia and arrhythmia via stimulation of medullary vagal nuclei.  Unlike other agents in the class, meperidine also has anticholinergic activity and may cause either bradycardia or tachycardia.  Therapy with opiate agonists should be administered cautiously in patients with a history of arrhythmias.  Clinical monitoring of cardiovascular status is recommended during therapy.  Bradycardia and other cholinergic effects produced by these agents may be controlled with atropine.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hilgenberg JC, Johantgen WC "Bradycardia after intravenous fentanyl during subarachnoid anesthesia." Anesth Analg 59 (1980):  162-3|Blair JR, Pruett JK, Crumrine RS, Balser JJ "Prolongation of QT interval in association with the administration of large doses of opiates." Anesthesiology 67 (1987):  442-3|Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982):  308-15|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Heaney RM "Left bundle branch block associated with propoxyphene hydrochloride poisoning." Ann Emerg Med 12 (1983):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51542, 17985, 'Fentanyl', 'Arrhythmias, Cardiac', 'Opiate agonists have cholinergic activity.  Large doses and/or rapid intravenous administration may produce bradycardia and arrhythmia via stimulation of medullary vagal nuclei.  Unlike other agents in the class, meperidine also has anticholinergic activity and may cause either bradycardia or tachycardia.  Therapy with opiate agonists should be administered cautiously in patients with a history of arrhythmias.  Clinical monitoring of cardiovascular status is recommended during therapy.  Bradycardia and other cholinergic effects produced by these agents may be controlled with atropine.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hilgenberg JC, Johantgen WC "Bradycardia after intravenous fentanyl during subarachnoid anesthesia." Anesth Analg 59 (1980):  162-3|Blair JR, Pruett JK, Crumrine RS, Balser JJ "Prolongation of QT interval in association with the administration of large doses of opiates." Anesthesiology 67 (1987):  442-3|Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982):  308-15|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Heaney RM "Left bundle branch block associated with propoxyphene hydrochloride poisoning." Ann Emerg Med 12 (1983):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51543, 18952, 'Fentanyl', 'Arrhythmias, Cardiac', 'Opiate agonists have cholinergic activity.  Large doses and/or rapid intravenous administration may produce bradycardia and arrhythmia via stimulation of medullary vagal nuclei.  Unlike other agents in the class, meperidine also has anticholinergic activity and may cause either bradycardia or tachycardia.  Therapy with opiate agonists should be administered cautiously in patients with a history of arrhythmias.  Clinical monitoring of cardiovascular status is recommended during therapy.  Bradycardia and other cholinergic effects produced by these agents may be controlled with atropine.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hilgenberg JC, Johantgen WC "Bradycardia after intravenous fentanyl during subarachnoid anesthesia." Anesth Analg 59 (1980):  162-3|Blair JR, Pruett JK, Crumrine RS, Balser JJ "Prolongation of QT interval in association with the administration of large doses of opiates." Anesthesiology 67 (1987):  442-3|Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982):  308-15|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Heaney RM "Left bundle branch block associated with propoxyphene hydrochloride poisoning." Ann Emerg Med 12 (1983):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51544, 18953, 'Fentanyl', 'Arrhythmias, Cardiac', 'Opiate agonists have cholinergic activity.  Large doses and/or rapid intravenous administration may produce bradycardia and arrhythmia via stimulation of medullary vagal nuclei.  Unlike other agents in the class, meperidine also has anticholinergic activity and may cause either bradycardia or tachycardia.  Therapy with opiate agonists should be administered cautiously in patients with a history of arrhythmias.  Clinical monitoring of cardiovascular status is recommended during therapy.  Bradycardia and other cholinergic effects produced by these agents may be controlled with atropine.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hilgenberg JC, Johantgen WC "Bradycardia after intravenous fentanyl during subarachnoid anesthesia." Anesth Analg 59 (1980):  162-3|Blair JR, Pruett JK, Crumrine RS, Balser JJ "Prolongation of QT interval in association with the administration of large doses of opiates." Anesthesiology 67 (1987):  442-3|Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982):  308-15|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Heaney RM "Left bundle branch block associated with propoxyphene hydrochloride poisoning." Ann Emerg Med 12 (1983):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51545, 18955, 'Fentanyl', 'Arrhythmias, Cardiac', 'Opiate agonists have cholinergic activity.  Large doses and/or rapid intravenous administration may produce bradycardia and arrhythmia via stimulation of medullary vagal nuclei.  Unlike other agents in the class, meperidine also has anticholinergic activity and may cause either bradycardia or tachycardia.  Therapy with opiate agonists should be administered cautiously in patients with a history of arrhythmias.  Clinical monitoring of cardiovascular status is recommended during therapy.  Bradycardia and other cholinergic effects produced by these agents may be controlled with atropine.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hilgenberg JC, Johantgen WC "Bradycardia after intravenous fentanyl during subarachnoid anesthesia." Anesth Analg 59 (1980):  162-3|Blair JR, Pruett JK, Crumrine RS, Balser JJ "Prolongation of QT interval in association with the administration of large doses of opiates." Anesthesiology 67 (1987):  442-3|Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982):  308-15|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Heaney RM "Left bundle branch block associated with propoxyphene hydrochloride poisoning." Ann Emerg Med 12 (1983):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51546, 30532, 'Fentanyl', 'Arrhythmias, Cardiac', 'Opiate agonists have cholinergic activity.  Large doses and/or rapid intravenous administration may produce bradycardia and arrhythmia via stimulation of medullary vagal nuclei.  Unlike other agents in the class, meperidine also has anticholinergic activity and may cause either bradycardia or tachycardia.  Therapy with opiate agonists should be administered cautiously in patients with a history of arrhythmias.  Clinical monitoring of cardiovascular status is recommended during therapy.  Bradycardia and other cholinergic effects produced by these agents may be controlled with atropine.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hilgenberg JC, Johantgen WC "Bradycardia after intravenous fentanyl during subarachnoid anesthesia." Anesth Analg 59 (1980):  162-3|Blair JR, Pruett JK, Crumrine RS, Balser JJ "Prolongation of QT interval in association with the administration of large doses of opiates." Anesthesiology 67 (1987):  442-3|Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982):  308-15|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Heaney RM "Left bundle branch block associated with propoxyphene hydrochloride poisoning." Ann Emerg Med 12 (1983):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51547, 4838, 'Ferrous sulfate anhydrous', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51548, 4838, 'Ferrous sulfate anhydrous', 'Achlorhydria', 'Gastric acidity increases iron bioavailability by maintaining the ingested iron in a reduced form as ferrous ions, which are more readily absorbed than ferric ions.  Therefore, when iron therapy is administered orally, higher dosages may be necessary for patients with decreased gastric acid production.  Also, a liquid formulation is recommended in these patients because dissolution of the tablet coating depends on normal gastric acidity.', '2', '"Product Information. Feosol (ferrous sulfate)." SmithKline Beecham|"Product Information. Ferrous Gluconate (ferrous gluconate)." Paddock Laboratories Inc  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51549, 4838, 'Ferrous sulfate anhydrous', 'Gastrointestinal Diseases', 'Iron can be irritating and damaging to gastrointestinal mucosa.  Iron therapy should be administered cautiously in patients with peptic ulcer disease, enteritis, or ulcerative colitis.', '2', '"Product Information. Feosol (ferrous sulfate)." SmithKline Beecham|"Product Information. Ferrous Gluconate (ferrous gluconate)." Paddock Laboratories Inc  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51550, 0, 'Ferric carboxymaltose', 'Hypertension', 'Transient elevation of blood pressure has been reported in clinical trials in patients receiving ferric carboxymaltose.  These elevations generally occurred immediately after dosing and resolved in 30 minutes.  Patients should be monitored for symptoms or signs of hypertension following treatment.', '2', '"Product Information. Injectafer (ferric carboxymaltose)." American Regent Laboratories Inc  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51551, 0, 'Ferric carboxymaltose', 'Hypophosphatemia', 'Patients with malabsorption of fat-soluble vitamins or phosphate, or using medications affection proximal renal tubular function, hyperparathyroidism, vitamin D deficiency, or malnutrition may experience symptomatic hypophosphatemia.  Cases occur mostly after repeat exposure.  Most cases resolved within 3 months.  Monitor serum phosphate in at risk patiens requiring repeat treatment.', '2', '"Product Information. Injectafer (ferric carboxymaltose)." American Regent Laboratories Inc  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51552, 0, 'Ferric carboxymaltose', 'Hypersensitivity, Immediate', 'Serious hypersensitivity reactions, including anaphylaxis- type reactions, some of which have been life-threatening have been reported in patients using some injection iron products.  Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse.  These products should be administered cautiously, especially in patients with a history of significant allergies.  Patients should be monitored during and at least 30 minutes after the administration.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', '"Product Information. Feraheme (ferumoxytol)." Alza Pharmaceuticals  (2009):|"Product Information. Injectafer (ferric carboxymaltose)." American Regent Laboratories Inc  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51553, 4838, 'Ferrous fumarate', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51554, 4838, 'Ferrous fumarate', 'Achlorhydria', 'Gastric acidity increases iron bioavailability by maintaining the ingested iron in a reduced form as ferrous ions, which are more readily absorbed than ferric ions.  Therefore, when iron therapy is administered orally, higher dosages may be necessary for patients with decreased gastric acid production.  Also, a liquid formulation is recommended in these patients because dissolution of the tablet coating depends on normal gastric acidity.', '2', '"Product Information. Feosol (ferrous sulfate)." SmithKline Beecham|"Product Information. Ferrous Gluconate (ferrous gluconate)." Paddock Laboratories Inc  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51555, 4838, 'Ferrous fumarate', 'Gastrointestinal Diseases', 'Iron can be irritating and damaging to gastrointestinal mucosa.  Iron therapy should be administered cautiously in patients with peptic ulcer disease, enteritis, or ulcerative colitis.', '2', '"Product Information. Feosol (ferrous sulfate)." SmithKline Beecham|"Product Information. Ferrous Gluconate (ferrous gluconate)." Paddock Laboratories Inc  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51556, 0, 'Ferric derisomaltose', 'Iron Overload', 'Ferric derisomaltose should not be administered to patients with iron overload.', '2', '"Product Information. Monoferric (ferric derisomaltose)." Pharmacosmos Therapeutics  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51557, 4866, 'Finasteride', 'Liver Diseases', 'Finasteride and dutasteride are extensively metabolized by the liver.  Therapy with these drugs should be administered cautiously in patients with liver disease as exposure could be higher.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):|"Product Information. Duagen (dutasteride)." GlaxoSmithKline Healthcare  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51558, 19040, 'Finasteride', 'Liver Diseases', 'Finasteride and dutasteride are extensively metabolized by the liver.  Therapy with these drugs should be administered cautiously in patients with liver disease as exposure could be higher.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):|"Product Information. Duagen (dutasteride)." GlaxoSmithKline Healthcare  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51559, 22859, 'Finasteride', 'Liver Diseases', 'Finasteride and dutasteride are extensively metabolized by the liver.  Therapy with these drugs should be administered cautiously in patients with liver disease as exposure could be higher.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):|"Product Information. Duagen (dutasteride)." GlaxoSmithKline Healthcare  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51560, 23699, 'Finasteride', 'Liver Diseases', 'Finasteride and dutasteride are extensively metabolized by the liver.  Therapy with these drugs should be administered cautiously in patients with liver disease as exposure could be higher.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):|"Product Information. Duagen (dutasteride)." GlaxoSmithKline Healthcare  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51561, 25330, 'Finasteride', 'Liver Diseases', 'Finasteride and dutasteride are extensively metabolized by the liver.  Therapy with these drugs should be administered cautiously in patients with liver disease as exposure could be higher.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):|"Product Information. Duagen (dutasteride)." GlaxoSmithKline Healthcare  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51562, 25372, 'Finasteride', 'Liver Diseases', 'Finasteride and dutasteride are extensively metabolized by the liver.  Therapy with these drugs should be administered cautiously in patients with liver disease as exposure could be higher.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):|"Product Information. Duagen (dutasteride)." GlaxoSmithKline Healthcare  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51563, 25399, 'Finasteride', 'Liver Diseases', 'Finasteride and dutasteride are extensively metabolized by the liver.  Therapy with these drugs should be administered cautiously in patients with liver disease as exposure could be higher.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):|"Product Information. Duagen (dutasteride)." GlaxoSmithKline Healthcare  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51564, 25403, 'Finasteride', 'Liver Diseases', 'Finasteride and dutasteride are extensively metabolized by the liver.  Therapy with these drugs should be administered cautiously in patients with liver disease as exposure could be higher.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):|"Product Information. Duagen (dutasteride)." GlaxoSmithKline Healthcare  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51565, 26382, 'Finasteride', 'Liver Diseases', 'Finasteride and dutasteride are extensively metabolized by the liver.  Therapy with these drugs should be administered cautiously in patients with liver disease as exposure could be higher.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):|"Product Information. Duagen (dutasteride)." GlaxoSmithKline Healthcare  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51566, 33561, 'Finasteride', 'Liver Diseases', 'Finasteride and dutasteride are extensively metabolized by the liver.  Therapy with these drugs should be administered cautiously in patients with liver disease as exposure could be higher.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):|"Product Information. Duagen (dutasteride)." GlaxoSmithKline Healthcare  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51567, 4866, 'Finasteride', 'Urethral Obstruction', 'Patients with large residual urinary volume and/or severely diminished urinary flow should be carefully monitored for obstructive uropathy.  These patients may not be candidates for finasteride therapy.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51568, 19040, 'Finasteride', 'Urethral Obstruction', 'Patients with large residual urinary volume and/or severely diminished urinary flow should be carefully monitored for obstructive uropathy.  These patients may not be candidates for finasteride therapy.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51569, 22859, 'Finasteride', 'Urethral Obstruction', 'Patients with large residual urinary volume and/or severely diminished urinary flow should be carefully monitored for obstructive uropathy.  These patients may not be candidates for finasteride therapy.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51570, 23699, 'Finasteride', 'Urethral Obstruction', 'Patients with large residual urinary volume and/or severely diminished urinary flow should be carefully monitored for obstructive uropathy.  These patients may not be candidates for finasteride therapy.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51571, 25330, 'Finasteride', 'Urethral Obstruction', 'Patients with large residual urinary volume and/or severely diminished urinary flow should be carefully monitored for obstructive uropathy.  These patients may not be candidates for finasteride therapy.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51572, 25372, 'Finasteride', 'Urethral Obstruction', 'Patients with large residual urinary volume and/or severely diminished urinary flow should be carefully monitored for obstructive uropathy.  These patients may not be candidates for finasteride therapy.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51573, 25399, 'Finasteride', 'Urethral Obstruction', 'Patients with large residual urinary volume and/or severely diminished urinary flow should be carefully monitored for obstructive uropathy.  These patients may not be candidates for finasteride therapy.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51574, 25403, 'Finasteride', 'Urethral Obstruction', 'Patients with large residual urinary volume and/or severely diminished urinary flow should be carefully monitored for obstructive uropathy.  These patients may not be candidates for finasteride therapy.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51575, 26382, 'Finasteride', 'Urethral Obstruction', 'Patients with large residual urinary volume and/or severely diminished urinary flow should be carefully monitored for obstructive uropathy.  These patients may not be candidates for finasteride therapy.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51576, 33561, 'Finasteride', 'Urethral Obstruction', 'Patients with large residual urinary volume and/or severely diminished urinary flow should be carefully monitored for obstructive uropathy.  These patients may not be candidates for finasteride therapy.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51577, 0, 'Ferumoxytol', 'Hypersensitivity, Immediate', 'Serious hypersensitivity reactions, including anaphylaxis- type reactions, some of which have been life-threatening have been reported in patients using some injection iron products.  Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse.  These products should be administered cautiously, especially in patients with a history of significant allergies.  Patients should be monitored during and at least 30 minutes after the administration.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', '"Product Information. Feraheme (ferumoxytol)." Alza Pharmaceuticals  (2009):|"Product Information. Injectafer (ferric carboxymaltose)." American Regent Laboratories Inc  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51578, 0, 'Ferumoxytol', 'Hypotension', 'Clinically significant hypotension has been reported in clinical trials and postmarketing after the administration of ferumoxytol injection.  Patients should be monitored for signs and symptoms of hypotension after administration.', '2', '"Product Information. Feraheme (ferumoxytol)." Alza Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51579, 0, 'Fibrinogen human', 'Thromboembolism', 'Thrombotic events have been reported in patients receiving human fibrinogen concentrate.  Treatment with human fibrinogen concentrate has been associated with risk of thrombosis at target fibrinogen levels that were less than 150 mg/dL, and the risk may be greater when the target fibrinogen plasma level is 150 mg/dL.  Weigh the benefits of fibrinogen administration versus the risks of thrombosis.  Patients receiving fibrinogen should be monitored for signs and symptoms of thrombosis.  Inform patients that blood clots with or without consequent obstruction of blood flow may occur and that any symptoms of blood clots (unexplained chest and/or leg pain or swelling of the legs or arms, coughing up blood, shortness of breath, increased rate of breathing or unexplained symptoms related to the nervous system such as stroke or weakness) should be reported to their physician immediately.', '2', '"Product Information. RiaSTAP (fibrinogen)." CSL Behring LLC  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51580, 0, 'Aminophylline', 'Peptic Ulcer', 'Methylxanthines are known to stimulate peptic acid secretion.  Therapy with products containing methylxanthines should be administered with extreme caution in patients with active peptic ulcer disease.  Some manufacturers consider their use to be contraindicated under such circumstance.', '3', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51581, 0, 'Aminophylline', 'Kidney Diseases', 'The metabolites of theophylline, which are generally undetectable in patients with normal renal function, may accumulate in patients with renal impairment and contribute to the toxicity of theophylline.  In addition, the plasma protein binding of theophylline may be significantly decreased in renal impairment, resulting in elevated free drug concentrations and further increasing the risk of toxicity.  Therapy with theophyllines should be administered cautiously in patients with impaired renal function.  Dosage adjustments and more intensive monitoring of serum theophylline concentrations may be required.', '3', 'Reidenberg MM, Restivo K "The binding of theophylline to serum proteins of hemodialysis patients." J Dial 3 (1979):  375-81|Bauer LA, Bauer SP, Blouin RA "The effect of acute and chronic renal failure on theophylline clearance." J Clin Pharmacol 22 (1982):  65-8|Shaw LM, Fields L, Mayock R "Factors influencing theophylline serum protein binding." Clin Pharmacol Ther 32 (1982):  490-6|Leakey TE, Elias-Jones AC, Coates PE, Smith KJ "Pharmacokinetics of theophylline and its metabolites during acute renal failure: a case report." Clin Pharmacokinet 21 (1991):  400-8|Nicot G, Charmes JP, Lachatre G, et al. "Theophylline toxicity risks and chronic renal failure." Int J Clin Pharmacol Ther Toxicol 27 (1989):  398-401|Vanholder R, Van Landschoot N, De Smet R, Schoots A, Ringoir S "Drug protein binding in chronic renal failure: evaluation of nine drugs." Kidney Int 33 (1988):  996-1004|Leopold D, Webb D, Buss DC, Fifield RA, Smith AP, Routledge PA "The ex vivo plasma protein binding of theophylline in renal disease." Br J Clin Pharmacol 19 (1985):  823-5|Kraan J, Jonkman JH, Koeter GH, et al. "The pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis and in patients with chronic renal disease." Eur J Clin Pharmacol 35 (1988):  357-62', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51582, 0, 'Aminophylline', 'Epilepsy', 'The use of theophyllines is considered by some manufacturers to be contraindicated in patients with underlying seizure disorders unless they are receiving adequate anticonvulsant therapy.  Theophyllines may cause seizures, which have generally been associated with toxic drug levels but have also been reported at therapeutic concentrations in patients with head trauma or cerebral infarct.  If theophylline therapy is administered in patients with these or other risk factors for seizures, serum drug levels should be monitored closely and maintained in the low therapeutic range.  Intractable seizures and death have been reported during acute theophylline toxicity.', '3', 'Hendeles L, Weinberger M, Johnson G "Monitoring serum theophylline levels." Clin Pharmacokinet 3 (1978):  294-312|Sessler CN "Theophylline toxicity: clinical features of 116 consecutive cases." Am J Med 88 (1990):  567-76|Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO "Inpatient theophylline toxicity: preventable factors." Ann Intern Med 114 (1991):  748-53|Nakada T, Kwee IL, Lerner AM, Remler MP "Theophylline-induced seizures: clinical and pathophysiologic aspects." West J Med 138 (1983):  371-4|Aderka D, Shavit G, Garfinkel D, et al. "Life-threatening theophylline intoxication in a hypothyroid patient." Respiration 44 (1983):  77-80|Covelli HD, Knodel AR, Heppner BT "Predisposing factors to apparent theophylline-induced seizures." Ann Allergy 54 (1985):  411-5|Bahls FH, Ma KK, Bird TD "Theophylline-associated seizures with "therapeutic" or low toxic serum concentrations: risk factors for serious outcome in adults." Neurology 41 (1991):  1309-12|Albert S "Aminophylline toxicity." Pediatr Clin North Am 34 (1987):  61-73|Milgrom H, Bender B "Current issues in the use of theophylline." Am Rev Respir Dis 147 (1993):  s33-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Stewart JT "Prolongation of ECT-induced seizures with theophylline." J Am Geriatr Soc 44 (1996):  475', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51583, 0, 'Aminophylline', 'Gastroesophageal Reflux', 'Methylxanthines increase gastric acidity and may also relax lower esophageal sphincter, which can lead to gastric reflux into the esophagus.  Therapy with products containing methylxanthines should be administered cautiously in patients with significant gastroesophageal reflux.', '2', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51584, 0, 'Aminophylline', 'Diseases requiring hemodialysis', 'Theophylline is removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', 'Levy G, Gibson TP, Whitman W, Procknai J "Hemodialysis clearance of theophylline." JAMA 237 (1977):  1466-7|Lee CS, Marbury TC, Perrin JH, Fuller TJ "Hemodialysis of theophylline in uremic patients." J Clin Pharmacol April (1979):  219-26|Kradjan WA, Martin TR, Delaney CJ, et al. "Effect of hemodialysis on the pharmacokinetics of theophylline in chronic renal failure." Nephron 32 (1982):  40-4|Anderson JR, Poklis A, McQueen RC, Purtell JN, Slavin RG "Effects of hemodialysis on theophylline kinetics." J Clin Pharmacol 23 (1983):  428-32|Lee CS, Peterson JC, Marbury TC "Comparative pharmacokinetics of theophylline in peritoneal dialysis and hemodialysis." J Clin Pharmacol 23 (1983):  274-80|Vaziri ND, Barton CH, Ness R, Clark D "Dialysability of theophylline." J Dial 2 (1978):  243-9|Slaughter RL, Green L, Kohli R "Hemodialysis clearance of theophylline." Ther Drug Monit 4 (1982):  191-3|Blouin RA, Bauer LA, Bustrack JA, Record KE, Bivins BA "Theophylline hemodialysis clearance." Ther Drug Monit 2 (1980):  221-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51585, 0, 'Aminophylline', 'Tachycardia', 'The use of theophyllines is associated with an increase in heart rate which may progress to supraventricular tachycardia or ventricular arrhythmia at high serum drug concentrations.  Appearance of cardiac adverse effects is generally an indication of theophylline toxicity, although patients with a history of tachyarrhythmias may be more susceptible to the chronotropic effect of these drugs.  Therapy with theophyllines should be administered cautiously in such patients.  Caution is also advised in patients with hypertension, hyperthyroidism, angina pectoris, or recent myocardial infarction, since high dosages of the drugs are associated with positive inotropic as well as chronotropic effects.  Clinical monitoring of serum drug concentrations is recommended to prevent toxicity.', '2', 'Hendeles L, Weinberger M, Johnson G "Monitoring serum theophylline levels." Clin Pharmacokinet 3 (1978):  294-312|Sessler CN "Theophylline toxicity: clinical features of 116 consecutive cases." Am J Med 88 (1990):  567-76|Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO "Inpatient theophylline toxicity: preventable factors." Ann Intern Med 114 (1991):  748-53|Marchlinski FE, Miller JM "Atrial arrhythmias exacerbated by theophylline: response to verapamil and evidence for triggered activity in man." Chest 88 (1985):  931-4|Levine JH, Michael JR, Guarnieri T "Multifocal atrial tachycardia: a toxic effect of theophylline." Lancet 1 (1985):  12-4|Taniguchi A, Ohe T, Shimorura K "Theophylline-induced ventricular tachycardia in a patient with chronic lung disease: sensitivity to verapamil." Chest 96 (1989):  958-9|Bittar G, Friedman HS "The arrhythmogenicity of theophylline: a multivariate analysis of clinical determinants." Chest 99 (1991):  1415-20|Patel AK, Skatrud JB, Thomsen JH "Cardiac arrhythmias due to oral aminophylline in patients with chronic obstructive pulmonary disease." Chest 80 (1981):  661-5|Albert S "Aminophylline toxicity." Pediatr Clin North Am 34 (1987):  61-73|Milgrom H, Bender B "Current issues in the use of theophylline." Am Rev Respir Dis 147 (1993):  s33-9|Chazan R, Karwat K, Tyminska K, Tadeusiak W, Droszcz W "Cardiac arrhythmias as a result of intravenous infusions of theophylline in patients with airway obstruction." Int J Clin Pharmacol Ther 33 (1995):  170-5|Mccarthy M "Theophylline, beta-agonists, and cardiovascular death." Lancet 349 (1997):  33', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51586, 0, 'Ferumoxides', 'Anaphylaxis', 'The possibility of a reaction including serious, life-threatening, fatal, anaphylactoid or cardiovascular reactions should always be considered when using ferumoxides.  Increased risk is associated with a known sensitivity to iron or dextran, history of previous reaction to a radiographic contrast agent, known allergies, other hypersensitivities, and underlying immune disorders, autoimmunity or immunodeficiencies that predispose to specific or non specific mediator release.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51587, 0, 'Ferumoxides', 'Autoimmune Diseases', 'Ferumoxides has not been studied in patients with immune disease, but a high rate of adverse reactions to injectable iron formulations have been reported in the published literature.  Caution is advised.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51588, 0, 'Ferumoxides', 'Iron Overload', 'Ferumoxides which contains iron, should be used with caution in patients with disorders associated with iron over load (e.g., hemosiderosis, chronic hemolytic anemia with frequent blood transfusions).', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51589, 19888, 'Ferrous gluconate', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51590, 19888, 'Ferrous gluconate', 'Achlorhydria', 'Gastric acidity increases iron bioavailability by maintaining the ingested iron in a reduced form as ferrous ions, which are more readily absorbed than ferric ions.  Therefore, when iron therapy is administered orally, higher dosages may be necessary for patients with decreased gastric acid production.  Also, a liquid formulation is recommended in these patients because dissolution of the tablet coating depends on normal gastric acidity.', '2', '"Product Information. Feosol (ferrous sulfate)." SmithKline Beecham|"Product Information. Ferrous Gluconate (ferrous gluconate)." Paddock Laboratories Inc  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51591, 19888, 'Ferrous gluconate', 'Gastrointestinal Diseases', 'Iron can be irritating and damaging to gastrointestinal mucosa.  Iron therapy should be administered cautiously in patients with peptic ulcer disease, enteritis, or ulcerative colitis.', '2', '"Product Information. Feosol (ferrous sulfate)." SmithKline Beecham|"Product Information. Ferrous Gluconate (ferrous gluconate)." Paddock Laboratories Inc  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51592, 14760, 'Fesoterodine', 'Gastroparesis', 'The use of fesoterodine is contraindicated in patients with gastric retention.  Fesoterodine is a competitive muscarinic receptor antagonist and exerts direct antispasmodic effects on smooth muscles.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51593, 14761, 'Fesoterodine', 'Gastroparesis', 'The use of fesoterodine is contraindicated in patients with gastric retention.  Fesoterodine is a competitive muscarinic receptor antagonist and exerts direct antispasmodic effects on smooth muscles.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51594, 20038, 'Fesoterodine', 'Gastroparesis', 'The use of fesoterodine is contraindicated in patients with gastric retention.  Fesoterodine is a competitive muscarinic receptor antagonist and exerts direct antispasmodic effects on smooth muscles.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51595, 20039, 'Fesoterodine', 'Gastroparesis', 'The use of fesoterodine is contraindicated in patients with gastric retention.  Fesoterodine is a competitive muscarinic receptor antagonist and exerts direct antispasmodic effects on smooth muscles.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51596, 14760, 'Fesoterodine', 'Glaucoma, Angle-Closure', 'The use of fesoterodine is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Fesoterodine is a competitive muscarinic receptor antagonist.  Its use can result in increased intraocular pressure and loss of accommodation.  Caution is advised even when using this agent in patients being treated for narrow-angle glaucoma.', '3', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51597, 14761, 'Fesoterodine', 'Glaucoma, Angle-Closure', 'The use of fesoterodine is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Fesoterodine is a competitive muscarinic receptor antagonist.  Its use can result in increased intraocular pressure and loss of accommodation.  Caution is advised even when using this agent in patients being treated for narrow-angle glaucoma.', '3', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51598, 20038, 'Fesoterodine', 'Glaucoma, Angle-Closure', 'The use of fesoterodine is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Fesoterodine is a competitive muscarinic receptor antagonist.  Its use can result in increased intraocular pressure and loss of accommodation.  Caution is advised even when using this agent in patients being treated for narrow-angle glaucoma.', '3', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51599, 20039, 'Fesoterodine', 'Glaucoma, Angle-Closure', 'The use of fesoterodine is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Fesoterodine is a competitive muscarinic receptor antagonist.  Its use can result in increased intraocular pressure and loss of accommodation.  Caution is advised even when using this agent in patients being treated for narrow-angle glaucoma.', '3', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51600, 14760, 'Fesoterodine', 'Urinary Retention', 'The use of fesoterodine is contraindicated in patients with urinary retention.  Fesoterodine is a competitive muscarinic receptor antagonist and exerts direct antispasmodic effects on smooth muscles.  Caution is advised even when using this agent in patients with clinically significant bladder outlet obstruction because of the risk of urinary retention.', '3', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51601, 14761, 'Fesoterodine', 'Urinary Retention', 'The use of fesoterodine is contraindicated in patients with urinary retention.  Fesoterodine is a competitive muscarinic receptor antagonist and exerts direct antispasmodic effects on smooth muscles.  Caution is advised even when using this agent in patients with clinically significant bladder outlet obstruction because of the risk of urinary retention.', '3', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51602, 20038, 'Fesoterodine', 'Urinary Retention', 'The use of fesoterodine is contraindicated in patients with urinary retention.  Fesoterodine is a competitive muscarinic receptor antagonist and exerts direct antispasmodic effects on smooth muscles.  Caution is advised even when using this agent in patients with clinically significant bladder outlet obstruction because of the risk of urinary retention.', '3', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51603, 20039, 'Fesoterodine', 'Urinary Retention', 'The use of fesoterodine is contraindicated in patients with urinary retention.  Fesoterodine is a competitive muscarinic receptor antagonist and exerts direct antispasmodic effects on smooth muscles.  Caution is advised even when using this agent in patients with clinically significant bladder outlet obstruction because of the risk of urinary retention.', '3', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51604, 14760, 'Fesoterodine', 'Liver Diseases', 'The use of fesoterodine has not been studied in patients with severe hepatic impairment and therefore is not recommended for use in this patient population.  No dose adjustment is recommended in patients with mild or moderate hepatic impairment.  Use caution when using this agent in patients with severe hepatic impairment.', '2', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51605, 14761, 'Fesoterodine', 'Liver Diseases', 'The use of fesoterodine has not been studied in patients with severe hepatic impairment and therefore is not recommended for use in this patient population.  No dose adjustment is recommended in patients with mild or moderate hepatic impairment.  Use caution when using this agent in patients with severe hepatic impairment.', '2', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51606, 20038, 'Fesoterodine', 'Liver Diseases', 'The use of fesoterodine has not been studied in patients with severe hepatic impairment and therefore is not recommended for use in this patient population.  No dose adjustment is recommended in patients with mild or moderate hepatic impairment.  Use caution when using this agent in patients with severe hepatic impairment.', '2', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51607, 20039, 'Fesoterodine', 'Liver Diseases', 'The use of fesoterodine has not been studied in patients with severe hepatic impairment and therefore is not recommended for use in this patient population.  No dose adjustment is recommended in patients with mild or moderate hepatic impairment.  Use caution when using this agent in patients with severe hepatic impairment.', '2', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51608, 14760, 'Fesoterodine', 'Myasthenia Gravis', 'Fesoterodine is a competitive muscarinic receptor antagonist.  Fesoterodine should be used with caution in patients with myasthenia gravis, a disease characterized by decreased cholinergic activity at the neuromuscular junction.', '2', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51609, 14761, 'Fesoterodine', 'Myasthenia Gravis', 'Fesoterodine is a competitive muscarinic receptor antagonist.  Fesoterodine should be used with caution in patients with myasthenia gravis, a disease characterized by decreased cholinergic activity at the neuromuscular junction.', '2', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51610, 20038, 'Fesoterodine', 'Myasthenia Gravis', 'Fesoterodine is a competitive muscarinic receptor antagonist.  Fesoterodine should be used with caution in patients with myasthenia gravis, a disease characterized by decreased cholinergic activity at the neuromuscular junction.', '2', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51611, 20039, 'Fesoterodine', 'Myasthenia Gravis', 'Fesoterodine is a competitive muscarinic receptor antagonist.  Fesoterodine should be used with caution in patients with myasthenia gravis, a disease characterized by decreased cholinergic activity at the neuromuscular junction.', '2', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51612, 14760, 'Fesoterodine', 'Kidney Diseases', 'Doses of fesoterodine fumarate greater than 4 mg are not recommended in patients with severe renal impairment.  No dose adjustment is recommended in patients with mild or moderate renal impairment.', '2', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51613, 14761, 'Fesoterodine', 'Kidney Diseases', 'Doses of fesoterodine fumarate greater than 4 mg are not recommended in patients with severe renal impairment.  No dose adjustment is recommended in patients with mild or moderate renal impairment.', '2', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51614, 20038, 'Fesoterodine', 'Kidney Diseases', 'Doses of fesoterodine fumarate greater than 4 mg are not recommended in patients with severe renal impairment.  No dose adjustment is recommended in patients with mild or moderate renal impairment.', '2', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51615, 20039, 'Fesoterodine', 'Kidney Diseases', 'Doses of fesoterodine fumarate greater than 4 mg are not recommended in patients with severe renal impairment.  No dose adjustment is recommended in patients with mild or moderate renal impairment.', '2', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51616, 0, 'Flecainide', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', 'Halkin H, Meffin P, Melmon KL, Rowland M "Influence of congestive heart failure on blood levels of lidocaine and its active monodeethylated metabolite." Clin Pharmacol Ther 17 (1975):  669-76|Crouthamel WG "The effect of congestive heart failure on quinidine pharmacokinetics." Am Heart J 90 (1975):  335-9|Ravid S, Podrid PJ, Lampert S, Lown B "Congestive heart failure induced by six of the newer antiarrhythmic drugs." J Am Coll Cardiol 14 (1989):  1326-30|Swiryn S, Kim SS "Quinidine-induced syncope." Arch Intern Med 143 (1983):  314-6|Gottlieb SS, Packer M "Deleterious hemodynamic effects of lidocaine in severe congestive heart failure." Am Heart J 118 (1989):  611-2|Ochs HR, Grube E, Greenblatt DJ, Arendt R "Intravenous quinidine in congestive cardiomyopathy." Eur J Clin Pharmacol 19 (1981):  173-6|Prescott LF, Adjepon-Yamoah KK, Talbot RG "Impaired lignocaine metabolism in patients with myocardial infarction and cardiac failure." Br Med J 1 (1976):  939-41|"Product Information. Cordarone (amiodarone)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Xylocaine (lidocaine)." Astra-Zeneca Pharmaceuticals  (2002):|"Product Information. Quinidex Extentabs (quiNIDine)." Wyeth-Ayerst Laboratories|"Product Information. Quiniglute (quinidine)." Berlex, Richmond, CA.|"Product Information. Adenocard (adenosine)." Fujisawa  (2001):|"Product Information. Mexitil (mexiletine)." Boehringer-Ingelheim  (2001):|Thomson P, Melmon K, Richardson J, Cohn K Steinbrunn W, Cudihee R, Rowland M "Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans." Ann Intern Med 78 (1973):  499-508|Singh SN, Fletcher RD, Fisher SG, et al. "Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia." N Engl J Med 333 (1995):  77-82|"Product Information. Cordarone (amiodarone)." Apothecon Inc  (2022):|"Product Information. Corvert (ibutilide)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51617, 0, 'Flecainide', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', 'Anderson JL, Popat KD "Paradoxical ventricular tachycardia and fibrillation after intravenous bretylium therapy." Arch Intern Med 141 (1981):  801-2|Sclarovsky S, Lewin RF, Kracoff O, Strasberg B, Arditti A, Agmon J "Amiodarone-induced polymorphous ventricular tachycardia." Am Heart J 105 (1983):  6-12|Strasberg B, Sclarovsky S, Erdberg A, et al. "Procainamide-induced polymorphous ventricular tachycardia." Am J Cardiol 47 (1981):  1309-14|Stratmann H, Walter K, Kennedy H "Torsade de pointes associated with elevated N-acetylprocainamide levels." Am Heart J 109 (1985):  375-6|Lo KS, Gantz KB, Stetson PL, et al. "Disopyramide-induced ventricular tachycardia." Arch Intern Med 140 (1980):  413-4|Kinney EL, Field EH, Salmon MP, Zelis R "Cardiac arrhythmias associated with disopyramide." N Engl J Med May (1990):  1146|Chia BL "Disopyramide induced atypical ventricular tachycardia." Aust N Z J Med 10 (1980):  665-8|Tzivoni D, Keren A, Stern S, Gottlieb S "Disopyramide-induced Torsade de pointes." Arch Intern Med 141 (1981):  946-7|Schweitzer P, Mark H "Torsade de pointes caused by disopyramide and hypokalemia." Mt Sinai J Med 49 (1982):  110-4|Riccioni N, Castiglioni M, Bartolomei C "Disopyramide-induced QT prolongation and ventricular tachyarrhythmias." Am Heart J 105 (1983):  870-1|Andrivet P, Beaslay V, Canh VD "Torsades de pointe with flecainide-amiodarone therapy." Intensive Care Med 16 (1990):  342-3|Cocco G, Strozzi C, Chu D, Pansini R "Torsades de pointes as a manifestation of mexiletine toxicity." Am Heart J 100 (1980):  878-80|Nora MO, Chandrasekaran K, Hammill SC, Reeder GS "Prolongation of ventricular depolarization: ECG manifestation of mexiletine toxicity." Chest 95 (1989):  925-8|Morganroth J, Pratt CM "Prevalence and characteristics of proarrhythmia from moricizine (themozine)." Am J Cardiol 63 (1989):  172-6|Damle R, Levine J, Matos J, et al. "Efficacy and risks of moricizine in inducible sustained ventricular tachycardia." Ann Intern Med 116 (1992):  375-81|Nathan AW, Hellestrand KJ, Bexton RS, Camm AJ "Fatal ventricular tachycardia in association with propafenone, a new class IC antiarrhythmic agent." Postgrad Med J 60 (1984):  155-6|Stavens CS, McGovern B, Garan H, Ruskin JN "Aggravation of electrically provoked ventricular tachycardia during treatment with propafenone." Am Heart J 110 (1985):  24-9|Hii JT, Wyse DG, Gillis AM, et al. "Propafenone-induced torsade de pointes: cross-reactivity with quinidine." Pacing Clin Electrophysiol 14 (1991):  1568-70|Cheesman M, Ward DE "Exacerbation of ventricular tachycardia by tocainide." Clin Cardiol 8 (1985):  47-50|Bauman JL, Bauernfeind RA, Hoff JV, et al. "Torsade de pointes due to quinidine: observations in 31 patients." Am Heart J 107 (1984):  425-30|Koenig W, Schinz AM "Spontaneous ventricular flutter and fibrillation during quinidine medication." Am Heart J 105 (1983):  863-5|Morganroth J, Horowitz LN "Incidence of proarrhythmic effects from quinidine in the outpatient treatment of benign or potentially lethal ventricular arrhythmias." Am J Cardiol 56 (1985):  585-7|Au PK, Bhandari AK, Bream R, et al. "Proarrhythmic effects of antiarrhythmic drugs during programmed ventricular stimulation in patients without ventricular tachycardia." J Am Coll Cardiol 9 (1987):  389-97|Engler RL, LeWinter M "Tocainide-induced ventricular fibrillation." Am Heart J 101 (1981):  494-6|Wesley RC Jr, Turnquest P "Torsades de pointe after intravenous adenosine in the presence of prolonged QT syndrome." Am Heart J 123 (1992):  794-6|Orebaugh SL, Handy M "Intravenous adenosine therapy accelerating rate of paroxysmal supraventricular tachycardia." Am J Emerg Med 10 (1992):  326-30|Reed R, Falk JL, O''Brien J "Untoward reaction to adenosine therapy for supraventricular tachycardia." Am J Emerg Med 9 (1991):  566-70|Meurer MK "A 21-year-old woman with rapid atrial fibrillation after adenosine administration." J Emerg Nurs 17 (1991):  135-6|Dougherty AH, Gilman JK, Wiggins S, Jalal S, Naccarelli GV "Provocation of atrioventricular reentry tachycardia: a paradoxical effect of adenosine." Pacing Clin Electrophysiol 16 (1993):  8-12|"Product Information. Tonocard (tocainide)." Merck & Co., Inc  (2002):|"Product Information. Ethmozine (moricizine)." DuPont Pharmaceuticals  (2002):|"Product Information. Cordarone (amiodarone)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Bretylol (bretylium)." DuPont Pharmaceuticals  (2002):|"Product Information. Xylocaine (lidocaine)." Astra-Zeneca Pharmaceuticals  (2002):|"Product Information. Procan SR (procainamide)." Parke-Davis  (2001):|"Product Information. Pronestyl (procainamide)." Apothecon Inc  (2001):|Raehl CL, Patel AK, LeRoy M "Drug-induced torsade de pointes." Clin Pharm 4 (1985):  675-90|Buss J, Neuss H, Bilgin Y, Schlepper M "Malignant ventricular tachyarrhythmias in association with propafenone treatment." Eur Heart J 6 (1985):  424-8|Sulke AN, Holt P, Sowton GE "Acceleration of conduction within an accessory pathway with propafenone." Int J Cardiol 28 (1990):  105-7|"Product Information. Adenocard (adenosine)." Fujisawa  (2001):|"Product Information. Tambocor (flecainide)." 3M Pharmaceuticals  (2001):|"Product Information. Mexitil (mexiletine)." Boehringer-Ingelheim  (2001):|"Product Information. Rythmol (propafenone)." Knoll Pharmaceutical Company|Ben-Sorek ES, Wiesel J "Ventricular fibrillation following adenosine administration. A case report." Arch Intern Med 153 (1993):  2701-2|Said SAM, Somer ST, Luttikhuis HAO "Flecainide-induced JT prolongation, t wave inversion and ventricular tachycardia during treatment for symptomatic atrial fibrillation." Int J Cardiol 44 (1994):  285-7|Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH "Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs." JAMA 270 (1993):  2590-7|"Product Information. Norpace (disopyramide)." Searle  (2001):|Oberg KC, Otoole MF, Gallastegui JL, Bauman JL "''''late'''' proarrhythmia due to quinidine." Am J Cardiol 74 (1994):  192-4|Romer M, Candinas R "Adenosine-induced non-sustained polymorphic ventricular tachycardia." Eur Heart J 15 (1994):  281-2|Hohnloser SH, Klingenheben T, Singh BN "Amiodarone-associated proarrhythmic effects - a review with special reference to torsade de pointes tachycardia." Ann Intern Med 121 (1994):  529-35|Celiker A, Tokel K, Cil E, Ozkutlu S, Ozme S "Adenosine induced torsades de pointes in a child with congenital long QT syndrome." Pacing Clin Electrophysiol 17 (1994):  1814-7|Exner DV, Muzyka T, Gillis AM "Proarrhythmia in patients with the Wolff-Parkinson-White Syndrome after standard doses of intravenous adenosine." Ann Intern Med 122 (1995):  351-2|Williamson BD, Hummel J, Niebauer M, Man C, Strickberger SA, Daoud E, Morady F "Bradycardia-facilitated polymorphic ventricular tachycardia caused by amiodarone after radiofrequency modification of atrioventricular conduction." Am Heart J 130 (1995):  399-401|Dhein S, Schott M, Gottwald E, Klaus W "Electrocardiological profile and proarrhythmic effects of quinidine, verapamil and their combination: a mapping study." Naunyn Schmiedebergs Arch Pharmacol 352 (1995):  94-101|"Product Information. Cordarone (amiodarone)." Apothecon Inc  (2022):|Hohnloser SH, Vandeloo A, Baedeker F "Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine." J Am Coll Cardiol 26 (1995):  852-8|"Product Information. Corvert (ibutilide)." Pharmacia and Upjohn  (2001):|Silverman AJ, Machado C, Baga JJ, Meissner MD, Lehmann MH, Steinman RT "Adenosine-induced atrial fibrillation." Am J Emerg Med 14 (1996):  300-1|Boriani G, Biffi M, Frabetti L, Azzolini U, Sabbatani P, Bronzetti G, Capucci A, Magnani B "Ventricular fibrillation after intravenous amiodarone in wolff-parkinson-white syndrome with atrial fibrillation." Am Heart J 131 (1996):  1214-6|Faggiano P, Gardini A, Daloia A, Benedini G, Giordano A "Torsade de pointes occurring early during oral amiodarone treatment." Int J Cardiol 55 (1996):  205-8|Heisler BE, Ferrier GR "Proarrhythmic actions of flecainide in an isolated tissue model of ischemia and reperfusion." J Pharmacol Exp Ther 279 (1996):  317-24|Strickberger SA, Man KC, Daoud EG, et al. "Adenosine-induced atrial arrhythmia: a prospective analysis." Ann Intern Med 127 (1997):  417-22', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51618, 0, 'Flecainide', 'Sick Sinus Syndrome', 'The use of flecainide is contraindicated in patients with cardiogenic shock, second- or third-degree AV block or right bundle-branch block when associated with a left hemiblock(bifascicular block) in the absence of a functional artificial pacemaker, or congenital QT prolongation.  Therapy with flecainide should be administered with extreme caution in patients with sick sinus syndrome or bradycardia-tachycardia syndrome due to the risk of sinus bradycardia, pause or arrest.', '3', 'Forbes WP, Hee TT, Mohiuddin SM, Hillman DE "Flecainide-induced cardiogenic shock." Chest 94 (1988):  1121|"Product Information. Tambocor (flecainide)." 3M Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51619, 0, 'Flecainide', 'Water-Electrolyte Imbalance', 'Electrolyte imbalance can alter the therapeutic effectiveness of antiarrhythmic agents.  Hypokalemia and hypomagnesemia can reduce the effectiveness of antiarrhythmic agents.  In some cases, these disorders can exaggerate the degree of QTc prolongation and increase the potential for torsade de pointes.  Hyperkalemia can potentiate the toxic effects of antiarrhythmic agents.  Electrolyte imbalance should be corrected prior to initiating antiarrhythmic therapy.  Clinical monitoring of cardiac function and electrolyte concentrations is recommended.', '2', '"Product Information. Tonocard (tocainide)." Merck & Co., Inc  (2002):|"Product Information. Ethmozine (moricizine)." DuPont Pharmaceuticals  (2002):|"Product Information. Cordarone (amiodarone)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Xylocaine (lidocaine)." Astra-Zeneca Pharmaceuticals  (2002):|"Product Information. Procan SR (procainamide)." Parke-Davis  (2001):|"Product Information. Pronestyl (procainamide)." Apothecon Inc  (2001):|"Product Information. Quinidex Extentabs (quiNIDine)." Wyeth-Ayerst Laboratories|"Product Information. Tambocor (flecainide)." 3M Pharmaceuticals  (2001):|"Product Information. Mexitil (mexiletine)." Boehringer-Ingelheim  (2001):|"Product Information. Rythmol (propafenone)." Knoll Pharmaceutical Company|"Product Information. Norpace (disopyramide)." Searle  (2001):|"Product Information. Cordarone (amiodarone)." Apothecon Inc  (2022):|"Product Information. Corvert (ibutilide)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51620, 0, 'Flecainide', 'Liver Diseases', 'Since flecainide elimination from plasma can be markedly slower in patients with significant hepatic impairment, flecainide should not be used in such patients unless the potential benefits clearly outweigh the risks.  If used, frequent and early plasma level monitoring is required to guide dosage.  Additionally, dosage increases should be made very cautiously when plasma levels have plateaued (after more than four days).', '2', 'McQuinn RL, Pentikainen PJ, Chang SF, Conrad GJ "Pharmacokinetics of flecainide in patients with cirrhosis of the liver." Clin Pharmacol Ther 44 (1988):  566-72|"Product Information. Tambocor (flecainide)." 3M Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51621, 0, 'Flecainide', 'Kidney Diseases', 'Flecainide is primarily eliminated by the kidney.  Approximately 30% (10% to 50%) of flecainide is excreted in the urine unchanged.  The serum concentration of flecainide is increased and the half-life prolonged in patients with renal impairment.  Rare conditions such as a strict vegetarian diet or renal tubular acidosis that significantly increase the urinary pH slow the urinary elimination of flecainide.  Adjustment of dosage is necessary and modification should be based on the degree of renal impairment.  Clinical monitoring of cardiac function (ECG) and renal function is recommended.', '2', 'Williams AJ, McQuinn RL, Walls J "Pharmacokinetics of flecainide acetate in patients with severe renal impairment." Clin Pharmacol Ther 43 (1988):  449-55|Hertrampf R, Gundert-Remy U, Beckmann J, et al. "Elimination of flecainide as a function of urinary flow rate and pH." Eur J Clin Pharmacol 41 (1991):  61-3|Forland SC, Burgess E, Blair AD, et al. "Oral flecainide pharmacokinetics in patients with impaired renal function." J Clin Pharmacol 28 (1988):  259-67|Braun J, Kollert JR, Becker JU "Pharmacokinetics of flecainide in patients with mild and moderate renal failure compared with patients with normal renal function." Eur J Clin Pharmacol 31 (1987):  711-4|Borgeat A, Biollaz J, Freymond B, Bayer-Berger M, Chiolero R "Hemofiltration clearance of flecainide in a patient with acute renal failure." Intensive Care Med 14 (1988):  236-7|Bailie GR, Waldek S "Pharmacokinetics of flecainide in a patient undergoing continuous ambulatory peritoneal dialysis." J Clin Pharm Ther 13 (1988):  121-4|Forland SC, Cutler RE, McQuinn RL, Kvam DC, Miller AM, Conard GJ, Parish S "Flecainide pharmacokinetics after multiple dosing in patients with impaired renal function." J Clin Pharmacol 28 (1988):  727-35|Ziegelbaum M, Lever H "Acute urinary retention associated with flecainide." Cleve Clin J Med 57 (1990):  86-7|"Product Information. Tambocor (flecainide)." 3M Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51622, 13308, 'Filgrastim', 'Glomerulonephritis', 'Although it has been reported that renal dysfunction has no effect on the pharmacokinetics of colony stimulating factors (CSF), filgrastim and pegfilgrastim may cause glomerulonephritis.  Symptoms include swelling of the face or ankles, dark colored urine, or blood in the urine, or a decrease in urine production.  Advise patients to report signs or symptoms of glomerulonephritis immediately.  Monitoring of patients with renal dysfunction is recommended.', '3', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):|"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51623, 19035, 'Filgrastim', 'Glomerulonephritis', 'Although it has been reported that renal dysfunction has no effect on the pharmacokinetics of colony stimulating factors (CSF), filgrastim and pegfilgrastim may cause glomerulonephritis.  Symptoms include swelling of the face or ankles, dark colored urine, or blood in the urine, or a decrease in urine production.  Advise patients to report signs or symptoms of glomerulonephritis immediately.  Monitoring of patients with renal dysfunction is recommended.', '3', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):|"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51624, 19670, 'Filgrastim', 'Glomerulonephritis', 'Although it has been reported that renal dysfunction has no effect on the pharmacokinetics of colony stimulating factors (CSF), filgrastim and pegfilgrastim may cause glomerulonephritis.  Symptoms include swelling of the face or ankles, dark colored urine, or blood in the urine, or a decrease in urine production.  Advise patients to report signs or symptoms of glomerulonephritis immediately.  Monitoring of patients with renal dysfunction is recommended.', '3', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):|"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51625, 21172, 'Filgrastim', 'Glomerulonephritis', 'Although it has been reported that renal dysfunction has no effect on the pharmacokinetics of colony stimulating factors (CSF), filgrastim and pegfilgrastim may cause glomerulonephritis.  Symptoms include swelling of the face or ankles, dark colored urine, or blood in the urine, or a decrease in urine production.  Advise patients to report signs or symptoms of glomerulonephritis immediately.  Monitoring of patients with renal dysfunction is recommended.', '3', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):|"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51626, 23445, 'Filgrastim', 'Glomerulonephritis', 'Although it has been reported that renal dysfunction has no effect on the pharmacokinetics of colony stimulating factors (CSF), filgrastim and pegfilgrastim may cause glomerulonephritis.  Symptoms include swelling of the face or ankles, dark colored urine, or blood in the urine, or a decrease in urine production.  Advise patients to report signs or symptoms of glomerulonephritis immediately.  Monitoring of patients with renal dysfunction is recommended.', '3', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):|"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51627, 23641, 'Filgrastim', 'Glomerulonephritis', 'Although it has been reported that renal dysfunction has no effect on the pharmacokinetics of colony stimulating factors (CSF), filgrastim and pegfilgrastim may cause glomerulonephritis.  Symptoms include swelling of the face or ankles, dark colored urine, or blood in the urine, or a decrease in urine production.  Advise patients to report signs or symptoms of glomerulonephritis immediately.  Monitoring of patients with renal dysfunction is recommended.', '3', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):|"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51628, 23642, 'Filgrastim', 'Glomerulonephritis', 'Although it has been reported that renal dysfunction has no effect on the pharmacokinetics of colony stimulating factors (CSF), filgrastim and pegfilgrastim may cause glomerulonephritis.  Symptoms include swelling of the face or ankles, dark colored urine, or blood in the urine, or a decrease in urine production.  Advise patients to report signs or symptoms of glomerulonephritis immediately.  Monitoring of patients with renal dysfunction is recommended.', '3', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):|"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51629, 29848, 'Filgrastim', 'Glomerulonephritis', 'Although it has been reported that renal dysfunction has no effect on the pharmacokinetics of colony stimulating factors (CSF), filgrastim and pegfilgrastim may cause glomerulonephritis.  Symptoms include swelling of the face or ankles, dark colored urine, or blood in the urine, or a decrease in urine production.  Advise patients to report signs or symptoms of glomerulonephritis immediately.  Monitoring of patients with renal dysfunction is recommended.', '3', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):|"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51630, 29849, 'Filgrastim', 'Glomerulonephritis', 'Although it has been reported that renal dysfunction has no effect on the pharmacokinetics of colony stimulating factors (CSF), filgrastim and pegfilgrastim may cause glomerulonephritis.  Symptoms include swelling of the face or ankles, dark colored urine, or blood in the urine, or a decrease in urine production.  Advise patients to report signs or symptoms of glomerulonephritis immediately.  Monitoring of patients with renal dysfunction is recommended.', '3', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):|"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51631, 13308, 'Filgrastim', 'Leukemia, Myeloid', 'Colony stimulating factors primarily stimulates the proliferation of neutrophils but may also, theoretically, enhance tumor growth, particularly in myeloid malignancies.  Therapy with these drugs should be administered cautiously in patients with myeloid tumors.  Additionally, if used for PBPC (peripheral blood progenitor cell) collection in such patients, tumor cells may be released from the marrow and collected in the leukapheresis product.  The effect of reinfusion of tumor cells is uncertain at this time.', '3', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51632, 19035, 'Filgrastim', 'Leukemia, Myeloid', 'Colony stimulating factors primarily stimulates the proliferation of neutrophils but may also, theoretically, enhance tumor growth, particularly in myeloid malignancies.  Therapy with these drugs should be administered cautiously in patients with myeloid tumors.  Additionally, if used for PBPC (peripheral blood progenitor cell) collection in such patients, tumor cells may be released from the marrow and collected in the leukapheresis product.  The effect of reinfusion of tumor cells is uncertain at this time.', '3', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51633, 19670, 'Filgrastim', 'Leukemia, Myeloid', 'Colony stimulating factors primarily stimulates the proliferation of neutrophils but may also, theoretically, enhance tumor growth, particularly in myeloid malignancies.  Therapy with these drugs should be administered cautiously in patients with myeloid tumors.  Additionally, if used for PBPC (peripheral blood progenitor cell) collection in such patients, tumor cells may be released from the marrow and collected in the leukapheresis product.  The effect of reinfusion of tumor cells is uncertain at this time.', '3', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51634, 21172, 'Filgrastim', 'Leukemia, Myeloid', 'Colony stimulating factors primarily stimulates the proliferation of neutrophils but may also, theoretically, enhance tumor growth, particularly in myeloid malignancies.  Therapy with these drugs should be administered cautiously in patients with myeloid tumors.  Additionally, if used for PBPC (peripheral blood progenitor cell) collection in such patients, tumor cells may be released from the marrow and collected in the leukapheresis product.  The effect of reinfusion of tumor cells is uncertain at this time.', '3', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51635, 23445, 'Filgrastim', 'Leukemia, Myeloid', 'Colony stimulating factors primarily stimulates the proliferation of neutrophils but may also, theoretically, enhance tumor growth, particularly in myeloid malignancies.  Therapy with these drugs should be administered cautiously in patients with myeloid tumors.  Additionally, if used for PBPC (peripheral blood progenitor cell) collection in such patients, tumor cells may be released from the marrow and collected in the leukapheresis product.  The effect of reinfusion of tumor cells is uncertain at this time.', '3', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51636, 23641, 'Filgrastim', 'Leukemia, Myeloid', 'Colony stimulating factors primarily stimulates the proliferation of neutrophils but may also, theoretically, enhance tumor growth, particularly in myeloid malignancies.  Therapy with these drugs should be administered cautiously in patients with myeloid tumors.  Additionally, if used for PBPC (peripheral blood progenitor cell) collection in such patients, tumor cells may be released from the marrow and collected in the leukapheresis product.  The effect of reinfusion of tumor cells is uncertain at this time.', '3', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51637, 23642, 'Filgrastim', 'Leukemia, Myeloid', 'Colony stimulating factors primarily stimulates the proliferation of neutrophils but may also, theoretically, enhance tumor growth, particularly in myeloid malignancies.  Therapy with these drugs should be administered cautiously in patients with myeloid tumors.  Additionally, if used for PBPC (peripheral blood progenitor cell) collection in such patients, tumor cells may be released from the marrow and collected in the leukapheresis product.  The effect of reinfusion of tumor cells is uncertain at this time.', '3', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51638, 29848, 'Filgrastim', 'Leukemia, Myeloid', 'Colony stimulating factors primarily stimulates the proliferation of neutrophils but may also, theoretically, enhance tumor growth, particularly in myeloid malignancies.  Therapy with these drugs should be administered cautiously in patients with myeloid tumors.  Additionally, if used for PBPC (peripheral blood progenitor cell) collection in such patients, tumor cells may be released from the marrow and collected in the leukapheresis product.  The effect of reinfusion of tumor cells is uncertain at this time.', '3', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51639, 29849, 'Filgrastim', 'Leukemia, Myeloid', 'Colony stimulating factors primarily stimulates the proliferation of neutrophils but may also, theoretically, enhance tumor growth, particularly in myeloid malignancies.  Therapy with these drugs should be administered cautiously in patients with myeloid tumors.  Additionally, if used for PBPC (peripheral blood progenitor cell) collection in such patients, tumor cells may be released from the marrow and collected in the leukapheresis product.  The effect of reinfusion of tumor cells is uncertain at this time.', '3', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51640, 13308, 'Filgrastim', 'Leukocytosis', 'Filgrastim and pegfilgrastim are growth factors for neutrophil progenitor cells.  Therefore, these should not be used in patients with leukocytosis.  If excessive white blood cell counts occur during CSF therapy, treatment should be interrupted or the dosage reduced.', '3', 'Hollingshead LM, Goa KL "Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions." Drugs 42 (1991):  300-30|"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51641, 19035, 'Filgrastim', 'Leukocytosis', 'Filgrastim and pegfilgrastim are growth factors for neutrophil progenitor cells.  Therefore, these should not be used in patients with leukocytosis.  If excessive white blood cell counts occur during CSF therapy, treatment should be interrupted or the dosage reduced.', '3', 'Hollingshead LM, Goa KL "Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions." Drugs 42 (1991):  300-30|"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51642, 19670, 'Filgrastim', 'Leukocytosis', 'Filgrastim and pegfilgrastim are growth factors for neutrophil progenitor cells.  Therefore, these should not be used in patients with leukocytosis.  If excessive white blood cell counts occur during CSF therapy, treatment should be interrupted or the dosage reduced.', '3', 'Hollingshead LM, Goa KL "Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions." Drugs 42 (1991):  300-30|"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51643, 21172, 'Filgrastim', 'Leukocytosis', 'Filgrastim and pegfilgrastim are growth factors for neutrophil progenitor cells.  Therefore, these should not be used in patients with leukocytosis.  If excessive white blood cell counts occur during CSF therapy, treatment should be interrupted or the dosage reduced.', '3', 'Hollingshead LM, Goa KL "Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions." Drugs 42 (1991):  300-30|"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51644, 23445, 'Filgrastim', 'Leukocytosis', 'Filgrastim and pegfilgrastim are growth factors for neutrophil progenitor cells.  Therefore, these should not be used in patients with leukocytosis.  If excessive white blood cell counts occur during CSF therapy, treatment should be interrupted or the dosage reduced.', '3', 'Hollingshead LM, Goa KL "Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions." Drugs 42 (1991):  300-30|"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51645, 23641, 'Filgrastim', 'Leukocytosis', 'Filgrastim and pegfilgrastim are growth factors for neutrophil progenitor cells.  Therefore, these should not be used in patients with leukocytosis.  If excessive white blood cell counts occur during CSF therapy, treatment should be interrupted or the dosage reduced.', '3', 'Hollingshead LM, Goa KL "Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions." Drugs 42 (1991):  300-30|"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51646, 23642, 'Filgrastim', 'Leukocytosis', 'Filgrastim and pegfilgrastim are growth factors for neutrophil progenitor cells.  Therefore, these should not be used in patients with leukocytosis.  If excessive white blood cell counts occur during CSF therapy, treatment should be interrupted or the dosage reduced.', '3', 'Hollingshead LM, Goa KL "Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions." Drugs 42 (1991):  300-30|"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51647, 29848, 'Filgrastim', 'Leukocytosis', 'Filgrastim and pegfilgrastim are growth factors for neutrophil progenitor cells.  Therefore, these should not be used in patients with leukocytosis.  If excessive white blood cell counts occur during CSF therapy, treatment should be interrupted or the dosage reduced.', '3', 'Hollingshead LM, Goa KL "Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions." Drugs 42 (1991):  300-30|"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51648, 29849, 'Filgrastim', 'Leukocytosis', 'Filgrastim and pegfilgrastim are growth factors for neutrophil progenitor cells.  Therefore, these should not be used in patients with leukocytosis.  If excessive white blood cell counts occur during CSF therapy, treatment should be interrupted or the dosage reduced.', '3', 'Hollingshead LM, Goa KL "Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions." Drugs 42 (1991):  300-30|"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51649, 13308, 'Filgrastim', 'Sepsis', 'When filgrastim is used in septic patients, clinicians should be alerted to the theoretical possibility of adult respiratory distress syndrome, which may occur as a result of the influx of neutrophils at the site of inflammation.  Monitoring of respiratory status may be appropriate in these patients.', '2', 'Hollingshead LM, Goa KL "Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions." Drugs 42 (1991):  300-30|"Product Information. Neupogen (filgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51650, 19035, 'Filgrastim', 'Sepsis', 'When filgrastim is used in septic patients, clinicians should be alerted to the theoretical possibility of adult respiratory distress syndrome, which may occur as a result of the influx of neutrophils at the site of inflammation.  Monitoring of respiratory status may be appropriate in these patients.', '2', 'Hollingshead LM, Goa KL "Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions." Drugs 42 (1991):  300-30|"Product Information. Neupogen (filgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51651, 19670, 'Filgrastim', 'Sepsis', 'When filgrastim is used in septic patients, clinicians should be alerted to the theoretical possibility of adult respiratory distress syndrome, which may occur as a result of the influx of neutrophils at the site of inflammation.  Monitoring of respiratory status may be appropriate in these patients.', '2', 'Hollingshead LM, Goa KL "Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions." Drugs 42 (1991):  300-30|"Product Information. Neupogen (filgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51652, 21172, 'Filgrastim', 'Sepsis', 'When filgrastim is used in septic patients, clinicians should be alerted to the theoretical possibility of adult respiratory distress syndrome, which may occur as a result of the influx of neutrophils at the site of inflammation.  Monitoring of respiratory status may be appropriate in these patients.', '2', 'Hollingshead LM, Goa KL "Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions." Drugs 42 (1991):  300-30|"Product Information. Neupogen (filgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51653, 23445, 'Filgrastim', 'Sepsis', 'When filgrastim is used in septic patients, clinicians should be alerted to the theoretical possibility of adult respiratory distress syndrome, which may occur as a result of the influx of neutrophils at the site of inflammation.  Monitoring of respiratory status may be appropriate in these patients.', '2', 'Hollingshead LM, Goa KL "Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions." Drugs 42 (1991):  300-30|"Product Information. Neupogen (filgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51654, 23641, 'Filgrastim', 'Sepsis', 'When filgrastim is used in septic patients, clinicians should be alerted to the theoretical possibility of adult respiratory distress syndrome, which may occur as a result of the influx of neutrophils at the site of inflammation.  Monitoring of respiratory status may be appropriate in these patients.', '2', 'Hollingshead LM, Goa KL "Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions." Drugs 42 (1991):  300-30|"Product Information. Neupogen (filgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51655, 23642, 'Filgrastim', 'Sepsis', 'When filgrastim is used in septic patients, clinicians should be alerted to the theoretical possibility of adult respiratory distress syndrome, which may occur as a result of the influx of neutrophils at the site of inflammation.  Monitoring of respiratory status may be appropriate in these patients.', '2', 'Hollingshead LM, Goa KL "Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions." Drugs 42 (1991):  300-30|"Product Information. Neupogen (filgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51656, 29848, 'Filgrastim', 'Sepsis', 'When filgrastim is used in septic patients, clinicians should be alerted to the theoretical possibility of adult respiratory distress syndrome, which may occur as a result of the influx of neutrophils at the site of inflammation.  Monitoring of respiratory status may be appropriate in these patients.', '2', 'Hollingshead LM, Goa KL "Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions." Drugs 42 (1991):  300-30|"Product Information. Neupogen (filgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51657, 29849, 'Filgrastim', 'Sepsis', 'When filgrastim is used in septic patients, clinicians should be alerted to the theoretical possibility of adult respiratory distress syndrome, which may occur as a result of the influx of neutrophils at the site of inflammation.  Monitoring of respiratory status may be appropriate in these patients.', '2', 'Hollingshead LM, Goa KL "Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions." Drugs 42 (1991):  300-30|"Product Information. Neupogen (filgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51658, 13308, 'Filgrastim', 'Thrombocytopenia', 'Filgrastim may occasionally lower platelet counts.  Thrombocytopenia has been reported, although most often the effects are mild or moderate and not associated with serious hemorrhagic sequelae.  Nevertheless, therapy with filgrastim should be administered cautiously in patients with preexisting thrombocytopenia.  Frequent blood counts are recommended, and the dosage of filgrastim adjusted if necessary.', '2', 'Wun T "The Felty syndrome and G-CSF-associated thrombocytopenia and severe anemia ." Ann Intern Med 118 (1993):  318-9|Balmer CM "Clinical use of biologic response modifiers in cancer treatment: an overview. Part II. Colony-stimulating factors and interleukin-2." DICP 25 (1991):  490-8|Momin F, Kraut M, Lattin P, Valdivieso M "Thrombocytopenia in patients receiving chemoradiotherapy and G-CSF for locally advanced non-small cell lung cancer (NSCLC) (meeting abstract)." Proc Annu Meet Am Soc Clin Oncol 11 (1992):  a983|"Product Information. Neupogen (filgrastim)." Amgen  (2002):|Kawachi Y, Watanabe A, Uchida T, Yoshizawa K, Kurooka N, Setsu K "Acute arterial thrombosis due to platelet aggregation in a patient receiving granulocyte colony-stimulating factor." Br J Haematol 94 (1996):  413-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51659, 19035, 'Filgrastim', 'Thrombocytopenia', 'Filgrastim may occasionally lower platelet counts.  Thrombocytopenia has been reported, although most often the effects are mild or moderate and not associated with serious hemorrhagic sequelae.  Nevertheless, therapy with filgrastim should be administered cautiously in patients with preexisting thrombocytopenia.  Frequent blood counts are recommended, and the dosage of filgrastim adjusted if necessary.', '2', 'Wun T "The Felty syndrome and G-CSF-associated thrombocytopenia and severe anemia ." Ann Intern Med 118 (1993):  318-9|Balmer CM "Clinical use of biologic response modifiers in cancer treatment: an overview. Part II. Colony-stimulating factors and interleukin-2." DICP 25 (1991):  490-8|Momin F, Kraut M, Lattin P, Valdivieso M "Thrombocytopenia in patients receiving chemoradiotherapy and G-CSF for locally advanced non-small cell lung cancer (NSCLC) (meeting abstract)." Proc Annu Meet Am Soc Clin Oncol 11 (1992):  a983|"Product Information. Neupogen (filgrastim)." Amgen  (2002):|Kawachi Y, Watanabe A, Uchida T, Yoshizawa K, Kurooka N, Setsu K "Acute arterial thrombosis due to platelet aggregation in a patient receiving granulocyte colony-stimulating factor." Br J Haematol 94 (1996):  413-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51660, 19670, 'Filgrastim', 'Thrombocytopenia', 'Filgrastim may occasionally lower platelet counts.  Thrombocytopenia has been reported, although most often the effects are mild or moderate and not associated with serious hemorrhagic sequelae.  Nevertheless, therapy with filgrastim should be administered cautiously in patients with preexisting thrombocytopenia.  Frequent blood counts are recommended, and the dosage of filgrastim adjusted if necessary.', '2', 'Wun T "The Felty syndrome and G-CSF-associated thrombocytopenia and severe anemia ." Ann Intern Med 118 (1993):  318-9|Balmer CM "Clinical use of biologic response modifiers in cancer treatment: an overview. Part II. Colony-stimulating factors and interleukin-2." DICP 25 (1991):  490-8|Momin F, Kraut M, Lattin P, Valdivieso M "Thrombocytopenia in patients receiving chemoradiotherapy and G-CSF for locally advanced non-small cell lung cancer (NSCLC) (meeting abstract)." Proc Annu Meet Am Soc Clin Oncol 11 (1992):  a983|"Product Information. Neupogen (filgrastim)." Amgen  (2002):|Kawachi Y, Watanabe A, Uchida T, Yoshizawa K, Kurooka N, Setsu K "Acute arterial thrombosis due to platelet aggregation in a patient receiving granulocyte colony-stimulating factor." Br J Haematol 94 (1996):  413-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51661, 21172, 'Filgrastim', 'Thrombocytopenia', 'Filgrastim may occasionally lower platelet counts.  Thrombocytopenia has been reported, although most often the effects are mild or moderate and not associated with serious hemorrhagic sequelae.  Nevertheless, therapy with filgrastim should be administered cautiously in patients with preexisting thrombocytopenia.  Frequent blood counts are recommended, and the dosage of filgrastim adjusted if necessary.', '2', 'Wun T "The Felty syndrome and G-CSF-associated thrombocytopenia and severe anemia ." Ann Intern Med 118 (1993):  318-9|Balmer CM "Clinical use of biologic response modifiers in cancer treatment: an overview. Part II. Colony-stimulating factors and interleukin-2." DICP 25 (1991):  490-8|Momin F, Kraut M, Lattin P, Valdivieso M "Thrombocytopenia in patients receiving chemoradiotherapy and G-CSF for locally advanced non-small cell lung cancer (NSCLC) (meeting abstract)." Proc Annu Meet Am Soc Clin Oncol 11 (1992):  a983|"Product Information. Neupogen (filgrastim)." Amgen  (2002):|Kawachi Y, Watanabe A, Uchida T, Yoshizawa K, Kurooka N, Setsu K "Acute arterial thrombosis due to platelet aggregation in a patient receiving granulocyte colony-stimulating factor." Br J Haematol 94 (1996):  413-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51662, 23445, 'Filgrastim', 'Thrombocytopenia', 'Filgrastim may occasionally lower platelet counts.  Thrombocytopenia has been reported, although most often the effects are mild or moderate and not associated with serious hemorrhagic sequelae.  Nevertheless, therapy with filgrastim should be administered cautiously in patients with preexisting thrombocytopenia.  Frequent blood counts are recommended, and the dosage of filgrastim adjusted if necessary.', '2', 'Wun T "The Felty syndrome and G-CSF-associated thrombocytopenia and severe anemia ." Ann Intern Med 118 (1993):  318-9|Balmer CM "Clinical use of biologic response modifiers in cancer treatment: an overview. Part II. Colony-stimulating factors and interleukin-2." DICP 25 (1991):  490-8|Momin F, Kraut M, Lattin P, Valdivieso M "Thrombocytopenia in patients receiving chemoradiotherapy and G-CSF for locally advanced non-small cell lung cancer (NSCLC) (meeting abstract)." Proc Annu Meet Am Soc Clin Oncol 11 (1992):  a983|"Product Information. Neupogen (filgrastim)." Amgen  (2002):|Kawachi Y, Watanabe A, Uchida T, Yoshizawa K, Kurooka N, Setsu K "Acute arterial thrombosis due to platelet aggregation in a patient receiving granulocyte colony-stimulating factor." Br J Haematol 94 (1996):  413-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51663, 23641, 'Filgrastim', 'Thrombocytopenia', 'Filgrastim may occasionally lower platelet counts.  Thrombocytopenia has been reported, although most often the effects are mild or moderate and not associated with serious hemorrhagic sequelae.  Nevertheless, therapy with filgrastim should be administered cautiously in patients with preexisting thrombocytopenia.  Frequent blood counts are recommended, and the dosage of filgrastim adjusted if necessary.', '2', 'Wun T "The Felty syndrome and G-CSF-associated thrombocytopenia and severe anemia ." Ann Intern Med 118 (1993):  318-9|Balmer CM "Clinical use of biologic response modifiers in cancer treatment: an overview. Part II. Colony-stimulating factors and interleukin-2." DICP 25 (1991):  490-8|Momin F, Kraut M, Lattin P, Valdivieso M "Thrombocytopenia in patients receiving chemoradiotherapy and G-CSF for locally advanced non-small cell lung cancer (NSCLC) (meeting abstract)." Proc Annu Meet Am Soc Clin Oncol 11 (1992):  a983|"Product Information. Neupogen (filgrastim)." Amgen  (2002):|Kawachi Y, Watanabe A, Uchida T, Yoshizawa K, Kurooka N, Setsu K "Acute arterial thrombosis due to platelet aggregation in a patient receiving granulocyte colony-stimulating factor." Br J Haematol 94 (1996):  413-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51664, 23642, 'Filgrastim', 'Thrombocytopenia', 'Filgrastim may occasionally lower platelet counts.  Thrombocytopenia has been reported, although most often the effects are mild or moderate and not associated with serious hemorrhagic sequelae.  Nevertheless, therapy with filgrastim should be administered cautiously in patients with preexisting thrombocytopenia.  Frequent blood counts are recommended, and the dosage of filgrastim adjusted if necessary.', '2', 'Wun T "The Felty syndrome and G-CSF-associated thrombocytopenia and severe anemia ." Ann Intern Med 118 (1993):  318-9|Balmer CM "Clinical use of biologic response modifiers in cancer treatment: an overview. Part II. Colony-stimulating factors and interleukin-2." DICP 25 (1991):  490-8|Momin F, Kraut M, Lattin P, Valdivieso M "Thrombocytopenia in patients receiving chemoradiotherapy and G-CSF for locally advanced non-small cell lung cancer (NSCLC) (meeting abstract)." Proc Annu Meet Am Soc Clin Oncol 11 (1992):  a983|"Product Information. Neupogen (filgrastim)." Amgen  (2002):|Kawachi Y, Watanabe A, Uchida T, Yoshizawa K, Kurooka N, Setsu K "Acute arterial thrombosis due to platelet aggregation in a patient receiving granulocyte colony-stimulating factor." Br J Haematol 94 (1996):  413-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51665, 29848, 'Filgrastim', 'Thrombocytopenia', 'Filgrastim may occasionally lower platelet counts.  Thrombocytopenia has been reported, although most often the effects are mild or moderate and not associated with serious hemorrhagic sequelae.  Nevertheless, therapy with filgrastim should be administered cautiously in patients with preexisting thrombocytopenia.  Frequent blood counts are recommended, and the dosage of filgrastim adjusted if necessary.', '2', 'Wun T "The Felty syndrome and G-CSF-associated thrombocytopenia and severe anemia ." Ann Intern Med 118 (1993):  318-9|Balmer CM "Clinical use of biologic response modifiers in cancer treatment: an overview. Part II. Colony-stimulating factors and interleukin-2." DICP 25 (1991):  490-8|Momin F, Kraut M, Lattin P, Valdivieso M "Thrombocytopenia in patients receiving chemoradiotherapy and G-CSF for locally advanced non-small cell lung cancer (NSCLC) (meeting abstract)." Proc Annu Meet Am Soc Clin Oncol 11 (1992):  a983|"Product Information. Neupogen (filgrastim)." Amgen  (2002):|Kawachi Y, Watanabe A, Uchida T, Yoshizawa K, Kurooka N, Setsu K "Acute arterial thrombosis due to platelet aggregation in a patient receiving granulocyte colony-stimulating factor." Br J Haematol 94 (1996):  413-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51666, 29849, 'Filgrastim', 'Thrombocytopenia', 'Filgrastim may occasionally lower platelet counts.  Thrombocytopenia has been reported, although most often the effects are mild or moderate and not associated with serious hemorrhagic sequelae.  Nevertheless, therapy with filgrastim should be administered cautiously in patients with preexisting thrombocytopenia.  Frequent blood counts are recommended, and the dosage of filgrastim adjusted if necessary.', '2', 'Wun T "The Felty syndrome and G-CSF-associated thrombocytopenia and severe anemia ." Ann Intern Med 118 (1993):  318-9|Balmer CM "Clinical use of biologic response modifiers in cancer treatment: an overview. Part II. Colony-stimulating factors and interleukin-2." DICP 25 (1991):  490-8|Momin F, Kraut M, Lattin P, Valdivieso M "Thrombocytopenia in patients receiving chemoradiotherapy and G-CSF for locally advanced non-small cell lung cancer (NSCLC) (meeting abstract)." Proc Annu Meet Am Soc Clin Oncol 11 (1992):  a983|"Product Information. Neupogen (filgrastim)." Amgen  (2002):|Kawachi Y, Watanabe A, Uchida T, Yoshizawa K, Kurooka N, Setsu K "Acute arterial thrombosis due to platelet aggregation in a patient receiving granulocyte colony-stimulating factor." Br J Haematol 94 (1996):  413-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51667, 13308, 'Filgrastim', 'Anemia, Sickle Cell', 'Severe and sometimes fatal sickle cell crises have been reported in sickle cell disease patients receiving filgrastim products.  Consider the potential risks and benefits prior to initiating therapy in these patients.', '2', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51668, 19035, 'Filgrastim', 'Anemia, Sickle Cell', 'Severe and sometimes fatal sickle cell crises have been reported in sickle cell disease patients receiving filgrastim products.  Consider the potential risks and benefits prior to initiating therapy in these patients.', '2', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51669, 19670, 'Filgrastim', 'Anemia, Sickle Cell', 'Severe and sometimes fatal sickle cell crises have been reported in sickle cell disease patients receiving filgrastim products.  Consider the potential risks and benefits prior to initiating therapy in these patients.', '2', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51670, 21172, 'Filgrastim', 'Anemia, Sickle Cell', 'Severe and sometimes fatal sickle cell crises have been reported in sickle cell disease patients receiving filgrastim products.  Consider the potential risks and benefits prior to initiating therapy in these patients.', '2', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51671, 23445, 'Filgrastim', 'Anemia, Sickle Cell', 'Severe and sometimes fatal sickle cell crises have been reported in sickle cell disease patients receiving filgrastim products.  Consider the potential risks and benefits prior to initiating therapy in these patients.', '2', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51672, 23641, 'Filgrastim', 'Anemia, Sickle Cell', 'Severe and sometimes fatal sickle cell crises have been reported in sickle cell disease patients receiving filgrastim products.  Consider the potential risks and benefits prior to initiating therapy in these patients.', '2', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51673, 23642, 'Filgrastim', 'Anemia, Sickle Cell', 'Severe and sometimes fatal sickle cell crises have been reported in sickle cell disease patients receiving filgrastim products.  Consider the potential risks and benefits prior to initiating therapy in these patients.', '2', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51674, 29848, 'Filgrastim', 'Anemia, Sickle Cell', 'Severe and sometimes fatal sickle cell crises have been reported in sickle cell disease patients receiving filgrastim products.  Consider the potential risks and benefits prior to initiating therapy in these patients.', '2', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51675, 29849, 'Filgrastim', 'Anemia, Sickle Cell', 'Severe and sometimes fatal sickle cell crises have been reported in sickle cell disease patients receiving filgrastim products.  Consider the potential risks and benefits prior to initiating therapy in these patients.', '2', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51676, 13308, 'Filgrastim', 'Neoplasms', 'Tbo-filgrastim can act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia disease, diseases for which its use has not been approved.', '2', '"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51677, 19035, 'Filgrastim', 'Neoplasms', 'Tbo-filgrastim can act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia disease, diseases for which its use has not been approved.', '2', '"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51678, 19670, 'Filgrastim', 'Neoplasms', 'Tbo-filgrastim can act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia disease, diseases for which its use has not been approved.', '2', '"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51679, 21172, 'Filgrastim', 'Neoplasms', 'Tbo-filgrastim can act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia disease, diseases for which its use has not been approved.', '2', '"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51680, 23445, 'Filgrastim', 'Neoplasms', 'Tbo-filgrastim can act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia disease, diseases for which its use has not been approved.', '2', '"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51681, 23641, 'Filgrastim', 'Neoplasms', 'Tbo-filgrastim can act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia disease, diseases for which its use has not been approved.', '2', '"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51682, 23642, 'Filgrastim', 'Neoplasms', 'Tbo-filgrastim can act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia disease, diseases for which its use has not been approved.', '2', '"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51683, 29848, 'Filgrastim', 'Neoplasms', 'Tbo-filgrastim can act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia disease, diseases for which its use has not been approved.', '2', '"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51684, 29849, 'Filgrastim', 'Neoplasms', 'Tbo-filgrastim can act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia disease, diseases for which its use has not been approved.', '2', '"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51685, 24890, 'Aminolevulinic acid (topical)', 'Porphyrias', 'Photoactivation following topical application of aminolevulinic acid topical gel occurs when aminolevulinic acid (prodrug) is metabolized to protoporphyrin IX, a photoactive compound which accumulates in the skin.  Therapy with aminolevulinic acid topical gel increases photosensitivity and it may cause uncontrolled phototoxic effects.  Its use in contraindicated in patients with porphyria or photodermatoses.', '3', '"Product Information. Levulan Kerastick (aminolevulinic acid)." Berlex Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51686, 24890, 'Aminolevulinic acid (topical)', 'Hemorrhage', 'The use of aminolevulinic acid topical gel increases the risk of bleeding in patients with coagulation disorders.  Care should be exercised during lesion preparation to avoid bleeding.', '2', '"Product Information. Levulan Kerastick (aminolevulinic acid)." Berlex Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51687, 5457, 'Flavoxate', 'Intestinal Obstruction', 'The use of flavoxate is contraindicated in patients with GI obstruction, ileus, atony, and obstructive uropathy.  Flavoxate exerts direct antispasmodic effects on smooth muscles and possesses weak anticholinergic activity.', '3', '"Product Information. Urispas (flavoxATE)." SmithKline Beecham', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51688, 23407, 'Flavoxate', 'Intestinal Obstruction', 'The use of flavoxate is contraindicated in patients with GI obstruction, ileus, atony, and obstructive uropathy.  Flavoxate exerts direct antispasmodic effects on smooth muscles and possesses weak anticholinergic activity.', '3', '"Product Information. Urispas (flavoxATE)." SmithKline Beecham', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51689, 5457, 'Flavoxate', 'Glaucoma, Angle-Closure', 'Flavoxate exerts mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow angle) glaucoma.  Therapy with flavoxate should be administered cautiously in patients with angle-closure glaucoma.', '2', '"Product Information. Urispas (flavoxATE)." SmithKline Beecham', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51690, 23407, 'Flavoxate', 'Glaucoma, Angle-Closure', 'Flavoxate exerts mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow angle) glaucoma.  Therapy with flavoxate should be administered cautiously in patients with angle-closure glaucoma.', '2', '"Product Information. Urispas (flavoxATE)." SmithKline Beecham', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51691, 291, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51692, 292, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51693, 293, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51694, 383, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51695, 384, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51696, 385, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51697, 4719, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51698, 4720, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51699, 4721, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51700, 4853, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51701, 4854, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51702, 4857, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51703, 6172, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51704, 7761, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51705, 7762, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51706, 11246, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51707, 11247, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51708, 11248, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51709, 11589, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51710, 13777, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51711, 13778, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51712, 13792, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51713, 18855, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51714, 18856, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51715, 18862, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51716, 18863, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51717, 18864, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51718, 19024, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51719, 19025, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51720, 19027, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51721, 19029, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51722, 19030, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51723, 21853, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51724, 24263, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51725, 24264, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51726, 25712, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51727, 25713, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51728, 26547, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51729, 26548, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51730, 32786, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51731, 6486, 'Flibanserin', 'Alcoholic Intoxication', 'The use of flibanserin is contraindicated along with the ingestion of alcohol, as it increases the risk of hypotension and syncope.  It is important to assess the likelihood of the patient abstaining from alcohol, taking into account the current and past drinking behavior.', '3', '"Product Information. Addyi (flibanserin)." Sprout Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51732, 14290, 'Flibanserin', 'Alcoholic Intoxication', 'The use of flibanserin is contraindicated along with the ingestion of alcohol, as it increases the risk of hypotension and syncope.  It is important to assess the likelihood of the patient abstaining from alcohol, taking into account the current and past drinking behavior.', '3', '"Product Information. Addyi (flibanserin)." Sprout Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51733, 19135, 'Flibanserin', 'Alcoholic Intoxication', 'The use of flibanserin is contraindicated along with the ingestion of alcohol, as it increases the risk of hypotension and syncope.  It is important to assess the likelihood of the patient abstaining from alcohol, taking into account the current and past drinking behavior.', '3', '"Product Information. Addyi (flibanserin)." Sprout Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51734, 31966, 'Flibanserin', 'Alcoholic Intoxication', 'The use of flibanserin is contraindicated along with the ingestion of alcohol, as it increases the risk of hypotension and syncope.  It is important to assess the likelihood of the patient abstaining from alcohol, taking into account the current and past drinking behavior.', '3', '"Product Information. Addyi (flibanserin)." Sprout Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51735, 6486, 'Flibanserin', 'Hypotension', 'The use of flibanserin can cause hypotension and syncope.  The benefits and risks of therapy should be considered in patients with preexisting conditions that predispose to hypotension.  Flibanserin should be used with caution in these patients.', '3', '"Product Information. Addyi (flibanserin)." Sprout Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51736, 14290, 'Flibanserin', 'Hypotension', 'The use of flibanserin can cause hypotension and syncope.  The benefits and risks of therapy should be considered in patients with preexisting conditions that predispose to hypotension.  Flibanserin should be used with caution in these patients.', '3', '"Product Information. Addyi (flibanserin)." Sprout Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51737, 19135, 'Flibanserin', 'Hypotension', 'The use of flibanserin can cause hypotension and syncope.  The benefits and risks of therapy should be considered in patients with preexisting conditions that predispose to hypotension.  Flibanserin should be used with caution in these patients.', '3', '"Product Information. Addyi (flibanserin)." Sprout Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51738, 31966, 'Flibanserin', 'Hypotension', 'The use of flibanserin can cause hypotension and syncope.  The benefits and risks of therapy should be considered in patients with preexisting conditions that predispose to hypotension.  Flibanserin should be used with caution in these patients.', '3', '"Product Information. Addyi (flibanserin)." Sprout Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51739, 6486, 'Flibanserin', 'Liver Diseases', 'Flibanserin may accumulate in patients with hepatic impairment.  Therapy with flibanserin is contraindicated in patients with compromised hepatic function.', '3', '"Product Information. Addyi (flibanserin)." Sprout Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51740, 14290, 'Flibanserin', 'Liver Diseases', 'Flibanserin may accumulate in patients with hepatic impairment.  Therapy with flibanserin is contraindicated in patients with compromised hepatic function.', '3', '"Product Information. Addyi (flibanserin)." Sprout Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51741, 19135, 'Flibanserin', 'Liver Diseases', 'Flibanserin may accumulate in patients with hepatic impairment.  Therapy with flibanserin is contraindicated in patients with compromised hepatic function.', '3', '"Product Information. Addyi (flibanserin)." Sprout Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51742, 31966, 'Flibanserin', 'Liver Diseases', 'Flibanserin may accumulate in patients with hepatic impairment.  Therapy with flibanserin is contraindicated in patients with compromised hepatic function.', '3', '"Product Information. Addyi (flibanserin)." Sprout Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51743, 0, 'Floxuridine', 'Dihydropyrimidine Dehydrogenase Deficiency', 'An inherited deficiency of dihydropyrimidine can alter the clearance of 5- FU and result in severe toxicity such as stomatitis, diarrhea, neutropenia and neurotoxicity. When administered as a continuous intra-arterial infusion, floxuridine (FUDR) is metabolized to FDUMP.  However, with rapid intra-arterial injection, FUDR is metabolized to 5-FU.  5-FU requires metabolized to an inactive form by dihydropyrimidine dehydrogenase.   FUDR should not be administered by rapid intra-arterial infusion to patients with dihydropyrimidine deficiency.', '3', '"Product Information. FUDR (floxuridine)." Roche Laboratories  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51744, 0, 'Floxuridine', 'Infections', 'The use of floxuridine (FUDR) is contraindicated in patients with potentially serious infectious diseases.  FUDR can induce myelosuppression.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during therapy with FUDR.  Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. FUDR (floxuridine)." Roche Laboratories  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51745, 0, 'Floxuridine', 'Malnutrition', 'Floxuridine therapy is contraindicated for patients in a poor nutritional state.', '3', '"Product Information. FUDR (floxuridine)." Roche Laboratories  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51746, 0, 'Floxuridine', 'Bone Marrow Failure Disorders', 'The use of floxuridine (FUDR) is contraindicated in patients with bone marrow suppression.  FUDR induces myelosuppression at recommended dosages.  Therapy with FUDR should be administered cautiously in patients who have had prior high-dose pelvic irradiation or alkylating agents or who have widespread metastatic tumor involvement of the bone marrow.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended and therapy should be withheld if platelet counts falls below 100,000/mm3 and/or white blood cell (WBC) counts falls below 3500/mm3 or a rapid fall in WBC is noted.', '3', '"Product Information. FUDR (floxuridine)." Roche Laboratories  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51747, 0, 'Floxuridine', 'Stomatitis', 'Floxuridine induces stomatitis within the gastrointestinal tract.  Therapy with floxuridine should be administered with extreme caution in patients with peptic ulcer disease and ulcerative colitis.', '3', '"Product Information. FUDR (floxuridine)." Roche Laboratories  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51748, 0, 'Floxuridine', 'Hemorrhagic Disorders', 'Floxuridine (FUDR) induces myelosuppression.  Therapy with FUDR should be administered cautiously in patients with bleeding tendencies.  Therapy with FUDR should be promptly discontinued following bleeding from any sight.  Patients should be instructed to immediately report any signs or symptoms suggesting bleeding such as petechiae, purpura, hematuria, or melena.   Close clinical monitoring of hematopoietic function is recommended.  Therapy with FUDR should be withheld if platelet counts falls below 100,000/mm3.', '2', '"Product Information. FUDR (floxuridine)." Roche Laboratories  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51749, 0, 'Flunisolide', 'Adrenocortical Hyperfunction', 'The use of inhaled and nasal corticosteroids may rarely precipitate or aggravate conditions of hyperadrenocorticism.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during inhaled or nasal corticosteroid therapy may indicate excessive use.', '2', 'Kimmerle R, Rolla AR "Iatrogenic Cushing''s syndrome due to dexamethasone nasal drops." Am J Med 79 (1985):  535-7|Monk B, Cunliffe WJ, Layton AM, Rhodes DJ "Acne induced by inhaled corticosteroids." Clin Exp Dermatol 18 (1993):  148-50|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Clark TJ "Safety of inhaled corticosteroids." Eur J Respir Dis Suppl 122 (1982):  235-42|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|van As A, Bronsky E, Grossman J, Meltzer E, Ratner P, Reed C "Dose tolerance study of fluticasone propionate aqueous nasal spray in patients with seasonal allergic rhinitis." Ann Allergy 67 (1991):  156-62|Stevens DJ "Cushing''s syndrome due to the abuse of betamethasone nasal drops." J Laryngol Otol 102 (1988):  219-21|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Robinson DS, Geddes DM "Inhaled corticosteroids: benefits and risks." J Asthma 33 (1996):  5-16|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51750, 0, 'Flunisolide', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Horton DJ, Spector SL "Clinical pulmonary tuberculosis in an asthmatic patient using a steroid aerosol." Chest 71 (1977):  540-2|Carrel TP, Schaffner A, Schmid ER, Schneider J, Bauer EP, Laske A, von Segesser LK, Turina MI "Fatal fungal pericarditis after cardiac surgery and immunosuppression." J Thorac Cardiovasc Surg 101 (1991):  161-4|Vogt FC "The incidence of oral candidiasis with use of inhaled corticosteroids." Ann Allergy 43 (1979):  205-10|Milne LJ, Crompton GK "Beclomethasone dipropionate and oropharyngeal candidiasis." Br Med J 3 (1974):  797-8|Toogood JH, Jennings B, Greenway RW, Chuang L "Candidiasis and dysphonia complicating beclomethasone treatment of asthma." J Allergy Clin Immunol 65 (1980):  145-53|Webb EL "Nasal candidiasis in a patient on long-term topical intranasal corticosteroid therapy." J Allergy Clin Immunol 91 (1993):  680-1|Shaikh WA "Pulmonary tuberculosis in patients treated with inhaled beclomethasone." Allergy 47 (1992):  327-30|Kesten S, Hyland RH, Pruzanski WR, Kortan PP "Esophageal candidiasis associated with beclomethasone dipropionate aerosol therapy." Drug Intell Clin Pharm 22 (1988):  568-9|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Executive Committee American Academy of Allergy and Immunology "Inhaled corticosteroids and severe viral infections." J Allergy Clin Immunol 92 (1993):  223-8|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51751, 0, 'Flunisolide', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51752, 0, 'Flunisolide', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Fraunfelder FT, Meyer SM "Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids." Am J Ophthalmol 109 (1990):  489-90|Karim AK, Thompson GM, Jacob TJ "Steroid aerosols and cataract formation." BMJ 299 (1989):  918|Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen B "Steroid aerosols and cataract formation." BMJ 299 (1989):  432-3|Kewley GD "Possible association between beclomethasone diproprionate aerosol and cataracts." Aust Paediatr J 16 (1980):  117-8|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Ghanchi F "Young patients on inhaled steroids and cataract." Lancet 342 (1993):  1306-7|Dreyer EB "Inhaled steroid use and glaucoma." N Engl J Med 329 (1993):  1822|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Spaeth GL, Rodrigues MM, Weinreb S "Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects." Trans Am Ophthalmol Soc 75 (1977):  353-81|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Garbe E, LeLorier J, Boivin JF, Suissa S "Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma." JAMA 277 (1997):  722-7|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Cumming RG, Mitchell P, Leeder SR "Use of inhaled corticosteroids and the risk of cataracts." N Engl J Med 337 (1997):  8-14|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Agertoft L, Larsen FE, Pedersen S "Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide." Eur Resp J 12 (1998):  130-5|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51753, 0, 'Flunisolide', 'Osteoporosis', 'Prolonged use of inhaled corticosteroids may be associated with a reduction in bone density.  This effect appears to be dose-related and has been reported primarily with high dosages (>= 800 mcg/day of beclomethasone or equivalent for >= 1 year).  Reduced levels of total body calcium have also been demonstrated in patients receiving lower dosages.  Long-term therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with osteoporosis.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Toogood JH, Crilly RG, Jones G, Nadeau J, Wells GA "Effect of high-dose inhaled budesonide on calcium and phosphate metabolism and the risk of osteoporosis." Am Rev Respir Dis 138 (1988):  57-61|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|Konig P, Hillman L, Cervantes C, Levine C, Maloney C, Douglass B, Johnson L, Allen S "Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate." J Pediatr 122 (1993):  219-26|Kinberg KA, Hopp RJ, Biven RE, Gallagher JC "Bone mineral density in normal and asthmatic children." J Allergy Clin Immunol 94 (1994):  490-7|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|Toogood JH, Baskerville JC, Markov AE, Hodsman AB, Fraher LJ, Jennings B, Haddad RG, Drost D "Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma." J Allergy Clin Immunol 96 (1995):  157-66|Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S "Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids." J Allergy Clin Immunol 96 (1995):  571-9|Martinati LC, Bertoldo F, Gasperi E, Micelli S, Boner AL "Effect on cortical and trabecular bone mass of different anti-inflammatory treatments in preadolescent children with chronic asthma." Am J Respir Crit Care Med 153 (1996):  232-6|Packe GE, Douglas JG, McDonald AF, Robins SP, Reid DM "Bone density in asthmatic patients taking high dose inhaled beclomethasone diproprionate and intermittent systemic corticosteroids." Thorax 47 (1992):  414-7|Reid DM, Nicoll JJ, Smith MA, Higgins B, Tothill P, Nuki G "Corticosteroids and bone mass in asthma: comparisons with rheumatoid arthritis and polymyalgia rheumatica." BMJ 293 (1986):  1463-6|Ali NJ, Capewell S, Ward MJ "Bone turnover during high dose inhaled corticosteroid treatment." Thorax 46 (1991):  160-4|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Packe GE, Robb O, Robins SP, Reid DM, Douglas JG "Bone density in asthmatic patients taking inhaled corticosteroids: comparison of budesonide and beclomethasone dipropionate." J R Coll Physicians Lond 30 (1996):  128-32|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|Luengo M, delRio L, Pons F, Picado C "Bone mineral density in asthmatic patients treated with inhaled corticosteroids: a case-control study." Eur Respir J 10 (1997):  2110-3|Wisniewski AF, Lewis SA, Green DJ, Maslanka W, Burrell H, Tattersfield AE "Cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma." Thorax 52 (1997):  853-60|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|Wong CA, Walsh LJ, Smith CJP, Wisniewski AF, Lewis SA, Hubbard R, Cawte S, Green DJ, Pringle M, Tattersfield AE "Inhaled corticosteroid use and bone-mineral density in patients with asthma." Lancet 355 (2000):  1399-403|Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS "Effects of inhaled glucocorticoids on bone density in premenopausal women." N Engl J Med 345 (2001):  941-7|Sharma PK, Malhotra S, Pandhi P, Kumar N "Effect of inhaled steroids on bone mineral density: a meta-analysis." J Clin Pharmacol 43 (2003):  193-7|Boulet LP, Milot J, Gagnon L, Poubelle PE, Brown J "Long-term influence of inhaled corticosteroids on bone metabolism and density. Are biological markers predictors of bone loss?" Am J Respir Crit Care Med 159 (1999):  838-44', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51754, 347, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51755, 682, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51756, 785, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51757, 1992, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51758, 3542, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51759, 3663, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51760, 3664, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51761, 3665, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51762, 3666, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51763, 3667, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51764, 4360, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51765, 4960, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51766, 4993, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51767, 4994, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51768, 5203, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51769, 8612, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51770, 11598, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51771, 12546, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51772, 13070, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51773, 13446, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51774, 13531, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51775, 14067, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51776, 14150, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51777, 14151, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51778, 14152, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51779, 15757, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51780, 17257, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51781, 17642, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51782, 19147, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51783, 19201, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51784, 19202, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51785, 19208, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51786, 21162, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51787, 23321, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51788, 23322, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51789, 23323, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51790, 23324, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51791, 27679, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51792, 28496, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51793, 28497, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51794, 28730, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51795, 31820, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51796, 32275, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51797, 33255, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51798, 347, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51799, 682, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51800, 785, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51801, 1992, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51802, 3542, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51803, 3663, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51804, 3664, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51805, 3665, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51806, 3666, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51807, 3667, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51808, 4360, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51809, 4960, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51810, 4993, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51811, 4994, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51812, 5203, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51813, 8612, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51814, 11598, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51815, 12546, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51816, 13070, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51817, 13446, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51818, 13531, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51819, 14067, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51820, 14150, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51821, 14151, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51822, 14152, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51823, 15757, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51824, 17257, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51825, 17642, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51826, 19147, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51827, 19201, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51828, 19202, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51829, 19208, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51830, 21162, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51831, 23321, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51832, 23322, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51833, 23323, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51834, 23324, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51835, 27679, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51836, 28496, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51837, 28497, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51838, 28730, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51839, 31820, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51840, 32275, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51841, 33255, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51842, 347, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51843, 682, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51844, 785, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51845, 1992, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51846, 3542, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51847, 3663, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51848, 3664, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51849, 3665, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51850, 3666, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51851, 3667, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51852, 4360, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51853, 4960, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51854, 4993, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51855, 4994, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51856, 5203, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51857, 8612, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51858, 11598, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51859, 12546, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51860, 13070, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51861, 13446, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51862, 13531, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51863, 14067, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51864, 14150, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51865, 14151, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51866, 14152, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51867, 15757, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51868, 17257, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51869, 17642, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51870, 19147, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51871, 19201, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51872, 19202, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51873, 19208, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51874, 21162, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51875, 23321, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51876, 23322, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51877, 23323, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51878, 23324, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51879, 27679, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51880, 28496, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51881, 28497, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51882, 28730, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51883, 31820, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51884, 32275, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51885, 33255, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51886, 347, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51887, 682, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51888, 785, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51889, 1992, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51890, 3542, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51891, 3663, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51892, 3664, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51893, 3665, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51894, 3666, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51895, 3667, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51896, 4360, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51897, 4960, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51898, 4993, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51899, 4994, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51900, 5203, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51901, 8612, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51902, 11598, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51903, 12546, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51904, 13070, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51905, 13446, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51906, 13531, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51907, 14067, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51908, 14150, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51909, 14151, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51910, 14152, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51911, 15757, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51912, 17257, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51913, 17642, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51914, 19147, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51915, 19201, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51916, 19202, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51917, 19208, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51918, 21162, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51919, 23321, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51920, 23322, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51921, 23323, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51922, 23324, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51923, 27679, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51924, 28496, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51925, 28497, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51926, 28730, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51927, 31820, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51928, 32275, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51929, 33255, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51930, 5621, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51931, 5622, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51932, 5623, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51933, 5624, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51934, 5625, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51935, 5626, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51936, 6601, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51937, 17469, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51938, 17470, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51939, 17471, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51940, 17472, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51941, 17473, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51942, 17474, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51943, 17475, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51944, 17476, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51945, 17477, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51946, 17479, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51947, 17480, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51948, 17484, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51949, 17488, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51950, 17500, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51951, 17501, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51952, 17502, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51953, 17503, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51954, 17504, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51955, 17505, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51956, 17506, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51957, 17507, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51958, 17510, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51959, 19908, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51960, 19909, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51961, 19910, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51962, 19912, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51963, 19913, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51964, 19914, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51965, 19915, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51966, 19916, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51967, 19917, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51968, 19918, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51969, 19919, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51970, 19920, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51971, 19921, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51972, 19922, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51973, 19923, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51974, 19924, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51975, 19925, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51976, 19927, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51977, 19928, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51978, 19929, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51979, 19930, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51980, 19931, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51981, 19932, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51982, 19933, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51983, 19934, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51984, 19935, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51985, 19936, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51986, 19937, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51987, 19938, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51988, 19939, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51989, 19940, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51990, 19941, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51991, 32919, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51992, 0, 'Flucytosine', 'Bone Marrow Failure Disorders', 'Flucytosine may frequently cause bone marrow toxicity, which can be irreversible and fatal in immunosuppressed patients.  Flucytosine should be used with extreme caution in patients with preexisting bone marrow suppression.  Frequent blood counts are recommended.', '3', 'Record CO, Skinner JM, Sleight P, Speller DC "Candida endocarditis treated with 5-fluorocytosine." Br Med J 01/30/71 (1971):  262-4|Harder EJ, Hermans PE "Treatment of fungal infections with flucytosine." Arch Intern Med 135 (1975):  231-7|Wise GJ, Goldberg P, Kozinn PJ, Nawabi IU "Agranulocytosis associated with flucytosine for urinary candidiasis." Urology 8 (1976):  490-1|Kauffman CA, Frame PT "Bone marrow toxicity associated with 5-fluorocytosine therapy." Antimicrob Agents Chemother 11 (1977):  244-7|Bennett JE, Dismukes WE, Duma RJ, et al. "A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis." N Engl J Med 301 (1979):  126-31|Stamm AM, Diasio RB, Dismukes WE, et al. "Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis." Am J Med 83 (1987):  236-42|"Product Information. Ancobon (flucytosine)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51993, 0, 'Flucytosine', 'Kidney Diseases', 'Flucytosine must be given with extreme caution to patients with impaired renal function.  Flucytosine is excreted primarily by the kidneys, and renal impairment may lead to accumulation of the drug.  Serum concentrations of the drug should be monitored to determine the adequacy of renal excretion in such patients.  Dosage adjustments should be made in patients with renal insufficiency to prevent progressive accumulation of active drug.  Close monitoring of renal, hematologic and hepatic function in all patients is recommended.', '3', 'Wade DN, Sudlow G "The kinetics of 5-fluorocytosine elimination in man." Aust N Z J Med 2 (1972):  153-8|Drouhet E, Babinet P, Chapusot JP, Kleinknecht D "5-fluorocytosine in the treatment of candidiasis with acute renal insufficiency." Biomedicine 19 (1973):  408-14|Dawborn JK, Page MD, Schiavone DJ "Use of 5-fluorocytosine in patients with impaired renal function." Br Med J 11/17/73 (1973):  382-4|Schonebeck J, Polak A, Fernex M, Scholer HJ "Pharmacokinetic studies on the oral antimycotic agent 5-fluorocytosine in individuals with normal and impaired kidney function." Int J Exp Clin Chemother 18 (1973):  321-36|Cutler RE, Blair AD, Kelly MR "Flucytosine kinetics in subjects with normal and impaired renal function." Clin Pharmacol Ther 24 (1978):  333-42|"Product Information. Ancobon (flucytosine)." Roche Laboratories  (2002):|Lau AH, Kronfol NO "Elimination of flucytosine by continuous hemofiltration." Am J Nephrol 15 (1995):  327-31', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51994, 0, 'Flucytosine', 'Diseases requiring hemodialysis', 'Flucytosine is substantially removed by hemodialysis and should be administered after dialysis.', '2', 'Drouhet E, Babinet P, Chapusot JP, Kleinknecht D "5-fluorocytosine in the treatment of candidiasis with acute renal insufficiency." Biomedicine 19 (1973):  408-14|Dawborn JK, Page MD, Schiavone DJ "Use of 5-fluorocytosine in patients with impaired renal function." Br Med J 11/17/73 (1973):  382-4|Schonebeck J, Polak A, Fernex M, Scholer HJ "Pharmacokinetic studies on the oral antimycotic agent 5-fluorocytosine in individuals with normal and impaired kidney function." Int J Exp Clin Chemother 18 (1973):  321-36|Cutler RE, Blair AD, Kelly MR "Flucytosine kinetics in subjects with normal and impaired renal function." Clin Pharmacol Ther 24 (1978):  333-42|"Product Information. Ancobon (flucytosine)." Roche Laboratories  (2002):|Lau AH, Kronfol NO "Elimination of flucytosine by continuous hemofiltration." Am J Nephrol 15 (1995):  327-31', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51995, 0, 'Flucytosine', 'Hypokalemia', 'Flucytosine may cause hypokalemia.  Patients with preexisting hypokalemia should be monitored closely for worsening electrolyte disturbances during therapy with flucytosine.', '2', 'Stamm AM, Diasio RB, Dismukes WE, et al. "Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis." Am J Med 83 (1987):  236-42|"Product Information. Ancobon (flucytosine)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51996, 17327, 'Aminosalicylic acid', 'Kidney Diseases', 'The use of aminosalicylic acid is contraindicated in patients with severe renal impairment.  Both aminosalicylic acid and its acetyl metabolite are primarily eliminated by the kidney, and the latter tends to accumulate extensively in patients with renal failure.  Some accumulation may also occur in patients with lesser degrees of renal dysfunction.  Caution is advised when aminosalicylic acid is used in these patients.', '3', '"Product Information. Paser D/R (aminosalicylic acid)." Jacobus Pharmaceutical Company', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51997, 17328, 'Aminosalicylic acid', 'Kidney Diseases', 'The use of aminosalicylic acid is contraindicated in patients with severe renal impairment.  Both aminosalicylic acid and its acetyl metabolite are primarily eliminated by the kidney, and the latter tends to accumulate extensively in patients with renal failure.  Some accumulation may also occur in patients with lesser degrees of renal dysfunction.  Caution is advised when aminosalicylic acid is used in these patients.', '3', '"Product Information. Paser D/R (aminosalicylic acid)." Jacobus Pharmaceutical Company', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51998, 17329, 'Aminosalicylic acid', 'Kidney Diseases', 'The use of aminosalicylic acid is contraindicated in patients with severe renal impairment.  Both aminosalicylic acid and its acetyl metabolite are primarily eliminated by the kidney, and the latter tends to accumulate extensively in patients with renal failure.  Some accumulation may also occur in patients with lesser degrees of renal dysfunction.  Caution is advised when aminosalicylic acid is used in these patients.', '3', '"Product Information. Paser D/R (aminosalicylic acid)." Jacobus Pharmaceutical Company', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51999, 26475, 'Aminosalicylic acid', 'Kidney Diseases', 'The use of aminosalicylic acid is contraindicated in patients with severe renal impairment.  Both aminosalicylic acid and its acetyl metabolite are primarily eliminated by the kidney, and the latter tends to accumulate extensively in patients with renal failure.  Some accumulation may also occur in patients with lesser degrees of renal dysfunction.  Caution is advised when aminosalicylic acid is used in these patients.', '3', '"Product Information. Paser D/R (aminosalicylic acid)." Jacobus Pharmaceutical Company', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52000, 26476, 'Aminosalicylic acid', 'Kidney Diseases', 'The use of aminosalicylic acid is contraindicated in patients with severe renal impairment.  Both aminosalicylic acid and its acetyl metabolite are primarily eliminated by the kidney, and the latter tends to accumulate extensively in patients with renal failure.  Some accumulation may also occur in patients with lesser degrees of renal dysfunction.  Caution is advised when aminosalicylic acid is used in these patients.', '3', '"Product Information. Paser D/R (aminosalicylic acid)." Jacobus Pharmaceutical Company', 'DDInter', 0);